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Abstract 
Urogenital schistosomiasis, caused by the parasite helminth Schistosoma haematobium, is one 
of the major parasitic diseases affecting millions of preschool-aged children (PSAC), i.e. aged 
5 years and below, in sub-Saharan Africa. Diagnosis is via microscopic detection of parasite 
eggs in urine, and treatment is by administration of the antihelminthic drug of choice, 
praziquantel. Epidemiological studies show that PSAC are infected as early as a year old, with 
negative impacts on nutrition, growth, cognition, and overall health. Despite recommendations 
to treat PSAC with schistosomiasis, this age group is still excluded from treatment 
programmes for various reasons including: a) the lack of a child-friendly formulation of 
praziquantel, b) lack of a coherent strategy to access PSAC for screening and treatment, and 
c) lack of compelling evidence on infection, disease and treatment dynamics. Currently, the 
global infection and disease burden is not fully known in this age group, and longitudinal 
studies to describe the incidence of infection and morbidity, especially the early events that 
occur during the very first infection and treatment in PSAC are lacking. In addition, the 
mechanistic pathways of disease, treatment, and immunity are poorly understood in this age 
group. Operational difficulties including obtaining parasitology samples for diagnosis, failure 
to detect light infections, and inadequate knowledge about risk factors have also contributed 
to a lower research focus on PSAC, relative to school-aged children and adults.  
To address these, I completed a series of studies, based on a larger longitudinal study on 
paediatric urogenital schistosomiasis (population age range: 6 months–5 years) conducted in 
the Shamva district of Zimbabwe. The aim was to determine the dynamics of infection, 
morbidity and treatment of the first S. haematobium infection, and to examine the impact of a 
regular screening and treatment strategy on (re)infections. I also determined the early host 
metabolic changes associated with the first S. haematobium infection as well as the impact of 
schistosome infection on the gut microbiome, and how these relate to disease progression, 
morbidity and overall health. 
  iv 
I determined that 92% of microhaematuria, 38% of stunting, and between 9%–34% of 
malnutrition (depending on what index is used) are attributable to S. haematobium infection 
in PSAC; schistosome-positive children were more likely to present with microhaematuria (25 
times) and stunting (2 times), compared to uninfected children. I demonstrated the annual 
incidence of first schistosome infections (17.4%) and urinary morbidity (microhaematuria; 
20.4%), with significant incidences recorded every quarter. I showed that within 3 months of 
the first infection, a significant amount of urinary morbidity, i.e. microhaematuria (61%) 
occurs, and is resolved 3 months post-praziquantel treatment.  
In PSAC with no history of schistosome infection, regular quarterly screening and treatment 
of the first S. haematobium infection reduces the actual time at risk of infection in the 
population, and results in reduced rates of subsequent new infections. A single praziquantel 
treatment of schistosome infections (upon first infection) was associated with reduced 
reinfection rates and intensity a year later; an effect comparable to that observed post-treatment 
in chronically-infected children.  
In young children experiencing their first schistosome infection, there are significant increases 
(≥2-fold) in serum metabolites primarily linked with energy (glycolysis, pentose phosphate 
pathway, starch, and galactose) and purine metabolism. The observed changes were 
commensurate with increasing infection intensity and were restored 3 months post-curative 
antihelminthic treatment. The affected metabolic pathways and its implications on the natural 
adaptive metabolic responses were consistent with parasite survival and development of 
schistosome morbidity in PSAC, including malnutrition, stunting and poor physical and 
cognitive performance. 
Metagenomic analysis of the gut microbiota showed that the abundance of bacteria and fungi 
phyla from Proteobacteria, Ascomycota, and Basidiomycota, differed between schistosome-
infected versus uninfected children. Specifically, infection was associated with increases in 
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Pseudomonas, Stenotrophomonas, Derxia, Thalassospira, Aspergillus, Tricholoma, and 
Periglandula, and a decrease in Azospirillum. I found evidence of 262 antimicrobial resistance 
genes, from 12 functional drug classes, but these showed no association with individual-
specific data, including schistosome infection. This points to microbiome dysbiosis as an 
additional consequence of schistosome infection, with implications for morbidity, immunity, 
and overall health. 
Taken together, the findings of this thesis show that early in the first S. haematobium infection, 
PSAC present with significant morbidity, and this resolves quickly with praziquantel 
treatment. A routine screen-and-treat strategy will optimise the chances of detecting and 
treating infections early, while reducing the risk of new and reinfections. The findings further 
highlight microbiome and metabolic alterations during schistosome infection, which may be 
relevant for disease pathogenesis. This thesis presents an integrative approach to 
schistosomiasis studies in PSAC, which contributes to evidence on infection/disease burden 
and dynamics, the applicability of currently available tools in the diagnosis, treatment and 
control of schistosomiasis, as well as the systemic impacts of infection on the host microbiome, 
metabolism, and overall health. It also adds to the repository of information, by providing a 
novel metagenomics and metabolomics dataset of PSAC from Zimbabwe. The findings 
reaffirm the need for early diagnosis and treatment of schistosome infections in PSAC to avert 
accumulative morbidity, and will inform stakeholders in providing new and appropriate 
interventions targeted at reducing schistosome-related pathology in young children. 
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Lay Summary 
Millions of preschool-aged children (PSAC), i.e. aged 5 years and below, in sub-Saharan 
Africa suffer from a neglected tropical disease caused by helminth parasitic worms, known as 
schistosomiasis (commonly referred to as bilharzia or snail fever). In these young children, the 
disease has severe consequences including impacts on nutrition, growth, cognition, and overall 
health. This thesis focused on the species that causes urinary and genital disease, Schistosoma 
haematobium, which accounts for about two-thirds of all schistosomiasis cases in Africa. The 
disease can be diagnosed by microscopic detection of parasite eggs in urine, and treatment is 
by administration of the antihelminthic drug of choice, praziquantel. Despite current 
recommendations to treat PSAC with schistosomiasis, this age group is still excluded from 
treatment programmes for various reasons including: a) the lack of a child-friendly formulation 
of praziquantel, b) lack of a coherent strategy to access PSAC for screening and treatment, and 
c) lack of compelling evidence on infection, disease and treatment dynamics. Currently, the 
global infection and disease burden is not fully known in this age group. Long-term research 
to track the early events that occur during the very first schistosome infection and treatment, 
as well as the associated health impacts are lacking. In addition, the molecular and biochemical 
processes underlying disease, treatment, and protection from infection are poorly understood 
in this age group. 
In this thesis, I worked to address these knowledge and research gaps, by following a natural 
time-course of schistosome infections in PSAC (age range 6 months–5 years) living in a 
schistosome-endemic area in Zimbabwe (Shamva district). The aim was to determine the 
dynamics of infection, morbidity and treatment of the first schistosome infection, and to assess 
the impact of a regular screening and treatment strategy on (re)infection. I also determined the 
early changes that occur with metabolism (the set of complex life-sustaining biochemical 
reactions in the body), during the first schistosome infection. The impact of schistosome 
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infection on the ecosystem of microbes that inhabit the human gut (microbiota) and perform 
vital roles in nutrition and health, was also determined. 
The results showed that during the first schistosome infection, PSAC quickly develop clinical 
disease, as measured by urinary morbidity (blood in urine). Schistosome infection and 
morbidity can be detected early in PSAC, using parasitology (microscopic egg counts) and 
dipstick techniques (detection of blood in urine) within 3 months of first infection, and 
morbidity is resolved 3 months after curative treatment with praziquantel. Chronic 
growth/nutrition-related morbidity including malnutrition and stunting are attributable to 
schistosome infection, and these indices can help identify high-risk groups and measure the 
health impacts of infection and treatment in endemic areas. In PSAC with no history of 
schistosome infection, regular quarterly screening and treatment of the first infection, reduces 
the actual time at risk of infection in the population and reduces the rates of subsequent new 
infections. A single praziquantel treatment of schistosome infections (upon first infection) was 
associated with reduced reinfection rates and intensity a year later; an effect comparable to 
that observed post-treatment in children with longer-term infections.  
In young children experiencing their first schistosome infection, there are significant 
alterations in energy and purine metabolism, consistent with development of schistosome 
morbidity in PSAC, including malnutrition, stunting and poor physical and cognitive 
performance. These changes correlated with increasing infection burden and were restored to 
almost pre-infection levels, 12 weeks after treatment. Compared to uninfected children, 
schistosome infection was associated with significant alterations in the abundance of specific 
gut microbiota populations, which may be relevant for disease progression and negative 
impacts on overall health. 
Overall, this thesis presents an integrative approach to schistosomiasis studies in PSAC, which 
contributes to evidence on infection/disease burden and dynamics, the applicability of 
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currently available tools in the diagnosis, treatment and control of schistosomiasis, as well as 
an understanding into the factors underlying disease progression and overall health. The 
findings reaffirm the need for early diagnosis and treatment of schistosome infections in PSAC 
to avert accumulative morbidity. It will also inform stakeholders in providing new and 
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Chapter 1 Introduction 
Parts of this chapter have been published as a review article (Osakunor et al., 2018b), and a 
copy of the publication is included in Appendix E. 
1.1 Background 
After performing an autopsy on infected patients in Egypt in 1851, the German pathologist 
Theodore Maximilian Bilharz was first to describe a parasitic disease in humans, which 
became known as bilharzia (Bilharz 1853). Although the terms bilharzia or snail fever are still 
commonly used, the most widely accepted scientific term for the disease today is 
schistosomiasis (Ross et al., 2002, World Health Organization 2020b). Schistosomiasis is a 
water-borne tropical and subtropical disease that mostly affects communities with limited 
access to both safe water and adequate sanitation provision (Gryseels et al., 2006, Colley et 
al., 2014, World Health Organization 2020b). World estimates show that over 250 million 
people are infected (World Health Organization 2020b), with sub-Saharan Africa accounting 
for more than 90% of cases (Steinmann et al., 2006, Colley et al., 2014, World Health 
Organization 2020b). In endemic areas children carry most of the infection burden, with about 
123 million infected children worldwide. Of this number, at least 25 million are preschool-
aged children (PSAC), i.e. children who are 5 years old and below (WHO Expert Committee 
2002, World Health Organization 2011). The health impacts of schistosomiasis thus start 
during the preschool age, and include protein wasting, malnutrition, poor growth and cognitive 
development, anaemia, and reduced physical activity during childhood (Freer et al., 2018, 
McManus et al., 2018). Later life consequences of schistosomiasis include chronic diarrhoea, 
poor sexual and reproductive health, susceptibility to coinfections, organ-related cancers, 
chronic or end-stage organ damage, and in some serious cases, death (Gelfand et al., 1967, 
Lichtenberg 1975, Ishida and Hsieh 2018, McManus et al., 2018, Tuffour et al., 2018). 
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Diagnosis is typically by microscopic detection of eggs in urine or stool, depending on the 
species, and treatment is by administration of the antihelminthic drug of choice, praziquantel 
(PZQ) (McManus et al., 2018, World Health Organization 2020b). In schistosome-endemic 
areas, infection rates and intensity are typically highest in populations aged between 6–20 
years (Woolhouse 1998, Mitchell et al., 2011). This is because exposure to schistosome 
infection is cumulative (Woolhouse et al., 2000) and infection prevalence and intensity 
increase with age (Wami et al., 2014), up until the teenage years when worm burden begins to 
decline due to natural worm death and onset of development of partial acquired immunity 
(McManus et al., 2018). Hence, schistosome control programmes follow preventive 
chemotherapy (PC) by mass drug administration (MDA) and monitoring of infections in 
school-aged children (SAC; ≥6 years old) and adolescents (WHO Expert Committee 2002). 
Epidemiological studies have shown evidence of schistosome infection in PSAC as early as 
six months old (Woolhouse et al., 2000, Bosompem et al., 2004, Odogwu et al., 2006, Mutapi 
et al., 2011, Kemal et al., 2019, Mutsaka-Makuvaza et al., 2019, Sacolo-Gwebu et al., 2019). 
However, PSAC are excluded from treatment through MDA programmes (Stothard et al., 
2011, Stothard et al., 2013). The World Health Organization (WHO) published a major 
recommendation in 2011 to include PSAC for treatment, based on evidence of schistosome 
infection and treatment in this age group (World Health Organization 2011). To date, the 29 
schistosome-endemic countries in Africa that have implemented MDA programmes are yet to 
include PSAC (World Health Organization 2018). Moreover, where vaccine trials have been 
conducted in schistosome-endemic areas, these have included children aged from 6–11 years 
old (Riveau et al., 2018, Tendler et al., 2018). This creates a “treatment gap” and a health 
inequity (Stothard et al., 2011, Stothard et al., 2013), while PSAC remain significant reservoirs 
for infection transmission and thereby hamper elimination efforts (Lelo et al., 2014, Njenga et 
al., 2014). 
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Several reasons have been given for the exclusion of PSAC from schistosome treatment 
programmes, especially for those that started before the WHO recommendation. These include 
the unavailability of a child-friendly formulation of PZQ, lack of a consensus on safety and 
dosing of the current tablet form of the drug, and the absence of a coherent strategy to access 
and treat PSAC (Stothard et al., 2013, Mutapi 2015a, Mduluza and Mutapi 2017). The 
historical perspective of a low risk of infection and a low disease burden (Sacko et al., 2011), 
the assumption that PSAC cannot mount a protective immune response to schistosome 
infection, or that treatment efficacy depends on a mature immune system have also contributed 
to this treatment exclusion (Mutapi 2015a). Even if infected, the impact on the health of PSAC 
was unknown or considered negligible. In addition, operational difficulties including obtaining 
parasitology samples for diagnosis, failure of conventional diagnostics to detect early and light 
infections in PSAC, and the ease of accessing SAC in schools have biased research focus 
towards older children (Colley et al., 2014). This has led to a poor understanding of 
schistosome exposure, infection, disease dynamics and treatment in PSAC.  
Although concerted efforts have been made by providing scientific evidence to refute such 
misconceptions and barriers to schistosome treatment and research focus, there is still a need 
for improved research and knowledge, as well as adapting and refocusing current control and 
intervention strategies in PSAC (Tchuem Tchuenté et al., 2017). To date, schistosomiasis 
studies in PSAC have focused on describing the prevalence of infection and morbidity in 
endemic areas, while longitudinal studies are lacking. For instance, studies to describe the 
incidence of infection and morbidity, especially the early events that occur during the very 
first infection and treatment in PSAC are lacking. Knowledge of screening and treatment times 
for primary infections, and follow-up studies to determine the impact of such strategies on 
reinfection are also limited. In addition, studies elucidating the host-parasite interactions at the 
molecular level, that contribute to parasite survival and disease development in PSAC are 
needed. If we are to strengthen schistosomiasis elimination programmes, addressing these 
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knowledge gaps is important in order to deliver sustainable control of schistosome infection 
and disease, and to inform development of specific interventions targeted at reducing 
morbidity. 
Therefore, the work presented in this thesis aims to address the knowledge gaps outlined 
above, in relation to infection and disease dynamics, and the health impacts of infection and 
treatment in PSAC, focusing on S. haematobium species. It also adds to understanding the 
mechanistic pathways of disease and treatment in this age group, as it relates to the host 
metabolic system and the gut microbiome (the assembly of genomes of the diverse ecosystem 
of microbes associated with humans). 
In this chapter, I summarise the current knowledge of schistosome infection, host–parasite 
interactions and disease dynamics, as well as treatment and immune mechanisms as pertains 
to PSAC. In relation to these areas, I identify important knowledge gaps in paediatric 
schistosomiasis practice, and how the work presented in subsequent chapters of this thesis 
(with a focus on S. haematobium species) contributes to closing these gaps. The rationale and 
specific aims of the work presented in each chapter as well as an outline of this thesis are also 
included. 
1.2 Schistosome biology and clinical relevance 
Schistosomiasis is caused by parasitic trematode worms of the genus Schistosoma. The most 
common species that infect humans are S. haematobium, which causes the urogenital form of 
the disease, and S. mansoni and S. japonicum which cause intestinal disease (Colley et al., 
2014). The species S. guineensis, S. intercalatum and S. mekongi although rarely reported in 
humans, also cause intestinal disease (Gryseels et al., 2006). 
Like other trematodes, Schistosoma species have a complex life cycle consisting of both free-
living and parasitic forms. A schematic diagram of the complete life cycle and its clinical 
relevance as used in this thesis is shown in Figure 1.1. Schistosome eggs are released by the 
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definitive vertebrate host, either directly or carried by rains into freshwater via urine  
(S. haematobium) or faeces (S. mansoni and other intestinal forms). The eggs can stay viable 
for up to about seven days before they reach fresh water. The life cycle of schistosomes 
however require an asexual reproductive phase within an intermediate host snail – for S. 
haematobium this is Bulinus spp., for S. mansoni, Biomphalaria spp., and for S. japonicum, 
Oncomelania spp. (Steinmann et al., 2006). Thus, the life cycle and transmission may be 
interrupted at this point with snail control interventions. Upon reaching fresh water, the eggs 
hatch and release miracidia that swim by ciliary movement (guided by light and chemical 
stimuli) to locate and penetrate a suitable freshwater snail host. In the snail, miracidia multiply 
asexually into multicellular sporocysts and again into cercarial larvae (the free-swimming 
stage which penetrates the definitive host). The cercariae start shedding from the snail 4–6 
weeks after infection, and back into fresh water (guided by light). In humans, infection occurs 
by contact with fresh water contaminated by infective cercariae during domestic, occupational 
or recreative activities (King and Dangerfield-Cha 2008); cercariae are attracted to shadows, 
warmth and turbulence, e.g. human movement. Upon contact, cercariae penetrate the intact 
skin, and shed their fork-like tails (the heads are now called schistosomulae). Once inside the 
host, they migrate via the venous circulation, through the lungs and then the left side of the 
heart, and into the liver where they mature. Separate sexed adult worms then pair off and 
migrate via the portal vein system to the mesenteric veins of the intestines (intestinal forms), 
or the venous plexus of the bladder (S. haematobium) where sexual reproduction results in the 
female laying eggs. The eggs secrete proteolytic enzymes that enable them to migrate to 
specific sites (the bladder for S. haematobium or the intestines for other species) to be passed 
via the urine or faeces. At this point, schistosome eggs can be detected by direct microscopic 
examination of the urine or faeces. Pathology from schistosome infection results mostly from 
host immune reactions to trapped eggs attempting to migrate through to the intestinal or 
bladder lumen (Colley et al., 2014). Migration of eggs also causes epithelial damage that leads 
to detectable blood in urine and faeces. Adult schistosomes can live for as long as 30 years 
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with one schistosome pair producing up to 600 billion schistosome eggs (Basch 1991, Ross et 
al., 2002, Gryseels et al., 2006). 
 
 
Figure 1.1: Schematic diagram of the schistosome life cycle and its clinical relevance 
The figure shows the infective water (specific fresh-water snail intermediate host stage) and the human 
host stages of the life cycle. The cross signs indicate key points at which the life cycle can be interrupted 
to break the life cycle and transmission of the parasite. A, eggs of the urinary form Schistosoma 
haematobium; B and C, eggs of intestinal forms S. japonicum, and S. mansoni respectively. Image 
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1.3 Epidemiology 
1.3.1 The parasites 
As shown in Figure 1.2a, the different species of schistosomes that can infect humans have 
varying geographical distributions. Sub-Saharan Africa alone accounts for more than 90% of 
global schistosomiasis cases (Colley et al., 2014, World Health Organization 2020b). 
Schistosoma haematobium alone (which this thesis focuses on) accounts for about two-thirds 
of cases and has been reported in 54 countries. It is the most common species occurring in sub-
Saharan Africa and the Middle East (McManus et al., 2018, World Health Organization 
2020b). A recent outbreak of urogenital schistosomiasis was however reported in Corsica, 
France (Boissier et al., 2016). Schistosoma mansoni is endemic in sub-Saharan Africa, the 
Middle East, Brazil, the Caribbean islands, Puerto Rico, Suriname and Venezuela (Colley et 
al., 2014, World Health Organization 2020b). Schistosoma japonicum (zoonotic) in the past, 
was endemic in Japan (Rollinson et al., 2013), but now in China, the Philippines and Indonesia. 
With a much lower global prevalence, S. guineensis and S. intercalatum occur in Central and 
West Africa, and S. mekongi (zoonotic) occurs in the southern parts of Cambodia (Mekong 
river in Lao People’s Democratic Republic) (Colley et al., 2014, World Health Organization 
2020b). Some countries including Algeria and India have successfully reduced infection to 
very low levels, but the WHO is yet to verify whether interruption of transmission has been 
achieved (see Figure 1.2b). 
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Figure 1.2: Worldwide distribution of schistosomiasis and status of endemic countries 
a) Map of the worldwide distribution of schistosomiasis as at 2012. Source from the World Health 
Organization (WHO) online resource: http://gamapserver.who.int/mapLibrary/[Accessed 12/04/2020]. 
b) Status of schistosomiasis-endemic countries as at 2018. Source from the WHO online resource 
https://apps.who.int/neglected_diseases/ntddata/sch/sch.html [Accessed 12/04/2020]. 
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1.3.2 Schistosomiasis in preschool-aged children 
In schistosome-endemic areas, a significant amount of the exposure to infection in PSAC is 
passive, particularly in the youngest children (e.g. use of contaminated water in the home, or 
children being bathed/sitting in a dish of contaminated fresh water while the guardian conducts 
domestic chores). Exposure becomes more active as the children grow (e.g. accompanying 
carers to water sources for domestic chores) (Odogwu et al., 2006, Garba et al., 2010). 
Therefore, in infants and young children, exposure to infection is closely linked to that of the 
caregiver. This dissociates as children grow older and become more independent, frequenting 
contaminated water sources by themselves or with friends and/or older siblings. Although 
exposure may be dependent on the level of submersion and time spent in infected water, 
infection is highly likely for PSAC, due in part to lengthened play times (Mduluza and Mutapi 
2017). Evidence of exposure in PSAC as observed from field studies by our research group, 
Parasite Immuno-epidemiology Group is shown in Figure 1.3. 
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Figure 1.3: Evidence of exposure to schistosome infection in preschool-aged children (PSAC) 
Children accompany the caregiver to a water contact site, playing while she performs her daily chores. 
Source: Observations from field work conducted by our research group, Parasite Immuno-epidemiology 
Group, in schistosome-endemic communities in Zimbabwe. Credit: Prof. Mark Woolhouse. 
 
Exposure to infection is cumulative, and almost all children in high transmission areas will 
have been exposed to schistosome cercariae by age one, with infection prevalence and 
intensity increasing with age (Woolhouse et al., 2000, Wami et al., 2014). Thus, there is a need 
for inclusion of PSAC in large-scale projects mapping the distribution of schistosomiasis. This 
will inform planning for drug procurement and operational strategies for including these 
children in national control programmes. In addition to the lack of global estimates of 
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schistosome infection and disease burden in PSAC, there is a paucity of incidence data in this 
age group. The work in Chapter 3 of this thesis contributes to addressing these gaps, using a 
longitudinal study tracking the incidence of the first schistosome infection (S. haematobium) 
and associated health impacts at an early age. 
1.4 Risk factors for schistosome infection 
One outstanding feature of schistosomiasis is the focal distribution of infection prevalence and 
intensity (Gryseels et al., 2006). Several factors influence the risk for schistosome infection in 
PSAC, including those already identified for other age groups (see Figure 1.4). Environmental 
factors including higher temperature, seasonal rainfall patterns, and high altitude favour 
parasite development in the intermediate host snail as well as survival of the snail host itself, 
affecting the force of infection/transmission (Yang et al., 2009, Koukounari et al., 2011, 
McCreesh et al., 2015). Exposure patterns of the human host are also affected by climatic 
changes, e.g. hotter seasons encourage increased recreational use of infected water sources; 
this varies in both the surface area exposed as well as the duration and frequency of exposure 
(Rudge et al., 2008). 
Susceptibility/resistance to (re)infection is affected by the development of acquired immunity, 
which in turn is a function of the history of infection (Woolhouse et al., 1991). 
Epidemiological studies of both S. haematobium and S. mansoni infection, show that the 
history of antihelminthic treatment also affects the rate of development of acquired protective 
immunity (Mutapi et al., 1998, Mutapi 2001, Black et al., 2010a, Mitchell et al., 2012, Rujeni 
et al., 2013). Various social factors have an indirect impact on infection transmission, through 
activities that contaminate water sources and favour infection transmission (Yang et al., 2009, 
Ugbomoiko et al., 2010, Ayalew et al., 2011). The relative contribution of these factors in 
PSAC however remains to be determined. A schematic diagram of various risk factors that 
influence schistosome infection in PSAC is shown in Figure 1.4. 
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Figure 1.4: Risk factors for schistosome infection in preschool-aged children (PSAC) 
Sources from: 1 (Yang et al., 2009); 2 (Rudge et al., 2008, Yang et al., 2009); 3 (Kapito-Tembo et al., 
2009); 4 (Rudge et al., 2008), 5 (Rudge et al., 2008, Ugbomoiko et al., 2010); 6 (Yang et al., 2009, 
Koukounari et al., 2011); 7 (Pruss et al., 2002); 8 (Yang et al., 2009); 9 (Ugbomoiko et al., 2010); 10 
(Ayalew et al., 2011); 11 (Hall et al., 2012a). 
 
In addition to these well-studied risk factors, the scientific community is beginning to 
appreciate the role of the human gut microbiome on schistosome infection and disease (Saad 
et al., 2012, Dubourg et al., 2013, Glendinning et al., 2014). The gut microbiome plays a vital 
role in maintaining barrier integrity, and subsequently, impacts the host immune system (Klose 
and Artis 2016) and explains some of the observed differences in infection patterns across 
populations (Zupancic et al., 2012). The gut microbiome is believed to be particularly variable 
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in the early years of life (Kay et al., 2015, Rodriguez et al., 2015), and infections that PSAC 
are exposed to may influence the structure (abundance and diversity) and function of the 
microbiome. Recently, a significant difference in the microbiome structure between S. 
haematobium-infected and uninfected Zimbabwean children aged 1 to 10 years was reported 
(Kay et al., 2015). The direction of this schistosome–microbiome relationship, influence by 
other factors, and the mechanistic pathways of this effect are yet to be elucidated. Of 
importance in this age group is the impact of gut microbiome dysbiosis on nutritional status. 
Emerging ideas from initiatives such as the Human Microbiome Consortium suggest that, our 
focus on PSAC should be to understand how the microbiome functions and influences innate 
susceptibility to schistosome infection and disease progression (Arumugam et al., 2011). 
Helminths modulate host immune responses for their survival and this has a negative impact 
on the host microbiome structure and nutrition (Glendinning et al., 2014), and in turn, 
children’s risk of schistosome infection (Hall et al., 2012b). This provides an avenue for non-
invasive manipulation of the host microbiome through diet and supplementation. Further 
evidence on the systemic impacts of schistosome infection, including host–parasite 
interactions on the microbiome, metabolic and immune systems are discussed in detail in 
Section 1.6. 
At present, schistosomiasis interventions targeting the microbiome remain theoretical, as 
mechanistic studies to establish causal relationships in PSAC are lacking. In schistosome-
endemic areas, malnutrition and undernourishment are significant childhood problems, and 
studies quantifying the relationship between nutrition and the gut microbiome are needed. In 
addition, there are no studies detailing the attributable fraction of malnutrition due to 
schistosomiasis or importantly, the impact of schistosomiasis treatment on these factors. 
Findings in Chapter 3 of this thesis establish the role or relevance of anthropometric measures 
as a tool for identifying S. haematobium-related nutrition and growth disorders, and identifies 
the independent risk to nutritional disorders from S. haematobium infection in PSAC. The 
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work in Chapter 6 also characterises the gut microbiome in PSAC and relates it to  
S. haematobium infection and anthropometric measures of malnutrition and growth. 
1.5 Schistosome-specific immune responses and clinical 
relevance 
The interest in immunity in schistosome infections is two-fold. First, hosts in endemic areas 
develop protective acquired immunity against reinfection, and second, the severe and chronic 
clinical manifestations of schistosomiasis are immune-mediated. Our understanding of the 
immune responses to human schistosome infection has been largely informed by experimental 
models (Colley and Secor 2014). These have given insights into the development of 
schistosome-specific immune responses mediating resistance to reinfection and pathology, as 
well as the aetiology and clinical manifestations of morbidity and immunopathology (Colley 
and Secor 2014). However, the paradigms presented by these studies are not easy to 
extrapolate to PSAC, due to differences in the natural history of infection. For instance, while 
a single exposure to cercariae can result in infection in mouse models, human infection in 
endemic areas is more likely due to repeated exposure (Cheever et al., 2002). Immunology 
studies in animal models are also limited in their inability to recapitulate morbidity and 
pathology occurring in the natural human host. For instance, eggs implanted in mice were 
recently used to develop an experimental model for urogenital schistosomiasis pathology (Fu 
et al., 2012), but the relevance of this to the human disease forms in young children is still 
unclear. 
Human schistosome immunology is complex and is compounded by numerous heterogeneities 
across individuals. Nonetheless, some strong patterns have emerged across populations. In 
brief, schistosome-specific immune responses are mediated by humoral and cellular responses 
initiated after antigen interaction with antigen-presenting cells (APCs), e.g. dendritic cells, 
which direct T-cells towards T-helper type 1 (Th1), T-helper type 2 (Th2), or regulatory  
T-cell (Treg) phenotypes, influencing disease sequelae (Colley et al., 2014, Babu and Nutman 
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2019). Th1 immune responses are pro-inflammatory and are responsible for killing 
intracellular parasites and autoimmune responses. Th2 responses on the other hand are more 
anti-inflammatory and are capable of counteracting the pro-inflammatory effects of Th1 
responses (Berger 2000, Spellberg and Edwards 2001). Immune responses to schistosome 
infection is thus dependent on a complex balance between Th1 and Th2 responses, as well 
antibody-mediated immunity (Babu and Nutman 2019). 
1.5.1 Acute stage 
In individuals exposed to schistosomes for the first time, innate immune responses to dying or 
dead larvae after cercarial penetration of the skin, leads to hypersensitivity (commonly Arthus-
type and delayed hypersensitivity) reactions. This can cause a maculopapular pruritic reaction 
called cercarial dermatitis, at the site of penetration (McManus et al., 2018). In endemic areas 
however, the acute stage of schistosomiasis, including the symptomatic stage, Katayama fever 
(the systemic hypersensitivity response to migrating schistosomula or the start of egg 
deposition) (Ross et al., 2007), receive very little research interest or clinical intervention, 
compared to non-endemic areas (BMJ Best Practice 2016). It has been suggested that the acute 
stage of schistosomiasis is rarely observed in endemic areas due to in-utero de-sensitisation to 
schistosome antigens in infants born to infected mothers, and from repeated exposure from 
living in such areas (Ross et al., 2007, Sanin et al., 2015, McManus et al., 2018). However, 
Katayama fever is not only restricted to primary infections (Ross et al., 2007), and early 
exposure and infection at the preschool age warrant elucidating acute schistosomiasis in 
PSAC. The immune responses occurring in the early stages of infection are poorly documented 
in humans, and elucidating these events in PSAC would provide useful information on the 
nature and development of both pathological and parasite-specific protective immunity. 
During the early stages of infection, Th1 cells (CD4+ T-lymphocytes) produce tumour 
necrosis factor (TNF), interferon gamma, interleukin (IL)-1, IL-2, and IL-6. These are linked 
with a Th1 response that is crucial for a pro-inflammatory response in the acute stage (Olveda 
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et al., 2014). Immunological studies of peripheral blood mononuclear cell supernatants from 
acute schistosomiasis patients have demonstrated the production of these cytokines (de Jesus 
et al., 2002). The Th1 response is important for protection against infection, and evidence 
suggests that this response is dampened in chronic long-standing infections and reinfections 
(Babu and Nutman 2019). 
At about 6 weeks post-infection when schistosome worms mature and start producing eggs, 
Th1 responses begin to decrease, marked by the emergence of a Th2 response (Pearce and 
MacDonald 2002). One of the mechanisms includes the role of innate immune system 
components such as epithelial cells, dendritic cells, and macrophages in inducing Th2 
cytokines in helminth infection (Babu and Nutman 2019). For example, tissue destruction as 
a result of schistosome infection leads to the secretion of cytokines and alarmins from 
epithelial cells, including IL-1, IL-25, and IL-33. These act on natural helper cells (a new 
population of innate lymphocytes; see Moro et al., (2010)) to induce Th2 cytokines including 
IL-5 for eosinophilia and IL-13 for goblet cell hyperplasia, both of which are important in the 
early phase of the anti-helminth response. Cytokines IL-25 and IL-33 also induce the release 
of IL-4 from basophils and mast cells (Hammad and Lambrecht 2015, Babu and Nutman 
2019). In addition, egg deposition can also prime the shift in immune responses from Th1 to 
Th2. For example, schistosome egg antigens interact with dendritic cells, partially through the 
action of omega-1 carbohydrate epitopes, for Th2 priming (Everts et al., 2012). Overall, the 
Th2 polarisation downregulates effector functions of pro-inflammatory mediators, suppresses 
Th1 promoting cytokines, and primes the body for an established Th2 response in the chronic 
stage (Babu and Nutman 2019). 
1.5.2 Chronic stage 
When infection is left untreated, egg antigens stimulate a greater Th2 response, mediated by 
IL-10. This contributes to granulomas and fibrosis (Cheever et al., 2000), also mediated by 
IL-13 (Lee et al., 2001). Th2 cells secrete the cytokines IL-4, IL-5, IL-10 and IL-13, 
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accompanied by high production of eosinophils (stimulated by IL-5), all of which contribute 
to granuloma formation (Olveda et al., 2014). The Th2 response performs a dual function by 
promoting host survival, as well as allowing chronic infections to become established and 
persist to promote disease transmission (Brunet et al., 1997). A review of the nature of immune 
responses from experimental studies, as relates to human schistosomiasis, suggests that these 
processes occur after about 12 weeks post-infection (Pearce and MacDonald 2002, Colley and 
Secor 2014). 
Schistosomes have mechanisms for evading and modulating the immune system to promote 
their long-term survival. In vitro studies show that one main mechanism is the ability for 
schistosome worms to use their somatic stem cells to regenerate their outer tegument, and to 
incorporate host proteins into their outer surface to reduce their antigenicity and escape 
immune recognition (Collins et al., 2013). Schistosomes weaken immune attacks by 
compromising complement function, degrading immunoglobulins, or mimicking and 
neutralising host immune molecules (Colley and Secor 2014). The worms downregulate 
immune response by inducing Tregs or anti-inflammatory cytokines (IL-10 and transforming 
growth factor beta (TGF-β)). The parasites can also utilise host-released cytokines such as  
IL-5, IL-6 and IL-7 for their growth, development and migration (Maizels and Yazdanbakhsh 
2003). 
When infection remains untreated, the late chronic stages of infection, especially in the teenage 
years, is characterised by a gradual decline in the worm burden, as partial immunity begins to 
develop and worms from early infections begin to die naturally (McManus et al., 2018). The 
egg burden and associated granulomas begin to reduce, and granulomas are then replaced by 
fibrous tissue and symptoms become less severe. 
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1.5.3 Natural and drug-induced protective immunity 
Protective immune responses to schistosomes develop slowly, over about 10–15 years 
(Woolhouse et al., 1991), contributing to the distinctive age-related patterns in infection and 
immunity, where adolescents and adults are more resistant to infection, compared to PSAC 
(Mutapi et al., 1997, Woolhouse et al., 2000, Mitchell et al., 2011, Appleby et al., 2012). This 
is supported by findings from a sero-epidemiological study, which showed that the diversity 
and intensity of parasite-specific antibodies in serum increased with age and duration of 
exposure, peaking in the oldest individuals in the study who were 18 years old (Mutapi et al., 
2008). Explanations for this include the fact that the immunomodulatory mechanisms induced 
during schistosome infection, contribute to a delay in the development of protective immunity 
against schistosomes (McManus et al., 2018). In addition, the hypothesis that partial immunity 
develops in the host after worms begin to die naturally after about 3–10 years, releasing 
antigens that can cross-react with antigens of schistosome larvae and stimulate protective 
immunoglobulin (Ig)E responses, also partly explains this delay (Fitzsimmons et al., 2012). 
Modelling studies however suggest that the gradual accumulated exposure to antigens from 
other life-cycle stages over several years also contributes to this observation, without the role 
of dying worms (Mitchell et al., 2011). These explanations would imply that PSAC could not 
mount a protective immune response to schistosomiasis, but this has been shown to not be the 
case if children are treated for schistosome infection (as described below). 
One of the consequences of the previous schistosome treatment guidelines was that studies on 
the effects of PZQ were focused on those targeted by treatment, i.e. SAC and adults. Thus, the 
immunological consequences of PZQ treatment in PSAC remain poorly characterised. Studies 
in older children (7 years and above) and adults have shown that the death of adult schistosome 
worms by treatment with PZQ, enhances schistosome-specific immune responses (Mutapi et 
al., 2005, Bourke et al., 2013, Nausch et al., 2015, Schmiedel et al., 2015). This leads to  
(i) removal of the immuno-suppressive effects caused by the adult worms (Mitchell et al., 
                                                [Paediatric Schistosomiasis: Dynamics and Consequences] 
[Introduction]  19 
2012, Nausch et al., 2015, Schmiedel et al., 2015), and (ii) introducing sufficient amounts of 
parasite-specific antigens to the immune system to reach the threshold required to induce an 
immune response (Mutapi et al., 2005, Mutapi et al., 2008, Bourke et al., 2013). Modelling 
studies consistent with the field patterns of age-related immunity demonstrate that, protective 
immunity to schistosome infection is stimulated by the death of adult worms and reduced 
fecundity (Mitchell et al., 2012). Previous work conducted by our research group has 
demonstrated the effect of PZQ on enhancing schistosome-specific immune responses in 
PSAC. The results showed an increase in anti-parasite IgE titres, 6 weeks post-treatment with 
PZQ, and this was associated with resistance to reinfection (Rujeni et al., 2013). Thus, the 
immunological effects of PZQ treatment mimics and accelerates the development of naturally-
acquired immunity (Mutapi et al., 2005, Watanabe et al., 2007, Nausch et al., 2011). These 
changes are associated with reduced reinfection rates, and suggest that pre-treatment infection 
levels may affect the level of protection against reinfection post-treatment (Black et al., 2010b, 
Bourke et al., 2013).  
Evidence from experimental studies suggest that the early timing of antihelminthic treatment 
may have additional benefits beyond the transient removal of infection, and may also speed 
up the development of protective immunity more effectively than treating longer-lasting 
chronic infections (Behnke and Robinson 1985). In addition, proof-of-principle human clinical 
studies of malaria infection have already demonstrated that the approach of early infection 
treatment is successful at inducing long-lasting anti-malaria protective immunity (Roestenberg 
et al., 2009, Roestenberg et al., 2011, Bhardwaj et al., 2016). Therefore, early treatment of the 
first helminth infection may induce earlier and greater levels of protection against reinfection, 
by preferentially inducing the effector rather than regulatory responses (van Riet et al., 2007, 
de Oliveira Fraga et al., 2010a, de Oliveira Fraga et al., 2010b). The rationale behind treating 
first infections is that chronic infection induces a constant state of anti-parasite Th2 responses, 
reducing the overall effect of Th1 effector responses required to fight new infections (Malhotra 
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et al., 2015). This suggests that treatment of the first schistosome infection could have a longer 
lasting impact on reducing susceptibility to reinfection, and presents the possibility of targeting 
treatment for maximum benefit in terms of the future health of the child. A recent study showed 
that a single PZQ treatment can induce resistance to reinfection in PSAC (Wami et al., 2016), 
suggesting that if treatment of PSAC is optimally timed, then repetitive treatments may be 
reduced (de Oliveira Fraga et al., 2010a, de Oliveira Fraga et al., 2010b). 
In Chapter 4 of this thesis, evidence on the health benefits associated with treatment of both 
acute and chronic S. haematobium infections in PSAC, in terms of reinfection rates and 
subsequent new infections is discussed. 
1.6 Systemic impacts of schistosome infection and clinical 
relevance 
1.6.1 The gut microbiota in early life: diversity and disease risks 
The human gut comprises a diverse ecosystem of microbes, predominantly bacteria, in 
addition to viruses, fungi and other eukaryotes, collectively known as the microbiota. The 
assembly of genomes of the gut microbiota, their products and that of their surrounding 
intestinal environment make up the microbiome (Lukes et al., 2015). Humans rely on the 
microbiota for essential functions including extracting essential nutrients from food, as a first 
line of protection from enteric pathogens, and as a mechanism for shaping the immune system 
(Human Microbiome Project Consortium 2012). However, these core functions are not 
fulfilled by the same microbiota in all people, with some varying even within the same 
individual over the course of life (Shafquat et al., 2014). In fact, microbial colonisation of the 
gut has been hypothesised to begin in utero (Collado et al., 2016). 
In very young children, the gut microbial population continues to evolve until about age 3–5 
years, and with time, the microbiota diversity within an individual increases while that 
between individuals within the same communities decrease (Yatsunenko et al., 2012). As 
reviewed by Glendinning and colleagues, several factors influence the structure (abundance 
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and diversity) of the microbiome from birth (Glendinning et al., 2014) (see Figure 1.5). Given 
the vital role of the human gut microbiota, a window of opportunity exists, during which any 
alterations in the establishment of the microbiota in early life, either directly or through 
systemic routes, has implications on long-term health and disease (Laforest-Lapointe and 
Arrieta 2017). Evidence of the factors influencing early life microbiota and the role of 
microbiota alterations in disease risks are summarised in Figure 1.5 below. 
 
Figure 1.5: Factors influencing the child microbiota diversity, and risk of disease from microbiota 
alterations 
Sources from 1 (Dominguez-Bello et al., 2010), 2 (Yatsunenko et al., 2012, Rodriguez et al., 2015), 3 
(Fallani et al., 2010), 4 (Bartosch et al., 2004, Dethlefsen et al., 2008), 5 (De Filippo et al., 2010, Fan 
et al., 2014, Senghor et al., 2018), 6 (Goodrich et al., 2014), 7 (Martinez et al., 2015) 8 (Mishra et al., 
2014), 9 (Bisgaard et al., 2011, Abrahamsson et al., 2014), 10 (Kostic et al., 2015) 11 (Schwiertz et al., 
2010, Gevers et al., 2014), 12 (Bervoets et al., 2013, Riva et al., 2017) 13 (Hosny et al., 2017). 
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1.6.2 Helminth–microbiota interactions 
Helminths occupy different host niches for all or part of their life cycle, and play important 
roles in human health (Glendinning et al., 2014). Nematodes such as the soil-transmitted 
helminths (STH) Trichuris trichiura, (whipworm), Ascaris lumbricoides (round worm), 
Necator americanus (hookworm), and Ancylostoma duodenale (hookworm) occupy the 
human intestinal tract (Hotez et al., 2008). Schistosomes however occupy the mesenteric veins 
of the intestines (S. mansoni) and the venous plexus of the bladder (S. haematobium) (Gryseels 
et al., 2006). Enteric helminths occupying such different niches may affect the structure of 
intestinal microbial communities through multiple parallel routes, either through direct or 
systemic interactions (Brosschot and Reynolds 2018). For instance, Lactobacilli species 
capable of inducing host regulatory responses (Wells 2011), have been shown to increase 
during helminth infection in animal models (Plieskatt et al., 2013, Reynolds et al., 2014, 
Kreisinger et al., 2015). The evidence of such mutually beneficial relationships and the 
characteristic regulatory response associated with helminth infections, is demonstrated by the 
fact that Lactobacilli species can promote the persistence of helminth infection (Walk et al., 
2010, Reynolds et al., 2014). The magnitude, direction, and taxonomic specificity of such 
helminth-elicited changes in the host can vary due to factors including the helminth species 
and size, niche specificity, infection intensity, as well as baseline socio-demographic and 
physiological differences between host individuals (Brosschot and Reynolds 2018). Much of 
our understanding of the helminth interactions with the gut microbiota in humans has been 
facilitated by experimental studies, and studies from natural human infections are limited. 
Direct interactions that result in helminths modifying the gut microbiota occupying the same 
niche as they are have been shown. The excretory-secretory products of helminths have been 
demonstrated to have antimicrobial properties that can modify microbiota composition, as 
revealed by animal models of Heligmosomoides polygyrus (Hewitson et al., 2011) and 
Trichuris suis (Abner et al., 2001). In addition, changes in intestinal mucus dynamics during 
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helminth infection could favour the growth or otherwise of select microbiota species, as 
reviewed by Hooper et al., (2012). 
However, the influence of helminths on the microbiota does not necessarily occur only when 
helminths occupy the same niche as the microbiota, and indirect systemic interactions may 
occur. For example, although primarily occupies the bile ducts, the helminth Opisthorchis 
viverrini induces alterations in the gut microbiome of hamsters (Plieskatt et al., 2013).  
1.6.2.1 Schistosome–microbiota interactions 
For schistosome infections where adult worms primarily occupy blood vessels, a parallel of 
the indirect systemic interaction with the gut microbiota is likely to occur. Both experimental 
and human studies measuring host metabolites associated with the gut microbiota have 
indicated significant changes in the gut microbiota during schistosome infection (Wang et al., 
2004, Balog et al., 2011). Recently, fluctuations in the composition of the gut microbiota of 
mice infected with S. mansoni, before and after intestinal damage from egg transmission was 
shown (Jenkins et al., 2018). Furthermore, the absence of microbiota during schistosome 
infection in mice results in diminished faecal egg excretion (Holzscheiter et al., 2014). 
The factors underlying the indirect effects of schistosome infections on the microbiota are 
dependent on the Th2 immune responses elicited during helminth infections. A case of 
microbiota-dependent immune modulation includes the upregulation of the host antimicrobial 
peptide, angiogenin-4, during murine T. muris (D'Elia et al., 2009, Forman et al., 2012) and 
Nippostrongylus brasiliensis (Datta et al., 2005, Fricke et al., 2015) infection, which is 
associated with Th2 immune responses and shifts in microbiota composition. This is consistent 
with the observation that exogenous administration of IL-25, a factor for initiating Th2 
immune responses in the absence of live helminth infections (Saenz et al., 2008), replicates 
the host antimicrobial peptide expression and shifts in microbiota composition phenotype 
observed in mice infected with N. brasiliensis (Fricke et al., 2015). The increased production 
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of IL-22 during human helminth infections (Broadhurst et al., 2010) also functions as a 
cytokine mediator between the gut microbiota, the intestinal mucosa, and host immunity 
(Leung and Loke 2013). Mouse and in vitro studies have identified that this occurs by IL-22 
stimulating the production of antimicrobial peptides such as the β-defensins (Liang et al., 
2006, Wolk et al., 2006), as well as maintaining mucosal barrier homeostasis by promoting 
inflammation, tissue repair, and reduced dissemination of intestinal commensal bacteria to the 
spleen and liver (Sonnenberg et al., 2011). The overall effects of Th2 immune responses on 
increased antimicrobial peptides, IL-22, and mucus production, is in line with the need for host 
tissue repair post-infection (Sonnenberg et al., 2011, Turner et al., 2013, Peterson and Artis 
2014); IL-22 during schistosome infection has been shown to protect the host against egg-
induced fibrosis and cirrhosis in humans (Sertorio et al., 2015), and from granulomas in vitro 
(Nady et al., 2017). Furthermore, schistosome worms have direct access to host blood flow 
and nutrients, and hence utilise large amounts of host glucose (Bueding 1950). Utilizing large 
amounts of the host’s glucose compromises epithelial glucose absorption, as revealed by  
H. polygyrus murine models (Shea-Donohue et al., 2001). Thus, the reduced availability of 
intestinal nutrients to resident microbiota may be another plausible explanation for the 
significant impacts of schistosome infection on the host microbiota. 
1.6.2.2 Helminth–microbiota interactions and immune homeostasis 
Although schistosomes can directly evade and modulate the immune system (as described 
earlier in Section 1.5.2), the effects of schistosome infection on the gut microbiome can 
indirectly influence immune responses, as reviewed for helminth infections (Leung and Loke 
2013). Differences in gut microbiota composition have been associated with the differentiation 
of Tregs (Gaboriau-Routhiau et al., 2009, Atarashi et al., 2011, Atarashi et al., 2013) and 
mucosal Th17 cells (Gaboriau-Routhiau et al., 2009, Ivanov et al., 2009), as well as 
susceptibility to allergies (Reynolds and Finlay 2013) and inflammatory bowel disease (Nell 
et al., 2010). The role of increased Treg populations from gut microbiota differences, in the 
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production of helminth-associated regulatory cytokines such as IL-10, independent of Th2 
immune responses has been shown in mice (Anderson et al., 2007, Rubtsov et al., 2008); its 
role in the production of other regulatory cytokines like TGF-β has also been reviewed 
(Reynolds et al., 2012, Reynolds and Maizels 2012). These suggest that the helminth 
interactions that result in microbiota alterations can influence host immune homeostasis, and 
thus differences in infection and disease patterns. 
Furthermore, the microbial population in the intestinal tract provides colonisation resistance 
against concurrent infections, and the relationship between the microbiota and susceptibility 
or resistance to infection has been extensively reviewed (Kamada et al., 2013, Vogt et al., 
2015). A loss or increase in abundance of specific microbial taxa can contribute to 
susceptibility to infectious diseases (Kamada et al., 2013), growth and/or virulence of enteric 
pathogenic bacteria (Vogt et al., 2015), and to the observed differences in infection and disease 
patterns across human populations (Zupancic et al., 2012). 
In the case of schistosomiasis, there is an age-dependent infection pattern, with the gradual 
development of protective immune responses with age (Woolhouse 1998). Given the 
helminth-associated shifts in microbiota and immune responses described above, the time of 
helminth infection relative to the establishment of the gut microbiota in early life may be an 
important determinant of overall health outcome, especially in PSAC whose microbiota are 
still evolving. 
1.6.3 Schistosome–metabolism interactions 
Historically, schistosome worms have been thought to adapt to the definitive host’s 
environment. In addition to the ability to evade attack from the host's immune system, 
schistosome worms can exploit host endocrine, metabolite and immune factors for survival 
(Halton 1997). Like for schistosome–microbiota interactions, much of the knowledge on the 
effects of schistosome infection on host metabolism is from experimental models, and human 
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studies showing such interactions are limited. Experimental studies have shown that 
schistosome worms require host-derived endocrine steroid and thyroid hormones in order to 
establish themselves and survive (de Mendonca et al., 2000, Saule et al., 2002, You et al., 
2015). Without such host factors available to schistosome worms, there are parasite-specific 
morphological abnormalities including poor growth and reduced fecundity, as well as 
attenuated granuloma formation in host liver (Cheng et al., 2008, Lamb et al., 2010, Tang et 
al., 2013). The findings from the studies described above suggest evidence of the direct host–
parasite interactions that lead to schistosome worms manipulating the host metabolism. 
Schistosome worms reside directly in blood vessels close to the intestine or urinary bladder, 
with direct access to the flow of nutrients. Experimental studies demonstrate that schistosome 
worms import glucose across their body surface and through the gut (Wu et al., 2010b), 
consuming their dry body weight’s worth of glucose every 5–6 hours (Bueding 1950). In 
addition, the liver injury caused by schistosomes during murine infection (Wu et al., 2010b) 
is marked by stimulated host glycolysis, manifested by reduced plasma glucose as well as 
reduced glucose and glycogen stores in the liver (Wang et al., 2004). This is supported by 
studies in S. japonicum-infected mice, indicating the high expression of genes involved in 
catabolism (glucose uptake, glycolysis and fatty acid oxidation), and the suppression of genes 
involved in anabolism (glycogen synthesis) in the liver (Xu et al., 2019). Schistosome worms 
have long been known to also lack the ability to synthesize de novo sterols, fatty acids and 
purines, which they require for growth and development (Levy and Read 1975a). The in vitro 
evidence available suggests that the worms resort to the uptake of host purine (Levy and Read 
1975b) and lipid molecules (Meyer et al., 1970). 
The Th2 immune responses elicited during schistosome infection can also alter host metabolic 
function, disease patterns, and overall health (Brestoff and Artis 2015). Studies show that the 
prolonged production of cytokines IL-10, IL-4, and interferon-gamma are associated with a 
reduced likelihood of type 1 diabetes in mice (Zaccone et al., 2003). Some of the mechanisms 
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observed from experimental studies include the ability of helminth-induced adipose tissue 
eosinophilia to enhance glucose tolerance and alleviate insulin resistance (Wu et al., 2011). 
Taken together, the evidence from experimental (Zaccone et al., 2003, Stanley et al., 2009, 
Wu et al., 2010b) and limited human studies (Chen et al., 2013, Wolde et al., 2019) suggest 
that, chronic helminth infection and its impact on reduced host glucose and lipids may have 
the potential to prevent or delay the occurrence of the metabolic syndrome and related 
dysfunctions (van der Zande et al., 2019, Wolde et al., 2019). 
There is also current evidence as reviewed by Rowland et al., (2018), that the gut microbiota 
produce and utilize gut metabolites, and have profound effects on regulating host metabolism. 
Therefore, the overall parasite-elicited metabolic alterations can be thought of as the combined 
result of altered host, microbiota, and helminth production of metabolites, as well as altered 
host utilization, excretion, and absorption of metabolites. 
1.6.4 Impact of host–parasite interactions on host nutrition 
Given the vital role of the microbiome and metabolism on host nutrition and overall health, 
the systemic schistosome–microbiota–metabolism interactions may thus play a role in the 
aetiology of childhood malnutrition (Kane et al., 2015). 
The direct alteration of host metabolism, uptake of essential nutrients and metabolites by 
schistosome worms, and the increased energy demands on the host (as outlined in Section 
1.6.3), contribute to reduced nutrient availability, and subsequently the malnutrition and 
growth-related sequelae observed in children with schistosomiasis (Freer et al., 2018). The gut 
microbiota produce and utilize gut metabolites (Rowland et al., 2018). In addition, host 
enzymes alone are incapable of breaking down many complex carbohydrates (Flint et al., 
2012). Thus, the helminth-induced changes to the microbiota may alter the extent to which the 
host receives nutrition. The evidence available for this however suggests that these effects may 
depend on the physiological state of the host and will vary across gut microbiota species. For 
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instance, experimental studies have shown that infection with Trichuris species is associated 
with reduced carbohydrate metabolism, which coincided with significant declines in 
abundance of Ruminoccocus, Prevotella, Roseburia, and Parabacteroides, all of which are 
carbohydrate-utilizing bacteria (Li et al., 2012, Lee et al., 2014, Ramanan et al., 2016). 
Microbiome dysbiosis during helminth infection is also accompanied by a decrease in 
breakdown products of dietary plant-derived carbohydrates and intermediates involved in the 
synthesis of amino acids, and a reduction in the detection of breakdown products of haem, 
leading to weight loss in mice (Houlden et al., 2015). 
These findings point to the contribution of such helminth-induced mechanisms to the observed 
malnutrition and weight loss associated with schistosome infection (Stephenson 1993, 
Stephenson et al., 2000, Bustinduy et al., 2013, Freer et al., 2018). However, a vast majority 
of the evidence available for host-helminth interactions are from animal studies, while there 
are limited human studies on the impact of schistosome infection on host microbiome and 
metabolism. In particular, the events that occur during early life in PSAC, including infections, 
have implications on health and disease later in life. Better strategies for schistosome control, 
including vaccines, will rely on a better understanding of how schistosomes utilize essential 
host nutrients and molecules for their survival. Further research into the systemic impacts of 
schistosome infections, especially on the human host microbiome and metabolism, should 
present opportunities to develop simple non-invasive nutritional interventions targeted at 
populations at risk of infection. For example, if schistosome infection in PSAC is associated 
with metabolic and microbiota alterations that are associated with malnourishment and altered 
immunity, then supplementation would be a useful complementary therapeutic tool to 
accompany standard PZQ treatment, particularly in PSAC. There is already a global vitamin 
A supplementation programme for PSAC in tropical countries (World Health Organization 
1997), and increasing research in nutraceuticals should inform additional child 
supplementation programmes in affected countries. Work from Chapters 5 and 6 in this thesis 
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characterises the association of S. haematobium infection with alterations in host metabolism 
and gut microbiota composition respectively. It further discusses how such changes are related 
to disease burden, and the schistosome-associated morbidity observed in PSAC.  
1.7 Pathology and morbidity 
Schistosome pathology and morbidity are still being defined in older children and adults. For 
example, urinary schistosomiasis was recently renamed urogenital schistosomiasis to reflect 
the increasing recognition of the genital manifestations of S. haematobium-related disease 
(World Health Organization 2009). Pathology and morbidity remain poorly described and 
studied in PSAC, compared to SAC (Odogwu et al., 2006). However, studies are beginning to 
shed light on schistosome morbidity in this age group. For instance, a recent study using 
ultrasound has contributed to describing schistosome-associated urinary morbidity, including 
bladder wall thickening and hydronephrosis in PSAC (Barda et al., 2017). 
In PSAC in endemic areas, clinical symptoms upon schistosome exposure and infection (e.g. 
cercarial dermatitis and fever) may go unrecognised (Lambertucci 1993, Bottieau et al., 2006, 
Gryseels et al., 2006), or be mistaken for other febrile illnesses such as malaria, which present 
with similar symptoms. In the established and chronic stages of the disease, organ-specific 
morbidity can develop and this is determined by the type of schistosome species involved 
(intestinal or urogenital) (King and Dangerfield-Cha 2008). This is mostly caused by host 
immune reactions to trapped or accumulated parasite eggs in tissues, the development of 
granuloma and fibrosis, as well as migration of parasite eggs through tissues and into the 
intestinal or urinary bladder lumen (Pearce and MacDonald 2002, van Riet et al., 2007, 
McManus et al., 2018). Migrating eggs secrete proteolytic enzymes, which stimulate 
inflammatory and granulomatous reactions at specific sites (Cheever et al., 2000), and is often 
accompanied by sloughing, ulceration and bleeding at specific sites. Disease manifestation is 
however influenced by factors including the nature and magnitude of immune responses 
(Pearce and MacDonald 2002). Variation in host genetics (Isnard et al., 2011), infection 
[Paediatric Schistosomiasis: Dynamics and Consequences] 
30  [Introduction] 
intensity and egg-patency (Stothard et al., 2011, Colley et al., 2014) and in utero sensitization 
to schistosome antigens (Maizels et al., 2014) give rise to heterogeneities in schistosome 
morbidity/pathology. Further studies elucidating the relative impact of these factors will be 
important to inform complementary interventions on reducing schistosome-related morbidity 
in PSAC. Morbidity associated with schistosomiasis in PSAC is summarised in Table 1.1. As 
this thesis focuses on paediatric schistosomiasis, morbidity described here was limited to this 
age group. A detailed review of morbidity from schistosomiasis from birth to adulthood can 
be found in Freer et al., (2018). 
Table 1.1: Morbidity associated with schistosomiasis in preschool-aged children (PSAC) 
Urinary  Intestinal Generalized pathology 
(S. haematobium) (S. mansoni, S. japonicum)  
Dysuria Pseudopolyposis Anaemia 
Pollakisuria Microulcerations Malnutrition 
Proteinuria Superficial bleeding Stunting 
Ulceration and pseudopolyposis of 
vesical and ureteral walls 
Hepatosplenomegaly Fatigue 
Fibrosis of the bladder and lower 
ureters 
Fibrosis Poor cognition 
Hydroureter and hydronephrosis   
Genital lesions   
Sources: (Cheever et al., 1978, Gryseels and Polderman 1987, Gryseels 1992, Poggensee and Feldmeier 
2001, Gryseels et al., 2006, King and Dangerfield-Cha 2008, Colley et al., 2014). 
 
Schistosome infections damage epithelial barriers, and chronic infection results in anaemia, 
poor nutrition and growth (Bustinduy et al., 2013, Okafor-Elenwo and Elenwo 2014, Guerrant 
et al., 2016). Thus, even with the low parasite burdens in PSAC, the pro-inflammatory 
response generated can quickly lead to chronic morbidity (Leenstra et al., 2006). For example, 
schistosome-associated anaemia and malnutrition in older Kenyan children (5–18 years old) 
was attributed to pathology beginning at the preschool age (Bustinduy et al., 2013). The 
nutritional effects of schistosome infection could also be attributed to microbiome dysbiosis 
and alterations in host metabolism as described in Section 1.6.4. Such growth-related 
morbidities can be accompanied with poor cognition, which is usually seen in the school-going 
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years (Colley et al., 2014). Thus, the impact of schistosomiasis in PSAC should be an integral 
part of interventions targeted at improving early child health and development. 
It is also possible that schistosome infections have wider impacts on childhood health. In 
PSAC, chronic prenatal exposure or sensitisation to helminth infection is reported to be 
associated with reduced efficacy of childhood vaccines, through induction of a persistent Th2 
immune response phenotype (Chen et al., 2012, Gebreegziabiher et al., 2014). Chronic 
exposure is also thought to be associated with environmental enteropathy, which affects the 
efficacy of vaccines at infancy (Levine 2010). Reduced vaccine efficacy will mean 
susceptibility to infection and disease from many vaccine-preventable infections. Thus, 
controlling schistosomiasis in PSAC may have the added health benefit of improving vaccine 
efficacy, and as such requires appropriate studies to investigate and provide the scientific 
evidence required to promote policy change. 
Poor awareness, recognition, and lack of understanding and quantification of schistosome-
associated morbidity had previously made schistosome control in PSAC a lower priority than 
in older children and adults. Concerted efforts are now beginning to correct this. There is a 
need for biomarkers of environmental enteropathy in PSAC (Guerrant et al., 2016), 
mechanistic studies to infer causality, and well-defined predictors of growth and nutrition in 
PSAC exposed to schistosomiasis. The work presented in Chapter 3 of this thesis also focuses 
on the incidence of schistosome-related morbidity from the first schistosome infection, as well 
as how quickly this presents and can be detected post-infection, using currently available tools. 
1.8 Paediatric schistosomiasis in coinfected hosts 
Similar to all other age groups in tropical regions, PSAC in schistosome-endemic areas are at 
risk of coinfections and therefore, comorbidities, some of which may arise later in life. For 
instance, urogenital lesions from S. haematobium infection may remain until puberty 
(Subramanian et al., 1999), and a compromised urogenital epithelium has been associated with 
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an increased risk of HIV infection (Kjetland et al., 2005, Wall et al., 2018). Studies in older 
children (5–18 years) indicate that the presence of multiple parasitic infections in endemic 
areas lead to significant morbidity, including anaemia and malnutrition, and these are 
important in the formative years of PSAC (Bustinduy et al., 2013). Specific coinfection studies 
include malaria–schistosomiasis, where studies in SAC suggest that malaria severity is 
compounded by schistosome infection, and that malaria treatment is more effective when 
schistosome infection is treated (Mbah et al., 2014, Getie et al., 2015). However, no detailed 
studies have been conducted to determine the fraction of malaria deaths in PSAC that are 
attributable to schistosome coinfection. In another instance, in vitro studies have shown that 
Salmonella can evade optimal antibiotic treatment by binding to schistosomes using fimbral 
proteins (FimH) present on its surface. This can result in significant increases in the 
Salmonella population, and eventually, antimicrobial resistance from repetitive ineffective 
therapy (Barnhill et al., 2011). Conversely, this interaction can complicate schistosomiasis 
treatment, as effective therapy could result in the release of Salmonella, thereby causing 
septicaemia (Gendrel et al., 1994). Such findings need validation in PSAC to allow the 
implementation of appropriate interventions. The significance of such indirect interactions 
between schistosomes (S. haematobium), intestinal bacteria (microbiota) and antimicrobial 
resistance gene abundance and diversity is also discussed in Chapter 6 of this thesis. 
Considering that schistosome infections induce an immune response, the timing and type of 
response (i.e. Th1 or Th2) induced may exacerbate or lessen the impact of other infections. 
For example, chronic sensitisation or exposure to schistosome infection in utero 
(predominantly involving Th2 immune responses) is associated with reduced vaccine efficacy 
at birth (as this depends on Th1 immune responses), and thus susceptibility to vaccine-
preventable infections (Elias et al., 2005, Chen et al., 2012, Gebreegziabiher et al., 2014). 
Schistosoma haematobium infection has been shown to reduce the level of protective IgG 
responses to malaria vaccine candidates including the merozoite surface protein and 
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glutamate-rich protein in humans (Courtin et al., 2011). Equally, synergistic responses against 
schistosome infections are known to cross-protect individuals from infection by other 
pathogens such as T. muris (Pearce and MacDonald 2002), and protect against higher 
Plasmodium falciparum densities (Briand et al., 2005). There is contrasting evidence showing 
no independent association between schistosome infection or PZQ treatment during pregnancy 
and vaccine efficacy or immune response to vaccines in infancy (Webb et al., 2011, Malhotra 
et al., 2015). However, some of the studies on schistosome–vaccine interactions are limited 
by methodological problems including study design and sample size (Gebreegziabiher et al., 
2014), and the use of diagnostic methods such as serology, which can detect past infections 
that may have no effect on in utero exposure (Malhotra et al., 2015). However, such findings 
are important in the formative years of PSAC. Elucidating the susceptibility or otherwise of 
PSAC to coinfections in schistosome-endemic areas, and their impact on disease sequelae and 
relevance to integrated healthcare will be of interest. 
1.9 Diagnosis of infection 
The current guidelines for the treatment of schistosomiasis in PSAC is that diagnosis is made 
before treatment, unlike the MDA approach where SAC are treated without diagnosis (World 
Health Organization 2011, Bustinduy et al., 2016a). This means that in the “diagnose and 
treat” model where treatment of PSAC will be on a case-by-case basis through regular health 
services, accurate point-of-care (POC) diagnostics are key to guide the targeted treatment. In 
addition, diagnosis must be sensitive and specific in relation to prevalence and intensity of 
infection in PSAC (Inwig et al., 2002, Raslich et al., 2007). 
1.9.1 Parasitological techniques 
The direct parasitological methods, Kato–Katz (Katz et al., 1972) and urine filtration (Mott et 
al., 1982) for intestinal and urogenital schistosomiasis respectively, are the conventional 
diagnostic methods recommended by the WHO (World Health Organization 2020b). These 
involve the microscopic detection of parasite eggs in stool or urine samples, and are 
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convenient, specific, rapid, cheap, and suitable for field applications in PSAC (De Vlas et al., 
1997, Yu et al., 2007). Details of these methods as used in the diagnosis of schistosome 
infection in this thesis are described in Chapter 2. 
Infection intensity increases with age (Woolhouse et al., 2000, Mitchell et al., 2011, Appleby 
et al., 2012, Wami et al., 2014), hence PSAC usually present with low infection burden, while 
some may carry only single-sex infections (Stothard et al., 2011, Colley et al., 2014). 
Parasitological methods therefore have reduced sensitivity in PSAC and lack the ability to 
detect pre-patent infections (Bergquist et al., 2009, Coulibaly et al., 2013, Wami et al., 2014, 
Utzinger et al., 2015). Light infections in PSAC may be missed by parasitological techniques, 
thus underestimating the prevalence of schistosome infection (Le and Hsieh 2017). 
Nonetheless, in addition to the already known limitations of low sensitivity of the 
parasitological methods, these methods have the added operational challenge of obtaining 
adequate urine and stool samples from PSAC (Stothard 2009). Particularly, egg excretion may 
show daily, diurnal and within-specimen variation, as well as clumping of eggs in stool, all of 
which reduce precision and sensitivity (Doehring et al., 1983, Engels et al., 1996, Utzinger et 
al., 2001). To improve sensitivity, it is recommended to collect replicate samples over 
consecutive days (Engels et al., 1996), but this can be a challenge in very young children. 
1.9.2 Other methods for infection and disease diagnosis 
To address the issues of sensitivity, other methods have been developed in the laboratory, and 
are at different stages of translation into field tools. Immunological tests that employ the 
detection of antibodies and cytokines, including immunoglobulins (Beck et al., 2008), TNF, 
interferons, and interleukins (Pearce and MacDonald 2002, Colley and Secor 2014) are more 
sensitive and can be used in areas with low egg burden (Gonçalves et al., 2006). For instance, 
immunological detection of schistosome-specific IgM antibodies in sera has been shown to be 
more sensitive in diagnosing infection in PSAC than parasitological methods (Wami et al., 
                                                [Paediatric Schistosomiasis: Dynamics and Consequences] 
[Introduction]  35 
2014). Issues of cost, cross-reactivity and blood sampling of PSAC however pose challenges 
(Kanamura et al., 1998, Oliveira et al., 2005). Nonetheless, such tests can be very useful in 
travellers, and in PSAC and older people with little or no egg excretion (Whitty et al., 2000). 
It can also aid in understanding evidence of exposure, susceptibility, and immune mechanisms 
during schistosome infection. 
Circulating anodic antigen (CAA) (Feldmeier et al., 1986, Gundersen et al., 1992) and 
circulating cathodic antigen (CCA) (Coulibaly et al., 2013), are waste products that are 
released when schistosomes feed on red blood cells (Deelder et al., 1980). The non-invasive 
detection of these worm antigens in urine as point-of-care (POC)–CCA and CAA tests have 
also been evaluated in PSAC. They have shown to be a reliable tool in diagnosing  
S. mansoni (Coulibaly et al., 2013, Ochodo et al., 2015), but less so in S. haematobium 
diagnosis (Ashton et al., 2011, Sousa et al., 2019). Models using data in older children have 
shown that in endemic areas, POC–CCA is a better predictor of infection prevalence than egg-
based techniques, especially for post-treatment monitoring (Prada et al., 2018). The enhanced 
sensitivity of such diagnostics (Kittur et al., 2016) and the logistic advantage of its use on urine 
instead of more cumbersome samples like stool or blood (Utzinger et al., 2015) will make it a 
useful tool in PSAC, given that this age group usually presents with low intensity infections 
(Stothard et al., 2011, Colley et al., 2014). Issues of cost in low-resource settings, as well as 
limited applicability in low endemicity areas where individuals may have very few worms, 
would however need to be overcome (Kanamura et al., 2002, McManus et al., 2018). 
Increasing sample volumes for testing has been suggested as a potential to overcome 
sensitivity issues, especially with developing accurate POC–CAA for S. haematobium 
diagnosis (Knopp et al., 2015). 
The advent of molecular techniques such as polymerase chain reaction (PCR)-based 
techniques, holds promise of additional diagnostic tools in PSAC (Oliveira et al., 2010, He et 
al., 2016). Compared to CCA and parasitology, PCR was most effective in detecting low 
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intensity S. mansoni and S. haematobium infections (Ibironke et al., 2012, Lodh et al., 2013). 
The use of cell-free parasite DNA present in urine and saliva (Kato-Hayashi et al., 2013) in 
PCR techniques can ease sampling difficulties in PSAC and detect early infections (Kato-
Hayashi et al., 2010). MicroRNAs have been characterised in animal models of S. japonicum 
(Cheng et al., 2013) and S. mansoni (Hoy et al., 2014). Despite conflicting reports on the utility 
of miR-223 as a biomarker for helminth infections (He et al., 2013, Hoy et al., 2014), 
microRNAs have great diagnostic potential in PSAC and should be explored further. The 
drawback of molecular diagnosis is that in the absence of POC versions of these tests, expertise 
and specialised equipment are required (Pontes et al., 2003), and this poses a challenge in 
resource-poor settings. 
Point-of-care ultrasonography (POCUS) is becoming a popular tool for indirect diagnosis in 
large-scale trials for schistosomiasis control, to assess organ-specific pathology associated 
with schistosomiasis (Richter et al., 2000, Akpata et al., 2015). As applied for S. mekongi in 
Cambodia, the effect of schistosomiasis interventions on morbidity can be monitored using 
this method (Chigusa et al., 2006). Available evidence and experiences of POCUS for 
detecting schistosome-associated morbidity has been thoroughly reviewed; a simplified WHO 
protocol to reduce turnaround time and increase its field applicability has been recommended 
(Bélard et al., 2016). 
1.9.3 Operational need for better diagnostics in preschool-aged 
children 
Following current WHO guidelines for PSAC, diagnosis is required before treatment, i.e. a 
“diagnose and treat” strategy, and not PC (World Health Organization 2011, Bustinduy et al., 
2016a). Missing an infection due to insensitive diagnostics will mean missed treatments, and 
this can have a significant impact on the health of the child, particularly in light of the 
knowledge that most schistosome infections lead to clinical symptoms and substantial 
morbidity (Sacko et al., 2011, King 2015). Moreover, untreated PSAC may act as reservoirs 
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for transmission and infection, consequently hampering elimination efforts. With PSAC 
presenting with light and/or pre-patent infections, the sensitivity of conventional methods is 
reduced and infections may be missed (Bergquist et al., 2009, Coulibaly et al., 2013, Wami et 
al., 2014, Utzinger et al., 2015). Thus, the applicability of current conventional methods as 
used in SAC and adults in endemic areas may not be the most appropriate in this context. 
Realistically looking ahead to primary health care for infants and young children in helminth-
endemic areas, more useful diagnostics will be POC tests that integrate diagnosis of several 
conditions/comorbidities, e.g. schistosomiasis, malaria, anaemia. 
1.10 Morbidity markers for schistosomiasis 
The majority of morbidity biomarkers associated with schistosomiasis are non-specific, 
relating to physiological, biochemical and immunological changes. As such, their 
interpretation in the light of coinfections and comorbidities in endemic areas is complex, and 
calls for better defined schistosome morbidity indicators in PSAC (Webster et al., 2009). 
Operationally useful morbidity markers should: (i) provide more information than that 
obtained from parasitological detection of infection (Vennervald et al., 2000), (ii) be 
measurable in one sample and at any time (Vennervald et al., 2000), (iii) detect early degrees 
of morbidity (Hatz et al., 1992), and (iv) predict development of severe disease (Vennervald 
et al., 1998). 
The classic urinary markers, haematuria and proteinuria (excretion of blood and protein in 
urine respectively), occur as a result of epithelial damage during the passage of eggs in the 
urogenital tract during S. haematobium infection, and are useful morbidity markers in SAC 
and in adults (Wilkins et al., 1979, Feldmeier et al., 1982, Mott et al., 1983, Sousa-Figueiredo 
et al., 2009, Webster et al., 2009, King and Bertsch 2013, Ismail et al., 2014, Ochodo et al., 
2015). They can be evaluated using inexpensive urine dipstick methods (microhaematuria) as 
well as visual colorimetry (visible haematuria) (Lengeler et al., 2002, Bocanegra et al., 2015). 
Their significance as POC field markers has been demonstrated in PSAC in Nigeria (Salawu 
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and Odaibo 2014) and Zimbabwe (Wami et al., 2015). This is particularly useful as haematuria 
strongly correlates with infection intensity (Ismail et al., 2014, Ochodo et al., 2015) and has 
proven to be useful during post-treatment monitoring surveys, as morbidity reverses with 
treatment (King and Bertsch 2013). In addition, studies have shown that even in populations 
with the same infection intensity, the sensitivity and utility of microhaematuria decreases with 
age (Nduka et al., 1995, Akogun and Obidiah 1996, Mafe 1997, Etard 2004a). Hence, 
microhaematuria is more likely to perform better as a morbidity marker in PSAC. A high urine 
albumin–creatinine ratio (UACR) translates to impaired kidney function due to increased 
albuminuria and decreased creatinine clearance (Snyder and Pendergraph 2005). UACR 
correlates with patent S. haematobium infections and urinary tract pathology in SAC 
(Rollinson et al., 2005, Stothard et al., 2009). In a recent study evaluating field markers of S. 
haematobium-related morbidity in Zimbabwean PSAC, UACR was found to be most reliable, 
and correlated with haematuria and proteinuria (Wami et al., 2015). This suggests the 
significance of multiple field tools as morbidity indicators in PSAC, especially for S. 
haematobium. 
Detection of soluble Schistosoma egg antigens and eosinophil cationic proteins (Kahama et 
al., 1999, Reimert et al., 2000) are more sensitive than indirect measures of morbidity (e.g. 
egg counts), as they detect early inflammatory reactions from S. haematobium infections in 
the urogenital tract (Reimert et al., 1993). Thus, they can be useful field indictors of 
schistosome infection and morbidity, as seen in SAC (Reimert et al., 2000). However, since 
disease sequelae may vary even in individuals with the same infection intensity (as detected 
by egg counts), elucidating their applicability in PSAC will be useful. 
Faecal occult blood (FOB), the presence of cryptic blood in stool, results when S. mansoni 
eggs perforate the intestinal mucosa and cause a small release of blood into the bowel (Proietti 
and Antunes 1989, Betson et al., 2010). Calprotectin, a multimeric complex of calcium-
binding proteins MRP8/S100A8 and MRP14/S100A9, is secreted into the gut lumen when 
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calprotectin-containing granulocytes relocate into the intestinal mucosa in response to 
inflammation caused by schistosome eggs perforating the intestinal lining (Foell et al., 2009). 
In this regard, the utility of FOB and calprotectin have been evaluated as morbidity indicators 
of intestinal schistosomiasis in PSAC in Uganda (Betson et al., 2010, Betson et al., 2012). In 
the aforementioned studies, FOB and calprotectin correlated positively with S. mansoni 
infection pre- and post-treatment. 
Currently, there is a need to understand comorbidities due to different infections in PSAC, and 
how morbidity markers can be used to detect and determine the impact of schistosomiasis 
(Ouma et al., 2001). The challenge with non-specific markers of morbidity is to determine 
how schistosomiasis influences them. However, this is a difficult task because even 
determining the fraction of morbidity attributable to schistosome infection does not indicate 
causation. Equally important is the lack of specific information on what they mean in terms of 
the child’s overall current and future health. There is a need for a knowledge base addressing 
these two issues, if these morbidity markers are to form part of the diagnostic tool kit to inform 
the “diagnose and treat” approach for PSAC. The work presented in Chapter 3 further reports 
findings on S. haematobium-related morbidity using morbidity markers including 
microhaematuria and malnutrition, and their corresponding morbidity attributable fractions to 
schistosome infection in PSAC. 
1.11 Schistosome treatment in preschool-aged children 
Praziquantel, discovered in 1979 (McMahon and Kolstrup 1979), is the antihelminthic drug of 
choice for treating schistosomiasis (World Health Organization 2020b). It comes in a 600 or 
500 mg tablet used at a recommended dose of 40 or 60 mg/kg body weight. The lower dose is 
recommended for S. haematobium and S. mansoni infections while the higher dose (in two 30 
mg/kg administrations) is recommended for S. japonicum and S. mekongi infections (WHO 
Expert Committee 2002). The safety and efficacy of PZQ, as measured by cure rate (CR) and 
egg reduction rate (ERR) has enabled its widespread use for schistosomiasis treatment. A 
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meta-analysis of studies showed that CR of between 63.5%–94.7% and ERR of 86.3%–95% 
for individual and mixed species infections, can be achieved with the recommended dose 
(Zwang and Olliaro 2014). Global and community-based schistosomiasis control programmes 
use PZQ through MDA for treatment, with an initial focus on morbidity reduction (World 
Health Organization 2020b). In resource-poor settings, a height–dose pole is used as a 
surrogate to weight scales for operational purposes (Hall et al., 1999). Modifications have now 
been made to extend the original dose pole used for SAC and adults, to include height ranges 
for treatment of PSAC (Sousa-Figueiredo et al., 2010, Sousa-Figueiredo et al., 2012). 
The current WHO recommended control strategy of PC with PZQ does not target PSAC 
(WHO Expert Committee 2002). It is recommended to treat PSAC with PZQ on a case-by-
case basis, administered as crushed tablets with juice or bread (World Health Organization 
2011, Bustinduy et al., 2016a). This is due to the absence of a suitable paediatric formulation 
of PZQ for inclusion in MDA, as well as concerns over dosage and safety (Bustinduy et al., 
2016b); the drug was formally licensed for 4-year olds and above (Colley et al., 2014, Bayer 
and Merck & Co 2020). There is increasing literature that the currently available PZQ is safe 
and efficacious in PSAC (Mutapi et al., 2011, Coulibaly et al., 2017, Montresor and Garba 
2017, Coulibaly et al., 2018). Recent randomised dose-ranging trials showed that a single 40 
mg/kg dose of PZQ is effective for schistosomiasis treatment in PSAC (Coulibaly et al., 2017, 
Coulibaly et al., 2018). As described in previous sections of this chapter, a challenge to 
effective treatment in PSAC is the need for improved diagnostics. Other challenges that remain 
unique to PSAC include a drug that is more child-friendly, increased availability of treatment 
for PSAC in endemic areas, how to access PSAC for treatment, as well the ability to integrate 
treatment of PSAC into existing health systems (Stothard et al., 2013, Bustinduy et al., 2016a). 
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1.11.1 Praziquantel in preschool-aged children 
Although PZQ is confirmed safe and efficacious, there is little information on its 
pharmacokinetics in PSAC (Cioli et al., 2014, Olliaro et al., 2014), and this is compounded 
by variable bioavailability, influenced by brand or co-administration with food (Mandour et 
al., 1990, Dayan 2003). There is still a lack of knowledge surrounding PZQ’s mechanism 
of action against schistosome adult worms. The mechanism of PZQ action thus far 
described, is that the drug affects parasite glutathione reductase and intracellular calcium 
levels, with secondary effects on parasite metabolism. The parasites die following disruption 
of calcium ion homeostasis, paralytic muscular contraction, and tegumental damage. This 
exposes the parasite antigens on the surface of the worm to attack by the immune system. The 
worms are then displaced from their site of action into systemic circulation or destroyed 
through phagocytosis (Dollery 1999, Doenhoff et al., 2008, Thomas and Timson 2018). PZQ 
however lacks efficacy against immature juvenile schistosomes (Gönnert and Andrews 1977), 
which later mature, pair up and begin to deposit eggs; this contributes to the observed low cure 
rates and morbidity associated with the disease in certain instances (Ross et al., 2015). 
In humans, PZQ is nearly completely absorbed by passive diffusion after oral administration 
(Dinora et al., 2005), with peak serum levels in 3–4 hours (Dayan 2003) and a half-life of 1.5 
hours (Dollery 1999). Administration of PZQ with a carbohydrate meal enhances absorption 
and bioavailability of PZQ, including in PSAC (Mandour et al., 1990, Castro et al., 2000, 
Castro et al., 2002). PSAC tolerate PZQ well with few reports of adverse effects, normally 
abdominal pain, vomiting, fatigue, and diarrhoea that resolve within 24 hours (Sousa-
Figueiredo et al., 2010, Mutapi et al., 2011, Namwanje et al., 2011, Coulibaly et al., 2017, 
Coulibaly et al., 2018). Contrary to suggestions of a higher efficacy dose in PSAC (i.e. >40 
mg/kg) (Olliaro et al., 2011), recent studies have reported on the efficacy and safety of 
escalating doses of PZQ in PSAC (i.e. 20 mg/kg, 40 mg/kg and 60 mg/kg) (Coulibaly et al., 
2017, Coulibaly et al., 2018). PZQ showed a flat dose-dependent efficacy in PSAC, with the 
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maximum effect observed at the 40mg/kg dose; the same dose presently used (40 mg/kg) in 
SAC and adults therefore remains the best option in PSAC (Montresor and Garba 2017). 
There are also limited human studies on the efficacy of PZQ administered along with other 
drugs or food. In PSAC living in helminth-endemic areas, PZQ is commonly administered 
with the antihelminthic drug albendazole as a deworming package, per WHO 
recommendations (World Health Organization 2006). A study published in 2011, reported that 
administering PZQ along with albendazole results in a greater combined effect of PZQ action, 
than PZQ alone (Lima et al., 2011). Elucidating the effects PZQ may also have on the total 
exposure of albendazole when co-administered will be important to improve therapeutic 
strategies (Pawluk et al., 2015). A recent study suggests that crushing of tablets and 
administration with food and drinks in PSAC also leads to pharmacokinetic differences when 
compared to adults (Bustinduy et al., 2016b). Further studies elucidating the mechanisms 
behind such effects in PSAC will improve therapeutic efficacy. 
As shown in experimental studies, PZQ is metabolised by the cytochrome P450 enzymes 
(Masimirembwa and Hasler 1994, Li et al., 2003b). Thus, the growing evidence of genetic 
diversity for cytochrome P450 variants in schistosome-endemic regions in Africa (Rajman et 
al., 2017) has implications for PZQ metabolism and treatment efficacy. With regards to PZQ 
metabolism and efficacy, PSAC should therefore be considered as a separate entity, especially 
in studies on treatment strategies and in the development of a paediatric PZQ formulation. This 
is because genetic variations, especially across African populations can influence the 
pharmacological effect of PZQ, and these must be taken into account (Buzkova et al., 2006). 
For instance, investigations into cases of PZQ resistance as observed in experimental and field 
studies, indicate that parasite sensitivity accounts for a limited proportion of reduced PZQ 
efficacy, and thus such inherent population characteristics are important (Cupit and 
Cunningham 2015, Vale et al., 2017). 
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1.11.2 Need for a paediatric praziquantel formulation 
The WHO has recognised that PSAC in schistosome-endemic areas are at a high risk for 
infection, and that schistosomiasis presents a significant public health problem in this age 
group. It is recommended that treatment with the current PZQ tablets be administered through 
regular health services on a case-by-case basis, in the absence of an appropriate paediatric 
formulation (World Health Organization 2011). Despite the availability of a PZQ syrup that is 
equally efficient (Navaratnam et al., 2012), limited availability, limited field utility, and high 
cost makes its use a challenge (World Health Organization 2011). Operationally, the large size 
and bitter taste of the existing PZQ tablet are associated with administration and compliance 
difficulties in PSAC (Stothard et al., 2008, Sousa-Figueiredo et al., 2010). The current tablet 
has to be broken into smaller pieces to obtain appropriate paediatric doses (based on weight), 
and is often crushed and administered with fruit juice or bread to make it palatable (World 
Health Organization 2011). These existing operational gaps make the use of the current tablets 
and treatment approach expensive and time-consuming (Navaratnam et al., 2012). In addition, 
until recently when dose-ranging trials where conducted in PSAC (Coulibaly et al., 2017, 
Coulibaly et al., 2018), there had been concerns over knowledge gaps on dosage and safety, 
as the current 40mg/kg was an extrapolation of the SAC and adult dosing system (Bustinduy 
et al., 2016b). Regulatory gaps still exist, as the current tablet was formally licensed for, and 
based on safety profiles, established in children 4 years old and above, as previously mentioned 
(Colley et al., 2014, Bayer and Merck & Co 2020). 
Based on existing operational, knowledge and regulatory gaps, and to ensure correct dosage 
and safe administration of treatment, a target product profile (TPP) has been recommended for 
the formulation of a flexible solid oral paediatric PZQ tablet (World Health Organization 
2012b, Mduluza and Mutapi 2017). This TPP includes: (i) masked taste, (ii) oral dispersibility, 
(iii) fewer side effects, (iv) smaller size, and (v) environmental stability. The Paediatric 
Praziquantel Consortium, a public–private partnership, has produced a product meeting this 
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TPP, where the S–enantiomer (D-PZQ) that contributes to the bitter taste in the current tablet 
formulation has been removed, leaving the R-enantiomer (L-PZQ) associated with the 
antischistosomal properties of PZQ. A phase III clinical trial in children aged 3 months–6 years 
is currently ongoing in countries including the Ivory Coast and Kenya (Paediatric Praziquantel 
Consortium 2020). Longitudinal studies to determine the optimal timing and frequency of 
treatment in PSAC will be vital to inform deployment of this treatment. As detailed below, it 
will also be critical to investigate the best strategy to access PSAC for treatment. 
1.12 Accessing preschool-aged children for schistosome 
treatment and control 
In helminth-endemic areas, PC programmes targeting SAC are conducted via MDA with 
antihelminthics, usually PZQ and albendazole, administered in the school setting (WHO 
Expert Committee 2002, World Health Organization 2006). PSAC are not accessible in 
schools (although some may be in early child development centres), and the “diagnose and 
treat” recommendation, pending roll-out of the paediatric PZQ, makes it difficult to treat them 
outside a health setting. A retrospective study in Kenya found that four years of school-based 
MDA, resulted in a significant reduction in infection prevalence among school children but 
not at the population level (Lelo et al., 2014). Thus, there is the need to upscale treatment 
strategies in order to render preventive measures more effective. It has been suggested that the 
increased treatment costs for accessing and treating PSAC will still render treatment 
programmes more cost-effective than current school-based strategies (Lo et al., 2015). 
One strategy is to access PSAC through the Expanded Programme on Immunization (EPI) in 
primary health centres (World Health Organization 2011). Studies in Zimbabwe have utilised 
the local primary health centres as a means to access PSAC, showing high compliance even in 
follow-up studies (Mutapi et al., 2011, Mutsaka-Makuvaza et al., 2018). In other countries, 
Child Health Days and Mother and Child Days offer a potential opportunity for easily reaching 
PSAC (World Health Organization 2011). The utility of such public health interventions has 
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been demonstrated in Uganda for albendazole treatments (Alderman et al., 2006). However, 
in some health systems Child Health Days and EPI programmes may already be overwhelmed 
from implementing multiple interventions at the same time. Hence studies to monitor any 
changes or constraints of such integrated activities on existing health intervention 
programmes, as well as into alternative access strategies are required. Recently, an approach 
of empowering health workers to identify clinical cases (i.e. non-specific signs of suspected 
cases), making PZQ available in health centres, and integrating the paediatric PZQ into 
immunization programmes have also been suggested (Bustinduy et al., 2016a). Some of the 
strategies outlined above can also be crucial for including PSAC in monitoring and evaluation 
of treatment across endemic countries, for more accurate national and regional schistosomiasis 
metrics (Faust et al., 2020). Longitudinal studies are needed to ascertain the best approach and 
timing suitable to access PSAC for chemotherapy across a diversity of endemicities. 
1.13 Complementary schistosome control methods 
Modelling studies have postulated that treatment strategies alone, without other interventions 
such as snail control and improved sanitation conditions will not be sufficient to achieve 
sustainable schistosomiasis control and elimination (Gurarie et al., 2015, Secor and Colley 
2018). Fundamental facets that are key to ensuring reduced schistosome transmission, and 
ultimately, elimination in endemic countries include improved water, sanitation and hygiene 
(WASH), behavioural change, targeted education, and snail control (Sokolow et al., 2016). 
A review of evidence shows that WASH interventions designed to prevent contact with 
infective water sources and reduce transmission are likely to reduce the odds of schistosome 
infection (Grimes et al., 2015). With regards to PSAC, an overall safe environment can be 
provided through provision of latrines, alternative water sources, and education on good 
hygiene practices for older individuals and caregivers, all of which indirectly promote efforts 
at reducing contact and infection in PSAC. Education of the caregiver (through interactive 
materials) can change customs and behaviours that put PSAC at risk of infection, and also 
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encourage carer participation in control programmes with their young ones (WHO Expert 
Committee 2002, Beanland et al., 2006). Snail control measures include chemical methods 
such as mollusciciding (Yuan et al., 2011), and biological methods such as the introduction of 
biological competitors like Tilapia melanopluera (Stauffer et al., 2006) and river prawns 
(Sokolow et al., 2015). However, chemical methods as used in parts of China can be expensive 
and time-consuming, especially for large areas, and can be toxic to other aquatic life (Yang et 
al., 2010). Despite the challenges, snail control measures target all age groups at risk of 
infection, by interrupting the complex life cycle of schistosomes. This is important to reduce 
the number of water-borne infectious cercariae, and ultimately the risk of (re)infection. 
Environmental control methods including vegetation and silt removal from water bodies and 
the use of improved farming methods (e.g. improved excreta storage), have also proved useful 
in agricultural settings (Jordan et al., 1993).  
Praziquantel treatment alone will not be sufficient for sustainable schistosomiasis control and 
elimination (Secor and Colley 2018). Integrated schistosomiasis control that includes 
improved treatment coverage combined with the complementary methods outlined above, has 
been shown to be more cost-effective over time (Lo et al., 2018). 
1.14 Outlook 
There is now a global move for increasing research on paediatric schistosomiasis and 
promoting control of the disease. This is not only to benefit child health but also to move 
towards the goal of eliminating schistosomiasis. The clinical definition of schistosome 
pathology and morbidity in PSAC remains to be improved and refined. Better diagnostic tools 
are key for schistosomiasis control in PSAC. High hopes rest on the results of the Phase III 
clinical trials of the leading formulation of paediatric PZQ from the Paediatric Praziquantel 
Consortium. Studies on strategies to access PSAC for treatment as well as to determine the 
optimal time to treat, will inform its deployment. This chapter of my thesis brings into context 
important current knowledge and gaps in paediatric schistosomiasis research and practice, and 
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how the work in subsequent chapters contribute to the current body of knowledge. In the next 
sections, I describe the specific aims and rationale, along with the outline of this thesis. 
1.15 Thesis rationale 
Over the last decade the WHO’s goal has been to reduce schistosomiasis morbidity by 2020, 
and eliminate schistosomiasis as a public health burden by the year 2025 (World Health 
Organization 2012a). It appears this milestone will be missed. As we enter the new decade, 
the WHO has published an updated neglected tropical disease (NTD) roadmap for 2021–2030 
(World Health Organization 2020a). The updated roadmap indicates that despite recent efforts, 
critical action is required for expanding research and treatment to all populations, especially 
PSAC, and for sustainable control and elimination of schistosomiasis. In schistosome-endemic 
areas, children carry most of the infection burden, and at least 25 million of these are PSAC 
(WHO Expert Committee 2002, World Health Organization 2011). Despite evidence of 
schistosome infection and the recommendation to treat PSAC with schistosomiasis (World 
Health Organization 2011), this age group is still excluded from treatment programmes in most 
endemic areas. The consequences of such inequity in health are that while PSAC remain 
significant reservoirs for infection transmission and hamper elimination efforts (Lelo et al., 
2014, Njenga et al., 2014), the intensity of infection continues to accumulate until about age 
6 years, when they receive their first treatment through school-based MDA. Some of the 
knowledge gaps for excluding PSAC from treatment include a poor understanding of 
schistosome exposure, infection, disease dynamics and treatment, and a lack of a coherent 
strategy to access and treat PSAC. Operational difficulties in the diagnosis of infection, as well 
as the perspective of a low infection risk (Sacko et al., 2011) and lack of a known immune 
response to infection or response to treatment have also been contributing factors (Mutapi 
2015a). 
Currently, the global infection and disease burden is not fully known in this age group; the 
best estimates available on the burden of paediatric schistosomiasis are from published data 
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from scientific studies, focused on describing the prevalence of infection and morbidity in 
endemic areas (Woolhouse et al., 2000, Bosompem et al., 2004, Odogwu et al., 2006, Mutapi 
et al., 2011, Kemal et al., 2019, Mutsaka-Makuvaza et al., 2019, Sacolo-Gwebu et al., 2019). 
Longitudinal studies to describe the incidence of infection and morbidity, especially the early 
events that occur during the very first infection and treatment in PSAC are lacking. In addition, 
parasite-related growth and nutritional disorders are significant childhood problems in 
schistosome-endemic areas (Freer et al., 2018). However, there are no studies detailing the 
attributable fraction of malnutrition due to schistosomiasis, the impact of treatment on these 
factors, and their utility to identify high-risk groups in endemic areas. These knowledge gaps 
make it difficult to make operational and economic plans for controlling schistosomiasis in 
this age group. 
With the current recommendation to treat PSAC on a case-by-case basis and pending the roll 
out of the paediatric PZQ, longitudinal studies to determine different treatment timings and 
strategies for maximum health benefits of treatment in terms of reduced reinfection and 
morbidity rates are required. This is based on the evidence that as shown in older children and 
adults, PZQ treatment in PSAC also induces schistosome-specific immune responses 
associated with resistance to reinfection (Rujeni et al., 2013). This will be important to 
determine strategies and opportunities for early screening and treatment of PSAC as part of 
routine health interventions, while reducing transmission and reinfection, and preventing 
irreversible pathology in PSAC. 
While there is an opportunity to influence the health of PSAC through specifically designed 
interventions such as nutraceuticals, there are limited human studies on the mechanistic 
pathways of disease and treatment in young children. Much of our understanding of the host-
parasite interactions that contribute to parasite survival and disease development are from 
experimental studies. There is a need for mechanistic studies that contribute more to 
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understanding the molecular and biochemical mechanisms underlying schistosome-related 
morbidity and treatment in PSAC. 
1.16 Thesis aims 
The specific aims of this thesis were as follows: 
 To determine using currently available field tools, the prevalence of  
S. haematobium infection and morbidity in PSAC, and the proportion of growth 
and nutritional sequelae associated with schistosome infection. The incidence of 
the first S. haematobium infection and morbidity, and the impact of treatment on 
infection and reversal of early morbidity was also determined. 
 To determine the operational health benefits of regular quarterly screening and 
treatment of schistosome infections (upon first infection), in terms of reducing 
subsequent new infections and reinfections in PSAC. The reinfection rates and 
intensity observed following a single PZQ treatment of the first schistosome 
infection in PSAC, was compared to that observed with the treatment of chronic 
infections. 
  To characterise the host metabolite profiles of PSAC before their first  
S. haematobium infection, and the changes that occur following infection and 
curative treatment. The impact of specific metabolite alterations on host metabolic 
pathways and schistosome-related morbidity was also determined. 
  To characterise the structure (abundance and diversity) of the gut microbiome 
and resistome in PSAC, and to determine the association between S. haematobium 
infection and the gut microbiome and resistome. 
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1.17 Thesis outline 
The study presented in this thesis explored the dynamics and consequences of S. haematobium 
infection and disease in PSAC. In this chapter, the current knowledge and gaps in paediatric 
schistosomiasis practice, and how the work presented in this thesis contributes to this 
knowledge base are described. 
Chapter 2 outlines the study design related to the specific aspects of this study, as well as 
methodological considerations related to field work and laboratory analysis. The main 
statistical methods used to analyse the data described in this thesis are also outlined. 
In contributing to data on the infection and disease burden in PSAC, Chapter 3 focuses on the 
utility of currently available tools to determine the incidence of the first S. haematobium 
infection and morbidity, how quickly disease develops post-infection, as well as the impact of 
treatment on infection and reversal of early morbidity in PSAC. It further describes the 
proportion of growth and nutritional sequelae observed in PSAC, that is attributable to 
schistosome infection. 
Chapter 4 examines the operational health benefits of regular quarterly screening and 
treatment of S. haematobium infections (upon first infection), in terms of reducing subsequent 
new infections and reinfections in PSAC. The health benefits (in terms reinfection rates and 
intensity) of a single PZQ treatment of the first S. haematobium infection in PSAC, versus that 
observed with the treatment of chronic long-standing infections was also examined. 
Chapter 5 describes the impact of S. haematobium infection and treatment on the host 
metabolic phenotype, as well as the impact of infection on metabolism and morbidity in PSAC. 
Chapter 6 characterises the structure of the gut microbiome and resistome of PSAC. It further 
describes the influence of S. haematobium infection on the abundance and structure of the gut 
microbiome and resistome, as well as its impacts on host health in PSAC. 
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Chapter 7 summarises and discusses the major findings presented in this thesis in broader 
terms. It further describes the contribution of my findings to paediatric schistosomiasis 
practice and health policy, and provides suggestions for further research. 
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Chapter 2 Methods 
2.1 Introduction 
Decades of studying host-pathogen interactions to understand infection and disease 
mechanisms relating to the aetiology, as well as clinical manifestations of morbidity and 
immunopathology, have relied heavily on experimental models of infection (Sarkar and Heise 
2019). In the case of schistosomiasis, studies in animal models have provided insights into 
infection and disease mechanisms. However, the paradigms presented by experimental 
schistosome studies are not easy to extrapolate to humans due to differences in the natural 
history of infection (Woolhouse 1998, Woolhouse et al., 2000). For example, while a single 
exposure to cercariae can result in infection in mouse models, human infection in endemic 
areas is more likely due to repeated exposure (Cheever et al., 2002). In addition, T-helper type 
1 (Th1) immune responses have been associated with protection from infection in mouse 
models, while predominantly T-helper type 2 (Th2) immune responses have been associated 
with protection in humans (Hagan et al., 1991, Hagan 1993, Mutapi et al., 1998, Mutapi et al., 
2006, Tebeje et al., 2016). Such marked differences and their relevance to the complex human 
disease forms and associated heterogeneities, highlight the need for more human studies. 
The challenges of conducting infection and mechanistic studies in humans have limited our 
understanding about the pathophysiology of the disease in humans, as illustrated by urogenital 
schistosomiasis (Rollinson 2009). The variations in susceptibility to infection, disease 
manifestation, genetics, underlying health issues, persistent coinfections, and demographic 
factors such as age and gender have limited human infection studies (Sarkar and Heise 2019). 
While human challenge infections are possible, limitations for such studies to be conducted in 
a controlled environment, with controlled infection doses or route of infection, and with self-
limiting disease (Selgelid and Jamrozik 2018), makes it difficult to follow and fully understand 
the natural time-course of infection and disease in humans. Ethical limitations also make it 
difficult to perform mechanistic studies in humans (Darton et al., 2015). It was only recently 
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that a controlled Schistosoma mansoni infection human model was developed (Langenberg et 
al., 2020). Although this is promising and paves the way for rapid proof-of-concept 
mechanistic, vaccine and drug studies, the infection dynamics and immune responses clearly 
differed from that observed in a natural course infection in endemic settings. For instance, 
infections were single-sex, and did not produce eggs that contribute to the chronic 
immunomodulatory mechanisms observed in natural infections (Langenberg et al., 2020). 
Thus, the work presented in this thesis was based on following natural schistosome infections 
(focusing on S. haematobium) in preschool-aged children (PSAC), aged 5 years and below, 
living in schistosome-endemic areas in Zimbabwe. The field study involved a baseline cross-
sectional survey followed by a longitudinal infection–treatment–reinfection study design, 
focusing on various aspects of infection, disease and treatment dynamics. Overall, the thesis 
involved quantitative analysis of epidemiological factors associated with S. haematobium 
infection and morbidity measured in the field, in combination with laboratory analysis of 
biological samples. 
For field studies, methods including the currently recommended parasitological detection of 
parasite eggs in urine or stool (World Health Organization 2020b), and the detection of 
haematuria as a measure of morbidity for S. haematobium (Lengeler et al., 2002, Bocanegra 
et al., 2015) were used. Despite the operational challenges of sampling and diagnostic 
sensitivity of current conventional methods (Bergquist et al., 2009, Coulibaly et al., 2013, 
Wami et al., 2014, Utzinger et al., 2015), there is lack of a more convenient, specific, rapid, 
and cheap alternative diagnostic suitable for field applications, especially for S. haematobium. 
Although immunological methods can overcome the issues of reduced sensitivity with 
parasitological diagnosis (e.g. in detecting low intensity infections, prepatent or single sex 
infections), issues of cost, cross-reactivity and difficulty in blood sampling of PSAC pose 
challenges in this case (Kanamura et al., 1998, Oliveira et al., 2005). In addition, the more 
sensitive point-of-care (POC)–CCA test to detect worm antigens in urine has also shown to be 
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a reliable tool for the diagnosis of S. mansoni infections (Coulibaly et al., 2013, Ochodo et al., 
2015), but less so for S. haematobium infections, the focus of this thesis (Ashton et al., 2011, 
Sousa et al., 2019). The use of parasitological methods to describe the dynamics of infection 
and treatment in this thesis enables comparison of findings to other studies, and to inform 
developing targeted interventions, while parasitological methods remain the predominant 
schistosome diagnostic in PSAC in schistosome-endemic areas. Schistosoma -omics research 
continues to contribute significantly to the understanding of disease dynamics and in the 
exploration of innovative diagnostics and treatment (Wang and Hu 2014). The integration of 
such methods into routine readouts in helminth studies has been recommended (Kokova and 
Mayboroda 2019). Thus, the work presented in this thesis also employed the methods of 
genomics and metabolomics, using a combination of DNA sequencing, spectroscopic 
methods, multivariate pattern recognition methods, and bioinformatic techniques. The use of 
such analytical techniques while controlling for confounding effects, is effective at 
overcoming the limitations of heterogeneity in human infection studies (Wang et al., 2004, 
Balog et al., 2011). These were used to analyse the overall changes in the metabolome and gut 
microbiome in response to schistosome infection and treatment, and how these relate to 
mechanisms of disease progression and morbidity in PSAC. Overall, the findings from this 
thesis, based on the methods used, contribute to gaps relating to infection, disease and 
treatment dynamics, as well as their implication on new ways of reducing current and future 
burden of schistosomiasis in PSAC. 
In this chapter, I describe the main study design on which the work from this thesis was based, 
the study participants and site, the field and laboratory methods used, as well as the statistical 
methods applied to answer specific research questions in this thesis. Specific details relating 
to the methods outlined here are in the relevant chapters as appropriate. 
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2.2 Field study 
2.2.1 Ethical approval and consent 
The study received institutional approval from the University of Edinburgh (fmutapi-0002) 
and ethical approval from the Medical Research Council of Zimbabwe (MRCZ/A/1964). 
Permission to conduct the study in the province was obtained from the Provincial Medical 
Director. Prior to enrolment, the overall and specific aims and procedures associated with the 
study were explained to all participants’ parents/guardians in their local language, Shona. 
Written informed consent was obtained from the participants’ parents/guardians as 
appropriate. Recruitment into the study was voluntary and parents/guardians were free to 
withdraw participants at any time with no further obligation. 
2.2.2 Study population and site 
The study was conducted in four villages, Chihuri, Mupfure, Madziwa, and Nyamaropa, 
located in the Shamva district, Northeast of Zimbabwe (17°10′0″S 31°40′0″E) (see Figure 
2.1). This is one of seven districts in the Mashonaland Central province of Zimbabwe, which 
has about 123,650 people living in a predominantly rural area of 2,695 km², according to the 
2012 national census (Zimbabwe National Statistics Agency 2012). The area was selected for 
this study on urogenital schistosomiasis because the prevalence of S. haematobium is high 
(>50% endemicity), while the prevalence of S. mansoni and soil-transmitted helminths (STH) 
is low (<15%) (Midzi et al., 2011, Midzi et al., 2014b). The inhabitants from the study villages 
are of similar ethnicity (Shona) and socioeconomic background (primarily subsistence 
farmers). There is poor sanitation provision and inadequate safe water sources (as indicated 
by study questionnaires and observations from the study site). Residents use nearby rivers for 
farming, domestic water supply, and recreational activities. Activities in the area confirm that 
exposure to schistosome infection in older children is active through direct water contact 
activities, while a significant amount of the exposure in PSAC is passive through activities of 
their caregivers, and becomes more active with age (Odogwu et al., 2006, Garba et al., 2010). 
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PSAC aged 5 years and below were recruited for the study. Recruitment was based in centres 
used by the community for the Expanded Program for Immunisation (EPI), i.e. crèches, early 
child development centres, preschools and primary health centres. Parents/guardians of 
children not in any educational programmes (e.g. children <3 years old) were invited through 
the village health workers to report to the sampling centres with their children for enrolment 
into the study. 
 
Figure 2.1: Map of study area showing locations of the four villages where participants were 
enrolled 
Map was produced using the software package ArcMap 10.1. 
 
2.2.3 Study design 
The work presented in this thesis was based on data obtained from field studies as part of a 
larger project, “Childhood Schistosomiasis: A Novel Strategy Extending the Benefits/Reach 
of Antihelminthic Treatment”, in collaboration with the University of Edinburgh and the 
University of Zimbabwe. The study was conducted from February 2016 to February 2018, and 
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included a baseline cross-sectional study, followed by a standard longitudinal infection–
treatment–reinfection study design. The study was designed to detect the difference in 
reinfection and schistosome-related morbidity rates between two groups of previously 
screened and treated PSAC (using quarterly versus annual regimes). There were two main 
aspects of the longitudinal study: (i) to determine and treat new schistosome infections using 
two different strategies, quarterly versus annual screen and treatment (year 1), and  
(ii) to determine the impact of quarterly versus annual screen and treatment in terms of 
reinfection and morbidity rates, at least 12 months post-treatment (year 2). A schematic 
diagram of the study design is shown in Figure 2.2. 
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Figure 2.2: Schematic diagram showing the larger field study design and survey follow-up times 
Post-baseline cross-sectional survey (S0), age- and sex-matched S. haematobium-negative children 
were randomly allocated to one of two groups. Group 1 was followed up every 3 months in surveys S1, 
S2, S3, S4, and at 12 months in survey S4 for Group 2, for parasitology and morbidity. Both groups 
were followed up at 24 (S5) months for parasitology and morbidity. Red cartoon, S. haematobium 
positive; Green cartoon, S. haematobium negative 
 
At baseline (survey S0), a cross-sectional study to diagnose S. haematobium infection and 
morbidity (measured by microhaematuria), and to exclude S. mansoni and other intestinal 
helminth infections was carried out. Children positive for schistosome infection by egg count 
were treated with praziquantel (PZQ) and excluded from further follow-up. Children 
confirmed egg-negative were age- and sex-matched, and randomly allocated into one of two 
groups, Group 1 and Group 2. Children in Group 1 were screened at 3, 6, 9, and 12 months 
(surveys S1–S4) for detection of infection and morbidity within 3 months of first infection. 
 
   S0: Baseline parasitology screening and praziquantel treatment 
           (Inclusion criteria for longitudinal study)    
 
     Enrolment (Egg-negative participants) 
 
 
       














            






























    Start incidence study to detect new infections 










     
            












    
   
   
S4
    
   S
3 




     
                Follow up 12 months-post S4 for (re)infection rates 
and treatment 
Group 2 


















[Paediatric Schistosomiasis: Dynamics and Consequences] 
60  [Methods] 
The 3-month screening interval takes into account the 10–12 week period for new  
S. haematobium infections to reach patency and be detectable by egg excretion (Webbe and 
James 1971, Smith et al., 1976, Wami et al., 2016). Children in Group 2 were screened and 
treated once at 12 months (survey S4). The 12-month period for Group 2 was chosen to 
represent the current practise of annual mass drug administration (MDA) in Zimbabwe 
(targeted at SAC and adults). 
PZQ treatment was offered to children found to be positive for infection at each survey. A 
post-treatment efficacy check was carried out for all treated children at each subsequent 
follow-up survey, i.e. 3 months post-previous survey for Group 1 (survey S1–S3), and 6 weeks 
post-S4 survey for both groups). To assess the impact of the different screening and treatment 
strategies on reinfection and morbidity, children in both groups were followed up at 24 months 
(survey S5) for reinfection and morbidity. 
2.2.4 Sample size calculation 
The sample size was calculated to address the primary aim of the larger project, which was to 
compare reinfection rates following different treatment regimens, i.e. between children 
receiving early screening and treatment upon first detection of infection (Group 1), versus 
children screened and treated annually (Group 2). Calculations were based on assumptions 
that early treatment of infection (Group 1) will reduce the reinfection rate by at least half 
(50%), in comparison with the current standard annual treatment method (Group 2). Based on 
the reinfection rates observed in children after 12 months from an earlier study conducted by 
our research group (Parasite Immuno-epidemiology Group) (Mutapi et al., 2011, Midzi et al., 
2014a), this corresponds to 15% in Group 1 versus an expected 30% in Group 2. Statistical 
power analysis was performed using Gpower version 3.1.5 (Faul et al., 2007). Based on an 
expected prevalence of 6.7%, as derived from our research group’s previous study in 1–5 year 
olds (Wami et al., 2016), and given α = 0.05, and power = 0.80, the sample size required given 
the effect size was 214 in each group, following the baseline survey. Allowing for a 20% 
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dropout rate, the minimum sample size required for each group during follow-up was 256 in 
each group. In order to obtain the number of infected children sufficient to detect the 
reinfection rates hypothesised, it was necessary to start with larger sample sizes of uninfected 
children for each group, by including all children found eligible for the longitudinal study, 
following the baseline survey. 
2.2.5 Eligibility criteria 
At baseline, the study included PSAC (£5 years old) who met the following inclusion criteria: 
(i) consent from parents/guardians, (ii) they were lifelong/permanent residents of the study 
area, (iii) they had no history of antihelminthic treatment (assessed by clinical records and 
questionnaires administered to parents/guardians for all children), (iv) they were exposed to 
infective water (as established by initial water contact questionnaire and malacology survey 
of the water contact sites), and (v) they had provided at least two urine samples for 
parasitological diagnosis of S. haematobium, and at least one stool sample for parasitological 
diagnosis of S. mansoni/STH on consecutive days, and (vi) they were negative for S. mansoni 
and STH (Hookworms, Ascaris lumbricoides or Trichuris trichiura). Children were excluded 
if they had pre-existing medical conditions, presented with clinical symptoms of tuberculosis, 
had malaria/fever or showed signs of being unhealthy, or had a recent major illness/surgery 
(assessed upon examination by field study clinicians, clinical records and reports from 
parents/guardians).  
To be included in the longitudinal cohort, children who had fulfilled the inclusion criteria 
described above had to meet an additional criterion of being diagnosed negative for  
S. haematobium infection by egg count at baseline, to track the incidence of first new 
infections. 
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2.2.6 Questionnaires 
A questionnaire, designed in English and translated into the local language (Shona), was 
administered by the research team to gather demographic data and establish exposure 
behaviour. Parents or guardians responded to the questionnaires on behalf of their children, in 
addition to validation from clinical records and child health cards. Prior to start of the study, 
the questionnaire was pretested in a sample of the population to ensure the questions and 
answers reflected accurate information as sought by the questionnaire. A copy of the 
questionnaire can be found in Appendix D. 
2.2.7 Anthropometry 
Anthropometric measurements were conducted by the research team, and for very young 
children, measurements were taken by local nurses from the Madziwa rural clinic (see Figure 
2.3). Weight (nearest 0.1 kg) and height (nearest 0.1 cm) without shoes and in light clothing 
was measured using an electronic scale (Seca 878dr, Seca GmbH & Co. KG., Birmingham, 
UK) and a stadiometer (Seca 217, Seca GmbH & Co. KG.) respectively. For very young 
children, height was measured with an infantometer baby board (Seca 416, Seca GmbH & Co. 
KG.), and weight measured with a baby weighing scale (Seca 384, Seca GmbH & Co. KG.). 
The mid-upper arm circumference (MUAC) was measured (nearest 1 mm) using a child 
MUAC tape (Ibis Medical Equipment & Systems Pvt. Ltd., India). This was measured on the 
left arm, midpoint between the shoulder and the tip of the elbow, with the arm relaxed and 
hanging down the body. 
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Figure 2.3: Panel showing images from anthropometric measurements in the field  
Image shows measurements for weight, height, and Mid-upper arm circumference (MUAC) as part of 
anthropometric measurements. 
 
2.2.8 Parasitological diagnosis 
Sample processing for parasitological tests were performed by the research team, and 
microscopy was done by trained field technicians from the University of Zimbabwe. 
Approximately 50 ml of at least two separate urine samples were collected from each 
participant on three successive days, and a stool specimen was collected on a single day from 
each participant. The collection of replicate samples on different days was done to improve 
sensitivity of diagnosis due to variation in egg excretion (Engels et al., 1996). Samples were 
collected between 10:00 hours and 14:00 hours and processed within two hours of collection. 
For very young children, urine bags (Hollister 7511 U-Bag Urine Specimen Collector, 
Hollister Inc., Chicago, IL, USA) and disposable diapers were used to collect urine and stool 
samples respectively. 
Urine samples were examined microscopically for S. haematobium infection, following the 
standard urine filtration method (Mott et al., 1982). In summary, each urine sample was 
thoroughly mixed, and 10 ml of urine was aspirated using a 10 ml plastic syringe. A 
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nitrocellulose mesh filter was then attached, and the urine slowly passed through. If present, 
parasite eggs were left trapped in the filter, which was then observed under a light microscope 
and number of eggs/10 ml of urine enumerated. Stool samples collected were processed using 
the Kato–Katz thick smear method (Katz et al., 1972). Stool samples were sieved to remove 
large particles, and duplicate slides were prepared using the standard 41.7 mg templates and 
stained with glycerol–malachite green (stains stool components but does not penetrate parasite 
eggs) to aid parasite egg identification. Parasite eggs of intestinal helminths were enumerated 
under a light microscope per gram of stool (41.7 mg multiplied by 24), as per World Health 
Organisation (WHO) guidelines (World Health Organization 1994). Children were diagnosed 
positive for helminth infection if at least one parasite egg was detected in their urine or stool 
samples. S. haematobium infection intensity was expressed as the arithmetic mean egg 
count/10 ml of at least two urine samples, collected on three consecutive days. A panel of 
images from sample processing and microscopy for parasitological diagnosis is shown in 
Figure 2.4. 
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Figure 2.4: Panel showing images from processing of urine and stool samples for parasitology in 
the field 
 
2.2.9 Diagnosis of morbidity 
Schistosoma haematobium-related morbidity, measured as the presence of blood in urine, was 
detected using a POC visual colorimetry and dipstick urinalysis method (Figure 2.5). Urine 
samples collected were first examined for macrohaematuria (visible haematuria) and recorded 
as positive or negative based on presence or absence of visible blood in urine respectively. 
Where quantities of blood in urine was too low to change the colour of urine and be detected 
visually, urine was assayed for microhaematuria using reagent strips (Uristix®, Uripath, 
Plasmatec, UK). The reagent end of the strip was dipped into fresh, well-mixed urine for about 
40 seconds, and the test area was compared to a standard colour chart as per manufacturer’s 
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instructions. Where no blood was present in urine, there was no colour change, and this was 
recorded as Negative. The strength of colour change on the strip, indicating varying 
concentrations of blood present in the sample was reported as Trace, Positive (+), Positive 
(++), Positive (+++), or Positive (++++). For analysis purposes as used in the work presented 
in this thesis, any colour change indicating microhaematuria (including Trace) was coded as 
Positive. 
 
Figure 2.5: Panel showing images from morbidity detection, measured by haematuria in the field 
 
2.2.10 Praziquantel treatment 
At all survey time points, PZQ was administered to children positive for schistosome infection 
at the recommended single standard oral dose of 40mg/kg, in tablet form (Cipla Ltd, India, 
manufactured for MedPharm) (World Health Organization 2011). Treatment was carried out 
and supervised by local nurses from the Madziwa rural clinic. Treatment was administered as 
crushed tablets, given with juice and bread to reduce the bitter taste and side effects of PZQ as 
recommended by the WHO (Mutapi et al., 2011, World Health Organization 2011). A post-
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treatment efficacy check (via egg count) was carried out for all previously treated participants, 
at each subsequent follow up, and participants who were found to be egg-positive were treated 
with a repeat 40 mg/kg dose of PZQ. Reports of adverse side-effects from PZQ treatment in 
PSAC are few, and limited to abdominal pain, vomiting, fatigue, and diarrhoea that resolve 
within 24 hours (Sousa-Figueiredo et al., 2010, Mutapi et al., 2011, Namwanje et al., 2011, 
Coulibaly et al., 2017, Coulibaly et al., 2018). All treated children were observed for an hour 
by field clinicians for immediate adverse side-effects, and to determine if treatment was lost 
through vomiting. Children were monitored again by field clinicians the following day (with 
the caregiver or parent present) to report any side-effects that were absent the day before. 
2.2.11 Stool DNA isolation and storage 
Aliquots of fresh stool samples were taken and processed for microbiome studies. Stool 
samples in 2 ml cryotubes were stored temporarily at 2–8 oC for a maximum of 24 hours prior 
to processing. Studies have shown that storage of fresh stool samples from 24–72 hours at 
room temperature or at 4 oC for up to 48 hours, does not significantly alter the observed 
microbiota sequences, when compared to freshly processed samples or samples rapidly stored 
at -20 oC or -80 oC (Wu et al., 2010a, Tedjo et al., 2015). All samples were preserved in the 
same manner to reduce inter-sample variation (Carruthers et al., 2019). 
DNA was extracted from stool using the QIAamp DNA Stool Mini Kit (QIAGEN, catalogue 
number 51504), according to manufacturer’s instructions. This method of DNA extraction 
from stool has been shown to be appropriate for microbiome studies (Li et al., 2003a). In brief, 
stool samples were homogenized in buffer and heated at 95 °C to lyse cells. An InhibitEx 
tablet was added to remove potential inhibitors, and the lysates were treated with proteinase-
K and buffer at 70 oC for 10 minutes to remove protein and polysaccharides. Isolated DNA 
was then precipitated by ethanol, applied to a column and washed twice with buffers. The 
DNA was eluted and then dissolved in buffer. DNA was stored at -20 oC in the field and 
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transferred to a -80 oC freezer in the laboratory at the University of Zimbabwe until shipped 
on ice to the University of Edinburgh for long-term storage at -80 oC. 
2.2.12 Blood sampling, processing and storage 
Collection of blood samples were carried out by local nurses from the Madziwa rural clinic. 
Up to 5 ml of venous blood was collected from each participant into serum separator tubes 
(BD Vacutainer®) and processed for serum for serological and biochemical assays. To 
minimise the effects of temporal and mealtime variability, especially on biochemical assays 
(serum metabolite analysis), non-fasting pre-meal samples were taken at about midday during 
field surveys (Kim et al., 2014). Blood samples were allowed to clot at room temperature for 
about 30 minutes, and were stored at 4 °C for a maximum of 4 hours prior to processing. 
Samples were centrifuged at 3000 rpm for 10 minutes to obtain serum. Aliquots of serum 
samples were frozen at -20 °C in the field and transferred to a -80 °C freezer in the laboratory 
at the University of Zimbabwe until shipped on ice to the University of Edinburgh for long-
term storage at -80 oC. 
2.2.13 Field data handling and cleaning 
In terms of field work, I was involved in each of the research methods and procedures 
described above, to obtain the data required for this study. All de-identified field data was 
entered in a Microsoft Excel spreadsheet, and to ensure accuracy, I facilitated a double entry 
verification. Prior to any statistical analyses, data was cleaned and verified to correct for any 
inconsistencies. Data cleaning and verification involved comparing spreadsheet data to all hard 
copy raw data entered from the field. 
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2.3 Metabolomics methods 
2.3.1 Sample preparation 
Approximately 50 μl each of serum samples were shipped on dry ice to Human Metabolome 
Technologies Inc. (HMT; Yamagata, Japan) for sample preparation and metabolite analysis. 
At HMT, each 50 μl sample was mixed with 450 μl of methanol containing HMT in-house 
internal standards (10 μM). Chloroform (500 μl) and Milli-Q water (200 μl) were then added, 
mixed thoroughly and centrifuged (2,300 x g, at 4℃ for 5min). The water layer (400 μl) was 
passed through a filter (ULTRAFREE-MC-PLHCC; HMT, Yamagata, Japan) to remove 
macromolecules, with a 5-kDa cut-off. The filtrate was centrifugally concentrated and 
resuspended in 50 μl of ultrapure water immediately before the measurement. 
2.3.2 Metabolite measurement 
Compounds were measured in the cation and anion modes of capillary electrophoresis time-
of-flight mass spectrometry (CE–TOF–MS)-based metabolome analysis (Soga and Heiger 
2000, Soga et al., 2002, Soga et al., 2003). To improve the quality of the capillary 
electrophoresis mass spectrometry (CE–MS) analysis, samples were diluted 1:2 and 1:5 for 
cation and anion modes respectively. 
Cationic metabolites (i.e. in cation mode) were analysed with a fused silica capillary  
(i.d. 50 μm × 80 cm), using Cation Buffer Solution (p/n: H3301-1001; HMT) as both the run 
and rinse buffer. Sample injection was done at a pressure of 50 mbar for 10 seconds at an 
applied capillary electrophoresis (CE) voltage of 27 kV. Electrospray ionization mass 
spectrometry (ESI–MS) was conducted in the positive ion mode with a capillary voltage of 
4,000 V. Mass spectrometer (MS) scanning range was a mass-to-charge ratio (m/z) of  
50–1,000 using an HMT in-house sheath liquid (p/n : H3301-1020). All other conditions were 
as used in cation analysis mass spectrometry (Soga and Heiger 2000). Anionic metabolites 
(i.e. in anion mode) were analysed with a fused silica capillary (i.d. 50 μm × 80 cm), using 
Anion Buffer Solution (p/n: H3302-1021; HMT) as both the run and rinse buffer. Sample 
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injection was done at a pressure of 50 mbar for 25 seconds at an applied CE voltage of 30 kV. 
ESI-MS was conducted in the negative ion mode with a capillary voltage of 3,500 V. MS 
scanning range was a m/z of 50–1,000 using an HMT in-house sheath liquid  
(p/n: H3301-1020). All other conditions were as used in anion analysis mass spectrometry 
(Soga et al., 2002). A schematic diagram of the metabolite measurement workflow is shown 
in Figure 2.6. Details of instrumentation are described in the following section. 
 
Figure 2.6: Schematic diagram of the serum metabolite mass spectrometry process 
 
2.3.3 Instrumentation 
CE–TOF–MS was carried out using an Agilent CE–TOF–MS system (Agilent Technologies 
Inc. Waldbronn, Germany), equipped with an Agilent 6210 time-of-flight mass spectrometer 
(TOF–MS), Agilent 1100 isocratic high-performance liquid chromatography (HPLC) pump, 
Agilent G1603A CE–MS adapter kit, and Agilent G1607A capillary electrophoresis 
electrospray ionization mass spectrometry (CE–ESI–MS) sprayer kit (all from Agilent 
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Technologies, Waldbronn, Germany). System control, data acquisition and evaluation were 
facilitated by Agilent G2201AA ChemStation software version B.03.01 for CE (Agilent 
Technologies). To facilitate thermostating of the capillary, the CE–MS adapter kit includes a 
capillary cassette. The CE–ESI–MS sprayer kit simplifies coupling the CE system with mass 
spectrometry systems equipped with an electrospray source. The sprayer is designed to give 
an orthogonal flow in order to reduce the detrimental effects caused by the charged particles 
or droplets (Voyksner and Lee 1999). 
2.4 Microbiome studies 
2.4.1 Sequence library preparation and sequencing 
DNA samples were shipped on dry ice for library preparation and sequencing at the Beijing 
Genomics Institute (BGI, Shenzhen, China). To ensure sample aliquots contained adequate 
amounts of purified DNA, each sample was quantified in-house at the University of Edinburgh 
using the Qubit fluorometer (ThermoFisher Scientific), prior to shipment for library 
preparation and DNA sequencing. At BGI, DNA was quantified using the Qubit fluorometer 
(ThermoFisher Scientific) and NanoDropTM (ThermoFisher Scientific). The integrity and 
purity of DNA was then assessed by a 1% agarose gel electrophoresis, run at 150V for 40 
minutes. DNA passing quality control was sheared by ultrasonication into fragments (Covaris 
S/E210). Fragments were mixed with End Repair Mix (BGI), adaptors were ligated to the ends 
of the DNA fragments, and then purified using the QIAquick Polymerase Chain Reaction 
(PCR) Purification Kit (QIAGEN). Adapter-ligated DNA fragments were separated by 
electrophoresis through a 2% agarose gel to recover the target fragments and purified using 
the QIAquick Gel Extraction kit (QIAGEN). Library preparation to enrich the adapter-ligated 
DNA was done via PCR amplification, size-separated by electrophoresis, and then purified 
using the QIAquick Gel Extraction Kit (QIAGEN). The final library was quantified using the 
Agilent 2100 bioanalyzer. The qualifying DNA libraries were amplified using the cBOT 
system (Illumina), and sequenced on the Illumina Hiseq 4000 platform (Illumina) using 
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paired-end 150-bp sequencing. Raw sequence data was received as FASTQ files for further 
processing and analysis (see Figure 2.7). 
 
Figure 2.7: Schematic diagram of the DNA sequencing process 
 
2.4.2 Mapping of sequence reads 
Direct mapping of sequence reads against reference sequence databases was done using a 
novel reference-based mapping and alignment tool known as k-mer alignment (KMA) 
(Clausen et al., 2018). This method was used because it is designed to improve mapping 
against redundant databases, and has been shown to outperform existing mapping methods, in 
terms of speed, precision and sensitivity (Clausen et al., 2018). In summary, KMA, employs 
heuristic mapping, which involves mapping k-mers between query sequences and selected 
template databases, including large redundant databases, then assigns a score to matching  
k-mers. K-mers with positive scores are then used as seeds from which to proceed for 
alignment; each matching seed is extended and given an optimal score and mismatch regions 
are identified. KMA then utilizes a special version of the Needleman-Wunsch algorithm 
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(Needleman and Wunsch 1970) to accurately align regions of mismatching k-mers. To ensure 
the best match template for the query reads, multi-mapping reads are then resolved using a 
novel sorting scheme known as ConClave. The scheme takes all initially accepted best 
matching templates and sums up the alignment scores for each template to obtain the ConClave 
score, from which the best matching sequence template is chosen. A unique ConClave score 
is computed for uniquely mapped reads, and for multi-mapped reads which may have the same 
ConClave score, the algorithm favours the first template added to the database. Although in 
such scenarios both templates will be equally suited candidates (and likely be variants of the 
same template), this is to ensure that by consistently favouring the parent template added to 
the database, there is reproducibility. 
The above processes enable assembly of reads which results in a final consensus sequence for 
the reference or template sequence. The strength of each called nucleotide is tested for 
overrepresentation using the McNemar test (α= 0.05), to rule out bias associated with base 
calling across different sequencing platforms (Kaas et al., 2014). A schematic diagram of the 
process is shown in Figure 2.8. 
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Figure 2.8: Overview of the k-mer alignment (KMA) algorithm 
Trims are read (1), then k-mers matched between query and database (2). Matching k-mer seeds are 
extended, regions with mismatching k-mers are identified (3a) and aligned using the Needleman-
Wunsch algorithm (3b). A Conclave scoring is then used to choose one best-aligning template per query 
sequence (4). Image adapted from (Clausen et al., 2018). 
 
2.5 Statistics and data visualisation 
Data were analysed using SPSS version 22 (IBM Corp.), and with the R software 
(www.bioconductor.org; www.r-project.org) (R Development Core Team 2011), unless 
otherwise stated. Data visualization was performed with R and with GraphPad Prism version 
7.02 or 8.2.0 (GraphPad Software, Inc.). Here, I present an overview of the main statistical 
methods used to summarise and test the different hypotheses used in this thesis. Specific 
details on where these were used to answer each research question are in the relevant chapters 
as appropriate. 
2.5.1 Univariate analyses 
For all analyses, data were first checked for normality, i.e. if they assumed a normal 
distribution. In addition to frequency distribution plots, the D'Agostino-Pearson normality test 
(omnibus K2 test) was used to ascertain normality of data (D'Agostino and Stephens 1986). 
The method first computes the skewness (measure of how symmetrical the data is) and kurtosis 
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(the degree of tailedness of the data relative to a normal distribution), compares these to the 
expected values of a normal Gaussian distribution, and computes a p-value from the sum of 
any discrepancies found. Where data was normally distributed, parametric statistics were used. 
In cases where data were aggregated or skewed, as with schistosome infection intensity, which 
is typically heavy in only a small proportion of people (Gryseels et al., 2006), data were 
transformed to meet normality assumptions and parametric statistics used.  
2.5.1.1 Parametric tests 
Parametric techniques used for data analyses include the following: 
 Descriptive statistics were used for exploratory data analyses, and to provide 
summaries on measures of central tendencies (i.e. mean), along with measures of 
dispersion including the range, standard deviation (SD), standard errors (SE). For 
example, as used in this thesis to determine the mean schistosome infection 
intensity. 
 The Pearson's correlation coefficient (r) was used to measure the strength and 
direction of linear relationships or associations between pairs of continuous 
variables or within and between sets of continuous variables. For example, as used 
in this thesis to determine the relationship between serum metabolite 
concentrations and schistosome infection intensity. 
  A fold change (FC) analysis was used to compare absolute value changes between 
two group means, such as to determine the mean fold changes in metabolite 
concentrations between groups. 
  The student's t-test was used to compare means between two independent groups 
or where appropriate, a paired t-test, to compare two means from the same group 
at different time points. For example, the t-test was used in this thesis to determine 
the difference in mean schistosome infection intensity between groups. 
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 A general linear model (GLM) was used to investigate the relationship between 
variables of interests to predict an outcome, and where appropriate, accounted for 
potential confounders. The method is flexible in that it allows the use of predictor 
(explanatory) variables measured on different scales (continuous and categorical), 
as was the case with the work presented in this thesis. This included the analysis 
of variance (ANOVA) and linear regression models, consisting of both categorical 
and continuous variables, e.g. to determine the influence of schistosome infection 
intensity and microbiota abundance. GLM assumes certain conditions; residuals 
(difference between predicted and actual values) are normally distributed, there is 
homogeneity of variance of residuals, the individual variables under consideration 
are independent, and an assumed linear relationship between the dependent and 
independent variables. 
2.5.1.2 Non-parametric tests 
Where normality assumptions were not met, or in cases where discrete or categorical data were 
involved, non-parametric statistics were used. 
 Descriptive statistics were used for exploratory data analyses, and to provide 
summaries on measures of central tendencies (i.e. median), along with measures 
of dispersion including the range and interquartile ranges (IQR), e.g. the median 
age of the study population. Categorical data were summarised as absolute 
numbers and percentages, e.g. proportion of schistosome positive and negative 
individuals. 
 The Chi-square (χ2) test was used to determine associations between independent 
categorical variables, and where appropriate, the McNemar's statistic for paired 
categorical data, e.g. as used to determine the difference in the schistosome 
infection rates observed at baseline and at follow up, compared between different 
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groups (independent) or within the same group (paired). Where small sample sizes 
were involved, the Fisher’s exact test was used. 
  The generalised linear model was used to model categorical response or 
dependent variables against independent variables. This is an extension of the 
GLM, which takes into account instances where response variable distributions 
did not meet normality assumptions. This included the multiple logistic 
regression, e.g. as used to determine the influence of schistosome infection status 
on the presence or absence of stunting (adjusted for age and sex), as well as the 
age-dependent modelling approach which was used to determine the predicted 
age–infection prevalence relationship, as proposed by Diamond and McDonald 
(1991) and Keiding (1991). 
2.5.2 Multivariate analyses 
Where analysis of data involved more than one dependent or response variable which were 
related or correlated with each other or had to be considered together (e.g. in this thesis, serum 
metabolite profiles), multivariate analyses were used. Below, I outline details of the 
multivariate analysis methods used in this thesis.  
2.5.2.1 Principal Component Analysis  
Principal Component Analysis (PCA) was used to provide an informative first-hand look at 
datasets, and to assess group clustering and separation trends. This method involves using data 
reduction techniques to summarise underlying variabilities in multiple dependent variables, 
through linear combinations of these variables (principal components), each of which explains 
a percentage variation (Le Cao et al., 2016). For example, this was used to uncover existing 
trends, clusters or outliers in the data set of microbiota abundance between schistosome-
infected versus uninfected children. Generally, the first component has the most variability, 
whiles the subsequent components are a linear combination of the maximum variance that is 
uncorrelated with the previous components. 
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2.5.2.2 Orthogonal Projections to Latent Structures Discriminant Analysis 
To determine variations in multiple dependent or response variables, relative to predicting 
differences between groups (e.g. metabolite signatures associated with schistosome infection), 
the Orthogonal Projections to Latent Structures Discriminant Analysis (OPLSDA) was used 
(Wiklund et al., 2008). This is a supervised method that is more reliable at overcoming the 
limitations of heterogeneity associated with analysis of data from human studies, where PCA 
does not reveal separation trends (Singer et al., 2007, Balog et al., 2011). For instance, 
OPLSDA was used to reveal discriminatory metabolite profiles between schistosome-infected 
and uninfected groups. 
OPLSDA is a modified version of the Partial Least Squares Discriminant Analysis (PLSDA) 
(Szymanska et al., 2012), and has the capability to distinguish between variations in a dataset 
both relevant and irrelevant to predicting groups, while incorporating an Orthogonal Signal 
Correction (OSC) filtering (Wold et al., 1998) into a partial least squares model. The model 
relates multiple response variables (Y) and “X” blocks of matrices (groups) by a linear 
multivariate model. It then separates the systematic variation between groups into two 
predictive (covariance between X and Y; between group variation) and orthogonal (systematic 
variation in X that is unrelated to Y; within group variation) components, free of interfering 
structured variation. Model statistics, R2 and Q2, were calculated for each model and used to 
assess the degree of fit and predictive reliability of the OPLSDA model respectively (Wold et 
al., 2001). R2 represents the fraction of the variance explained by a component in the model 
and is expressed as R2 = (1−RSS/SS), where RSS and SS are the fitted residual sum of squares 
and the sum of squares of the response variables respectively. The Q2 is the cross-validated 
R2, expressed as (1-PRESS/SS), where PRESS is prediction error of the sum of squares (Wold 
et al., 2001). 
A permutation testing that assumes there is no difference between any two groups compared 
was used to cross-validate and ensure the model was reliable and not over-fitted (Szymanska 
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et al., 2012). In summary, sample groups were randomly permuted, and a new classification 
model calculated. Model performance was then assessed by the R2 and Q2 diagnostic statistics, 
expected to be lower than that obtained for the original unpermuted dataset. The permutations 
were repeated 1000 times and the diagnostic statistics obtained were used to create a null 
distribution, H0, of models expected to be non-significant. The diagnostic statistics for the 
OPLSDA model from the original data set was related to that of the H0 distribution from the 
permuted data sets to determine the statistical significance (p-value) of the OPLSDA model: 
 ! =
1 + #('!! ≥ '!)
*
 (2.1) 
Where N is the number of permutations, #(Q2p ≥ Q2) is the number of elements in the null 
distribution H0, which are greater or equal to the Q2 for the original data set (or otherwise R2). 
2.5.2.3 (PER)MANOVA 
To determine if the mean differences between groups on the combination of multiple 
dependent or response variables is likely due to chance, a multivariate analysis of variance 
(MANOVA) was used. This is an extension of the ANOVA but incorporates multiple 
dependent or response variables (Weinfurt 1995), e.g. as used in this thesis to test the influence 
of schistosome infection status (adjusting for age and sex) on the combination of several host 
metabolite profiles (dependent variables). MANOVA creates a linear combination of each of 
the dependent variables (e.g. metabolite concentrations), which is then used to perform an 
ANOVA using the independent variables. The test assumes a normal distribution of the 
dependent variables, linearity between each pair of dependent variables, and homogeneity of 
variances and covariances (intercorrelations) of the dependent variables across the 
independent variables. Data was transformed to meet normality assumptions, and scatter plots 
were used to assess linearity between dependent variables. 
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In instances where the dependent or response variables were treated as dissimilarity measures 
(e.g. Euclidean distances, for abundance of microbiota), the permutational multivariate 
analysis of variance (PERMANOVA) was used. This was used to determine if there was any 
variation across a space of a multivariate dissimilarity measure, in response to one or more 
independent variables, while making no distributional assumptions (Anderson 2014). For 
instance, as used in this thesis to determine the variation in microbiota abundance with age, 
sex, village, and schistosome infection status. 
2.5.2.4 ANCOM 
To compare two or more populations accounting for the underlying compositional structure in 
a dataset (e.g. comparing two or more populations of microbial taxa), relative to two or more 
groups (independent variable, e.g. schistosome-infected versus uninfected groups), the 
analysis of composition of microbiomes (ANCOM) was used (Mandal et al., 2015). This was 
more appropriate in this case than standard statistical methods for comparison because, the 
relative abundance of microbes within a specimen (in this case stool samples) sums up to one 
(1), resulting in compositional data and not one in a Euclidean space. Like PERMANOVA, 
ANCOM makes no distributional assumptions and uses bootstrapped intervals to perform 
hypotheses tests, while generating a W-value denoting a count of the number of times the null 
hypothesis (e.g. there is no difference in abundance of taxa between two groups) is rejected 
for a particular taxon. By definition, the W-value (the number of times the null hypothesis is 
rejected for a given taxonomic group) is the ratio of a specific taxonomic group and a number 
of other groups (i.e. the W value) that are significantly different across two groups. In all 
analyses, a specific taxon was considered significant when it varied across the independent 
variable of interest with respect to 80% of the rest of the taxa in the dataset (W‐statistic cut 
off: 0.80). 
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2.5.3 General considerations 
Statistical models included where appropriate, all biologically meaningful interactions 
between the independent variables considered, and all insignificant interactions were excluded 
from the final model. For instance, the MANOVA model to determine the effects of age, and 
sex on host metabolite profiles included age and sex interaction as a variable. 
To control for multiple significance testing and to reduce the likelihood of type 1 error (false 
positives or the probability of rejecting the null hypothesis when it is true) the false discovery 
rate (FDR) approach was used (Benjamini and Hochberg 1995), unless otherwise stated. For 
example, the model on the effects of multiple metadata factors on microbiota taxa abundance 
was adjusted for multiple testing with an FDR threshold of 0.05. 
For all analyses and hypothesis testing, a p-value of <0.05 was considered significant. 
2.6 Estimating measures of growth and nutrition 
Based on anthropometric measures, growth and nutritional status were assessed using the 
WHO Anthro software, version 3.0.1 (http://www.who.int/childgrowth/en/) (Mondal et al., 
2012). This is a tool developed by the WHO, to facilitate nutritional surveys and to promote 
best practices and a standardised approach to data analyses and reporting of anthropometric 
indicators in children 5 years old and below. The tool, based on raw anthropometric and 
demographic data (including age and sex), generates anthropometric estimates based on four 
indicators; length/height–for–age, weight–for–age, weight–for–length/height, and body mass 
index (BMI)–for–age. The output was a set of generated Z-scores for the specific measures 
from which growth and nutritional status was measured; stunting determined by  
height–for–age Z-scores (HAZ), underweight by weight–for–age Z-scores (WAZ) and  
BMI–for–age Z-scores (BAZ), as well as malnutrition by MUAC Z-scores (MUAC and 
MUACZ) and weight–for–height Z-scores (WHZ). Measures with Z-scores <-2 were 
considered abnormal (MOH Malawi 2016). 
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Chapter 3 Dynamics of Schistosoma haematobium 
infection and morbidity in preschool-
aged children aged 6 months–5 years 
Part of this work has been published (Osakunor et al., 2018a) and a copy of the publication is 
included in Appendix E. 
3.1 Introduction 
In schistosome-endemic areas, exposure to schistosome infection is cumulative and increases 
as children grow. Almost all children will have been exposed to schistosome cercariae by age 
one, and the first infection typically occurs within the first 5 years of life (Woolhouse et al., 
2000, Wami et al., 2014). Epidemiological studies show evidence of schistosome infection in 
preschool-aged children (PSAC; 5 years old and below) as early as when they are a year old 
(Woolhouse et al., 2000, Bosompem et al., 2004, Odogwu et al., 2006, Mutapi et al., 2011, 
Kemal et al., 2019, Mutsaka-Makuvaza et al., 2019, Sacolo-Gwebu et al., 2019). Left 
untreated, infection can lead to significant morbidity including poor growth and cognitive 
development, chronic diarrhoea, and anaemia due to progressive blood losses (van der Werf 
et al., 2003, Freer et al., 2018). However, this age group has historically been considered to 
be at low risk of infection (Sacko et al., 2011), with several studies quantifying infection and 
morbidity in school-aged children (SAC), i.e. ≥6 years and adults (van der Werf et al., 2003, 
Gryseels et al., 2006), but not enough comparable studies in PSAC. Consequently, the 
schistosome infection and morbidity burden in this age group, especially the earliest events 
that occur during the first infection, are not fully known and is likely underestimated, with 
negative impacts on on-going schistosome control programmes (Garba et al., 2010). 
Schistosome pathology and morbidity are still being defined in older children and adults in 
order to reflect manifestations of the disease, for example, as with female genital 
schistosomiasis (Kjetland et al., 2012). In PSAC, pathology and morbidity are also still being 
defined in order to identify applicable morbidity markers of disease, for example, urine 
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albumin–creatinine ratio (UACR) (Wami et al., 2015). In addition, growth and nutrition-
related morbidities associated with schistosomiasis only recently became more widely 
recognized (King and Dangerfield-Cha 2008). Thus, in schistosome-endemic areas where 
coinfections and comorbidities are common, elucidating how much of these growth-related 
morbidities are due to schistosomiasis is of importance. There is therefore a need to address 
these gaps and to collate new knowledge to better define schistosomiasis in PSAC, where 
manifestations of disease are poorly described. 
Recently, the World Health Organization (WHO) made a recommendation for the treatment 
of PSAC with schistosomiasis (World Health Organization 2011). The lack of a paediatric 
formulation of the antihelminthic drug, praziquantel (PZQ), has led to the exclusion of PSAC 
from mass drug administration programmes in endemic countries (Stothard et al., 2011, 
Stothard et al., 2013). Concerted efforts are beginning to address this, while PSAC are treated 
upon diagnosis, on a case-by-case basis (Bustinduy et al., 2016a). However, in schistosome-
endemic areas where the first infection typically occurs in PSAC, there is lack of adequate 
knowledge on the earliest events that occur during the first infection in this age group. 
Questions that remain unanswered include: When does infection occur and when can it be 
detected? What are the early morbidity indicators of infection? What are the implications of 
infection in PSAC on current and future health? Longitudinal studies to quantify exposure 
patterns with age, to track the incidence of new schistosome infection and morbidity, and to 
determine implications on current and future health of PSAC are also lacking.  
To address these, I aimed to describe the dynamics of schistosome infection and morbidity in 
Zimbabwean PSAC exposed to Schistosoma haematobium, using existing field diagnostic and 
morbidity tools. I determined the prevalence of S. haematobium infection and morbidity in 
PSAC, and the proportion of growth and nutritional sequelae associated with the infection. 
Following a cohort of schistosome-negative children (not previously infected or treated) for a 
year, I determined the incidence of their first S. haematobium infection and morbidity, as well 
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as the impact of curative treatment on infection and morbidity. The findings of this chapter 
demonstrate the ability of existing diagnostic and morbidity tools to quantify and monitor early 
infection and morbidity in PSAC. It also contributes to addressing the knowledge gaps in the 
global infection and disease burden estimates, and the dynamics of infection and morbidity in 
PSAC. Consequently, this will inform the planning and implementation of control 
programmes targeted at this age group. 
3.2  Hypotheses 
 In schistosome-endemic areas, the first schistosome infection in PSAC can be 
detected early using the current predominant parasitological diagnostic methods. 
 The first infection with S. haematobium is associated with significant morbidity 
early in infection, and resolves following curative treatment with PZQ. 
 The chronic growth and nutritional disorders observed in PSAC in schistosome-
endemic areas are attributable to schistosome infection. 
3.3 Methods 
3.3.1 Study design, population and site 
This was a longitudinal study embedded within the larger paediatric urogenital schistosomiasis 
study, including PSAC aged 6 months to 5 years who met the inclusion criteria for recruitment 
at baseline, as previously described in Chapter 2. For the current study, a cross-sectional study 
was conducted at baseline, followed by a one-year longitudinal study. To be included in the 
longitudinal cohort, children must have fulfilled an additional criterion of being diagnosed 
negative for S. haematobium infection by egg count, as part of the baseline survey. A 
schematic diagram of the study design is shown in Figure 3.1. 
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Figure 3.1: Flow chart of study design 
 
At baseline, recruited children were screened for schistosome infection and morbidity, to 
describe infection and morbidity prevalence. Metadata on socio-demography (including age 
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(MUAC) gathered from questionnaires administered at the time of recruitment were used 
(described in Chapter 2). Of the children who were recruited and invited to participate at 
baseline (n=1783), 1502 children provided samples for parasitological diagnosis of 
schistosome infection. Following this, a group of children confirmed S. haematobium negative 
(n=525) and had not been previously infected or treated for schistosomiasis (assessed by health 
questionnaire and clinical records, as described in Chapter 2), were invited to form the 
longitudinal cohort. This group of children were followed up every quarter to detect their first 
schistosome infection by egg count, and morbidity by microhaematuria. The 3-month follow-
up period was chosen because experimental and previous field studies show that in 3 months, 
new S. haematobium infections can reach patency and thus be detectable by egg excretion 
(Webbe and James 1971, Smith et al., 1976, Wami et al., 2016). At each survey time point, 
all children who were positive for schistosome infection were treated with a single dose of 
PZQ at the standard 40 mg/kg body weight, as described in Chapter 2. A post-treatment 
efficacy check by parasitology was carried out for all previously treated children at each 
subsequent follow-up survey (3 months after each previous survey for S1–S3, and at 6 weeks 
post-treatment for the last survey at S4). 
3.3.2 Sample collection and processing 
Urine and stool samples were collected for parasitological diagnosis of S. haematobium 
infection (all survey time points) and to exclude S. mansoni and soil-transmitted helminths 
(baseline only) respectively. Schistosoma haematobium-related morbidity was measured as 
the presence of macrohaematuria and microhaematuria, using a point-of-care visual 
colorimetry and dipstick urinalysis respectively. Details are as previously described in 
Chapter 2. 
3.3.3 Data handling and statistical analyses  
Growth and nutritional indices adjusted for age and expressed as Z-scores (Mondal et al., 
2012) were calculated using the WHO Anthro software (version 3.0.1), as previously 
[Paediatric Schistosomiasis: Dynamics and Consequences] 
88  [S. haematobium infection dynamics] 
described in Chapter 2. Measures with Z-scores <-2 were considered abnormal (MOH 
Malawi 2016). Data analyses were performed using SPSS version 22 (IBM Corp.), and graphs 
were prepared using GraphPad Prism version 7.02 (GraphPad Software, Inc). Infection 
intensity was expressed as the arithmetic mean egg count/10 ml of at least two urine samples 
collected on three consecutive days. To meet the normality assumption of parametric statistics, 
infection intensity data was log-transformed (log10 [egg count + 1]). The Chi-square test (or 
Fisher’s exact test for small sample sizes) and the Mann-Whitney test were used to test for 
differences in categorical and continuous variables respectively. 
To determine the relationship between age and schistosome infection intensity, and to predict 
how infection intensity changes with age, a linear regression model was used. Age (years) was 
used as the explanatory variable and infection intensity as the response variable. To model the 
infection prevalence (based on a binary response; positive or negative for infection) as a 
function of age (explanatory), the age-dependent logistic regression model was used (Diamond 
and McDonald 1991, Keiding 1991). The prevalence was then fitted as the probability of being 
infected at a specific age, a, using the prevalence probabilities generated from the model. 
To determine the effect of multiple factors on the prevalence of schistosome infection and 
morbidity status (i.e. positive or negative for both indices), multiple logistic regression was 
used. This was done to determine the likelihood of presenting with schistosome infection and 
morbidity, based on multiple factors, and the results were reported as adjusted odds ratios 
(AOR) and 95% confidence intervals (CI), along with the test for significance. Models were 
built using the forward stepwise inclusion of the main terms and their interactions. This 
method was preferred because: (i) the main effects model was used as the baseline model, with 
no potential for inflated mean squared errors (average squared difference between the 
predicted and actual values), and thus a more accurate model, and (ii) the model can be easily 
assessed to avoid saturation with too many terms, which would compromise the consistency 
and efficiency of model parameter estimations (Gould and Lawless 1988). Two-way 
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interactions were included in all models, but none was statistically significant and therefore 
excluded from the final models. Schistosoma haematobium infection was included as a 
response variable (binary), with age (years), sex, microhaematuria, macrohaematuria, and all 
growth and nutritional indices, included as explanatory variables. Each morbidity indicator 
(i.e. microhaematuria, macrohaematuria, and all growth and nutritional indices) was also 
included in separate models, with age (years), sex and S. haematobium infection status as 
explanatory variables.  
The risk of associated morbidity in relation to S. haematobium infection was estimated using 
prevalence ratios (PR). The PR was calculated as a ratio of the proportion of infected 
individuals with the associated morbidity (e.g. microhaematuria) to the proportion of 
uninfected individuals with the same morbidity. A morbidity indicator with a PR >1, suggested 
an increased risk of the associated morbidity from schistosome infection (Booth 1998). The 
method of attributable fraction (AF) was used to estimate the proportion of morbidity that 
could be attributed to S. haematobium infection. The population attributable fraction (AFp) 
and attributable fraction in the exposed (AFe) were used to estimate the morbidity attributable 
fractions in the whole study population and among schistosome-infected children respectively, 
according to Miettinen’s formula (Miettinen 1974): 





The AF in the total population was calculated as: 
 +,! = 0- × +,- (3.2) 
Here, RR is the risk ratio of morbidity associated with infection, and Pe is the prevalence of 
morbidity among the infected population.  
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As suggested by Booth (1998), RR can be substituted with PR in helminth epidemiological 
studies conducted at the cross-sectional level, as is the case with the current study (i.e. the 
baseline survey). AFs were only estimated for morbidity indicators with PR >1, showing a 
positive association with S. haematobium infection.  
Treatment efficacy against S. haematobium infection was assessed by means of egg reduction 
rate (ERR) and cure rate (CR), limited to the cohort of children who were present for post-









× 100% (3.4) 
For all analyses, approximate 95% confidence intervals (CI) were calculated using the 
modified Wald method (Agresti and Coull 1998), and p-values <0.05 were considered 
significant. 
3.4 Results 
3.4.1 Participant characteristics and survey dynamics 
Of the 1502 children recruited, 794 (52.9%) were male. Median age was 3.5 years  
(IQR= 2.5–4.3; range= 0.5–5). Within this cohort, the youngest participant in whom  
S. haematobium infection was detected was a year old. Follow-up and infection rates at each 
survey time point throughout the study are shown in Figure 3.2. 
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Figure 3.2: Flow chart showing participant follow-up and infection rates 
+ve, positive; -ve, negative. 
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3.4.2 Baseline S. haematobium infection and age-dependent profiles 
At baseline, 127 participants (8.5%; 95% CI= 7.2–10.0) were positive for S. haematobium 
infection based on egg counts. Children positive for infection were older when compared to 
those negative for infection (median age 4.0 versus 3.5 years; p= 0.001). There was no 
significant difference in infection prevalence between males and females; 8.9%  
(95% CI= 7.1–11.1) and 8.1% (95% CI= 6.3–10.4; p= 0.067) respectively. The overall mean 
infection intensity was 1.5 eggs/10 ml urine (95% CI= 0.8–2.2) and the majority of children, 
119 (93.7%; 95% CI= 87.9–97.0) presented with light infections (<50 eggs/10 ml of urine) 
based on the WHO classification (WHO Expert Committee 2002). As shown in Figure 3.3,  
S. haematobium infection prevalence and intensity increased with age (p<0.001), supported 
by the age-dependent infection prevalence and intensity model. 
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Figure 3.3: Distribution of S. haematobium infection prevalence and intensity with age 
a) S. haematobium infection prevalence was associated with age (p <0.001), and b) the age-predicted 
probability of infection showed that infection prevalence increased with age (p= 0.002).  
c) S. haematobium infection intensity was associated with age (p <0.001), and d) the age-predicted 
infection intensity model showed that infection intensity increased with age. Error bars indicate 95% 
confidence intervals (panel a) or standard error of the mean (SEM) (panel c), and shaded areas indicate 
95% confidence intervals (panels b and d). 
 
3.4.3 Schistosome-related morbidity at baseline 
Prevalence of urinary morbidity was 0.7% (95% CI= 0.3–1.5) for macrohaematuria, and 8.6% 
(95% CI= 6.9–10.6) for microhaematuria. Prevalence of malnutrition as measured by different 
indices were as follows: MUAC, 2.2% (95% CI= 1.4–3.2), mid-upper arm circumference  
Z-scores (MUACZ), 7.4% (95% CI= 6.0–9.1), and weight–for–height Z-scores (WHZ), 8.2% 
(95% CI= 6.8–9.9). Prevalence of underweight measured by weight–for–age Z-scores (WAZ) 
was 10.1% (95% CI= 8.5–11.9), and that by body mass index–for–age Z-scores (BAZ) was 
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8.8% (95% CI= 7.4–10.6). Prevalence of stunting by height–for–age Z-scores (HAZ) was 
18.0% (95% CI= 16.0–20.3). Comparing infected versus uninfected children, prevalence of 
microhaematuria (43.5%; 95% CI= 34.8–52.6 versus 3.4%; 95% CI= 2.4–5.0 respectively;  
p <0.001) and stunting (27.0%; 95% CI= 19.9–35.6 versus 17.0%; 95% CI= 14.9–19.4 
respectively; p= 0.009) was significantly higher among children with S. haematobium 
infection (Figure 3.4). Prevalence of malnutrition and being underweight by all the different 
indices (MUAC, MUACZ, WHZ, WAZ, and BAZ) were not significant when compared 
between schistosome positive and negative children (p >0.05) (see Supplementary Figure 2 
in Appendix A). 
 
Figure 3.4: Prevalence of schistosome-related morbidity stratified by infection status 
a) Stunting and b) microhaematuria were significantly higher amongst S. haematobium positive 
children. Error bars indicate 95% confidence intervals of the observed prevalence. p-values show test 
for the difference in prevalence of morbidity between the two groups (Fisher’s exact test). 
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3.4.4 Morbidity attributable to S. haematobium infection 
The risk of morbidity from S. haematobium infection was estimated using prevalence ratios 
(PR), based on the different morbidity indices considered. All morbidity markers but one, 
underweight by BAZ, had PR >1, indicating a significant association with S. haematobium 
infection (Table 3.1). However, since morbidities from schistosome infection are not specific 
and may relate to different physiological, biochemical and immunological processes, I 
determined how much of the detected morbidity was attributable to schistosome infection, 
limited to the indices with PR >1. As shown in Figure 3.5, results indicated that 
microhaematuria was the most dominant morbidity attributable to schistosome infection, both 
in infected children (92.0%) and at the population level (40.0%). Macrohaematuria on the 
other hand was highly attributable to schistosome infection in infected children (71.0%), but 
this was not the case in the total population (1.2%). Of the anthropometric markers, stunting 
was the most attributable to schistosome infection both in infected children (38.0%) and at the 
population level (10.3%). 
Table 3.1: Prevalence ratios (PR) for schistosome-related morbidity 
Morbidity Diagnostic tool/index PR (95% CI) 
Microhaematuria Urine dipsticks 12.6 (11.6-14.1) 
Macrohaematuria Visual inspection (colorimetry) 3.4 (1.9-5.4) 
Stunting  HAZ 1.6 (1.05-2.31) 
Malnutrition 
WHZ 1.1 (0.9-1.4) 
MUACZ 1.5 (1.3-1.9) 
MUAC 1.3 (0.8-1.9) 
Underweight 
WAZ 1.4 (1.2-1.6) 
BAZ 1.0 (0.8-1.3) 
PR, prevalence ratio; HAZ, height–for–age Z-scores; WAZ, weight–for–age Z-scores; BAZ, BMI–for–
age Z-scores; MUAC, mid-upper arm circumference Z-scores; WHZ, weight–for–height Z-scores. 95% 
CI, 95% confidence interval. 
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Figure 3.5: Estimated proportion of morbidity attributable to S. haematobium infection 
HAZ, height-for-age Z-scores; MUAC, mid-upper arm circumference Z-scores; WAZ, weight-for-age 
Z-scores; MUAC, mid-upper arm circumference; WHZ, weight-for-height Z-scores. Error bars indicate 
95% confidence intervals. 
 
3.4.5 Risk of schistosome infection and morbidity 
As shown in Figure 3.6a, multiple logistic regression analysis showed that with every unit 
increase in age, children were more likely to acquire S. haematobium infection (AOR= 1.4; 
95% CI= 1.1–1.8; p= 0.005). Similarly, children who presented with microhaematuria were 
more likely to be positive for S. haematobium infection (AOR= 21.8; 95% CI= 11.7–40.7;  
p <0.001), compared to children who were negative for microhaematuria. Regarding 
schistosome-related morbidity, children with S. haematobium infection were 25 times more 
likely to present with microhaematuria (AOR= 25.6; 95% CI= 14.5–45.1; p <0.001), and two 
times more likely to be stunted (AOR= 1.7; 95% CI= 1.1–2.7; p= 0.014), compared to 
uninfected children (Figure 3.6b). 
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Figure 3.6: Odds of presenting with S. haematobium infection and morbidity 
The forest plots show a) the odds of presenting with S. haematobium infection, and b) the odds of 
presenting with microhaematuria and stunting. Error bars indicate the 95% confidence intervals. Non-
significant variables were excluded from the final multiple logistic regression model. 
 
3.4.6 Incidence of infection and morbidity 
The longitudinal cohort of 525 schistosome-negative children were followed quarterly for a 
year, and for each quarter, to determine their first schistosome infection and morbidity 
acquired in the previous 3 months. Annual incidence of S. haematobium infection was 17.4% 
(95% CI= 13.7–21.8) and the incidence of microhaematuria was 20.4% (95% CI= 15.8–26.0). 
Schistosoma haematobium incidence rates showed seasonal patterns. Incidence in the dry 
season was 4.9% in May (95% CI= 3.1–7.8) and 6.5% in August (95% CI= 4.1–9.9), while in 
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the rainy season incidence was 3.8% in November (95% CI= 2.1–6.6) and 3.7% in February 
(95% CI= 2.1–6.5). However, the difference in incidence rates between the dry (10.4%;  
95% CI= 7.6–14.1) and rainy seasons (7.4% total; 95% CI= 5.0–10.9) was not significant  
(p= 0.175). The quarterly incidence of microhaematuria recorded was 2.0% in May  
(95% CI= 0.4–5.9), 2.8% in August (95% CI= 1.0–6.6), 13.3% in November  
(95% CI= 9.6–18.3), and 4.3% in February (95% CI= 2.2–8.1). 
3.4.7 Treatment efficacy and effects of praziquantel treatment on 
morbidity 
Children who received praziquantel treatment for schistosome infection were followed up at 
subsequent surveys (12 weeks post-treatment for all surveys and 6 weeks post-treatment for 
the last survey) for a post-treatment efficacy check. Treatment efficacy was calculated for all 
children found to be positive for infection at baseline and throughout the year for the 
longitudinal study. Of a total 187 children treated for infection (i.e. 127 at baseline and 60 
from the longitudinal cohort), post-treatment data were available for 156 (follow up rate: 
83.4%) [see Figure 3.2]. PZQ was efficacious in reducing S. haematobium infection, as 
indicated by the high CR (96.2%; 95% CI= 91.7–98.4, 150 egg-negatives) and ERR  
(97.3%; 95% CI= 85.0–100, mean egg intensity of 21.60 eggs/10ml at pre-treatment versus 
0.58 eggs/10ml at post-treatment). None of the children included in the current study reported 
adverse side-effects from treatment, and this was confirmed by field clinicians as described in 
Chapter 2.  
The effects of treatment on morbidity was determined for participants from the baseline survey 
and the longitudinal cohort. Data for microhaematuria pre- and post-treatment was available 
for 78 of the 127 S. haematobium-positive cases identified at baseline. Within this cohort, 
42.3% (95% CI= 32.0–53.4) were positive for microhaematuria and this declined significantly 
post-treatment (10.3%; 95% CI= 5.1–19.2; p <0.001).  
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A pooled analysis of egg-positive children identified in the longitudinal cohort was done to 
determine the dynamics of microhaematuria before, during and after infection. Of the total 60 
new infections detected throughout the follow up period, microhaematuria was detected at 
least once, among 18 individuals; 6 (33.3%) pre-infection, 11 (61.1%) during infection, and 2 
(11.1%) post-treatment. In a majority of individuals (61.1%), microhaematuria coincided with 
the detection of S. haematobium infection (within 3 months), and had resolved by the next 
survey at 3 months post-treatment of infection (Figure 3.7). 
 
Figure 3.7: Impact of S. haematobium infection and treatment on morbidity (microhaematuria) 
Microhaematuria status for 18 individual participants is shown at three time points: before, during and 
post-infection (post-treatment). Each data set (dotted line path) represents one individual. Tall, red bars 
indicate positive microhaematuria, and a black dash indicates negative microhaematuria at specific time 
points. 
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3.5 Discussion 
Contrary to the previously held assumption of a low risk to schistosome infection in PSAC 
(Sacko et al., 2011), the evidence of schistosome infection in infants and young children is 
increasingly being recognised (Freer et al., 2018). The operational challenges with diagnosis 
and the lack of adequate knowledge on risks, burden estimates, and health impacts of infection 
and treatment in PSAC are a major challenge for control efforts. In this chapter, I determined 
in a cohort of PSAC, the incidence and dynamics of the first urogenital schistosome infection 
and morbidity, as well as the associated risks and health impacts of the infection. The findings 
showed that PSAC present with schistosome infection (estimated by egg count) and morbidity 
(determined by microhaematuria, growth and nutritional indices) from an early age. This 
infection and associated morbidity can be detected early in PSAC using parasitology and 
dipstick techniques (microhaematuria) within 3 months of the first infection, and is resolved 
after treatment. Chronic growth/nutrition-related morbidity can help identify high-risk groups 
and measure the health impacts of infection and treatment in endemic areas. 
The observed prevalence of S. haematobium infection (8.5%) is comparable to  
S. haematobium prevalence rates reported in other studies conducted in PSAC. Prevalence 
rates of 11.2% have been reported in Ghana (Bosompem et al., 2004), 10.7 % in Malawi (Poole 
et al., 2014), and in Zimbabwe, 13.5% (Wami et al., 2015), 6.7% (Wami et al., 2016) and 
13.3% (Mutsaka-Makuvaza et al., 2018, Mutsaka-Makuvaza et al., 2019). Consistent 
paediatric schistosomiasis research work carried out by our research group (Parasite Immuno-
epidemiology Group) in Zimbabwe, where PSAC are screened and all infected children treated 
with PZQ, may contribute to the lower prevalence rate observed in the current study. Through 
our studies, Schistosoma haematobium prevalence rates in PSAC have progressively declined 
over the years from 29% in the year 2000, to 13.5% as of 2015 (Woolhouse et al., 2000, Mutapi 
et al., 2011, Wami et al., 2015). In addition, the role of increased awareness/education for 
caregivers and parents of PSAC through such studies cannot be overemphasised. Education of 
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the caregiver (through interactive materials) is known to change customs and behaviours that 
put PSAC at risk of schistosome infection (WHO Expert Committee 2002, Beanland et al., 
2006). This may have contributed over time to reduced risk/exposure to schistosome infection, 
hence a lower infection prevalence. That notwithstanding, PSAC present with predominantly 
light infections (Stothard et al., 2011, Colley et al., 2014, Wami et al., 2014) and 
parasitological egg counts can underestimate the prevalence of schistosome infection (Wami 
et al., 2014, Le and Hsieh 2017). Thus, it is likely that the prevalence found in the current 
study may be higher if the more sensitive serological diagnostic tools are used (Wami et al., 
2014). 
In agreement with previous findings (Woolhouse et al., 2000, Kanamura et al., 2002, Lengeler 
et al., 2002, van Dam et al., 2004, Wami et al., 2014), infection prevalence and intensity 
increased as children grew older. The prevalence of infection and its age-associated trend in 
PSAC is an indication that infection, if left untreated, will likely lead to severe morbidity later 
in life (Stothard et al., 2011). 
The interpretation of biomarkers of schistosome-related morbidity in the light of coinfections 
and comorbidities in endemic areas is complex, and calls for better-defined schistosome 
morbidity indicators in PSAC. The majority of such morbidity indicators are non-specific and 
relate to various physiological, biochemical and immunological processes (Webster et al., 
2009). In the current study, the prevalence of morbidity and how much of this was attributable 
to S. haematobium infection was determined. Microhaematuria was the most dominant marker 
of schistosome-related morbidity, and children with S. haematobium infection were more 
likely to present with microhaematuria and vice versa. This agrees with previous findings from 
Zimbabwe (Wami et al., 2015) and Nigeria (Salawu and Odaibo 2014), on the significance of 
microhaematuria as a point-of-care field marker of morbidity for urogenital schistosomiasis in 
PSAC. Haematuria results from epithelial damage when parasite eggs of S. haematobium are 
passed through to the bladder lumen (Wilkins et al., 1979, Gryseels et al., 2006, Colley et al., 
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2014) and correlates with infection intensity (Ismail et al., 2014, Ochodo et al., 2015). Based 
on this, the field utility of microhaematuria in urogenital schistosomiasis has been validated in 
schistosome-endemic areas (Anosike et al., 2001, King and Bertsch 2013) and its applicability 
and sensitivity decreases with age (Akogun and Obidiah 1996, Etard 2004b). Therefore, as 
observed in the current study, microhaematuria is likely to perform better as a diagnostic tool 
for S. haematobium infections in PSAC, than in SAC and adults.  
The prevalence of stunting and malnutrition, and their association with S. haematobium 
infection in this cohort was also investigated. The results showed that of the growth and 
nutritional indices, stunting, as measured by HAZ, was the most dominant marker attributable 
to schistosome infection. Moreover, children with S. haematobium infection were more likely 
to have stunted growth, compared to uninfected children. To the best of my knowledge and at 
the time of writing this thesis, this is the first study showing the relationship between  
S. haematobium infection and chronic growth failure, i.e. stunting, in PSAC. Studies on 
polyparasitism (Mupfasoni et al., 2009, Bustinduy et al., 2013) and limited schistosome 
studies on S. mansoni (Assis et al., 1998) and S. japonicum (Coutinho et al., 2006) have 
however documented this effect in older children. In agreement with the findings of the current 
study, stunting as detected in older children and adolescents is believed to be the result of 
chronic parasite-induced inflammation which persists during childhood (Friedman et al., 
2005). However, causality is difficult to establish in the case of my current findings, due to the 
lag time between the initial infection and the time at which growth failure was measured, as 
well as the impact of confounding factors such as diet and coinfections on overall health. There 
is the need for longer-term studies investigating the impact of treatment on growth and 
development measures in PSAC. Statistical modelling suggests that with early, repetitive 
treatment of infection before the school age (i.e. 6 years old), “catch-up growth” can be 
effectively facilitated (Gurarie et al., 2011). 
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While the prevalence and intensity of schistosome infections have been described in PSAC 
from several African countries, studies describing the incidence of schistosome infection in 
PSAC are lacking. Moreover, although the first infection typically occurs at the preschool age 
in schistosome-endemic areas, knowledge on the earliest events that occur during the first 
infection is lacking; in particular is when infection and morbidity can occur and be detected 
following exposure in this age group. In the current study, I document the incidence of the first 
S. haematobium infection and morbidity in this PSAC population. This group of children had 
not been previously infected or treated for schistosomiasis (assessed by health questionnaire 
and clinical records), and were confirmed schistosome-negative (by egg count) at baseline, 
prior to recruitment into the longitudinal study. Results showed evidence of the first  
S. haematobium infections and morbidity (as measured by microhaematuria), every 3 months. 
This is an indication of the applicability of currently available tools, i.e. parasitology egg 
counts and urine dipstick techniques), to screen for early infection and morbidity in PSAC 
living in schistosome-endemic areas. The incidence of microhaematuria and the associated 
attributable fraction observed, demonstrates that even for the very first schistosome infection 
in PSAC, clinical symptoms and substantial morbidity develops early in infection (Sacko et 
al., 2011, King 2015). In the case of the current study, this was reflected as microhaematuria, 
which  is an indication of active bladder/ureteral lesions and blood losses (Wilkins et al., 1979, 
Gryseels et al., 2006, Colley et al., 2014) even in light intensity schistosome infections, as is 
the case in PSAC (Stothard et al., 2011, Colley et al., 2014). 
The seasonal pattern of infection incidence observed is in agreement with the fact that higher 
temperatures and seasonal rainfall patterns affect transmission, by favouring survival of 
intermediate snail host populations as well as parasite development stages in the snail 
(Chingwena et al., 2002, McCreesh and Booth 2014, Pedersen et al., 2014). During the dry 
seasons, snail vectors and larval schistosomes become concentrated at permanent and slow-
moving water sources, increasing the risk of infection in both the snail and human hosts 
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(Woolhouse and Chandiwana 1989, Rollinson et al., 2001, Monde et al., 2016). In addition, 
snail generation times decrease, and the time from larval infection to production of infective 
cercariae by snails also decreases with increasing temperatures (McCreesh and Booth 2014). 
Observations from the fieldwork conducted for the current study also indicates that during the 
wet seasons, households are less reliant on infective water sources for chores, and children are 
less likely to visit such water bodies for recreational purposes. The incidence dynamics 
observed in the current study confirm that conditions for schistosome exposure in PSAC vary, 
and operational plans for the control of infection in this age group should take such dynamics 
into consideration. 
In terms of the impact of treatment on infection and morbidity, the observed ERR and CR 
showed that a single standard dose of PZQ was effective against S. haematobium infection in 
this PSAC population. This is consistent with reports on PZQ efficacy for schistosomiasis in 
PSAC (Mutapi et al., 2011, Coulibaly et al., 2017, Coulibaly et al., 2018). In addition, studies 
have shown that PSAC tolerate PZQ well, with reports of very few side-effects, including 
abdominal pain, vomiting, fatigue, and diarrhoea that are self-limiting and resolve within 24 
hours (Sousa-Figueiredo et al., 2010, Mutapi et al., 2011, Namwanje et al., 2011, Coulibaly 
et al., 2017, Coulibaly et al., 2018). Thus, it is in line that in this cohort no adverse side-effects 
were reported. Microhaematuria occurred rapidly within 3 months of exposure to infection and 
resolved within 3 months after treatment with PZQ. This finding is in line with the fact that 
microhaematuria is associated with S. haematobium infection (Wilkins et al., 1979, Gryseels 
et al., 2006, Colley et al., 2014), and that treatment with PZQ reduces schistosome-related 
microhaematuria, as used in post-treatment monitoring during large-scale chemotherapy for 
SAC (Koukounari et al., 2007, Webster et al., 2009, King and Bertsch 2013). The observed 
impact of treatment is an important finding for the undelayed/early screening and treatment of 
schistosome infections in PSAC, to avert accumulative morbidity which can affect overall 
health. 
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Previous epidemiological schistosome studies conducted in PSAC have been limited to 
estimating the prevalence and intensity of infection and morbidity. In addition to adding to 
these estimates, the major strength of the current study is that it follows a natural time-course 
to detect the first S. haematobium infections in a preschool cohort, that had not been previously 
infected or treated for schistosome infection. It determines how quickly the very first infection 
can be detected following exposure, when infection-related morbidity develops and can be 
detected, as well as the impacts of treatment on infection and morbidity. Although the impact 
of schistosome infection on the health of children is likely to be greater than those explored 
here, interpretation of the above findings must be done considering the limitations of some of 
the study methods. A limitation of the parasitological detection of infection is that, some light 
infections may have been missed, resulting in misclassification and underestimation of the 
infection rates. Nonetheless, the current study allows comparison with other studies and 
contributes to knowledge on infection and morbidity burden and dynamics, while 
parasitological methods remain the predominant schistosome diagnostic in PSAC. 
3.6 Conclusions 
The current study demonstrates for the first time, incidence of the first schistosome infection 
and morbidity in PSAC, as estimated by egg counts and microhaematuria respectively. This 
infection and morbidity occur rapidly and can be detected within 3 months of first infection. 
More importantly for child health and development, treatment of schistosome infection leads 
to a significant resolution in microhaematuria, and this occurs within 3 months of PZQ 
treatment. In schistosome-endemic areas, chronic growth and nutrition-related morbidity such 
as stunting and malnutrition, are attributable to S. haematobium infection in PSAC. Taken 
together, the findings of this chapter add to the infection and disease burden estimates in 
PSAC, while describing the events that occur early during the first schistosome infection in 
endemic areas. The findings further demonstrate the ability of existing diagnostic and 
morbidity tools, to quantify and monitor early infection and morbidity in PSAC, especially 
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when used together. Undelayed screening and treatment of schistosome infections in PSAC is 
essential to avert accumulative morbidity, which can affect overall health. Operational and 
economic plans for control must take into account incidence rates and dynamics of infection 
and morbidity in this age group, as highlighted here.  
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Chapter 4 Impact of praziquantel treatment on 
Schistosoma haematobium infection and 
reinfection rates in preschool-aged 
children with no history of infection 
4.1 Introduction 
Praziquantel (PZQ) is the antihelminthic drug of choice for treating schistosomiasis (World 
Health Organization 2020b), and is safe and efficacious in preschool-aged children (PSAC), 
i.e. children who are 5 years old and below (Mutapi et al., 2011, Coulibaly et al., 2017, 
Montresor and Garba 2017, Coulibaly et al., 2018). There is increasing evidence that PZQ 
treatment of schistosome infections may have additional benefits beyond the removal of 
infection. PZQ treatment in older children and adults can induce immune responses associated 
with protection against reinfection (Black et al., 2010a, Black et al., 2010b, Bourke et al., 
2013). Recently, our research group (Parasite Immuno-epidemiology Group) demonstrated 
this phenomenon in Zimbabwean PSAC, showing an increase in post-treatment anti-parasite 
immunoglobulin E titres associated with resistance to reinfection (Rujeni et al., 2013). The 
mechanistic pathways of this long-term effect include the enhancement of schistosome-
specific immune responses, by removing the immuno-suppressive effects of infection 
(Mitchell et al., 2011, Nausch et al., 2015, Schmiedel et al., 2015), and introducing parasite-
specific antigens to the immune system to induce and accelerate protective immune responses 
(Mutapi et al., 2005, Mutapi et al., 2008, Bourke et al., 2013). One of the changes underlying 
the progression of schistosome-exposed individuals from a phenotype susceptible to 
infection/reinfection to a phenotype resistant to reinfection, is in the ratio of effector versus 
regulatory immune responses (Nausch et al., 2011). This mechanistic change has been shown 
to occur naturally with infection over longer periods, as well as following curative treatment 
of schistosome infections, but more rapidly with treatment (Mutapi et al., 2005, Watanabe et 
al., 2007, Nausch et al., 2011). 
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Schistosome infections start to become chronic after about 12 weeks post-infection, and with 
stronger immuno-suppressive effects in the host (Pearce and MacDonald 2002, Colley and 
Secor 2014). Therefore, given the current practise of mass drug administration programmes 
(MDA) where the most frequent treatment will be on an annual basis (World Health 
Organization 2006), inclusion of PSAC in MDA programmes will imply treating a majority 
of children who have had to carry infections for a longer time, possibly allowing the infection 
to become chronic and with debilitating effects (Secor 2015). However, pending roll out of the 
paediatric PZQ (undergoing phase III clinical trials) for inclusion in MDA, the currently 
recommended approach for this age group is treatment upon diagnosis, and on a case-by-case 
basis (World Health Organization 2011, Bustinduy et al., 2016a). Therefore, knowledge of 
optimal screening and treatment times to reduce infection, and to maximise the health benefits 
of treatment in terms of reinfection to avert severe or long-term morbidity, will be important 
for the control of paediatric schistosomiasis. 
In the preceding chapter (Chapter 3), I demonstrated the incidence of the first schistosome 
infection and morbidity in PSAC, and the impact of treatment on the reversal of early 
morbidity. This reaffirms the need for early detection and treatment in this age group, to 
prevent the development of severe morbidity, even with the very first infection. My findings 
and those from previous epidemiological field studies in PSAC (Woolhouse et al., 2000, 
Bosompem et al., 2004, Odogwu et al., 2006, Mutapi et al., 2011, Poole et al., 2014, Wami et 
al., 2015, Kemal et al., 2019, Mutsaka-Makuvaza et al., 2019, Sacolo-Gwebu et al., 2019), 
further heighten the need for optimum screening and treatment strategies to improve the health 
benefits associated with PZQ treatment, in terms of reinfection and reducing long-term 
morbidity. Here, I postulated that a single round of PZQ treatment, early in the course of the 
first schistosome infection, may help overcome the effect of regulatory responses, and thus 
allow the development of resistance against reinfection. This is based on the current 
understanding of the development of schistosome-protective immune responses with 
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treatment, and the fact that the rate of acquired resistance to schistosome reinfections is 
dependent on exposure history and repetitive rounds of cure, as seen with treatment of chronic 
infections (Black et al., 2010a, Black et al., 2010b). 
In the current study, I aimed to determine the operational health benefits of regular quarterly 
screening and treatment of schistosome infections (upon first infection), in terms of reducing 
subsequent new infections and reinfections in PSAC. This aim was two-fold; first was to 
determine in a cohort of PSAC experiencing their first schistosome infection, the impact of 
regular quarterly screening and treatment on subsequent infection and reinfection rates. 
Secondly, the reinfection rates and intensity observed following a single PZQ treatment of the 
first schistosome infection in PSAC, was compared to that observed with the treatment of 
chronic infections. Knowledge of a routine screen-and-treat strategy in PSAC, will optimise 
the early detection and treatment of schistosome infections before they become chronic, and 
maximise the health benefits of PZQ treatment, in terms of reduced reinfection and morbidity. 
4.2 Hypotheses 
 Regular quarterly screening and treatment of schistosome infections (upon first 
infection) in PSAC, results in reduced rates of subsequent new infections. 
 In previously uninfected PSAC, a single PZQ treatment of the first schistosome 
infection is associated with resistance to reinfection, similar to or greater than that 
observed following the treatment of chronic infections. This can be optimised to 
prevent severe schistosome-related morbidity in PSAC. 
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4.3 Methods 
4.3.1 Study design, population and site 
The current study followed a 2-year longitudinal infection–treatment–reinfection study design, 
including a subset of 633 PSAC (age range 1–5 years), who met the inclusion criteria for the 
larger paediatric urogenital schistosomiasis study described in Chapter 2. The subset of 
children included in the current study were recruited form the Chihuri, Madziwa and Mupfure 
villages. 
The current study was designed to detect the impact of antihelminthic treatment with PZQ on 
infection and reinfection rates in two groups of schistosome-infected PSAC, i.e. a group of 
children experiencing their first schistosome infection, and a group of children with chronic 
infections. A cross-sectional study was conducted at baseline to screen children for 
schistosome infection, followed by a 2-year longitudinal study to determine infection and 
reinfection rates. The main aspects of the study were: (i) in the first year, to determine the 
impact of treating chronic S. haematobium infection on reinfection rates, and to determine and 
treat first schistosome infections among previously uninfected children, (ii) in the second year, 
to determine the impact of treating the first S. haematobium infection on reinfection rates, at 
least 12 months post-treatment. Further reinfection rates from previously treated chronic 
infections at baseline was also to be determined. To be included in the longitudinal cohort of 
children to be followed up quarterly in the first year, children had to meet an additional 
criterion of being diagnosed negative for S. haematobium infection by egg count at baseline. 
A schematic diagram of the study design is shown in Figure 4.1. 
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At baseline (S0), 633 eligible children were screened for S. haematobium infection by 
parasitology (egg count). Metadata on socio-demography (including age and sex) gathered 
from questionnaires administered at the time of recruitment were used (described in  
Chapter 2). Following this, children confirmed positive for S. haematobium infection by egg 
count (n=109) were treated with a single dose of PZQ at the standard 40 mg/kg body weight 
(as described in Chapter 2), and formed the chronic group that was followed up annually for 
post-treatment reinfections. This group was considered “chronic” because they had no history 
of antihelminthic PZQ treatment prior to diagnosis at the baseline survey (assessed by health 
questionnaire and clinical records, as described in Chapter 2). Thus, children who were at 
least a year old (age range 1–5 years) in this group, were likely to have had infections for at 
least 12 weeks, when infection starts to become chronic (Pearce and MacDonald 2002, Colley 
and Secor 2014). Children confirmed negative for S. haematobium infection (n=524) formed 
the naive group that was followed up quarterly for their first S. haematobium infection and 
treatment in the first 12 months, and in whom reinfection rates would be detected a year later. 
This group was considered “naive” because they had no history of schistosome infection or 
antihelminthic PZQ treatment (assessed by health questionnaire and clinical records, as 
described in Chapter 2). 
For 12 months, the naive group was followed up every quarter (surveys S1, S2, S3, and S4) 
for parasitology to detect their first S. haematobium infection. Both experimental and previous 
field studies show that the 3-month period is the maximum time for new S. haematobium 
infections to reach patency, and thus be detectable by egg excretion in urine (Webbe and James 
1971, Smith et al., 1976, Wami et al., 2016). At each survey time point, all children who were 
positive for schistosome infection were treated with a single standard dose of PZQ (40 mg/kg). 
A post-treatment efficacy check by parasitology was carried out for all previously treated 
children at each subsequent follow-up survey (3 months after each previous survey for S1–S3, 
and at 6 weeks post-treatment at S4). 
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To determine the impact of PZQ treatment on reinfection, previously treated children in the 
chronic group, were followed up at 12 months and at 24 months (S4 and S5 respectively) for 
parasitology. Children previously treated for new schistosome infection in the naive group 
(from S1–S4) were followed up 12 months later (i.e. at 24 months at S5) for parasitology. In 
the naive group, egg-positive children identified at each survey who received treatment and 
were confirmed egg-negative at each subsequent follow-up survey, formed the cumulative 
reinfection cohort followed up at S5. At the end of the study, all children positive for 
schistosome infection were offered treatment. 
4.3.2 Sample collection and processing 
Urine and stool samples were collected for parasitological diagnosis of S. haematobium 
infection (all survey time points) and to exclude S. mansoni and soil transmitted helminths 
(baseline survey only) respectively. Details of sample collection and parasitological diagnosis 
are as previously described in Chapter 2. 
4.3.3 Compliance assessment 
Compliance as used in the current study, was defined as presence at each consecutive survey, 
and having provided the required parasitological samples for diagnosis or post-treatment 
efficacy check. If previously treated for S. haematobium infection, compliance also constituted 
being confirmed negative at post-treatment efficacy check, with no repeat PZQ treatment. 
None of the participants included in the current study received a repeat dose of PZQ treatment. 
4.3.4 Data handling and statistical analyses 
Data were analysed using SPSS version 22 (IBM Corp.), and graphs were prepared with 
GraphPad Prism version 7.02 (GraphPad Software, Inc.). Descriptive statistics were used to 
summarise measures of demography and infection. Continuous data are presented as  
mean ± standard deviation (SD), and categorical data are presented as absolute numbers and 
percentages. Infection intensity was expressed as the arithmetic mean egg count/10 ml of at 
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least two urine samples collected on three consecutive days. To meet the normality assumption 
of parametric statistics, infection intensity data was log-transformed (log10 [egg count + 1]). 
To determine the differences in (re)infection rates and infection intensity between two groups, 
Fisher’s exact test and the t-test were used to test for differences in categorical and continuous 
variables respectively. For all analyses, approximate 95% confidence intervals (CI) were 
calculated using the modified Wald method (Agresti and Coull 1998), and p-values <0.05 were 
considered significant. 
Infection and reinfection rates at a specified time, were calculated as the ratio of the number 
of infected participants to the number of participants seen at that time point, expressed as a 
percentage. Infection and reinfection rates were limited to compliant cohorts of both the naive 
and chronic groups. For the naive group, the rate of new infections at S4 was calculated as the 
cumulative number of infections over the 12-month quarterly follow-up period (S1-S4; 1year). 
The force of infection (FoI) was calculated as the number of S. haematobium infections 
acquired at 3-month intervals, expressed as the number of new infections per unit time. FoI 





Where, λ is the FoI, t is the time (expressed in years), and x(t) is the incidence or proportion 
of infection at the time, t. This was to determine the rate at which susceptible children in the 
naive group acquired schistosome infection. 
In order to determine the amount of time children were at risk of acquiring schistosome 
infection, the child life-years of infection was determined. Using the principle for estimation 
of person-years in a cohort (Vandenbroucke and Pearce 2012), the child life-years of infection 
was defined as the actual time at risk of S. haematobium infection in years, at specified time 
intervals or throughout the study period (cumulative). This was calculated as the number 
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infected at a particular time, multiplied by the risk-period (time to onset of infection) when the 
infection was acquired. The onset of infection was estimated as the midpoint of the time 
interval between being uninfected and becoming infected (i.e. 3 months) (Rothman et al., 
2008). Therefore, a risk-period of 1.5 months for each survey time point was used. 
4.4 Results 
4.4.1 Participant characteristics and survey dynamics 
Overall, 633 children (aged 1–5 years old) were recruited for the current study, with a mean 
age of 3.7 years ± 1.0. Of these, 337 (53.2%) were male and 296 were female (46.8%). At 
baseline, 524 children negative for S. haematobium infection formed the naive group, and 109 
children positive for S. haematobium infection formed the chronic infection group. The total 
number of children recruited, their demographics, and the number of children followed up at 
each survey throughout the first year are shown in Table 4.1. 
Table 4.1: Participant characteristics and survey statistics for the first 12 months 
 Variable Naive  Chronic 
Age in years (mean ± SD) 3.7 ± 0.9 3.79 ± 1.1 
Male 275 (52.5%) 62 (56.9%) 
Female 249 (47.5%) 47 (43.1%) 
Baseline participation (S0) 524 (100%) 109 (100%) 
 
Participation in subsequent surveys *  
 Total Without infection  
3 months (S1) 421 (80.3%) 421 (80.3%) 109 (100) 
6 months (S2) 324 (77.0%) 308 (73.2%) – 
9 months (S3) 269 (83.0%) 236 (76.6%) – 
12 months (S4) 236 (87.7%)  196 (83.1%)  87 (79.8%)  
The table summarises participant demographics and participation numbers in each study group at each 
survey timepoint. * The percentage of children followed up at each survey timepoint was calculated as 
the proportion of participants seen at each previous timepoint. Total= all children seen at a specified 
time point, including previously treated children (from previous time points) followed up for post-
treatment efficacy check. Without infection= number of children seen, including only children who had 
never tested positive at previous timepoints throughout the follow-up period. 
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4.4.2 Schistosome infection dynamics in the first 12 months 
In the first 12 months, incidence of first S. haematobium infections was recorded every quarter 
in the naive group, as indicated by the force of infection and the steady decline in the 
proportion of uninfected children (Figure 4.2 a and b). As shown in Figure 4.2c, the quarterly 
S. haematobium infection rates were 4.0% (95% CI: 2.5–6.4) at 3 months (S1), 5.8% (95% CI: 
3.7–9.1) at 6 months (S2), 5.1% (95% CI: 2.8–8.8) at 9 months (S3), and 6.1%  
(95% CI: 3.4–10.5) at 12 months (S4). 
At each survey time point, all S. haematobium-positive children were offered treatment with 
PZQ. Without quarterly screening and treatment of infections and assuming no natural loss in 
infections with time, the rate of new infections increased with time, showing a linear trend 
(Figure 4.2c). The impact of quarterly screening and early treatment of new infections on the 
number of child life-years of infection (the actual time at risk of S. haematobium infection in 
years) is shown in Figure 4.2d. Analysis showed a steady decline in the number of child life-
years of infection with quarterly screening and treatment, in contrast to that observed assuming 
no treatment with time (i.e. increased with time). The number of child life-years of infection 
at the end of the 12 months would have been a cumulative 7.4 years without treatment, whilst 
that observed with quarterly screening and treatment was 1.5 years. 
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Figure 4.2: S. haematobium infection and treatment dynamics in the first 12 months; naive group 
a) Kaplan–Meier plot showing the decline in the proportion of children followed up, and the decline in 
the proportion of uninfected children with time. b) Force of S. haematobium infection over 12 months. 
c) S. haematobium infection rates over time, comparing infection rates from quarterly screen and 
treatment of infections, with the cumulative prevalence rates assuming no natural loss in infections with 
time. d) Child life-years of S. haematobium infection over time, with and without quarterly treatment. 
Error bars indicate the 95% confidence intervals. 
 
4.4.3 Schistosome infection and reinfection rates at 12 and 24 months 
In the naive group, the annual rate of first infections was calculated as a proportion of the 
cumulative number of new infections to the total number of children followed up at 12 months, 
limited to the compliant group of children only. At 12 months, the cumulative number of egg-
positive children treated and followed up at each consecutive survey was 52, with a total 236 
children remaining/followed up (see Table 4.1) 
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To determine reinfection rates, previously treated compliant children from the chronic group 
at baseline, and previously treated compliant children from the naive group identified within 
the first 12 months, served as the reinfection cohorts for each group. The reinfection cohort 
from the chronic group was followed up at 12 months (S4) and at 24 months (S5), and the 
reinfection cohort from the naive group were followed up at 24 months (S5). In both groups, 
all previously treated children who were present for post-efficacy check were negative for  
S. haematobium infection, and children were excluded from the reinfection cohorts only as a 
result of losses to follow-up. Figure 4.3 shows the annual infection and reinfection rates 
recorded in the naive and chronic groups. 
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Figure 4.3: Flow chart showing the annual infection and reinfection rates 
The number of children (n) and (re)infection rates calculated at each annual time point was limited to 
the compliant group of children present at each consecutive survey point. Green box= new infection 
screen; Yellow box= reinfection screen. 
 
4.4.4 Impact of praziquantel treatment on reinfection rates 
Figure 4.4 shows the infection and reinfection rates compared between the naive and chronic 
groups. Compared to baseline, the rate of reinfection at 12 months post-treatment was 
significantly lower in the chronic group (6.9%, 95% CI= 2.9–14.5, p <0.001), whilst the rate 
of new infections in the naive group was significantly higher (22.0%, 95% CI= 17.2–27.7,  
p <0.001). The rate of new infections in the naive group was 3-fold higher than the rate of 
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reinfections in the previously treated chronic group (6.9%, 95% CI= 2.9–14.5, p= 0.001) [see 
Figure 4.4a]. 
In the naive group, the reinfection rate at 24 months post-treatment (4.9%, 95% CI= 0.5–17.0) 
was significantly lower than the rate of new infections at 12 months (22.0%, 95% CI= 17.2–
27.7, p= 0.009), as shown in Figure 4.4b. This rate of reinfection in the naive group at 24 
months (i.e. 4.9%) was similar to that observed within the same time period (i.e. 12 months) 
at 12 months post-treatment in the chronic group (6.9%, 95% CI= 2.9–14.5, p= 1.000), 
although slightly lower. In the chronic group, reinfection rates at 24 months post-treatment 
(8.7%, 95% CI= 3.7–18.0, p= 0.766) was similar to that observed at 12 months post-treatment 
(Figure 4.4b), with no reinfection rates recorded among those who received a second 
treatment for reinfection at 12 months (see Figure 4.3). 
 
Figure 4.4: Annual S. haematobium infection and reinfection rates, stratified by treatment group 
a) S. haematobium infection and reinfection rates at baseline and at 12 months. For the naive group, the 
rate of new infections is shown at 12 months, and for the chronic group, infection and reinfection rates 
are shown at baseline and at 12 months respectively. b) S. haematobium infection and reinfection rates 
at 12 months and at 24 months. For the naive group, the rate of new infections is shown at 12 months 
and reinfection rate shown at 24 months. For the chronic group, reinfection rates are shown at both 
survey points. Error bars indicate the 95% confidence intervals. p-values are for Fishers exact tests for 
comparisons between groups. 
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4.4.5 Impact of praziquantel treatment on the intensity of reinfection 
For the reinfection cohorts only, the mean infection intensity upon reinfection in both the naive 
and chronic groups were significantly lower, when compared to primary infection intensity 
levels (p <0.001) [Figure 4.5]. The mean infection intensity upon reinfection was similar for 
both groups (p= 0.707), and this was also true for the infection intensity at primary infection 
(p= 0.470). 
 
Figure 4.5: S. haematobium infection intensity at primary infection and upon reinfection, 
stratified by treatment group 
The scatter plot shows S. haematobium infection intensities at both time points and in both groups, 
limited to the reinfection cohorts only. Infection intensities were transformed [(log10 (egg count +1)] to 
meet normality assumptions for parametric tests. Horizontal lines represent mean (± standard error of 
the mean). p-values show t-tests for comparisons between groups; paired t-tests for within group 
comparisons at two time points. 
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4.5 Discussion 
Urogenital schistosomiasis remains a major public health burden among PSAC in tropical and 
subtropical regions. PZQ treatment for schistosomiasis is effective in PSAC (Mutapi et al., 
2011), and has been shown to have an added benefit of inducing/accelerating a protective 
immune response, which can last for more than a year in older children and adults (Bourke et 
al., 2013). In this chapter, I determined the impact of a single PZQ treatment on reinfection 
rates in a cohort of Zimbabwean PSAC experiencing their first schistosome infection. I tested 
the hypothesis that in previously uninfected children, a single treatment of the first schistosome 
infection is associated with resistance to reinfection, similar to that observed following 
treatment of chronic infections, as will occur with MDA treatment strategies. The results 
showed that in previously uninfected PSAC (naive group), regular quarterly screening and 
treatment of the first S. haematobium infection reduces the actual time at risk of infection in 
the population, and results in reduced rates of subsequent new infections. PZQ treatment of 
both the first and chronic schistosome infections, was associated with significantly lower 
reinfection rates a year later. The rate of reinfection following treatment of first infections was 
similar to that observed following treatment of chronic infections. The observed effect of 
treatment on reinfection was commensurate with infection intensity, showing that the infection 
intensity upon reinfection was significantly lower than the primary infection intensity levels. 
In the first year, regular quarterly screening and treatment of first infections in the naive group, 
resulted in reduced rates of subsequent new infections every quarter. This was reflected in the 
lower number of child life-years of infection, i.e. the actual time at risk of S. haematobium 
infection, when schistosome infections are detected and treated early in the population. This 
is consistent with evidence suggesting that antihelminthic treatment of infected children in the 
population, has the potential of lowering levels of contamination of shared water sources, and 
subsequently reduces exposure and infection transmission (Hodges et al., 2012, Senghor et 
al., 2016). It is also plausible that the regular quarterly screening within the community was 
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accompanied by increased awareness among the caregivers and parents of PSAC, resulting in 
positive changes to behaviours that put PSAC at risk of schistosome infection (WHO Expert 
Committee 2002, Beanland et al., 2006). 
In the current study, the impact of PZQ treatment on lower reinfection rates and intensity, 
compared to that of primary infections in both the naive and chronic groups, is consistent with 
reports from other epidemiological field studies (Wilkins et al., 1987, Wu et al., 1993, N'goran 
et al., 2001, Kabuyaya et al., 2017). This effect is further confirmed by the fact that within the 
same year (year 1), the annual rate of first infections in the naive group was about 3-fold 
higher, when compared to the annual reinfection rate observed in previously treated children 
from the chronic group. At the time of writing this thesis, the novelty of the current study lies 
in the fact that in addition to treatment of chronic infections, as will be the case in conventional 
MDA treatment strategies in endemic areas, my findings show this same effect using a single 
early treatment in PSAC experiencing their very first schistosome infection. Moreover, the 
rate of reinfection in the naive group was lower, although not significantly different from that 
observed in the chronic group. Hence, regular screening to detect and treat schistosome 
infections early in PSAC will have similar benefits to treating chronic schistosome infections, 
in terms of resistance to reinfection, if not greater. Residual morbidity or delay in resolution 
of morbidity post-treatment from chronic schistosome infections is common (Colley et al., 
2014). Therefore, as the crux of current treatment and control efforts is to reduce infection 
intensity and morbidity (Kabatereine et al., 2003), early detection and treatment may have the 
added benefit of averting long-standing schistosome-related morbidity in PSAC, in addition 
to reducing reinfection rates. 
In the sub-group of children from the chronic group at baseline who were reinfected a year 
post-treatment, a repeat dose of PZQ treatment was administered, and no reinfection was 
recorded in the second year. This is in agreement with human field studies in adults, showing 
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that schistosome-exposed individuals develop resistance to reinfection, with increasing rounds 
of multiple PZQ treatments (Karanja et al., 2002, Black et al., 2010b).  
While the mechanisms underlying the effects of PZQ treatment on reduced reinfection rates 
and intensity were beyond the scope of the current study, my findings can be contextualised 
within the current paradigm of the development of acquired protective immunity against 
schistosomiasis. The findings in the current study are consistent with human immuno-
epidemiology studies showing that PZQ treatment of schistosome infections in PSAC (Rujeni 
et al., 2013), older children, and adults (Watanabe et al., 2007, Black et al., 2010a, Black et 
al., 2010b, Bourke et al., 2013, Schmiedel et al., 2015), can induce effector responses 
associated with protection against reinfection. Experimental helminth infection in nematodes 
has shown that antihelminthic treatment of short-lived primary infections, results in greater 
levels of treatment-induced acquired protection against reinfection than that achieved by 
allowing adult worms to reside in the host for several weeks (Behnke and Robinson 1985). 
This may be relevant to PSAC experiencing their first schistosome infection; screening for 
and treating infections early may have the added benefit of not allowing infections to persist 
for longer periods, reducing the possibility of severe morbidity, and the possibility of inducing 
resistance to reinfection. 
This proof-of-principle study clearly demonstrates the health benefits of early treatment of the 
first schistosome infections in PSAC, in terms of reducing the rate of subsequent new 
infections, as well as reinfection rates and intensity. However, there is a need for larger studies 
determining the practical long-term operational and economic implications of regular 
screening to diagnose and treat primary schistosome infections of all species, early in PSAC. 
Failure to obtain significant differences in reinfection rates between the naive and chronic 
groups could be due to the smaller sample sizes of infected individuals followed up for 
reinfection. In addition, schistosome diagnosis by microscopically enumerating excreted eggs 
is less sensitive for very low intensity infections, especially in PSAC, thus underestimating the 
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primary infection rates observed in this study. This may also influence the lower numbers of 
infected individuals to be followed up for reinfection. Nonetheless, this does not affect the 
findings in the current study, as the comparison was between pre- and post-treatment infection 
rates, using the same diagnostic technique and within the same cohorts in each group. 
4.6 Conclusions 
I have demonstrated that in previously uninfected PSAC, PZQ treatment of the first 
schistosome infection is associated with a level of resistance to reinfection, similar to that 
observed following treatment of chronic infections. This effect was commensurate with 
schistosome infection intensity, showing a significantly lower infection intensity upon 
reinfection. Regular quarterly screening and treatment of the first S. haematobium infection 
results in reduced rates of subsequent new infections. Given the health consequences in terms 
of long-term morbidity from chronic schistosome infections, a regular screen-and-treat 
strategy as part of routine child health and development monitoring activities, will optimise 
the chances of detecting and treating schistosome infections early, while reducing the risk of 
new infections, reinfection, as well as severe morbidity. 
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Chapter 5 Differences in host metabolic profiles in 
Schistosoma haematobium infected vs. 
uninfected preschool-aged children 
5.1 Introduction 
Like all other parasites, schistosome worms living inside the definitive human host depend on 
host resources for survival, and cause it harm (Borgsteede 2004). In endemic areas with high 
infection transmission, infection with schistosomes is cumulative and can be acquired within 
the first year of birth (Woolhouse et al., 2000). The health impacts of Schistosoma 
haematobium infection thus begin at this early age and can include haematuria, protein wasting 
(Wilkins et al., 1979, Colley et al., 2014, Wami et al., 2015, Freer et al., 2018), malnutrition, 
poor growth, and cognitive impairment (Freer et al., 2018). Left untreated, infection can persist 
for years, leading to pathology including anaemia, poor reproductive health, increased 
susceptibility to sexually transmitted infections (Freer et al., 2018), prostate cancer (Tuffour 
et al., 2018), urothelial carcinogenesis (Gelfand et al., 1967, Ishida and Hsieh 2018), bladder 
dysfunction, fibrosis, and renal failure (Lichtenberg 1975, Ishida and Hsieh 2018). 
Interaction between the schistosome worm and its human host is central for parasite survival 
and to establish a parasitic relationship. For instance, schistosome worms rely on host glucose 
for survival (Bueding 1950, Wu et al., 2010b). Schistosome infection also induces parasite-
specific T-helper type 2 (Th2) immune responses and host immuno-modulation that promote 
parasite survival for decades (Pearce and MacDonald 2002, van Riet et al., 2007, Colley and 
Secor 2014, van der Zande et al., 2019); the changes in host immune responses can alter host 
metabolic function, disease susceptibility and patterns, and overall host health (Brestoff and 
Artis 2015). Experimental schistosome studies have shown that in order to establish 
themselves and survive in the host, schistosome worms require host-derived endocrine steroid 
and thyroid hormones (de Mendonca et al., 2000, Saule et al., 2002, You et al., 2015), CD4+ 
T-lymphocytes (Davies et al., 2001), as well as cytokines including tumour necrosis factor 
[Paediatric Schistosomiasis: Dynamics and Consequences] 
128  [S. haematobium and host metabolism] 
alpha (Amiri et al., 1992, Davies et al., 2004) and interleukin-7 (Saule et al., 2002). When 
such host factors are unavailable to the parasite, there is poor parasite development and 
fecundity, combined with reduced pathology in the host (Cheng et al., 2008, Lamb et al., 2010, 
Tang et al., 2013). Together, the available experimental evidence further indicates that parasite 
alterations in host pathways extend to metabolic homeostasis. The metabolic phenotypes of 
mice during Schistosoma infection show that infection and disease are linked to alterations in 
gut microbiota metabolism (Wang et al., 2004, Wu et al., 2010b), as well as changes in amino 
acid, lipid and energy metabolism (Ahmed and Gad 1995, Wang et al., 2004, Li et al., 2009, 
Wu et al., 2010b). Alterations in liver metabolism due to parasite egg-induced inflammatory 
responses have also been reported (Garcia-Perez et al., 2008). Studies characterising the host 
metabolic phenotype during human schistosomiasis are limited. Nonetheless, two studies 
(Balog et al., 2011, Panic et al., 2018) have analysed urine samples to characterise the host 
metabolic changes during human S. mansoni infection. The findings reported were similar to 
those from experimental models, in terms of alterations in energy, liver, and gut microbiota 
metabolism (Balog et al., 2011, Panic et al., 2018). 
While the significant detrimental effects of schistosome infections on host health are 
unarguable, some experimental and human epidemiological studies have suggested that the 
sustained host metabolic alterations from schistosome infections may reduce the occurrence 
and severity of other conditions, including metabolic syndrome (Zaccone et al., 2003, Stanley 
et al., 2009, Wu et al., 2010b, Chen et al., 2013, Wolde et al., 2019). The exact mechanisms 
of these effects however remain to be fully understood (van der Zande et al., 2019). There is 
therefore a need for further studies on the dynamics of host-parasite relations at the molecular 
level, to elucidate the pathways involved in pathology and disease progression versus those 
ameliorating metabolic syndromes. 
In the case of S. haematobium infection in infants and young children, little is known about 
the basic mechanisms underlying the pathophysiology of the disease, and the disease is poorly 
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understood at the molecular level (Rollinson 2009). There are limited human studies on the 
impact of schistosome infection on host metabolism, and metabolic phenotyping of blood 
samples from cases of human schistosomiasis has not been reported. The majority of previous 
investigations both in human and in animal models have been based on well-established late 
stage schistosome infections, not allowing the early metabolic changes associated with the first 
schistosome infection to be elucidated. Most studies have also focused on S. mansoni and S. 
japonicum infections, and there have not yet been any published studies on the impact of 
human S. haematobium infection on the host metabolism. 
The aim is of this chapter was to characterise the host metabolite profiles of preschool-aged 
children (PSAC; aged 5 years and below) before their first S. haematobium infection, and the 
changes that occur following infection and curative treatment. The impact of such metabolite 
alterations on host metabolic pathways and schistosome-related morbidity was also 
determined. Using capillary electrophoresis mass spectrometry (CE-MS), the serum 
metabolite profiles of S. haematobium-infected PSAC was determined and compared to that 
of uninfected children. The findings in this chapter add to the understanding into schistosome 
infection and its association with the host metabolism, disease progression and morbidity in 
PSAC. This will inform appropriate new strategies such as nutraceuticals, to reduce 
schistosome-associated morbidity in control programmes targeted at this age group. 
5.2 Hypotheses 
 Schistosoma haematobium infection in PSAC is associated with alterations in host 
metabolite profiles early in infection. 
 The alterations in host metabolite profiles are commensurate with infection 
intensity, and are linked with host metabolic pathways implicated in schistosome-
related morbidity. 
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5.3 Methods 
5.3.1 Study design, population and site 
The current study followed a longitudinal study design that included a subset of 83 children 
(aged 2–5 years), meeting the inclusion criteria for the larger paediatric urogenital 
schistosomiasis study described in Chapter 2. Children not previously infected or treated for 
schistosomiasis (assessed by health questionnaire and clinical records, as described in 
Chapter 2) were selected from the Madziwa village, and were followed to detect their first  
S. haematobium infection. The group of children included in the current study were selected 
based on the following: (i) consent from parents/guardians, (ii) availability of socio-
demographic data, (iii) availability of parasitology samples (urine and stool samples) for 
diagnosis at recruitment, (iv) confirmed schistosome negative by S. haematobium and S. 
mansoni egg count as part of the baseline survey, and (v) confirmed negative for soil-
transmitted helminths (STH). A schematic diagram of the study design is shown in Figure 5.1. 
 
Figure 5.1: Schematic diagram of study design 
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For the 83 schistosome-negative children recruited at baseline, metadata on socio-demography 
(including age and sex), and anthropometry (including weight, height, and mid-upper arm 
circumference) gathered from measurements and questionnaires administered at the time of 
recruitment were used (details in Chapter 2). Growth and nutritional indices (height–for–age 
Z-scores (HAZ), weight–for–age Z-scores (WAZ) and weight–for–height Z-scores (WHZ)) 
were calculated from anthropometric measurements, as described in Chapter 2. A venous 
blood sample was also collected from each child and later processed for serum metabolite 
analysis. Children were then followed up 3 months later to detect their first S. haematobium 
infection. Both experimental and previous field studies show that in 3 months the new S. 
haematobium infections would have reached patency and thus be detectable by egg excretion 
(Webbe and James 1971, Smith et al., 1976, Wami et al., 2016). At this follow up survey, a 
second blood sample was collected from all children for serum metabolite analysis to detect 
changes from baseline levels. All children who were positive for S. haematobium infection 
were treated with a single dose of praziquantel (PZQ) at the standard 40 mg/kg body weight 
(WHO Expert Committee 2002), as described in Chapter 2. For treated children, a post-
treatment efficacy check (by egg count) and blood sampling were carried out 3 months later 
for post-treatment serum metabolite analysis. 
5.3.2 Sample collection and processing 
Urine and stool samples were collected for parasitological diagnosis of S. haematobium 
infection and to exclude intestinal helminths respectively (S. mansoni and STH), as described 
in Chapter 2. Collection of blood samples and further processing for serum were as described 
in Chapter 2. Blood samples were preferred to urine samples for metabolite analysis because 
it is less susceptible to metabolite variations related to sample collection time and food intake 
(Kim et al., 2014). Other pre-analytical conditions including avoiding repeated freeze and 
thaw, and rejection of haemolysed samples were adhered to (Yin et al., 2015). Thus, sample 
collection and processing conditions followed standard considerations as recommended for 
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metabolite analysis (Yin et al., 2015). Aliquots of serum samples were shipped on dry ice for 
sample preparation and metabolite analysis at the Human Metabolome Technologies Inc. 
(HMT; Yamagata, Japan). Metabolite analysis were carried out by HMT using the capillary 
electrophoresis time-of-flight mass spectrometry (CE–TOF–MS)-based metabolomics 
technique, as described in Chapter 2. 
5.3.3 CE-TOF-MS data acquisition and processing  
Peak information including mass-to-charge ratio (m/z), migration time (MT), and peak area, 
were extracted using automatic integration software (MasterHands ver. 2.17.1.11 developed 
at Keio University) at HMT. Relative peak area was calculated using a peak detection limit 





For peak annotation, putative metabolites were then assigned from HMT’s standard library 
and Known–Unknown peak library, based on m/z and MT. In instances where a feature 
matched with multiple annotations within their m/z and MT windows, all alternatives are 
provided. The tolerance level was ±0.5 min in MT and ±10 ppm in m/z (Soga et al., 2003): 




× 10" (5.2) 
To quantify target metabolites, single-point (100 μM) calibrations were used to obtain standard 
curves for each internal metabolite standard added to the sample. Absolute metabolite 
concentrations were then calculated by normalizing the peak area of each target metabolite 
with respect to the area of the internal standard. This minimised technical variability in the 
entire run of the CE–TOF–MS analysis, and enabled sample to sample comparisons in data 
analysis. 
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Peak areas of putative metabolites along with concentrations of quantified metabolites, 
expressed in μM, were received as Excel files from HMT for further analysis. A total of 248 
metabolite peaks (145 in cation and 103 in anion mode respectively) were detected and 
annotated based on HMT’s standard and Known–Unknown peak library. Of these, 70 target 
metabolites were detected and quantified (40 in cation and 30 in anion mode respectively), 
and these were used for all downstream analysis. Individual samples for which a target peak 
or metabolite was below detection limits and thus could not be quantified, the peak area or 
concentration of the metabolite was captured as “Not detected (N.D)”. 
5.3.4 Data pre-processing 
Prior to any downstream analysis, a data integrity check and pre-processing was performed 
using MetaboAnalyst, a web‐based tool for the analysis of metabolomic data (Xia et al., 2009, 
Xia and Wishart 2011, Chong et al., 2018). First, the entire data set from all three time points 
was checked for missing values. Overall, metabolite concentration values should be non-
negative and without missing values (in this case “N.D”); these cause difficulties in data 
normalisation and downstream analysis. Since missing or zero values were caused by 
metabolites with abundance below the detection limit, and not a mere absence, these were 
replaced by a small pseudo value (i.e. half the minimum positive value in the entire data set= 
0.15 μM). 
Metabolite data sets were then processed to remove data for metabolites with a constant value 
across all samples. By default, MetaboAnalyst removes data for metabolites with a constant 
or a single value across all samples. For example, a metabolite with concentration values of 
0.15 μM across all 83 samples will be removed. For the metabolite data set at baseline, six 
metabolites were found and removed (adenosine triphosphate (ATP), anthranilic acid, betaine 
aldehyde + H2O, dihydroxyacetone phosphate, glycerol-3-phosphate, and phosphoenolpyruvic 
acid). 
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To determine the change in metabolite concentrations in response to schistosome infection, 
the change in metabolite concentrations (∆C) at baseline (C1) and at follow up for infection 
(C2) was calculated as, ∆C μM= C2 – C1 (μM). The resulting data set was then processed to 
remove data for metabolites with a constant value across all samples. Likewise, the six 
metabolites which were found and removed from the baseline metabolite data set were also 
removed by default. To improve statistical power, eight additional metabolites with less than 
n= 10 non-zero change in concentration values (∆C) across all samples were excluded from 
analysis with the change in concentration metabolite dataset (i.e. 14 metabolites in total 
excluded; the same six metabolites from baseline analysis, in addition to 2-phosphoglyceric 
acid, fumaric acid, guanosine diphosphate (GDP), glucose-1-phosphate, glyoxylic acid, 
guanine, uridine diphosphate (UDP), and uracil). 
To allow for biologically-related scaling of data and ensure that all metabolites are treated as 
equally important during downstream analysis, data were processed by range scaling (mean-
centred and divided by the value range of each variable) (van den Berg et al., 2006). 
5.3.5 Statistical analyses 
Data analyses and visualisation were performed using SPSS version 22 (IBM Corp.), 
MetaboAnalyst (Xia et al., 2009, Xia and Wishart 2011, Chong et al., 2018), and GraphPad 
Prism version 8.2.0 (GraphPad Software, Inc). Full details of the statistical methods used here 
are described in Chapter 2. A schematic diagram showing an overview of the statistical 
methodology used is shown in Figure 5.2. 
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Figure 5.2: Schematic diagram of statistical methodology 
MANOVA, Multivariate Analysis of Variance; PCA, Principal Component Analysis; OPLSDA, 
Orthogonal Projections to Latent Structures Discriminant Analysis 
 
To test the null hypothesis that the mean differences in metabolite profiles between groups of 
interest are likely due to chance, Multivariate Analysis of Variance (MANOVA; SPSS) with 
sequential sums of squares was used, as recommended for infectious disease data from human 
epidemiological studies (Mutapi and Roddam 2002). In this case, the effects of each term are 
adjusted only for the effects of terms preceding it in the model, and the order in which variables 
are entered into the model is essential; the variables of interest are thus entered after other 
confounding variables (Mutapi and Roddam 2002). Where a variable was found to be 
significant, the model was re-run without the significant variable, and the residuals from the 
resulting model were saved and subjected to further analysis to identify discriminatory 
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metabolites compared across that variable (MetaboAnalyst). This was to ensure that the 
confounding effects of factors such as age and sex were already accounted for, prior to 
downstream analysis to determine the most relevant metabolites accounting for differences in 
metabolite profiles between groups of interest. 
Age- and sex-dependent effects exist for metabolites (Gu et al., 2009, Fan et al., 2018). Thus, 
a MANOVA model to determine and account for underlying age and sex-related effects at 
baseline, which may account for differences in metabolite concentrations post-infection was 
run. The model included age (years), sex, and their interaction, in that order. To further identify 
specific metabolites associated with sex at baseline (significant in the initial MANOVA 
model), the model was re-run with age, and the residuals saved for further analysis in 
MetaboAnalyst. To determine the change in metabolite concentrations due to schistosome 
infection, a model including age (years), sex, infection status and their interactions, in that 
order was used. To further identify metabolites associated with schistosome infection status 
(significant in the initial MANOVA model), the model was re-run with age, sex, and their 
interaction, and residuals saved for further analysis. 
Residual metabolite concentration data sets (from MANOVA models) along with participant 
metadata were imported into MetaboAnalyst. Univariate analysis was used to identify 
metabolites that are potentially different between two groups, and to show metabolite variation 
patterns under different conditions. Fold change (FC) analysis was used to compare absolute 
value changes in metabolite concentrations between groups, and a concentration ratio (i.e. 
between the two groups) of at least 2-fold was considered significant (Patterson et al., 2006). 
Pattern correlation analysis (Pearson’s) was used to determine metabolites showing interesting 
patterns of change under different conditions, and to look for linear/periodic trends in the 
dataset. A false discovery rate (FDR) threshold of <0.05 (Benjamini and Hochberg 1995) was 
considered significant. 
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Multivariate analysis was then used to identify significant metabolites associated with sex and 
schistosome infection. For an informative first-hand look at the dataset, an unsupervised 
Principal Component Analysis (PCA) was used to assess clustering trends and group 
separation in the dataset. To identify the specific metabolites accounting for differences in 
metabolite profiles between groups of interest, a supervised multiple regression analysis 
method, Orthogonal Projections to Latent Structures Discriminant Analysis (OPLSDA) 
(Wiklund et al., 2008) with Orthogonal Signal Correction (OSC) filtering (Wold et al., 1998), 
was used to discriminate groups and identify the differentially expressed metabolites that drive 
group separation. This supervised method has been shown to be more reliable at overcoming 
the limitations of heterogeneity associated with analysis of human metabolomic data, where 
PCA does not reveal changes in metabolite profiles across groups (Singer et al., 2007, Balog 
et al., 2011). Cumulative model statistics, R2Y(cum) and Q2(cum), were calculated for each 
model and used to assess the degree of fit and predictive reliability respectively (Wold et al., 
2001). The significance of the model was evaluated using permutation testing (n= 1000), with 
a p-value threshold of <0.05 (Szymanska et al., 2012).  
5.3.5.1 Model selection of significant metabolites 
For all valid OPLSDA models, an S-plot showing the variable importance in a model, 
combining the covariance or contributions [X-axis; p(1)] and the correlation or reliability 
coefficient [Y-axis; p(corr)] loading profile was generated. This was used to identify and select 
significant metabolites with the highest correlation coefficient within groups (p(corr)) and with 
the highest contribution to the model separation between groups (p(1)). The p(corr) values are 
robust to variable selection in the OPLSDA model and are thus comparable between different 
models (Wheelock and Wheelock 2013). The variable importance in the projection (VIP), a 
weighted sum of squares of the partial least square (PLS) loadings, taking into account the 
amount of explained group variation in each dimension, was also calculated for each 
component. As recommended, a combination of the S-plot [cut of: absolute p(corr) >0.5] and 
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a VIP value (cut off: VIP ≥1.5) was used to identify and select significant differentially 
expressed metabolites between groups (Wheelock and Wheelock 2013). 
5.3.5.2 Relationship with infection burden 
To further determine the relationship between significant differentially expressed metabolites 
during S. haematobium infection and infection burden, range-scaled residuals from the change 
in concentration metabolite data set (from MANOVA models) were regressed on the log-
transformed infection intensity (log10 [egg count+1]). 
5.3.5.3 Pathway enrichment analysis and topology analysis 
To identify metabolic pathways associated with schistosome infection and facilitate further 
biological interpretation of the metabolite alterations observed, metabolite pathway analysis 
was performed using MetaboAnalyst. Data for the differentially expressed metabolites 
identified from the infection status OPLSDA model were queried against associated Homo 
sapiens metabolic pathway libraries (downloaded on 04.06.2019), curated from Kyoto 
Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg/). The pathway 
analysis combines results from powerful pathway enrichment analysis with pathway topology 
analysis to identify the most significant pathways. 
The pathway enrichment analysis entailed quantitative enrichment analysis, using the 
metabolite concentration values to identify subtle but consistent changes amongst metabolites 
involved in the same biological pathway. As MetaboAnalyst is a web-based tool, the Global 
Test was used and p-values were approximated based on the asymptotic distribution without 
using permutations; this is suitable when the most relevant pathways are to be identified, and 
thus the rank of the pathway is most essential. The Global Test allows the use of metabolites 
selected based on prior analysis, and to investigate groups of differentially expressed 
metabolites of biological interest (Goeman et al., 2004). The pathway topology analysis in 
MetaboAnalyst takes into consideration the structure of biological pathways to estimate 
significant pathways that change under different conditions. The method of out-degree 
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centrality, which represents the number of links that are initiated from a node (metabolite), 
was used. Under this method, it is assumed that nodes upstream will have regulatory roles for 
the downstream nodes, not vice versa (i.e. assuming that upstream metabolites will have 
regulatory effects on downstream metabolites but not vice versa, and that changes in more 
important positions of a network will trigger a more severe impact) (Aittokallio and 
Schwikowski 2006). 
5.4 Results 
5.4.1 Population characteristics 
As shown in Table 5.1, median age was 3 years (range; 2–5 years) and 41 (49.4%) of the 
children were female. At follow up, 11 (13.3%) were positive for S. haematobium infection 
with mean infection intensity of 0.8 (SEM= 0.3; 95% CI = 0.2–1.5) eggs/10 mL of urine. 
Table 5.1: Participant characteristics 
Variable Total Female Male Baseline 
Age (years)    
Median 3 (3-4) 3 (3-4) 3.5 (3-4.3) 
2  8 (9.6) 4 (9.8) 4 (9.5) 
3 35 (42.2) 18 (43.9) 17 (40.5) 
4 25 (30.1) 14 (34.1) 11 (26.2) 
5 15 (18.1) 5 (12.2) 10 (23.8) 
Height (cm)  96.0 (91.0-102.0) 96.0 (91.5-98.0) 
100.0 (91.0-
104.0) 
Weight (kg)  14.0 (12.7-16.0) 14.0 (12.1-15.0) 15.0 (13.0-16.0) 
MUAC (cm) 15.0 (14.0-16.0) 14.6 (14.0-15.4) 15.0 (14.0-16.0) 
Mean WHZ -0.29 (1.29) -0.30 (1.23) -0.28 (1.36) 
Mean WAZ -0.59 (1.19) -0.62 (1.23) -0.56 (1.16) 
Mean HAZ -0.70 (1.38) -0.69 (1.45) -0.71 (1.33) 
 Follow up (3 months) 
S. h Infection status     
Negative 72 (86.7) 34 (82.9) 38 (90.5) 
Positive 11 (13.3) 7 (17.1) 4 (9.5) 
S. h Infection intensity 
(eggs/10 ml urine)  0.8 (0.2–1.5) 0.5 (0.1–1.0) 1.1 (0–2.3) 
The table shows characteristics of the sample population at baseline and at follow up. Growth and 
nutritional indices adjusted for age and expressed as Z-scores (Mondal et al., 2012), were calculated 
using the WHO Anthro software (version 3.0.1), as previously described in Chapter 2. Data are 
expressed as median (IQR) or n (%), except for WHZ, WAZ, and HAZ, which are mean (SD). S. 
haematobium infection intensity is shown as mean (95% confidence interval). S. h., S. haematobium; 
WHZ, weight–for-height Z-scores; WAZ, weight–for-age Z-scores HAZ, height-for-age Z-scores. 
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5.4.2 Metabolic differences associated with age and sex 
Initial MANOVA models were built using baseline metabolite profiles to identify any 
underlying age and sex metabolite variations in the study population, pre-infection, and to 
identify any potential confounders. From the baseline model, metabolites were found to vary 
across sex, but not age. The model was then re-run with age only, and the residuals were used 
to identify the specific metabolites that vary with sex (Table 5.2). 
Table 5.2: Baseline MANOVA output for age and sex influence on metabolite data 







Intercept 0 64 16 0 1.000 
Age 1.259 64 16 0.834 0.314 
Sex 2.736 64 16 0.916 0.014 
Age * Sex 0.619 64 16 0.712 0.910 
Equation: Intercept + Age + Sex +Age * Sex 
  
Model to obtain residuals 
Intercept 1.066 64 18 0.791 0.462 
Age 1.133 64 18 0.801 0.400 
Equation: Intercept + Age  
 
df, degrees of freedom. 
 
As shown in Figure 5.3, univariate FC analysis showed that the concentrations of 16 
metabolites were lower/down-regulated (≥2-fold) in females (panel a). Pattern correlation 
analysis showed that metabolite concentrations tend to be higher in males (panel b); of these, 
7 metabolites showing this pattern were statistically significant. This included creatinine (p 
<0.001), citrulline (p <0.001), cis-asconitic acid (p= 0.004), gamma-aminobutyric acid 
(GABA; p= 0.006), sarcosine (p= 0.014), 2-oxoisovaleric acid (p= 0.040), and isocitric acid 
(p= 0.040). After an FDR correction, creatinine (FDR <0.001) and citrulline (FDR <0.001) 
remained significant. The output details from FC and pattern correlation analysis are shown in 
Supplementary Tables 1 and 2 in Appendix B. 
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Figure 5.3: Metabolite profiles by sex (univariate) 
a) Metabolites identified by fold change (FC) analysis of female/male ratio with threshold of 2-FC. 
Values are on a log scale to show both up-regulated and down-regulated metabolites symmetrically. 
The plot shows metabolites that are up-regulated (positive-log scale) or down-regulated (negative log-
scale). Pink symbols represent metabolites above the 2-FC threshold. b) Pattern correlation analysis 
showing metabolites (based on unadjusted p-values), showing different patterns between female and 
male. GABA, gamma-aminobutyric acid; Ala, alanine; GMP, guanosine monophosphate; IMP, inosine 
monophosphate; UDP, uridine diphosphate; Asn, asparagine; F, female (n=41); M, male (n=42). ***,  
p <0.001; **, p <0.01; *, p <0.05. 
 
Based on the univariate analysis, multivariate analysis was used to determine significant 
metabolites associated with sex. Initial PCA analysis with a model of five components 
explaining 64.2% of the variability, was aimed at identifying clustering according to sex. The 
PCA model however did not show any clear clustering by sex (Supplementary Figure 1 in 
Appendix B). This reflects the heterogeneity of data associated with human metabolomic 
studies (Singer et al., 2007), in contrast to animal models where in-bred animals may 
contribute to clustering within the first few components (Wang et al., 2004). To unmask 
changes, a supervised OPLSDA model was used to identify significant metabolites associated 
with sex (N= 83, 1 predictive and 1 orthogonal component; Q2= 0.146, p= 0.001 and  
R2Y= 0.352, p= 0.033; validation plots are shown in Supplementary Figure 2 in  
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Appendix B), from which a coefficient S-plot was used to identify significantly contributing 
metabolites discriminating between male and female. Based on the set selection criteria, males 
were observed to have increased concentrations of creatinine (p(corr)= 0.8, VIP= 2.9), 
citrulline (p(corr)= 0.7, VIP= 3.1), sarcosine (p(corr)= 0.6, VIP= 1.7), and GABA (p(corr)= 
0.5, VIP= 2.4) compared to females (Figure 5.4; output details in Supplementary Table 3 in 
Appendix B). 
 
Figure 5.4: Metabolite profiles by sex (multivariate) 
a) Score plot and b) Coefficient S-plot based on OPLSDA model of metabolite distribution according 
to sex (Y variable). Metabolites that significantly influenced the model (absolute p(corr) >0.5 and VIP 
≥1.5) were creatinine, citrulline, sarcosine and GABA (gamma-aminobutyric acid). For the S-plot, the 
y-axis represents the correlation or reliability coefficient and the x–axis represents the covariance or 
contributions of each metabolite to the model with respect to sex. F, female (n=41); M, male (n=42). 
 
5.4.3 Metabolic profiles during early schistosome infection 
Due to the baseline variations in metabolite concentrations related to sex, subsequent models 
to determine change in metabolite concentrations with schistosome infection were verified to 
account for potential bias. MANOVA models were built on change in metabolite concentration 
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sex. Results showed that S. haematobium status was associated with metabolite concentrations. 
For further downstream analysis, the model was re-run with age and sex only, and the residuals 
were used to identify metabolite features that vary by S. haematobium infection status (see 
Table 5.3 below). 
Table 5.3: Follow-up MANOVA output for influence of infection on metabolite data 







Intercept 0 56 21 0 1.000 
Age 1.432 56 21 0.792 0.184 
Sex 0.742 56 21 0.664 0.813 
Infection status 2.231 56 21 0.856 0.023 
Age * Sex 0.960 56 21 0.719 0.567 
Sex * Infection status 1.901 56 21 0.835 0.053 
Age * Infection status 1.056 56 21 0.738 0.463 
Equation: Intercept + Age + Sex + Infection status+ Age * Sex + Sex * Infection status + 
Age * Infection status  
 Model to obtain residuals 
Intercept 0 56 24 0 1.000 
Age 1.214 56 24 0.739 0.307 
Sex 0.778 56 24 0.645 0.782 
Age * Sex 1.002 56 24 0.700 0.516 
Equation: Intercept + Age + Sex +Age * Sex 
df, degrees of freedom. 
 
Univariate FC analysis showed that 25 metabolites were either up-regulated or down-regulated 
in schistosome infection (>2-fold) (Figure 5.5a). Based on pattern correlation analysis, 
different metabolites showed either an increasing or decreasing pattern with schistosome 
infection (Figure 5.5b); of these, 16 metabolites showing this pattern were statistically 
significant. Metabolites that showed a pattern of increasing concentration with schistosome 
infection included adenosine diphosphate (ADP; p <0.001), 3-phosphoglyceric acid (3-PG;  
p <0.001), adenosine monophosphate (AMP; p <0.001), inosine (p= 0.012), asparagine  
(p= 0.016), 2-hydroxybutyric acid (p= 0.021), sarcosine (p= 0.023), guanosine monophosphate 
(GMP; p= 0.032); glucose-6-phosphate (G6P; p= 0.043), and ethanolamine phosphate  
(p= 0.043). Metabolites that showed a pattern of decreasing concentration with schistosome 
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infection included lactic acid (p= 0.017), choline (p= 0.017), serine (p= 0.020), cis-asconitic 
acid (p= 0.023), histidine (p= 0.031), and glutamic acid (p= 0.045). After an FDR correction, 
ADP (FDR= 0.003), 3-PG (FDR= 0.003), and AMP (FDR= 0.014) remained significant. The 
output details from FC and pattern correlation analysis are shown in Supplementary Tables 
4 and 5 in Appendix B). 
 
Figure 5.5: Metabolite profiles by schistosome infection status (univariate) 
a) Metabolites identified by fold change (FC) analysis by uninfected/infected ratio with threshold of  
2-FC. Values are on a log scale to show both up-regulated and down-regulated metabolites 
symmetrically. The plot shows metabolites that are up-regulated (positive-log scale) or down-regulated 
(negative log-scale). Pink symbols represent metabolites above the 2-FC threshold. b) Pattern 
correlation analysis showing the top 25 metabolites (based on unadjusted p-values), showing different 
patterns between schistosome negative (n=72) and positive (n=11) children. ADP, adenosine 
diphosphate; AMP, adenosine monophosphate; Asn: asparagine; GMP, guanosine monophosphate; 
Asp; aspartic acid, Phe, phenylalanine; Leu, leucine; Lys, lysine; Gly, glycine; Ala, alanine; Glu, 
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Multivariate analysis was used to determine significant metabolites associated with 
schistosome infection. Initial PCA analysis with a model of five components explaining 57.5% 
of the variability, was used to identify clustering according to infection status. Likewise, the 
PCA model did not show any clear clustering by infection status (Supplementary Figure 3 
in Appendix B), and heterogeneity in the data set may conceal metabolic changes 
characteristic of infection within the first few components (Singer et al., 2007). To unmask 
such changes, a supervised OPLSDA model was used (N= 83, 1 predictive and 1 orthogonal 
component; Q2= 0.197, p= 0.001 and R2Y= 0.465, p= 0.001; validation plots are shown in 
Supplementary Figure 4 in Appendix B), from which a coefficient S-plot was used to 
identify significant metabolites discriminating between infected and uninfected children. 
Based on the selection criteria, S. haematobium-infected children were found to have increased 
concentrations of AMP (p(corr)= 0.7, VIP= 1.6), 3-PG (p(corr)= 0.7, VIP= 1.5), ADP 
(p(corr)= 0.6, VIP= 2.3), and G6P (p(corr)= 0.6, VIP= 1.5) [Figure 5.6; details in 
Supplementary Table 6 in Appendix B]. 
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Figure 5.6: Metabolite profiles by schistosome infection status (multivariate) 
a) Score plot and b) coefficient S-plot based on OPLSDA model of metabolite distribution according to 
infection status (Y variable). Metabolites that significantly influenced the model (absolute p(corr) >0.5 
and VIP ≥1.5) were adenosine monophosphate (AMP), 3-phosphoglyceric acid (3-PG), adenosine 
diphosphate (ADP), and glucose-6-phosphate (G6P). For the S-plot, the y-axis represents the correlation 
or reliability coefficient and the x–axis represents the covariance or contributions of each metabolite to 
the model with respect to infection status. Infection status was coded as 0 and 1 for uninfected (n=72) 
and infected (n=11) respectively. 
 
Of interest, a MANOVA model to determine the influence of infection intensity on the 
significant metabolites identified by OPLSDA (accounted for age and sex), was significant  
(F-value= 5.178, Partial Eta-squared= 0.21, p= 0.001). As shown in Figure 5.7, concentrations 
of all observed metabolites associated with schistosome infection, increased as infection 
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Figure 5.7: Observed metabolite changes are commensurate with schistosome infection intensity. 
Figures a–d) Scatter plots showing linear regression analysis of infection intensity and change in 
metabolite concentration (∆C) of the specific metabolites identified by OPLSDA as associated with S. 
haematobium infection (n=83 independent samples). S. haematobium infection intensity was log-
transformed [log10 (egg count+1)]. Shaded areas indicate the 95% confidence intervals. AMP, adenosine 
monophosphate; ADP, adenosine diphosphate. 
 
5.4.4 Effects of curative treatment on metabolite profiles 
Of the 11 S. haematobium-positive children, a post-treatment follow-up sampling was 
conducted 3 months later to determine treatment efficacy, with a follow up rate of 6/11 
(54.5%). Cure rate and egg reduction rates (as estimated by egg counts) were 100% in the six 
children followed up, and the impact of treatment on the concentration of the observed 
metabolites was determined in these six children. As shown in the heat map below, pattern 
analysis across all three time points showed that metabolite concentrations increased at 
infection and reduced to near pre-infection levels, post-treatment. Although not significant  
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(p >0.05), pattern correlation analysis showed that metabolite features exhibit a decreasing 
trend from infection to when children are cured (Figure 5.8; output details in Supplementary 
Table 7 in Appendix B). 
 
 
Figure 5.8: Metabolite concentrations decrease to near-uninfected levels after treatment of 
infection 
a) Heatmap showing the mean concentration patterns of specific metabolites (associated with S. 
haematobium infection) at pre-infection, infection and at post-treatment. Colour scale (1 to -1) shows 
Pearson’s correlation co-efficient for up-regulated (positive scale) and down-regulated (negative scale) 
metabolites. b) Plot shows the absolute mean concentration of metabolites (associated with S. 
haematobium infection) at pre-infection, infection and at post-treatment. c) Pattern correlation analysis 
showing decreasing patterns from schistosome positive to negative at post-treatment (increasing order 
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5.4.5 Metabolite pathways associated with schistosome infection 
The metabolite pathway analysis assigned metabolite compounds in a total of seven pathways, 
which were identified together as important for the host response to schistosome infection (the 
full individual metabolic pathways are shown in Supplementary Figures 5 and 6 in 
Appendix B). The predominant hits were energy and purine pathways involved in glycolysis 
or gluconeogenesis, purine metabolism, pentose phosphate pathway (PPP), starch and sucrose 
metabolism, galactose metabolism, amino acid and nucleotide sugars metabolism, and 
nitrogen metabolism in order of decreasing impact and significance (Figure 5.9; output details 
in Supplementary Table 8 in Appendix B; the statistical p-values from enrichment analysis 
are further adjusted for multiple pathway testing). 
 
Figure 5.9: Summary of metabolite pathway analysis 
Pathway map showing the affected metabolic pathways. The map was generated in MetaboAnalyst and 
shows all matched pathways according to the p-values from the pathway enrichment analysis, and 
pathway impact values from the pathway topology analysis. The size of each circle represents the degree 
of impact on the pathway, and significance levels based on p-values range from yellow (least 
significant) to red (most significant). 
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Based on the pathway analysis, two biological hypotheses were proposed for the metabolite 
alterations observed (Figure 5.10). The adult worm uses large amounts of host glucose and 
energy (Bueding 1950). This stimulates host glycolysis and leads to an increase in host ADP 
and AMP (Carling et al., 2012, Hardie et al., 2012). Energy demand for increased protein 
synthesis could also lead to direct dephosphorylation of ATP, increasing host AMP. Energy 
demands from the parasite also increases host glycogenolysis, gluconeogenesis and fatty acid 
synthesis, increasing the levels of host G6P and 3-PG, essential to enhance the pentose 
phosphate pathway (PPP) and fatty acid synthesis respectively. In addition, schistosome 
tegumental phosphatases and phosphohydrolases e.g. SmAP (Cesari et al., 1981, Bhardwaj 
and Skelly 2011), dephosphorylate the increased exogenous host phosphate molecules (G6P, 
AMP, ADP), for parasite purine (i.e. adenosine) and glucose uptake. The resulting 
extracellular adenosine is also known to dampen host immunity (Hasko and Cronstein 2004, 
Bours et al., 2006, Gessi et al., 2007) and induce host immunomodulation (van Riet et al., 
2007) essential for parasite survival. 
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Figure 5.10: Pathway-based model related to the observed metabolic alterations in early S. 
haematobium infection 
In response to schistosome infection and increased demands from the host, there is ­ glycolysis,  
­ pentose phosphate pathway, ­ fatty acid synthesis ­ gluconeogenesis ­glycogenolysis, as well as  
­ purine synthesis for salvage by the parasite, leading to the observed increases in the host metabolites 
identified (i.e. AMP, ADP, 3-PG, and G6P). AMP, adenosine monophosphate; ADP, adenosine 
diphosphate; ATP, adenosine triphosphate; 3-PG, 3-phosphoglyceric acid; PPP, pentose phosphate 
pathway; SmAP, schistosome tegumental alkaline phosphatase. 
 
5.5 Discussion 
Host-parasite interactions during schistosome infection are underpinned by the exchange of 
essential metabolites between the host and the parasite (as described above in section 5.1). 
Metabolomic studies thus help to provide understanding of the host metabolic responses to 
infection. Unlike animal studies, the health and ethical challenges of conducting schistosome 
infection and mechanistic studies in humans (as discussed in Chapter 2) have limited our 
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understanding into infection and disease mechanisms relating to the aetiology, as well as 
clinical manifestations of morbidity and immunopathology. In experimental studies, it is 
possible to infect animals at specific time points, follow the course of infection, and investigate 
its impact on the host; this is however not possible in human hosts. To overcome this challenge, 
the current study followed S. haematobium infection of PSAC living in a schistosome-endemic 
area in Zimbabwe, using a natural infection time-course design. A cohort of PSAC for whom 
there was no evidence of previous infection by schistosomes, was followed to their first 
schistosome infection and curative treatment. This was informed by knowledge of exposure 
to infection, and from previous sero-epidemiology studies in PSAC conducted by our research 
group (Rujeni et al., 2013, Wami et al., 2014). Using a comprehensive mass spectrometry-
based approach, the results demonstrate that the first S. haematobium infection is associated 
with alterations in host metabolites, primarily linked with energy and purine metabolism. The 
observed changes were commensurate with increasing infection intensity, a confirmation that 
the changes were associated with the presence of S. haematobium infection. Metabolite levels 
were restored to almost pre-infection levels, following curative treatment with the 
antihelminthic drug, PZQ. 
The metabolic profiles of children were analysed at baseline in order to characterise 
metabolites in the absence of schistosome infection, as well as to account for confounding 
factors in subsequent analysis for metabolite changes upon schistosome infection. Levels of 
creatinine, citrulline, sarcosine/N-methylglycine and GABA were higher in males than in 
females. A potential explanation for this difference in amino acid metabolites could be 
differences in weight between the children. In adults, increased amino acid metabolites have 
been attributed to higher muscle mass in males (Lukaski 1996), and this is consistent with the 
higher weight and associated weight–for-age Z-scores (a standardised assessment of weight in 
young children, relative to age (MOH Malawi 2016)) in the male children included in the 
current study. However, there are limited studies on protein and amino acid metabolism in 
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healthy children, and there is a need for further studies to determine if the observations in 
adults translate to body profiles in young children (Markofski and Volpi 2011). 
At follow-up within 3 months of first schistosome infection, there were significant increases 
in AMP, ADP, 3-PG, and G6P, compared to uninfected children, and these increases correlated 
positively with infection intensity. Metabolic pathway analysis showed that the increases were 
related predominantly to energy (glycolysis, PPP, starch, and galactose) and purine 
metabolism. This is consistent with findings from studies conducted in experimental models 
of schistosome infection (Ahmed and Gad 1995, Wang et al., 2004, Liu et al., 2019), showing 
that such host metabolic alterations can begin as early as three weeks post-infection (Wu et 
al., 2010b). 
The observed increases in discriminatory metabolites associated with schistosome infection 
has a physiological explanation. S. haematobium predominantly resides in the venous plexus 
of the bladder with direct access to the flow of nutrients in blood. Experimental studies have 
shown that the schistosome worm relies on the host’s glucose for survival (Wu et al., 2010b). 
Studies have long established that every 5–6 hours, schistosome parasites utilise their dry body 
weight’s worth of glucose from the host, marked by increased lactate and reduced glucose levels in 
the host blood stream (Bueding 1950, Schiller et al., 1975, Bueding and Fisher 1982). Another 
consequence of schistosome infection is liver injury, as confirmed by histology in experimental 
studies (Wu et al., 2010b) and in enzymatic human studies  (Abdel-Rahim et al., 1990). The liver 
injury is marked by stimulated host glycolysis, manifested by reduced plasma glucose as well as 
glucose and glycogen stores in the liver, as early as 49 days post-infection (Wang et al., 2004). 
Under such nutrient-poor conditions in the host, one of the main results of increased consumption 
of energy is an increase in AMP and ADP, consistent with the observation in the current study 
(Carling et al., 2012, Hardie et al., 2012). These molecules act as sensors for energy homeostasis 
that help activate alternative pathways such as glycogenolysis, gluconeogenesis, and fatty acid 
synthesis in attempts to replenish energy stores. Also consistent with the observed increases 
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in AMP in such nutrient-poor conditions, is the enhanced energy demand for increased protein 
synthesis, especially for tRNA activation and guanosine triphosphate regeneration, which 
results in direct dephosphorylation of even more ATP to AMP by the host system (Pontes et 
al., 2015). Parallel to the increased glycolysis, the increased levels of G6P and 3-PG enhances 
the oxidative phase of the PPP (oxidising even more glucose to produce energy) to generate 
nicotinamide adenine dinucleotide phosphate (NADPH) for host anabolic reactions, including 
the biosynthesis of nucleic acids and fatty acids (Eggleston and Krebs 1974). Although this 
remains a pathway-based interpretation, the observed alteration in energy metabolism pathways 
including glycolysis and the PPP, are in line with current understanding that such pathways of 
glucose utilisation are predominantly stimulated during schistosome infection (Ahmed and 
Gad 1995, Wang et al., 2004, Wu et al., 2010b). Moreover, evidence from experimental 
studies show that the liver injury caused by schistosome infection (Wu et al., 2010b) is marked 
by stimulated host glycolysis, manifested by reduced plasma glucose as well as glucose and 
glycogen stores in the liver (Wang et al., 2004). Taken together, the results suggest an interplay 
between the host and schistosome worms, consistent with the parasite-related morbidity 
observed in young children, including malnutrition, poor growth, and poor physical and 
cognitive performance (Freer et al., 2018). 
Schistosome worms have essential phosphatases and phosphohydrolases such as SmAP, a 
schistosome tegumental alkaline phosphatase that cleave exogenous phosphates to generate 
various reaction products (Cesari et al., 1981, Bhardwaj and Skelly 2011). In addition, 
schistosome worms lack de novo synthesis of purines and resort to salvaging molecules from 
the host using these tegumental phosphatases (Levy and Read 1975a), through 
dephosphorylation and subsequent uptake of reaction products (Levy and Read 1975b). Thus, 
the observed increases in AMP, ADP, and G6P are important for parasite purine and energy 
uptake, via phosphate cleavage using tegumental enzymes. The resulting exogenous molecules 
such as adenosine have anti-inflammatory properties known to dampen host immunity (Hasko 
                                               [Paediatric Schistosomiasis: Dynamics and Consequences] 
[S. haematobium and host metabolism]  155 
and Cronstein 2004, Bours et al., 2006, Gessi et al., 2007). For instance, adenosine inhibits 
the production of pro-inflammatory cytokines and inflammatory mediators (Hasko et al., 
2000), inhibits lymphocyte adhesion, and attenuates the proliferative and cytotoxic responses 
of activated T-cells (Hoskin et al., 2002, Zhang et al., 2004). This would benefit schistosome 
parasites by creating a less inflammatory and immunologically friendly environment, key to 
survival of the parasite in the host. Data suggests that such essential functions of parasite 
phosphatases occur in vivo but less in vitro, consistent with the hypothesis of the benefits of 
such molecules for schistosome survival in the host (Bhardwaj and Skelly 2011). Another direct 
benefit of the enhanced PPP in generating molecules for fatty acid synthesis in the host is that, 
schistosomes rely on scavenging lipid precursors from the host to generate phospholipids, due their 
inability to synthesise fatty acids de novo (Meyer et al., 1970, Brouwers et al., 1997). Schistosome 
lipids have also been demonstrated to stimulate immunomodulation of the host to enhance parasite 
survival (van der Kleij et al., 2002, Giera et al., 2018).  
The correlation between metabolic alterations and increasing infection intensity is consistent 
with experimental studies of metabolic changes being linked to disease progression in 
schistosome infection (Li et al., 2009, Wu et al., 2010b). In addition, curative treatment with 
PZQ in schistosome-positive children showed a decrease in levels of the altered metabolites, 
3 months post-treatment. Consistent with normalisation of affected pathway enzymes upon 
treatment of schistosome infection in mice models (Ahmed and Gad 1995), this strengthens the idea 
that the observed changes are in response to or related to schistosome infection (Wu et al., 2010b). 
This observation is also consistent with the fact that curative treatment results in the reversal of early 
schistosome morbidity/pathology (Wami et al., 2016), and with suggestions that catch-up growth 
and development is possible in children, following curative PZQ treatment (Gurarie et al., 2011). It 
is thus plausible that the observed effect of curative treatment would have been more marked, had 
the children been surveyed for longer than 3 months post-treatment. This is because it may take 
longer than 3 months for metabolite levels to return to pre-infection levels. 
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The strength of the current study is that the study design allowed for analysis of matching pre- 
and post-infection samples, to gain understanding into the early metabolic responses leading 
to morbidity from the first schistosome infection in young children who had never been 
infected. However, it was limited to the fact that following a natural time-course of first 
schistosome infections meant there was no control over the number of infected or uninfected 
children included in the study post-baseline, hence smaller sample sizes especially for 
schistosome positive individuals. The urine filtration technique used for diagnosis of  
S. haematobium infection in the current study is less sensitive to detecting very low intensity, 
pre-patent or single sex infections. However, the current study allows comparison with other 
studies while parasitological egg count methods remain the predominant schistosome 
diagnostic in PSAC. Long-term studies relating measurable clinical manifestations of 
schistosome infection in children to such metabolic alterations, would give a stronger 
indication of the clinical implications of the schistosome-induced metabolic disturbances. 
5.6 Conclusions 
I showed that in a cohort of Zimbabwean PSAC (≤5 years old), the first infection with  
S. haematobium is associated with significant alterations in host energy and purine 
metabolism, early in infection. These changes correlated with infection intensity and resolved 
3 months post-curative antihelminthic treatment. The findings suggest an interplay between 
the host and schistosome worms, consistent with parasite survival, disease progression, and 
parasite-related morbidity including malnutrition, poor growth, and poor physical and cognitive 
performance in schistosome-infected children. The findings in this chapter will inform 
development of appropriate interventions in human helminth infections, such as nutraceuticals 
in child feeding programs, targeted at reducing morbidity associated with the disease. Further 
mechanistic studies will contribute to more understanding of the role of metabolic alterations 
in the aetiology of schistosome-related pathology in children. 
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Chapter 6 Differences in the gut microbiome and 
resistome in Schistosoma haematobium 
infected vs. uninfected preschool-aged 
children 
Part of this work has been published (Osakunor et al., 2020) and a copy of the publication is 
included in Appendix E. 
6.1 Introduction 
There is increasing evidence that humans rely on the gut microbiota (a diverse ecosystem of 
microbes) (Lukes et al., 2015) for essential functions including extracting essential nutrients 
from food, as a first line of protection from enteric pathogens, and as a mechanism for shaping 
the immune system (Human Microbiome Project Consortium 2012). These essential functions 
are however not facilitated by the same microbiota in all people (Shafquat et al., 2014). Large 
scale projects that have characterised the microbiome (the assembly of genomes of the 
microbiota) have shown that considerable heterogeneity exist among different human 
populations (Turnbaugh et al., 2007, Human Microbiome Project Consortium 2012). 
Studies have shown that the composition of the human gut microbiome is influenced by age 
(Yatsunenko et al., 2012, Rodriguez et al., 2015), diet and geography (De Filippo et al., 2010, 
Fan et al., 2014, Senghor et al., 2018), host genotype (Goodrich et al., 2014), exposure to 
maternal microbiota (Dominguez-Bello et al., 2010), as well as environmental factors 
(Martinez et al., 2015) including the role of protozoal and helminth parasites (Mishra et al., 
2014). However, populations in Africa have been underrepresented in microbiome studies, 
with a major focus on Western populations (Brewster et al., 2019). Limited number of studies 
have included African populations, but with a focus on elucidating the impact of geographical 
and lifestyle differences on the gut microbiome of African and Western populations (De 
Filippo et al., 2010, Yatsunenko et al., 2012, Rampelli et al., 2015). Studies that have focused 
on African populations have included older individuals (i.e. 20–40 years old) whose 
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microbiome structure (abundance and diversity) is already established (Schnorr et al., 2014), 
not allowing the factors inherent to African childhood to be fully disentangled.  
In Africa, children are exposed to several acute and chronic parasitic infections that can impact 
significantly on their growth and development (Bustinduy et al., 2013). In particular, 
schistosome worms can be contracted by children as young as 6 months of age (Mafiana et al., 
2003, Bosompem et al., 2004). Consequences of schistosome infection at this young age can 
include malnutrition, poor growth and cognitive development, as well as susceptibility to, and 
altered prognosis of coinfections (van der Werf et al., 2003, Freer et al., 2018). From birth, 
the gut microbial population continues to evolve until about age 3–5 years (Yatsunenko et al., 
2012, Rodriguez et al., 2015). Therefore, infections that young children are exposed to can 
influence the establishment of the microbiome, and has implications on overall health and 
disease (Laforest-Lapointe and Arrieta 2017). Microbiome research focused on preschool-
aged children (PSAC), i.e. 5 years old and below, will provide further insight for influencing 
health through the microbiome in infants and young children (Robertson et al., 2019). 
Evidence shows that schistosome infections acquired at the preschool age can persist into the 
second decade of life where they modulate the immune system to promote parasite survival, 
and cause long-term disease; reviewed by McManus et al., (2018). There are suggestions that 
the immunomodulatory effects of schistosome infection can extend to the gut microbiota 
through indirect systemic interactions (Mishra et al., 2014). Correlations between the gut 
microbiome and systemic diseases such as rheumatoid arthritis suggest the importance of such 
systemic interactions (Scher et al., 2013). Recently, fluctuations in the composition of the gut 
microbiota of mice infected with S. mansoni, before and after intestinal damage from egg 
transmission was shown (Jenkins et al., 2018). Furthermore, depletion of the gut bacteria was 
associated with reduced S. mansoni egg excretion, gut pathology and inflammation in mice 
(Holzscheiter et al., 2014). This is consistent with the role of the mammalian gut microbiota 
in the pathogenesis of schistosomiasis. However, unlike S. mansoni (intestinal form) that 
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inhabits blood vessels close to the same environment as the gut microbiota,  
S. haematobium predominantly resides in the venous plexus of the bladder (although it has 
occasionally been found in the mesenteric circulation (Cheever et al., 1977)), and thus presents 
a need for further studies into the indirect systemic impacts of the infection on the gut 
microbiota.  
Much of our understanding of the helminth interactions with the gut microbiota in humans has 
been facilitated by experimental studies (as discussed in Chapter 1), and phenotypic and 
mechanistic studies from natural human infections are limited. A recent study conducted in 
children 13 years old and below reported differences in gut microbiota abundance between  
S. haematobium infected versus uninfected children, suggesting the presence of different 
microbial communities during schistosome infection (Kay et al., 2015). This was supported 
by Schneeberger et al., (2018) in an S. mansoni study, suggesting that genetic and 
environmental factors may play an additional role. More recently, a study conducted among 
older children (11–15 years) in Nigeria suggested that microbiome disruptions may be a 
further consequence of urogenital schistosomiasis (Ajibola et al., 2019). However, substantial 
knowledge gaps on the interaction between the gut microbiota and schistosome infection in 
PSAC still exist (Mutapi 2015b). Further studies into the associations between human 
schistosome infection and the gut microbiota in PSAC are important to gain insight into 
variations in infection/disease burden and patterns. It will also provide insight into 
opportunities to design treatment regimens to improve overall child health and development. 
The biggest challenges are in the ability to demonstrate causation and elucidate mechanistic 
pathways for any existing interactions. 
6.1.1 The resistome in microbiome analysis 
Antimicrobial resistance (AMR) to bacteria is one of the largest threats to human health, and 
occurs when bacteria adapt to exposure and treatment with antibiotics (Wise and Soulsby 
2002). The microbiome is a reservoir for AMR genes (collectively known as the resistome) 
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(Qin et al., 2010, Hu et al., 2013), and provides an ideal environment for AMR gene exchange 
among the “resident” and transitory bacterial populations (Jernberg et al., 2010), contributing 
to AMR. Thus, it is plausible that any alterations in the gut microbiota could have an impact 
on AMR gene abundance and diversity. In examining the impact of interactions between 
helminth infections, including schistosomiasis, on the composition of the gut microbiome, it 
is important to examine other interactions relevant to the health of the host, including impacts 
on the resistome. One such example is the ability of Salmonella to persist in the body by 
attaching to intestinal schistosomes and evading repeated antibiotic treatments, as 
demonstrated by experimental studies (LoVerde et al., 1980, Barnhill et al., 2011). This 
phenomenon can lead to an increase in the Salmonella population, and eventually, potential 
antibiotic resistance from persistent antibiotic treatment (Barnhill et al., 2011). 
While AMR remains one of the largest threats to human health (Qin et al., 2010, Doron and 
Davidson 2011, De Waele et al., 2018), the majority of AMR gene studies are conducted in 
industrialised settings (Hu et al., 2013, Wellington et al., 2013, Woolhouse and Ward 2013, 
Blair et al., 2015, Holmes et al., 2016), which contrast with low- and middle-income countries 
in terms of access to safe water and sanitation, as well as access to antibiotics, with or without 
prescriptions (Okeke et al., 2005). The situation in developing countries is further 
compounded by complex socio-economic and behavioural factors (Okeke et al., 1999, 
Ayukekbong et al., 2017). 
6.2 Study aims 
The aim of this chapter was to characterise in a cohort of PSAC (1–5 years old), the abundance 
and diversity of the gut microbiota (including the fungi repertoire) and AMR genes, and to 
determine the association between S. haematobium infection and the gut microbiome and 
resistome. In addition, I determined how this relationship is influenced by host-related factors 
including socio-demography, growth and nutritional indices, as well as clinical history. The 
findings in this chapter add to understanding into schistosome infection and its association 
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with the gut microbiome. The chapter further adds to the repository of information on gut 
microbiome and AMR studies in PSAC in sub-Saharan Africa. 
6.3 Hypotheses 
 Schistosoma haematobium infection is associated with alterations in abundance 
and diversity of the gut microbiota in PSAC. 
 The schistosome-associated alterations in gut microbiota abundance and diversity 
are commensurate with schistosome infection intensity. 
 The schistosome-associated alterations in the gut microbiota are associated with 
AMR gene abundance and diversity. 
6.4 Methods 
6.4.1 Study design, population and site 
This was a cross-sectional study that included stool samples from a subset of 116 PSAC (age 
range 1–5 years), meeting the inclusion criteria as part of the baseline survey for the larger 
study described in Chapter 2. Children were selected from Mupfure and Chihuri villages. 
Metadata on socio-demography (including age, sex, village), growth and nutrition (including 
weight, height and feeding habits), and clinical history (including history of schistosome 
treatment and antibiotic use) gathered from questionnaires administered at the time of 
recruitment were used (details in Chapter 2). Clinical records were checked to obtain history 
of antibiotic use, within the 6 months preceding acquisition of stool samples. Children who 
tested positive for S. mansoni and soil-transmitted helminths (STH) as part of the baseline 
survey were excluded from the subset of 116 children selected. Thus, children were selected 
based on: (i) consent from parents/guardians, (ii) availability of socio-demographic data,  
(iii) availability of parasitology samples (urine and stool samples), (iv) availability of test 
results and clinical history, and (v) no current episodes of diarrhoea (assessed by questionnaire 
and visual stool examination). 
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There are limited schistosome–microbiome studies focusing solely on PSAC to inform sample 
size calculations. However, the recent studies conducted in older children (Kay et al., 2015, 
Schneeberger et al., 2018, Ajibola et al., 2019) show that sample sizes ranging from 34–139 
is sufficient to detect significant differences in the microbiome of schistosome-infected versus 
uninfected children. 
6.4.2 Sample collection and processing 
Urine and stool samples were collected for parasitological diagnosis of S. haematobium and 
to exclude intestinal helminths respectively (S. mansoni and STH) as described in Chapter 2. 
All children who were positive for schistosome infection were treated with a single dose of 
praziquantel (PZQ) at the standard 40 mg/kg body weight (details in Chapter 2). DNA was 
extracted from aliquots of stool samples and processed for library preparation and 
metagenomic sequencing at the Beijing Genomics Institute (BGI, Shenzhen, China), as 
described in Chapter 2. 
6.4.3 Quality control and trimming 
Raw FASTQ format (a text-based format for biological sequence outputs) sequences from 
each sample were quality assessed using FASTQC v0.10.0 (https://www.bioinformatics 
.babraham.ac.uk/projects/fastqc/). The output of the FASTQC analysis showed that the raw 
FASTQ sequences were of good quality, and the number of read pairs generated per sample 
ranged from 9,263,538 to 21,350,613. Subsequently, reads were trimmed, to include removing 
adaptors, using BBduk2 (BBMap—Bushnell B.— https://sourceforge.net/projects/bbmap/) 
with an output quality Phred threshold score of ≥20 and a minimum read length of 50 bp. K-
mer length for finding contaminants was k=19 to include shorter k-mers at read pairs down to 
k=11, and reads were trimmed at the right end. 
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6.4.4 Mapping of sequence reads 
Mapping of sequence reads was done using the method of k-mer alignment (KMA), as 
described in Chapter 2. To access the microbiome sequence component present in the 
samples, read pairs and singletons were aligned to a custom reference genomic database (last 
updated 04.04.2019). For both read pairs and singletons, mapped reads were counted as one 
copy. Unless otherwise specified below, databases were primarily downloaded via the 
National Center for Biotechnology Information (NCBI) GenBank clade specific 
assembly_summary.txt files (ftp://ftp.ncbi.nlm.nih.gov/genomes/genbank). The custom 
database consisted of the following: bacteria (closed genomes; downloaded 05.02.2019), 
archaea (downloaded 13.02.2019), MetaHitAssembly (PRJEB674–PRJEB1046; downloaded 
01.07.2014), HumanMicrobiome (genome assemblies; downloaded 02.07.2014), 
bacteria_draft (downloaded 05.02.2019), plasmid (downloaded 05.02.2019), virus (https:// 
bitbucket.org/genomicepidemiology/kvit_db; downloaded 05.02.2019; https://genome. 
jgi.doe.gov/portal/pages/dynamicOrganismDownload.jsf?organism=IMG_VR; downloaded 
28.01.2019), fungi (downloaded 13.02.2019), protozoa (downloaded 13.02.2019), and 
parasites (downloaded 04.04.2019). Sequences selected for the bacteria and bacteria_draft 
databases from the assembly_summary.txt file, were annotated with the tags version_status= 
‘latest’ and genome_rep= ‘Full’. Additional entries, assembly_level= ‘Complete genome’ or 
‘Chromosome’ in the bacteria database and refseq_category= ‘representative genome’ in the 
bacteria_draft database were also required. The plasmid database was constructed as a subset 
of the bacteria and bacteria_draft sequences; keyword in the FASTA entry header line, 
‘plasmid’. The total read count for each microbial community of interest in a sample was 
calculated as the sum of read counts from each of the databases of interest; bacteria (bacteria, 
bacteria_draft, MetaHitAssembly, and HumanMicrobiome), fungi, protozoa, and parasites. 
The primary (most similar) alignment obtained for mapped sequences was used to assign a 
taxonomy, based on the taxonID obtained. TaxonID’s and associated taxonomy classifications 
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were obtained from downloaded reference microbial genomes from NCBI 
(ftp://ftp.ncbi.nih.gov/pub/taxonomy/taxdump.tar.gz) and assignment at all taxonomic levels 
was done. Sequences that had no similarities detected in the nucleotide (nt) database to assign 
a taxonomic classification were deemed to be unknown sequences, and hence termed 
“unknown”. The classification of “unknown” in this case is time-sensitive but was appropriate 
and correct at the time of analysis. 
To identify AMR genes present in the samples, read pairs were aligned to AMR genes (3081 
genes) present in the ResFinder database (https://bitbucket.org/genomicepidemiology 
/resfinder_db; downloaded 13.02.2019). Parameters were set for a query gene to cover at least 
2/5 the length of the reference gene in order to be selected (Zankari et al., 2012). Alignments 
were filtered to retain those exhibiting a selected threshold of identity of 90% (i.e. >90% 
nucleotide identity between the query and reference gene over at least 90% of the length of 
reference gene). Zankari et al., (2017) showed that the minimum threshold percentage length 
of the resistance gene to be covered was 60%, and with ResFinder, a possibility to search for 
genes with specified similarity from 80%–100% identity (Zankari et al., 2012). This is to 
ensure that unlike with the default 100% identity, AMR genes identified spread over two 
contigs and/or that sequences located on the ends of the contig were not missed. For instance, 
resistance to some antimicrobial agents, in particular fluoroquinolones, can be caused by point 
mutations (Single Nucleotide Polymorphisms (SNPs)), and Zankari et al., (2017) have used 
PointFinder to detect point mutations known to confer antibiotic resistance. The threshold used 
in the current study (i.e. 90% identity and 90% coverage) thus ensured that while reducing 
noise associated with lower thresholds (e.g. mapping to fragments of genes), there was not 
only a higher chance of finding the appropriate genes but also finding them accurately. 
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6.4.5 Data handling and processing 
To accurately explain variations in the data using available participant metadata, three samples 
were excluded from the final data analysis using predefined criteria. Samples were included 
in data analysis provided they had at least one metadata variable from growth and nutritional 
indices, schistosome infection status, previous schistosome treatment, and antibiotic use data 
were used for all downstream analyses (i.e. n=113). To account for probable sample-wise 
sequencing depth differences, as well as a size-dependent probability of observing a reference, 
mapping counts from the custom genomic database and from the ResFinder database were 
normalised to the total genome sizes for the genomic database, and to the individual gene 
lengths for the ResFinder database. 
The total observed mapping counts are relative, and may account for confounding effects on 
downstream analyses (McMurdie and Holmes 2014). This may be due to limitations of an 
arbitrary total imposed by different sequencing platforms, technical variations in sequencing 
libraries amounts, or even random variation (Gloor et al., 2017). Thus, to obtain information 
about the abundances of features in the dataset relative to each other, datasets were treated as 
compositional (Gloor et al., 2017). Data were transformed using the log-ratio approach as 
introduced by Aitchison, to make the data symmetric, linear and in a log-ratio coordinate space 
(Aitchison 1986). However compositional methods such as this do not account for the presence 
of zeros associated with abundance datasets. To address this, a small pseudo count of half the 
smallest non-zero abundance per feature was added to each respective feature for all the 
normalised abundance matrices, prior to transformations (Calle 2019). Microbiota abundance 
data tables with counts, x, and k number of populations (taxa members), were centred log-ratio 
(clr) transformed, defined as (Calle 2019): 
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Where, B(A) = (∏A()#/$ is the geometric mean of the particular composition.  
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AMR gene abundances were additive log-ratio (alr) transformed, taking the bacterial 
component of the microbiome (xk) as the reference, defined as (Calle 2019): 
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Unless otherwise stated, clr and alr matrices were used for all downstream analyses. 
6.4.6 Visualization 
Data visualization was done using R (www.bioconductor.org; www.r-project.org)  
(R Development Core Team 2011). Bar plots from normalised, zero-corrected abundance 
matrices, were used to give an overview of the microbiota and AMR gene abundances across 
all samples. For cluster dendrograms, the Aitchison distance (Euclidean distance) was 
calculated using clr-transformed abundance data, and samples clustered based on distances 
(Complete-linkage-clustering). To explore underlying variabilities in the microbiota and AMR 
genes across the data set, clr-transformed abundance data for each matrix, centred on the 
geometric sample mean and scaled by the total variance was ordinated using Principal 
Component Analysis (PCA) (Calle 2019), based on eigenvectors and eigenvalues (Arfken 
1985). Box plots were used to highlight differences in microbiota abundance between two 
groups, and scatter plots to show the relationship between schistosome infection intensity and 
microbiota abundance. 
6.4.7 Statistical analyses  
Data were analysed using various Bioconductor packages in R software. Details of the 
statistical methods used here are described in Chapter 2. 
To test whether sample-related metadata were significant predictors of within-group 
dispersion of the microbiota and AMR genes, the Euclidean distances were calculated, using 
the R/Bioconductor package vegan (Oksanen et al., 2016). The effect of such metadata on 
sample dissimilarities were determined using permutational multivariate analysis of variance 
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(PERMANOVA; adonis2 function in the vegan package) using p <0.05 as the significance 
threshold. A Benjamini–Hochberg False Discovery Rate (FDR) correction was applied to 
counteract multiple testing (Benjamini and Hochberg 1995). 
To investigate further how specific taxa composition vary across the statistically significant 
metadata (from PERMOANOVA), while controlling for other variables of interest, analysis 
of composition of microbiomes (ANCOM) was used (Mandal et al., 2015). Analysis was based 
on log-ratio transformation of raw count data (clr), where the normalizing reference value is 
the abundance of all remaining taxa, taken one at a time. The FDR was set at 0.05 (Benjamini 
and Hochberg 1995), and a taxa member was considered at a W‐statistic cut off, 0.80. The 
ANCOM test for the association of S. haematobium infection was controlled for age, sex and 
village. 
As ANCOM only provides a list of taxa that vary in composition, the magnitude and direction 
of associations of taxa that vary in composition across independent variables was further 
determined. Box plots stratified by specific independent variables, using the clr-transformed 
abundance data of significant taxa previously identified by ANCOM were used to highlight 
differences in groups. To determine how these taxa varied with schistosome infection 
intensity, clr-transformed abundance data was regressed on the log-transformed infection 
intensity (log10 [egg count+1]). 
6.4.8 Data availability  
Raw sequence data files from all 116 samples and associated metadata used in the current 
study are deposited in the Sequence Read Archive (SRA) of the National Centre for 
Biotechnology Information (NCBI) database under the BioProject accession number 
PRJNA521455. All other data files including QC, sequence and Taxon ID mapping 
information (downloadable from: https://static-content.springer.com/esm/art%3A10.1038 
%2Fs42003-020-0859-7/MediaObjects/42003_2020_859_MOESM3_ESM.xlsx), and base 
[Paediatric Schistosomiasis: Dynamics and Consequences] 
168                                                         [S. haematobium, the microbiome and resistome] 
data from which all statistical analyses were done (downloadable from: https://static-
content.springer.com/esm/art%3A10.1038%2Fs42003-020-0859-7/MediaObjects/42003 
_2020_859_MOESM4_ESM.xlsx) are published in Osakunor et al., (2020). 
6.4.9 Code availability 
The updated R codes used for ANCOM are available on, https://github.com/zellerlab 
/crc_meta/blob/master/src/ANCOM_updated.R or from the author’s webpage at 
https://sites.google.com/site/siddharthamandal1985/research. 
6.5 Results 
6.5.1 Population characteristics 
Of the 113 participants included in the current study, the mean age was 3.7 ± 1.1 years, of 
which 56 (49.6%) were female and 57 (50.4%) were male. Sixty-eight (60.2%) and 45 (39.8%) 
children were from Chihuri and Mupfure villages respectively. Antimicrobial use data showed 
that 58 (51.3%) participants had received antibiotics [amoxicillin (31), co-trimoxazole (27), 
both (9)], while 18 (15.9%) had not; no information was obtained for the remaining 37 (32.7%) 
participants. Previous history of PZQ treatment was reported among 29/105 (27.6%) children. 
Schistosoma haematobium infection prevalence was 15.9% (18/113), with mean infection 
intensity of 1.79 eggs/10 ml urine (SEM= 0.76; range= 0–74). 
Data on the history of feeding habits and nutritional status showed that the majority (85.8%; 
97/113) were breastfed, with duration ranging from 2 to 48 months (median= 18 months IQR: 
17–20). Children were introduced to solid foods from between 1 to 24 months after birth. Diet 
comprised mainly of traditional maize flour porridges (97%; 96/103), the commercial 
Cerelac® porridge (1.9%; 2/103), and potatoes (1%; 1/103). Anthropometric measures, 
adjusted for age, were used to assess nutritional status as described in Chapter 2. Based on 
the weight-for-height Z-scores (WHZ), 3.7% (4/107) of individuals were malnourished, and 
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14.7% (16/109) were stunted based on the height-for-age Z-scores (HAZ) (MOH Malawi 
2016).  
6.5.2 Taxonomic composition of the microbiome 
The number of classified read pairs per sample ranged from 3,994,704 to 13,164,482. An 
average 45.1% of read pairs were mapped to specific reference sequences in the genomic 
database; this is similar to other studies with the proportion of unmapped reads ranging from 
42%–68% (Afshinnekoo et al., 2015, Nordahl Petersen et al., 2015, Hendriksen et al., 2019). 
At any taxonomic level, a taxonomic classification could not be assigned to at least 33% of 
the mapped read pairs and were thus classified as “unknown”. 
In the 113 stool samples, 845 bacteria genera (from 20 unique phyla), and 228 fungi genera 
(from 6 unique phyla) were detected. As shown in Figure 6.1, the most abundant bacteria 
phyla in decreasing order were Bacteroidetes (genera: Prevotella, Bacteroides, Alistipes), 
Firmicutes (genera: Eubacterium, Faecalibacterium, Clostridium, Roseburia), and 
Proteobacteria (genus: Succinatimonas). The most abundant fungi phyla were Ascomycota 
(genera: Protomyces, Aspergillus, Taphrina, Saccharomyces, Candida, Nakaseomyces), 
Microsporidia (genus: Enterocytozoon), and Zoopagomycota (genus: Entomophthora) [see 
Figure 6.2]. These phyla dominated the microbiome and were present in all samples. 
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Figure 6.1: Overview of the bacterial microbiota abundance and diversity 
From read mapping to the genomic database, abundance was calculated for each microbial taxon across 
all samples. Stacked bar charts show the most abundant bacteria a) phyla and b) genera per sample, 
proportional to the total microbiota within each sample (n=113 biologically independent samples). 
Charts were generated using normalised, zero-corrected abundance matrices. “Unknown” represents 
abundance data for which a taxonomic classification could not be assigned. “-Others” represents 
abundance data for all other taxa in the abundance data set. 
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Figure 6.2: Overview of the fungal microbiota abundance and diversity 
From read mapping to the genomic database, abundance was calculated for each microbial taxon across 
all samples. Stacked bar charts show the most abundant fungi a) phyla and b) genera per sample, 
proportional to the total microbiota within each sample (n=113 biologically independent samples). 
Charts were generated using normalised, zero-corrected abundance matrices. “-Others” represents 
abundance data for all other taxa in the abundance data set. 
 
6.5.3 Variation in the microbiome and association with participant 
metadata 
PCA was used to initially examine variability and patterns in the data set across the first two 
principal components. At the phylum level, PCA explained 62% and 42.0% of the total 
variation in fungi and bacteria respectively. At the genus level however, PCA explained 34% 
and 16% of the total variation in fungi and bacteria respectively. The model showed 
homogeneity in components with no distinct clustering according to metadata and may reflect 
a high diversity in the cohort. PCA plots and cluster dendrograms for bacteria and fungi 
content per sample is shown in Supplementary Figures 1–3, Appendix C. 
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PERMANOVA analysis showed a significant effect of age (FDR= 0.024), village  
(FDR= 0.039), schistosome infection status (FDR= 0.039), and schistosome infection intensity 
(FDR= 0.012) on bacteria genera, across samples. There was also a significant effect of 
schistosome infection status (FDR= 0.006) and schistosome infection intensity (FDR= 0.006) 
on fungi genera, across samples. For both bacteria and fungi genera, no such effects were 
found for sex, nutritional and growth variables, feeding, previous PZQ treatment, and 
antibiotic use (FDR >0.05). Summary output from the analysis is shown in Table 6.1. 









Age (years) 113 0.004 1344.6 82733.4 0.024 0.082 128.6 9489.2 0.197 
Sex 113 0.172 878.1 83200.0 0.258 0.439 82.8 9534.9 0.671 
Village 113 0.012 1254.0 82824.0 0.039 0.060 140.4 9477.4 0.180 
S. h. infection 
status (pos/neg) 113 0.013 1185.1 82892.9 0.039 0.001 339.0 9278.7 0.006 
S. h. infection 
intensity 113 0.001 1514.5 82563.6 0.012 0.001 670.1 8947.7 0.006 
Malnourished, 
yes/no (WHZ) 107 0.866 589.1 78498.2 0.913 0.830 59.5 9145.6 0.830 
Stunted, yes/no 
(HAZ) 109 0.407 754.6 79751.0 0.542 0.611 71.5 9227.2 0.671 
Months 
breastfed 90 0.082 954.9 64235.8 0.140 0.470 75.2 6985.0 0.671 
Months solid 
food introduced 102 0.913 573.1 75583.0 0.913 0.615 73.5 8792.0 0.671 
Previous PZQ 
treatment 105 0.071 991.9 77387.4 0.140 0.233 101.6 8934.5 0.466 
Amoxicillin 
(yes/no) 76 0.771 646.6 55603.4 0.913 0.531 78.4 6567.3 0.671 
Co-trimoxazole 
(yes/no) 76 0.030 1083.6 55166.4 0.072 0.048 158.3 6487.4 0.180 
Table represents PERMANOVA output for bacteria and fungi genera. Classification of nutritional status 
was based on a cut off <-2 Z–scores (MOH Malawi 2016). Schistosome infection intensity was log 
transformed (log10 [egg count+1]). S. h., S. haematobium; WHA, weight–for height Z-scores; HAZ, 
height-for-age Z-scores; pos/neg, positive /negative; p-value, unadjusted p-value; FDR, adjusted  
p-value (FDR-corrected); SS-E, explained sum of squares; SS Total, total sum of squares. 
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6.5.4 Microbiome analysis by child age and village 
From the PERMANOVA results, further analysis via ANCOM showed that the abundance of 
six specific bacteria genera were associated with age and village. Intestinibacter (W= 315), 
Mycoplasm (W= 298), and Turicibacter (W= 293) showed significant variation across age, 
and Senegalimassilia (W= 312), Mordavella (W= 296), and Azospirillum (W= 281), showed 
variation with village. The magnitude of the differences in abundance between groups are 
shown in Figure 6.3. Abundance of the identified genera did not increase or decrease as 
children grew per se, but rather, abundance was variable across all ages 1–5 years. Abundance 
of all the identified genera that varied with village was higher in Mupfure than in Chihuri. 
 
Figure 6.3: Bacteria genera whose abundance vary significantly across host age and village 
Figure a–c) Box plots showing the abundance of specific bacteria genera, grouped by age category in 
years. Figures d–f) Box plots showing the mean abundance of specific bacteria genera, grouped by 
village. Specific groups are represented on the x-axis and the abundances (clr-transformed) shown on 
the y-axis. The horizontal box lines represent the first quartile, the median and the third quartile. 
Whiskers denote the range of points within the first quartile − 1.5× the interquartile range and the third 
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6.5.5 Microbiome analysis by schistosome infection status and 
intensity 
ANCOM was used to determine specific bacteria and fungi genera abundance associated with 
S. haematobium infection, while controlling for age, sex and village. This was followed by 
evaluation for association with schistosome infection intensity. In total, eight genera were 
identified, five of which were bacteria (Pseudomonas; W= 347, Azospirillum; W= 346, 
Stenotrophomonas; W= 292, Derxia; W= 288, and Thalassospira; W= 292) and three were 
fungi (Aspergillus; W= 75, Tricholoma; W= 73, and Periglandula; W= 70). The magnitude of 
the differences in abundance between S. haematobium-infected and uninfected children are 
shown in Figure 6.4 and Figure 6.5. In schistosome-positive children, the abundance of all 
but Azospirillum was higher (Figure 6.4 a–e). This observation was consistent with infection 
intensity as shown in Figure 6.4 f–j [Pseudomonas (r= 0.3; p=0.001), Azospirillum (r= -0.4;  
p <0.001), Stenotrophomonas (r=0.4; p <0.001), Derxia (r= 0.6; p <0.001), and Thalassospira 
(r= 0.6; p <0.001)]. Likewise, the abundance of Aspergillus, Tricholoma, and Periglandula 
was higher in schistosome-positive children (Figure 6.5 a–c) and was consistent with infection 
intensity as shown in Figure 6.5 d–f [Aspergillus (r= 0.5; p <0.001), Tricholoma (r= 0.5;  
p <0.001), and Periglandula (r= 0.4; p <0.001)]. 
                                               [Paediatric Schistosomiasis: Dynamics and Consequences] 
[S. haematobium, the microbiome and resistome]  175 
 
Figure 6.4: Bacteria genera whose abundance vary significantly with schistosome infection 
Figure a–e) Box plots showing the abundance of specific bacteria genera, grouped by S. haematobium 
infection status. The horizontal box lines represent the first quartile, the median and the third quartile. 
Whiskers denote the range of points within the first quartile − 1.5× the interquartile range and the third 
quartile + 1.5× the interquartile range. Figures f–j) Scatter plots showing linear regression analysis of  
S. haematobium infection intensity and bacteria genera abundance. Figures f–j are plots matching the 
same genera shown in figures a–e. The clr-transformed abundance data was used for all plots. Infection 
status was coded as 0 and 1 for negative (n=95) and positive (n=18) respectively. S. haematobium 
infection intensity was log transformed [log10 (egg count+1)]. Shaded areas indicate the 95% 







































Infection intensity [log10(egg count+1)]






























































































































































































































































































































































































































































































































































0 10 0 1 0 1 0 1
Infection status
a b c d e
p=0.001 p<0.001 p<0.001 p<0.001 p<0.001
Pseudomonas Azospirillum Stenotrophomonas Derxia Thalassospira
[Paediatric Schistosomiasis: Dynamics and Consequences] 
176                                                         [S. haematobium, the microbiome and resistome] 
 
Figure 6.5: Fungi genera whose abundance vary significantly with schistosome infection 
Figure a–c) Box plots showing the mean abundance of specific fungi genera, grouped by  
S. haematobium infection status. The horizontal box lines represent the first quartile, the median and 
the third quartile. Whiskers denote the range of points within the first quartile − 1.5× the interquartile 
range and the third quartile + 1.5× the interquartile range. Figures d–f) Scatter plots showing linear 
regression analysis of S. haematobium infection intensity and fungi genera abundance. The clr-
transformed abundance data was used for all plots. Infection status was coded as 0 and 1 for negative 
(n=95) and positive (n=18) respectively. S. haematobium infection intensity was log transformed [log10 
(egg count+1)]. Shaded areas indicate the 95% confidence intervals. 
 
6.5.6 AMR gene characterization 
An average 0.06% of read pairs were mapped to AMR genes in the ResFinder database, and 
262 AMR genes, belonging to 12 functional drug classes were detected. AMR genes belonging 
to tetracycline were the most common, followed by beta-lactam, macrolide, sulphonamide and 
nitroimidazole. Of these, the most abundant genes were cfxA6, followed by tet(Q), tet(W), 
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Figure 6.6: Overview of antimicrobial resistance (AMR) gene abundance and diversity 
From read mapping to the ResFinder database, AMR abundance was calculated for each reference gene 
across all samples. Stacked bar charts show the most abundant a) AMR gene and b) drug class per 
sample, proportional to the total AMR within each sample (n=113 biologically independent samples). 
Charts were generated using gene length-normalised, zero-corrected abundance. “-Others” represents 
abundance data for all other AMR genes or drug classes in the abundance data set.  
 
6.5.7 Variation in the resistome and association with participant 
metadata 
PCA was used to initially examine variability and to identify clustering according to individual 
metadata. The model for the first two components explained 18.0% and 48.0% of the total 
variability in AMR genes and drug classes respectively. Similarly, there was no clustering 
according to individual metadata. PCA plots and cluster dendrograms of AMR genes and their 
drug classes per sample is shown in Supplementary Figures 4–5 in Appendix C. 
PERMANOVA analysis, did not show any significant association of AMR genes with age, 
village, sex, feeding, malnutrition, stunting, S. haematobium infection, previous PZQ 
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treatment, and antibiotic use. Model summaries of participant metadata and association with 
AMR genes is shown in Table 6.2. 
Table 6.2: Model summaries of participant metadata and association with the resistome 
Variable n p-value SS-E SS Total FDR 
Age (years) 113 0.079 179.9 14444.6 0.591 
Sex 113 0.847 98.3 14526.3 0.930 
Village 113 0.250 149.8 14474.8 0.591 
S. h. infection status (pos/neg) 113 0.296 143.1 14481.4 0.591 
S. h. Infection intensity 113 0.231 151.7 14472.9 0.591 
Malnourished, yes/no (WHZ) 107 0.924 86.0 13909.6 0.930 
Stunted, yes/no (HAZ) 109 0.818 102.0 14059.8 0.930 
Months breastfed 90 0.880 87.7 11391.0 0.930 
Months solid food introduced 102 0.755 107.7 13174.9 0.930 
Previous PZQ treatment 105 0.176 158.5 13479.4 0.591 
Amoxicillin (yes/no) 76 0.930 89.0 9822.9 0.930 
Co-trimoxazole (yes/no) 76 0.247 150.4 9761.5 0.591 
Table represents PERMANOVA output for bacteria and fungi genera. Classification of nutritional status 
was based on a cut off <-2 Z–scores (MOH Malawi 2016). Schistosome infection intensity was log 
transformed (log10 [egg count+1]). S. h., S. haematobium; WHA, weight–for height Z-scores; HAZ, 
height-for-age Z-scores; pos/neg, positive /negative; raw p, unadjusted p-value; FDR, adjusted p-value 
(FDR-corrected); SS-E, explained sum of squares; SS Total, total sum of squares. 
 
6.6 Discussion 
The human gut microbiome plays a vital role in maintaining overall health. Therefore, changes 
that occur, especially during establishment of the microbiota in early life, have implications 
on health and disease risk (Laforest-Lapointe and Arrieta 2017). Understanding the changes 
that occur in the microbiome and resistome during infection, especially in PSAC, will provide 
insight into the factors underlying disease progression, differences in disease and treatment 
patterns, as well as the potential of influencing health through the microbiome in infants and 
young children. In this chapter, I characterised the structure (abundance and diversity) of the 
human gut microbiome and resistome in a cohort of Zimbabwean PSAC (≤5 years old). I 
further test the hypothesis that in PSAC, infection with S. haematobium is associated with 
alterations in the abundance and diversity of the gut microbiota and associated AMR genes. 
The results showed that in this PSAC population, the microbiota are largely heterogeneous, 
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and are associated with age and location/geography. This reflects the impact of inherent 
population-specific characteristics on the structure of the microbiome. Schistosoma 
haematobium infection was associated with significant alterations in the abundance of 
microbiota. The observed microbiota alterations correlated with infection intensity, strongly 
supporting that the changes were associated with the presence of S. haematobium infection. 
Evidence of 262 AMR genes belonging to different functional drug classes were detected, but 
these were not associated with individual-specific metadata, including schistosome infection. 
Despite the indirect impact that alterations in gut microbiota populations may have on the 
abundance and diversity of AMR genes, the finding in the current study is in line with 
suggestions that other population anthropogenetic (of or relating to their origin and 
development) and socioeconomic factors greatly drive the resistome, and thus have major 
implications on AMR and health policy (Collignon et al., 2018, Hendriksen et al., 2019). 
Age (Yatsunenko et al., 2012, Rodriguez et al., 2015), dietary and environmental patterns (De 
Filippo et al., 2010, Fan et al., 2014, Martinez et al., 2015), ethnicity, and geography 
(Deschasaux et al., 2018, Senghor et al., 2018) have an impact on the taxonomic composition 
of the microbiome. Prevotella and Candida have been associated with carbohydrate-rich diets 
(Hoffmann et al., 2013, Gorvitovskaia et al., 2016) and Bacteroides, with protein-rich diets 
(Gorvitovskaia et al., 2016). The presence of these microbial genera in the microbiota is a 
reflection of the dietary lifestyle among populations in developing countries (De Filippo et al., 
2010, Martinez et al., 2015), including infants (Yassour et al., 2016), and these genera were 
among the most abundant bacteria and fungi genera found in the current study population. 
Microbiota composition differed significantly across villages, with three genera being more 
abundant in children from Mupfure than from Chihuri. In addition to evidence on the 
geographical disparities in microbiota composition (Deschasaux et al., 2018, Senghor et al., 
2018), Palmer and colleagues in a longitudinal study showed significant clustering of the 
microbiota of twins, highlighting the significance of the similarity in microbiota composition 
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among individuals living in a shared local environment (Palmer et al., 2007). Similar reasons 
for the observed differences across villages is based on evidence from experimental studies, 
showing that even with genetically similar families, the microbiota of mice were more similar 
within households than between households (Ley et al., 2005). Thus, community-specific 
social, environmental, and lifestyle characteristics may contribute to the observed differences. 
Similar to findings from previous studies (Kay et al., 2015), there was age but not sex-related 
associations in bacteria genus abundance and diversity. Given that the population in the current 
study was ≤5 years old, this is consistent with the microbiome being more dynamic in the early 
years of life before stabilizing to a more adult-like state (Yatsunenko et al., 2012, Rodriguez 
et al., 2015). 
Differences observed in the microbiome between developing and developed countries have 
been attributed to factors inherent to developing areas (De Filippo et al., 2010), which may 
include the role of persistent prevalence of helminth infections, as reviewed by Mishra and 
colleagues (Mishra et al., 2014). The findings in the current study are consistent with 
observations that schistosome infection is associated with alterations in the diversity and 
abundance of specific taxonomic groups in the microbiome (Kay et al., 2015, Schneeberger et 
al., 2018). In the aforementioned studies, which included preschool and school-aged children, 
16S rRNA sequencing showed that Prevotella and Proteobacteria were more abundant in 
children infected with S. haematobium (Kay et al., 2015) and S. mansoni (Schneeberger et al., 
2018) respectively, when compared to uninfected children. To the best of my knowledge and 
at the time of writing this thesis, the novelty of the current study is the fact that it focuses on 
children 5 years old and below, an age group whose gut microbiome structure is most likely 
still evolving (Yatsunenko et al., 2012, Rodriguez et al., 2015). The findings presented in this 
chapter thus provide an important insight into helminth infection and its association with 
changes during the establishment of the gut microbiome in PSAC in endemic areas. For the 
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first time, the use of metagenomic sequencing enabled elucidating this association to include 
the fungal component of the microbiome. 
Bacteria and fungi phyla that clearly differentiated the microbiome of schistosome-infected 
versus uninfected children in the current study were Proteobacteria, Ascomycota and 
Basidiomycota. These were among the top five most abundant bacteria and fungi and were 
present in all samples, thus make a major contribution to the overall microbiome composition. 
Proteobacteria has been shown to be present in lower abundances within the microbiota of 
healthy individuals, and any increases in abundance of members of this phylum confirm 
dysbiosis and a link with increased disease risk, progression and burden (Shin et al., 2015). 
Attempts have been made to expand the body of knowledge on the fungi repertoire and 
diversity in the human microbiome (Gouba et al., 2014) and their association with infection 
and disease (Mukherjee et al., 2014, Gouba and Drancourt 2015, Mar Rodriguez et al., 2015). 
However, the role of fungi within the gut microbiota community in health and disease is poorly 
understood. Studies in mice models have suggested that gut fungal populations directly or 
indirectly help to maintain healthy intestinal homeostasis, and that dysbiosis has 
immunological consequences relevant to disease risk progression (Wheeler et al., 2016). For 
example as observed in the current study, increases in specific fungi populations such as 
Aspergillus, have been associated with increased blood eosinophil levels (Bukelskienė et al., 
2006) and an exaggerated T-helper type 2 (Th2) response in mice (Wheeler et al., 2016). The 
resulting Th2 response is characteristic of schistosome infection, and is important to 
downregulate host immune responses and to promote parasite survival in the host (Pearce and 
MacDonald 2002, Colley and Secor 2014). This may explain the observed increases in 
abundance of specific fungal populations (Aspergillus, Tricholoma and Periglandula) in the 
schistosome-infected children. However, whether this was due to primary changes in the 
fungal population or was secondary to changes in the bacterial population is unclear, and 
further studies into the role of fungal dysbiosis in schistosome infection are warranted. 
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Although the ability to infer causation was beyond the scope of the current study, it shows that 
for the microbial genera differentiating the microbiome of the schistosome-infected versus 
uninfected children, there was a significant positive relationship between microbial abundance 
and schistosome infection intensity. This strongly supports the fact that the observed changes 
were associated with the presence of S. haematobium infection. However as S. haematobium 
worms mostly reside in the pelvic venous plexus (although some have occasionally been 
detected in the intestine in Egyptian autopsies (Cheever et al., 1977)), the effect of infection 
on the diversity of the microbiota is as suggested for intestinal helminths (Broadhurst et al., 
2012), but most likely through a more indirect or systemic route than through direct 
interactions, as discussed earlier in Chapter 1. Mishra and colleagues have suggested that the 
immunomodulatory effects of helminths can extend to the gut microbiota through both direct 
intestinal interactions and systemic interactions (Mishra et al., 2014). For example, by 
enhancing the mucosal barrier, tissue repair, production of anti-microbial peptides and 
reducing dissemination of microbiota to the spleen and liver (Mishra et al., 2014), the 
upregulation of IL-22 during helminth infection may favour the abundance of specific 
microbial taxa (Leung and Loke 2013). 
Overall, 262 AMR genes were identified, most of which encoded for resistance to tetracycline, 
beta-lactam, macrolide, and sulphonamide, posing risks to the successful treatment of various 
conditions including urinary, enteric and respiratory infections (Frank et al., 2007). 
Amoxicillin (beta-lactam) and co-trimoxazole (sulphonamide) were the most predominant 
antibiotics reported to have been used among the children in the current study. In addition, 
ceftriaxone, benzylpenicillin (both beta-lactams), and co-trimoxazole are among the most 
commonly used antibiotics in Zimbabwe (Zimbabwe National Antimicrobial Resistance Core 
Group 2017). Given that antibiotic use is selective for AMR in populations (Van De Sande-
Bruinsma et al., 2008, Davies and Davies 2010), it is not surprising that majority of the AMR 
genes identified belonged to these drug classes. However, because the current study did not 
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determine phenotypic resistance to antibiotics, it is not possible to ascertain that the presence 
of the AMR genes identified are due to use of these antibiotics within the study population. In 
addition, the current study did not enable determination of which bacteria species were 
associated with the AMR genes found, and whether these are encoded on plasmids or on 
chromosomes. Therefore, with limited studies of such nature in African populations, and given 
that the current study focused on an apparently healthy population, more research is needed to 
determine the clinical significance and public health relevance of the AMR genes identified in 
the current study. 
Increased antimicrobial use has a significant effect on the gut microbiota (Bartosch et al., 2004, 
Dethlefsen et al., 2008), and is selective for AMR in populations (Van De Sande-Bruinsma et 
al., 2008, Davies and Davies 2010). The limited association of the obtainable antimicrobial 
use data with both the microbiome and resistome in the current study might be surprising. 
Dethlefsen and colleagues showed that a majority of the human gut microbiota community 
that was depleted post-ciprofloxacin administration was restored after 4 weeks (Dethlefsen et 
al., 2008). The antimicrobial use data obtained in the current study was limited to antibiotic 
use within the immediate 6 months prior to sampling and was less heterogeneous. Thus, any 
marked differences in the microbiota abundance from antibiotic use may have been restored 
before sampling for the current study, and hence missed. The findings shown here are however 
consistent with those from recent studies on global sewage samples, where compared to 
antimicrobial use, a much stronger association between AMR genes and socio-economic 
factors related to health, sanitation, and education was shown (Collignon et al., 2018, 
Hendriksen et al., 2019). Suggestions are that the influence of multiple factors on AMR genes 
seems more likely to be the case in low-and middle-income countries, where a high contagion 
(the spread of resistant strains and genes) between individuals may take place, and any 
antimicrobial use in one individual may have general effects on the population as a whole 
[Paediatric Schistosomiasis: Dynamics and Consequences] 
184                                                         [S. haematobium, the microbiome and resistome] 
(Pehrsson et al., 2016). Thus antimicrobial use may explain some, but not all the variation in 
AMR genes in this population (Van De Sande-Bruinsma et al., 2008, Davies and Davies 2010). 
In addition, the microbiome is a reservoir for AMR genes (Qin et al., 2010, Hu et al., 2013), 
and alterations in the gut microbiota composition may impact on AMR gene abundance and 
diversity. However, suggestions that many inherent population anthropogenetic (of or relating 
to their origin and development), environmental and socio-economic factors greatly drive the 
resistome (Collignon et al., 2018, Hendriksen et al., 2019), is in line with the fact that the 
observed changes in the microbiota was not associated with AMR gene abundance and 
diversity. 
The strength of the current study lies in the fact that metagenomics sequencing to include the 
fungi component of the microbiome was used, instead of 16S rRNA sequencing, which targets 
the bacterial component. It also determined the relationship between schistosome infection, 
the microbiome and resistome, independent of host-related factors including socio-
demography, growth and nutritional indices, as well as clinical history. The current study 
nonetheless also had a few limitations. The cross-sectional study design allowed 
characterisation of the gut microbiome and its relationship with S. haematobium infection at a 
single time point. A longitudinal study following a natural time-course of schistosome 
infection and treatment, will inform on the dynamic relationship between schistosome 
infection and the gut microbiota, and help to elucidate causation and the mechanistic pathways 
underlying this relationship. A longitudinal study will also inform on any time-course or 
developmental-related trends in the observed microbiota and AMR gene profiles, and provide 
an indication of the dynamic features of how they are associated with individual-specific data. 
Furthermore, relating the presence of AMR genes to measurable phenotypic resistance of 
bacteria would give a stronger indication of the clinical implications of the AMR genes 
present. 
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6.7 Conclusion 
In the current study, I characterised the gut microbiome (to include the fungi repertoire) and 
resistome in a cohort of PSAC (≤5 years old) from Zimbabwe. The results showed that age 
and location-related differences are associated with abundance and diversity of the gut 
microbiota. Independent of host-related socio-demographic and clinical factors, there were 
differences in the gut microbiome but not the resistome, between schistosome-infected and 
uninfected children, showing largely, an increase in abundance of specific bacteria, and for the 
first time (as at the time of writing this thesis), fungi genera in infected children. The 
schistosome-associated alterations in abundance of microbiota populations correlated with 
infection intensity. Mechanistic studies are required to further explain this relationship. The 
findings in this chapter suggest microbiome alterations as an additional consequence of 
schistosome infection, which may be relevant for disease pathogenesis and influence on 
overall health of the host. It also adds to publicly available data on microbiome and resistome 
studies from an understudied human population (i.e. PSAC in sub-Saharan Africa). 
In the next chapter I discuss the major findings of this thesis in a broader context, their 
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Chapter 7 General discussion 
7.1 Introduction 
Schistosomiasis has debilitating consequences in preschool-aged children (PSAC), i.e. 
children aged 5 years and below. It has been recognised as a disease of public health 
importance that requires urgent attention in this age group (World Health Organization 2011). 
Contrary to previously held assumptions that the risk of schistosome infection in PSAC is low 
(Sacko et al., 2011), there is now a global move to increase research focus on paediatric 
schistosomiasis to promote disease control and improve child health. This paradigm will be 
important to achieve the goal of reducing disease-related morbidity and eventually eliminate 
schistosomiasis (World Health Organization 2020a). However, paediatric schistosomiasis 
control will only become a priority in endemic countries with limited health resources, when 
research provides compelling evidence on infection and disease burden and its impact on child 
health, and when cost-effective intervention tools can be utilised in control programmes. 
In this thesis, I address some key research and knowledge gaps in paediatric schistosomiasis, 
by following a natural time-course of schistosome infections in PSAC living in the Shamva 
district of Zimbabwe, a schistosome-endemic area (Midzi et al., 2011, Midzi et al., 2014a). I 
focused on urogenital schistosomiasis, which is caused by Schistosoma haematobium, the 
most common schistosome species occurring in sub-Saharan Africa (McManus et al., 2018, 
World Health Organization 2020b). The goal was to describe the incidence of the first 
schistosome infection and morbidity in PSAC, as well as the impact of praziquantel (PZQ) 
treatment on infection, reversal of morbidity, and reinfection rates. Of particular interest were 
the early events that occur during the very first schistosome infection and treatment in this age 
group. The impact of schistosome infection on the host microbiome and metabolism, and how 
this influences disease and overall health in PSAC was also studied. The thesis presents an 
integrative approach to schistosomiasis studies in this age group, which contributes to 
evidence on infection/disease burden and dynamics and the importance of the timing of 
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diagnosis and treatment in reducing (re)infection and morbidity. In addition, it elucidates the 
systemic impacts of schistosome infection on the host microbiome, metabolism, and overall 
health of PSAC. 
Here, the major findings in relation to the specific aims outlined in Chapter 1 are summarised 
and discussed in broader terms. I also consider the potential contribution of my findings in 
improving current paediatric schistosomiasis practice and health policy, and suggest how my 
research could be extended for further benefits. 
7.2 Scale of the problem: infection, morbidity and treatment 
dynamics  
In addition to the lack of a child-friendly formulation of PZQ, one of the major reasons for the 
exclusion of PSAC from schistosome treatment programmes is the lack of compelling 
evidence on infection, disease and treatment dynamics. Consequently, there is a lack of priority 
for paediatric schistosomiasis control in most schistosome-endemic areas. The findings from 
this thesis have demonstrated that PSAC present with schistosome infection (based on egg 
counts) and morbidity (microhaematuria, malnutrition and stunting) from an early age; the 
youngest child positive for infection in the study cohort was one year old. Further analysis also 
showed that the prevalence and intensity of schistosome infection increase as children grow 
older (see Chapter 3). This is in line with previous studies showing that exposure to 
schistosome infection can occur soon after birth through domestic water activities, and that 
infection prevalence and intensity is cumulative, increasing with age (Woolhouse et al., 2000, 
Kanamura et al., 2002, Lengeler et al., 2002, van Dam et al., 2004, Wami et al., 2014). This 
would suggest that until PSAC receive their first treatment through mass drug administration 
(MDA), which currently targets school-aged children (SAC; ≥6 years old), infection acquired 
at an earlier age will continue to accumulate, causing severe, and sometimes, irreversible 
morbidity. 
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In schistosome-endemic areas, coinfections and comorbidities influence health and nutrition 
in children. This makes the identification and interpretation of morbidity associated with 
schistosome infection challenging. To address this, the proportion of morbidity attributable to 
schistosome infection was determined (Chapter 3). Of the morbidity markers assessed, 
microhaematuria and stunting were the most dominant markers of schistosome-related 
morbidity in PSAC; schistosome-positive children were more likely to present with 
microhaematuria (25 times) and stunting (2 times), compared to uninfected children. In line 
with the present findings, microhaematuria is associated with S. haematobium infection 
(Wilkins et al., 1979, Gryseels et al., 2006, Colley et al., 2014) and can serve as a point-of-
care (POC) field marker of morbidity for urogenital schistosomiasis in PSAC (Salawu and 
Odaibo 2014, Wami et al., 2015). Studies in older children suggest that the observed effects 
of schistosome infection on stunting are as a result of chronic parasite-induced inflammation, 
which persists from infection during childhood (Assis et al., 1998, Friedman et al., 2005, 
Coutinho et al., 2006). It is however noteworthy that determining the fraction of morbidity 
attributable to schistosome infection, does not demonstrate causation by schistosome 
infection. Therefore, the morbidity attributable fraction explains some, but not all the 
schistosome-related morbidity observed in endemic areas. 
Currently, the global infection and disease burden remain unknown in PSAC; the best 
estimates (up to 50% prevalence) available are from published epidemiological schistosome 
studies (Woolhouse et al., 2000, Bosompem et al., 2004, Odogwu et al., 2006, Mutapi et al., 
2011, Kemal et al., 2019, Mutsaka-Makuvaza et al., 2019, Sacolo-Gwebu et al., 2019). Studies 
on the incidence of infection and morbidity, in particular, the early events that occur during 
the very first infection and treatment in PSAC are lacking. To address this, a cohort of 
previously uninfected children was followed to determine the incidence of the first 
schistosome infection and morbidity, and the impact of treatment on resolution of early 
morbidity (Chapter 3). Incidence of the first S. haematobium infection and morbidity  
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(i.e. microhaematuria) was recorded every 3 months for a year; the cumulative annual 
incidence of infection and morbidity was 17.4% and 20.4%, respectively. Therefore even for 
the very first schistosome infection, PSAC quickly develop clinical symptoms and substantial 
morbidity as previously suggested (Sacko et al., 2011, King 2015). Furthermore, although 
morbidity occurred rapidly within 3 months of first infection, this resolved quickly within 3 
months of curative treatment with a single standard dose of PZQ (i.e. 40 mg/kg body weight). 
Reinfection following curative treatment with PZQ (N'goran et al., 2001, Kabuyaya et al., 
2017, Mutsaka-Makuvaza et al., 2018, Woldegerima et al., 2019) has been suggested to occur 
at a higher rate in PSAC. Reasons are that infection and reinfection might be facilitated by 
young children staying still in water margins or being bathed in a basin of water collected from 
infected sources, compared to older children and adults who are more independent and mobile 
(Stothard et al., 2013). By following a group of previously uninfected children for 2 years, a 
proof-of-principle study was conducted to compare the effect of a single PZQ treatment on 
infection and reinfection rates (Chapter 4). Results showed that regular quarterly screening 
and treatment of the first S. haematobium infection, reduced the actual time at risk of infection 
(i.e. the child life-years of infection), and resulted in reduced rates of subsequent new 
infections. This is consistent with the long-term impacts of antihelminthic treatment in 
reducing infection transmission (Hodges et al., 2012, Senghor et al., 2016). Furthermore, a 
single dose PZQ treatment of primary schistosome infections was associated with reduced 
reinfection rates and intensity a year later. When compared with the reinfection rate observed 
following the treatment of chronic infections, the rate of reinfection in children who had been 
treated within 3 months of their first schistosome infection was lower, although not 
significantly different. These findings are consistent with reports on the impact of PZQ 
treatment on reduced reinfection rates, as would be the case of treating chronic infections in 
conventional MDA treatment strategies in schistosome-endemic areas (Wilkins et al., 1987, 
N'goran et al., 2001). Importantly, my findings show this effect after a single early treatment 
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in PSAC experiencing their very first schistosome infection. The impact of PZQ treatment on 
reduced (re)infection rates was also confirmed by the observation that within the first year, the 
annual rate of first infections was about 3-fold higher, when compared to the annual reinfection 
rate in previously treated chronically infected children. These observations can be 
contextualised within the current paradigm that in addition to its direct effects on the parasite, 
PZQ treatment has an added benefit of inducing/accelerating immune responses associated 
with protection against reinfection in PSAC (Rujeni et al., 2013), older children, and adults 
(Watanabe et al., 2007, Black et al., 2010a, Black et al., 2010b, Bourke et al., 2013, Schmiedel 
et al., 2015). 
Evidence presented in this thesis shows that PSAC in schistosome-endemic areas present with 
significant schistosome infection and morbidity. A significant proportion of the 
growth/nutrition-related morbidity common in children in these areas is attributable to 
schistosome infection. In addition, I have demonstrated how quickly the very first schistosome 
infection can be detected, and when infection-related morbidity develops and can be detected. 
I have also documented the impact of a single standard dose PZQ treatment in reversing early 
morbidity and reducing (re)infection rates. Early, regular screening for schistosome infections 
in PSAC will enhance the ability to detect and treat infections early, while reducing the risk of 
(re)infection, and preventing severe morbidity. 
7.3 Consequences of schistosome infection are systemic and 
influence overall health of the child 
Having determined the incidence of the first schistosome infection in PSAC, the development 
of early morbidity associated with this infection, and the impact of treatment on morbidity and 
(re)infection, I then determined the impact of schistosome infection on the host microbiome 
and metabolism, and how this influences disease and overall health in these children. 
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Experimental schistosome studies have shown that in order to establish themselves in the host, 
schistosome worms require essential host-derived hormones, nutrients and cytokines for 
survival (Amiri et al., 1992, de Mendonca et al., 2000, Davies et al., 2001, Saule et al., 2002, 
Davies et al., 2004, You et al., 2015). When such essential host factors are not present, there 
is poor parasite development and fecundity, and infection causes reduced pathology in the host 
(Cheng et al., 2008, Lamb et al., 2010, Tang et al., 2013). Therefore, a cohort of PSAC who 
had no evidence of previous infection by schistosomes was followed to their first schistosome 
infection and curative treatment, and the changes in serum metabolite profiles with infection 
and treatment were determined (Chapter 5). The results demonstrated that the first  
S. haematobium infection is associated with alterations in host metabolites, primarily linked 
with energy (glycolysis, pentose phosphate pathway, starch, and galactose) and purine 
metabolism. The observed changes were commensurate with increasing infection intensity and 
were restored to almost pre-infection levels, following curative treatment with PZQ. A 
pathway-based model and physiological interpretation indicated that the interplay between the 
host and schistosome worms is consistent with parasite-related morbidity including 
malnutrition, poor growth, and poor physical and cognitive performance, common in 
schistosome-infected children (Freer et al., 2018). The observed metabolite alterations were 
also consistent with the hypothesis that schistosome worms have the ability to manipulate the 
host metabolic system for molecules such as lipids (Meyer et al., 1970, Brouwers et al., 1997) 
and purines (Levy and Read 1975b), essential for their survival in the host. Studies of  
S. mansoni infection have reported similar findings in terms of alterations in energy and liver 
metabolism, in addition to gut microbiota metabolism (Balog et al., 2011, Panic et al., 2018); 
in these studies however, cohorts were not limited to PSAC. Together, my observations are in 
line with findings from studies conducted in experimental models of schistosome infection 
(Ahmed and Gad 1995, Wang et al., 2004, Liu et al., 2019), showing that such host metabolic 
alterations can begin as early as three weeks post-infection, and are essential for parasite 
development and disease progression (Wu et al., 2010b). 
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Given the vital role the human gut microbiome plays in maintaining overall health (discussed 
in Chapter 1) (Human Microbiome Project Consortium 2012), alterations in the gut 
microbiota population that may occur as a result of schistosome infection, have implications 
for disease susceptibility (Laforest-Lapointe and Arrieta 2017). In addition, the microbiome is 
a reservoir for antimicrobial resistance (AMR) genes (Qin et al., 2010, Hu et al., 2013), hence, 
it is possible that alterations in the gut microbiota could have an impact on AMR gene 
abundance and diversity. Hence, I characterised the structure (abundance and diversity) of the 
gut microbiome and resistome in a cohort of PSAC, and tested the hypothesis that infection 
with S. haematobium is associated with alterations in the abundance and diversity of the gut 
microbiota and associated AMR genes (Chapter 6). 
Independent of host-related factors including socio-demography, clinical history, and growth 
and nutritional indices, S. haematobium infection was associated with significant alterations 
in the abundance of specific gut microbiota populations; there was predominantly an increased 
abundance of bacterial and fungal phyla from Proteobacteria, Ascomycota and Basidiomycota 
in schistosome-infected children, compared to uninfected children. The observed microbiota 
alterations correlated with infection intensity, strongly supporting that the changes were 
associated with the presence of S. haematobium infection. Recently, differences in microbiota 
abundance between infected and uninfected children was reported during infection with S. 
haematobium (Kay et al., 2015, Ajibola et al., 2019) and S. mansoni (Schneeberger et al., 
2018). These studies included both PSAC and older children (ages 6 months to 15 years), 
whilst my findings focus on PSAC. Further analysis showed that individual-specific metadata, 
including schistosome infection, were not associated with the resistome in this cohort of 
PSAC. This may be explained by suggestions that many inherent population anthropogenetic 
(of or relating to their origin and development) and environmental factors greatly influence 
the resistome (Collignon et al., 2018, Hendriksen et al., 2019). 
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Much of our understanding of the schistosome–metabolism–microbiome interactions in 
humans has been facilitated by experimental studies (discussed in Chapter 1). For the work 
presented here, the analysis of matching pre- and post-infection samples in a cohort of PSAC 
with no infection history, allows for an understanding into the early metabolic responses that 
contribute to disease progression and morbidity from the first schistosome infection in PSAC. 
In addition, the gut microbial population in very young children continues to evolve until about 
age 3–5 years (Yatsunenko et al., 2012, Rodriguez et al., 2015). Thus, my findings provide 
understanding into the association between helminth infection and the changes that occur 
during the establishment of the gut microbiome in young children (i.e. £5 years old). It further 
suggests microbiome alterations as an additional consequence of schistosome infection, which 
may be relevant for disease pathogenesis and influence on overall health of the host. As our 
knowledge in the field of the schistosome–metabolism–microbiota interactions in humans 
expand, further phenotypic and mechanistic studies will contribute to a better understanding 
of the association between metabolic/microbiome disturbances and the aetiology of 
schistosome-related pathology in children. 
7.4 Implications of findings for improving paediatric 
schistosomiasis control and health policy 
There is now an increased recognition of the health consequences of schistosomiasis in PSAC, 
and concerted efforts are being made to address research and knowledge gaps, while ensuring 
access to treatment for PSAC in different endemicity settings. In this thesis, I was able to 
demonstrate the dynamics of schistosome infection and treatment in PSAC, using cross-
sectional and longitudinal field studies conducted in a schistosome-endemic area in 
Zimbabwe. In schistosome-endemic areas, preventive chemotherapy programmes conducted 
through MDA target SAC (WHO Expert Committee 2002, World Health Organization 2006). 
Unlike SAC, PSAC are not accessible in schools (although some may be in early child 
development centres) and accessing them for diagnosis and treatment is a challenge. Similar 
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to studies conducted in PSAC in schistosome-endemic areas (Mutapi et al., 2011, Mutsaka-
Makuvaza et al., 2018), and as recommended by the World Health Organization (WHO) 
(World Health Organization 2011), the work presented in this thesis demonstrates the utility 
of primary health care centres and current health intervention programmes such as Child 
Health Days and the Expanded Programme on Immunization (EPI), for the regular screening 
and treatment of schistosomiasis in PSAC. This suggests that pending the roll-out of the 
paediatric PZQ formulation for the treatment of schistosomiasis in PSAC through MDA 
programmes, access to treatment can be extended to include PSAC via primary health centres 
on a case-by-case basis (World Health Organization 2011, Bustinduy et al., 2016a). To 
eliminate schistosomiasis as a public health problem (currently defined as <1% of heavy 
intensity schistosomiasis infections), one of the critical action points highlighted in the 
recently published WHO neglected tropical diseases (NTD) roadmap for 2021–2030, is to 
extend treatment to all at-risk populations using more cost-effective strategies (World Health 
Organization 2020a). Thus, the use of primary health care centres to access and treat PSAC 
for schistosomiasis, as demonstrated in this thesis, presents an opportunity to extend treatment 
to PSAC who are excluded from treatment in most endemic countries. 
Determining the proportion of morbidity attributable to schistosome infection will make the 
identification and interpretation of schistosome-related morbidity easier; my findings highlight 
the role or relevance of urinary morbidity markers and anthropometric measures, as a tool for 
identifying schistosome-related morbidity in endemic areas. For example previous findings 
from Zimbabwe (Wami et al., 2015) and Nigeria (Salawu and Odaibo 2014) have 
demonstrated the significance of microhaematuria as a POC field marker of morbidity for 
urogenital schistosomiasis in PSAC. Chronic growth/nutrition-related morbidity indices such 
as stunting can also help identify high-risk groups, and measure the health impacts of infection 
and treatment in schistosome-endemic areas. My work further demonstrates that 
microhaematuria coincides with schistosome infection and is resolved with curative treatment; 
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this highlights the significance of microhaematuria in post-treatment monitoring of PSAC, as 
applied during large-scale chemotherapy for schistosomiasis in SAC (Koukounari et al., 2007, 
Webster et al., 2009, King and Bertsch 2013). 
As demonstrated in this thesis, a regular screening strategy to detect and treat schistosome 
infections early in PSAC, is essential to avert irreversible morbidity; this can be done using 
the currently available diagnostic, morbidity and treatment tools. Schistosome infection and 
morbidity can be detected early in PSAC using parasitology (egg counts) and dipstick 
techniques (microhaematuria) within 3 months of first infection, and morbidity resolves 3 
months after curative treatment with PZQ. There are ongoing phase III clinical trials for the 
leading paediatric PZQ formulation in countries including the Ivory Coast and Kenya (target 
age is 3 months–6 years) (Paediatric Praziquantel Consortium 2020). Preparations are also far 
advanced to conduct a similar trial in Zimbabwe, in which our research group is involved. 
While we await promising results from these trials, the findings reported here will have a great 
impact in planning and policy development for schistosomiasis control in endemic areas, in 
terms of determining the best treatment strategy to reduce subsequent new infections, 
reinfections, and long-term morbidity. For example, given the health consequences in terms 
of long-term morbidity from chronic schistosome infections, a routine screen-and-treat 
strategy as part of routine child health and development monitoring activities will optimise the 
chances of detecting and treating infections early, while reducing the risk of new infections, 
reinfection, and severe morbidity. 
The evidence presented on the effects of schistosome infection on the host microbiome and 
metabolism will have a major impact on helminth infection control in endemic areas. First, it 
adds to the repository of limited information on how the human gut microbiome and 
metabolism influence schistosome-related disease and morbidity in PSAC. Secondly, it 
contributes to our understanding on the factors underlying disease progression, differences in 
disease patterns, as well as the development of new strategies targeted at reducing 
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schistosome-associated morbidity in infants and young children. For instance, it will provide 
a basis for understanding the role of interventions such as nutraceuticals, in influencing health 
through the microbiome and enhanced nutrition/metabolism for selected helminth infections.  
It is also worth mentioning that after adoption of the Global Action Plan on antimicrobial 
resistance by the 68th session of the World Health Assembly in 2015 (Geneva, Switzerland), 
Zimbabwe put in place a framework to develop an AMR National Action Plan through a 
situational analysis of antimicrobial use and resistance in the country (Zimbabwe National 
Antimicrobial Resistance Core Group 2017). The work presented in this thesis in relation to 
characterising the resistome of this preschool population has already contributed to the 
development and launch of a One Health Antimicrobial Resistance National Action Plan for 
2017–2021 in Zimbabwe (https://www.ed.ac.uk/files/atoms/files/zimbabwe_nap_2_1.pdf). In 
keeping with calls from the WHO and the United Nations on strategic policies on global 
antibiotic use, scientific information comparable to the data provided in this thesis will help 
formulate policy and guide revisions in antibiotic use in the country, and for the rest of sub-
Saharan Africa. 
My findings together contribute to identifying appropriate morbidity indicators, alternative 
approaches for utilizing current interventions for maximum health benefits, developing new 
interventions for schistosomiasis control, and informing policy to improve infection and 
disease control. This is in line with the critical action points highlighted for schistosomiasis 
control and elimination in the new WHO NTD roadmap for 2021–2030 (World Health 
Organization 2020a). These action points are discussed in further detail in the subsequent 
section. 
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7.5 Treating paediatric schistosomiasis contributes to 
disease elimination and meeting the SDG targets 
The recently updated WHO NTD roadmap for 2021–2030 highlights three critical action 
points for eliminating schistosomiasis as a public health problem, i.e. <1% of heavy intensity 
schistosomiasis infections (World Health Organization 2020a). These include defining 
indictors of morbidity, extending treatment to those in need and ensuring access to 
medications, as well as developing new interventions for schistosomiasis control. Thus, the 
work and evidence presented here contributes to realising these goals, especially for improving 
paediatric schistosomiasis control, by demonstrating: 
 Evidence on the early events that occur during the first schistosome infection in 
PSAC in endemic areas. 
 The utility of current health systems and tools for extending treatment to PSAC. 
 The best approach and timing to access PSAC for treatment to reduce reinfection 
and morbidity. 
 The utility of growth and nutritional indices as indicators of schistosome-related 
morbidity and identification of high-risk groups. 
 Insight into the development of new interventions targeted at reducing morbidity, 
including the role of nutraceuticals for influencing health and improving nutrition-
related morbidity in schistosome-infected children.  
Extending the findings presented in this thesis to conduct further studies across different 
endemicity settings, will contribute to scientific evidence appropriate for improving disease 
control and eventually eliminate the disease in schistosome-endemic countries. 
Providing such compelling evidence (as demonstrated in this thesis) will help to ensure that 
paediatric schistosomiasis control becomes a priority in endemic countries with limited health 
resources. This will be important for achieving the Sustainable Development Goals (SDGs) 
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for health (i.e. Goal 3; ensure healthy lives and promote well-being for all at all ages). As part 
of this goal, NTDs are highlighted in target 3.3, which calls for ending the epidemic of NTDs 
by 2030. Thus, successful interventions against NTDs such as schistosomiasis could have an 
impact on and improve prospects for achieving the SDG targets and vice versa. For example, 
improving the health of children through improved paediatric schistosomiasis interventions 
will mean enabling children to have access to education and with good physical and cognitive 
performance (Goal 4), alleviating hunger by ensuring children make the most of their nutrition, 
free of infections (Goal 2), and reducing long-term morbidity for a productive future life and 
reduction of poverty (Goal 1). Conversely, achieving other SDGs will also impact positively 
on the control of schistosomiasis and other NTDs. For instance the provision of adequate 
water, sanitation and hygiene (WASH) (Goal 6) is a complementary schistosomiasis control 
method, whilst the provision of resilient infrastructure (Goal 9) will improve health care 
delivery, and promote a strong logistic chain for the delivery of treatment and essential 
resources to the remotest of endemic areas. 
Finally, in line with the public health measures in place for the recent COVID-19 pandemic, 
particularly physical distancing, the WHO in April 2020 recommended that all community-
based surveys and MDA activities be suspended until further notice (World Health 
Organization and the United Nations Children’s Fund (UNICEF) 2020). This will impact 
negatively on the current progress for schistosomiasis control, logistics and resource supply, 
the ongoing phase III clinical trials for the roll-out of the paediatric PZQ, and overall, the 
elimination targets set for 2030. Therefore, while the evidence presented here is important to 
improving schistosomiasis control, there is a need to examine the potential impact of the 
suspension/delay of MDA, the use of primary health facilities for diagnosis and treatment, as 
well as the utility of complementary measures such as WASH, education, and vector control 
measures in this scenario. This is essential to propose concrete mitigation approaches that will 
serve as a basis for providing remedial strategies in the context of scenarios of the current and 
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future pandemics of any kind. Modelling analysis currently being conducted by the Expanded 
Special Project for Elimination of Neglected Tropical Disease (ESPEN) will be a good starting 
point (see https://espen.afro.who.int/updates-events/covid-19). 
7.6 Prospects and recommendations 
The work presented in this thesis was conducted to answer a series of epidemiological, 
molecular and biochemical questions relating to schistosome infection and disease dynamics 
(aims outlined in Chapter 1). The main schistosome diagnostic method applied to answer 
these questions was the recommended conventional field-applicable parasitological methods, 
i.e. the urine filtration and Kato-Katz techniques (World Health Organization 2020b). There 
are operational challenges of sampling and diagnostic sensitivity associated with the current 
parasitological diagnostic methods (Bergquist et al., 2009, Coulibaly et al., 2013, Wami et al., 
2014, Utzinger et al., 2015). Schistosome infection in PSAC usually presents as low intensity 
infections, which may be missed by parasitological techniques, thus underestimating the 
prevalence of schistosome infection (Le and Hsieh 2017). However, there is lack of a more 
convenient, specific, rapid, and cheap alternative diagnostic method that is suitable for field 
applications in schistosome-endemic areas. Realistically looking ahead to primary health care 
for infants and children in schistosome-endemic areas, there is a need for further research into 
more sensitive rapid POC tests that integrate diagnosis for all Schistosoma species infections, 
suitable for large scale field applications. However, the use of parasitological methods for 
infection diagnosis in all aspects of this thesis allows to compare the present findings to other 
studies, and to inform developing targeted interventions, while parasitological methods remain 
the predominant schistosome diagnostic in PSAC in schistosome-endemic areas. 
Longitudinal studies across different epidemiological and endemicity settings are needed to 
evaluate the access, screening and treatment strategy used in this thesis. These should also 
include determining the immunological mechanisms underlying the resistance to reinfection 
associated with early treatment of schistosome infections in PSAC. For instance, it will be 
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imperative to determine the levels of various immunological markers, before and after 
treatment at the time of measuring reinfection rates. These could include T-helper type (Th)1 
cytokines such as interferon gamma, IL-1, IL-2, and IL-6, Th2 cytokines such as IL-4, IL-5, 
IL-10, and IL-13, as well as parsite-specific IgE and IgG antibody classes. There is also a need 
for larger studies to determine the practical long-term operational and economic implications 
of regular screening to diagnose and treat primary schistosome infections of all species in 
PSAC. Such studies will be important in contributing evidence to determine the best approach 
and timing to access PSAC for chemotherapy, and to reduce reinfection and long-term 
morbidity across a diversity of endemicity settings. In addition, the utility of growth and 
nutritional indices as indicators of schistosome-related morbidity will need to be included in 
such evaluations, to ascertain their utility as a tool for identification of high-risk groups, and 
to monitor morbidity. Given that several factors including dietary habits and socio-economic 
status can influence the growth and nutritional sequelae observed in children in schistosome-
endemic areas, studies which can separate the effects of schistosome infections from other 
confounders would be informative in identifying and apportioning causation for schistosome-
related morbidity attributable fractions. 
Metabolic alterations in response to schistosome infection, in conjunction with the metabolic 
pathway-based analysis and interpretation was described in this cohort of PSAC. This gave 
insight into the host-pathogen interactions that lead to establishment/survival of the parasite, 
and consequently, disease and morbidity, early in the first schistosome infection. However, 
long-term studies relating measurable clinical manifestations of schistosome infection in 
children to such metabolic alterations, would give a stronger indication of the clinical 
implications of the schistosome-induced metabolic disturbances. For instance, it will be 
important to conduct studies following a natural time-course of schistosome infection and 
treatment, which will measure metabolic profiles in PSAC in addition to developmental time-
course profiles of growth, nutrition, physical activity and cognition. 
[Paediatric Schistosomiasis: Dynamics and Consequences] 
202  [General discussion] 
The findings on the effects of schistosome infection on the microbiome indicate that 
phenotypic and mechanistic studies to understand the systemic interactions between 
schistosomes and the microbiome, and to elucidate causation in natural human infections are 
needed. Microbiome research studies that focus on PSAC, will provide further insight for 
developing specific interventions for influencing health through the microbiome in infants and 
young children (Robertson et al., 2019). Longitudinal studies tracking individuals over a long-
term after curative treatment (preferably at regular time point intervals), to ascertain whether 
and how quickly their microbiota returns to an uninfected state are recommended. Such studies 
will also help to clarify the causality of the observed changes, and the effect of curative 
treatment on reversal of morbidity associated with alterations in microbiota. Human 
microbiome studies that include characterising the resistome will also need to include relating 
the presence of AMR genes to measurable phenotypic resistance to bacteria, and what the 
clinical implications are. 
The studies on the association between schistosome infection and the host microbiome and 
metabolism were limited by sample size. This was especially so for the investigation on the 
effects of schistosome infection on the host metabolism, where following a natural time-course 
of first schistosome infections, meant that there was no control over the number of infected or 
uninfected children. Much of our understanding of the association between schistosome 
infection and the host microbiome and metabolism are from experimental studies (as described 
in Chapter 1). In addition, there are limited schistosome–microbiome and schistosome–
metabolism studies focusing solely on PSAC, to inform sample sizes for the work conducted 
in this thesis. Nonetheless, the current evidence available from studies including older 
individuals [for metabolomics; (Balog et al., 2011, Panic et al., 2018), and for microbiome 
studies (Kay et al., 2015, Schneeberger et al., 2018, Ajibola et al., 2019)], show that the sample 
sizes used were sufficient to detect significant differences. The findings indicate that it is 
important to extend these studies to larger preschool cohorts. 
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7.7 Final conclusions 
Based on the work described, the conclusions are as follows: 
 The results demonstrate for the first time, incidence of the first S. haematobium 
infection and morbidity in PSAC, as estimated by egg counts and 
microhaematuria respectively. This infection and morbidity occur rapidly, can be 
detected within 3 months of first infection using currently available tools, and 
morbidity resolves within 3 months of curative treatment with PZQ. Chronic 
growth and nutrition-related morbidity such as stunting and malnutrition are 
attributable to S. haematobium infection in PSAC, and can help identify high-risk 
groups, to quantify and monitor morbidity in PSAC. Undelayed screening and 
treatment of schistosome infections in PSAC is essential to avert accumulative 
morbidity, which can affect overall health. 
 PZQ treatment of the first schistosome infection in PSAC, is associated with 
resistance to reinfection. Regular quarterly screening and treatment of the first  
S. haematobium infection results in reduced rates of subsequent new infections. A 
routine screen-and-treat strategy as part of routine child health and development 
monitoring activities will optimise the chances of detecting and treating infections 
early, while reducing the risk of new infections, reinfection, as well as severe 
morbidity. 
 Early in the first S. haematobium infection, there are significant alterations in host 
metabolite profiles, primarily related to energy and purine metabolism. These 
changes correlated with infection intensity and resolved 12 weeks post-curative 
antihelminthic treatment. The findings suggest an interplay between the host and 
schistosome worms, consistent with parasite survival, disease progression, and 
parasite-related morbidity including malnutrition, poor growth, and poor physical 
and cognitive performance. 
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 There are significant differences in the gut microbiome but not the resistome, 
between schistosome-infected and uninfected PSAC; there is largely an increase 
in abundance of specific bacterial and fungal microbiota in infected children. The 
observed alterations in microbiota abundance correlated with infection intensity. 
This suggests microbiome alterations as an additional consequence of 
schistosome infection, which may be relevant for disease pathogenesis. 
This thesis provides an overview of the current knowledge and research in paediatric 
schistosomiasis practise, while identifying and addressing important research and knowledge 
gaps. Original research was conducted to answer important questions relating to schistosome 
infection and disease dynamics, and the health impacts of infection and treatment, during the 
first infection event in PSAC (i.e. £5 years old). This thesis also answers questions on the 
biochemical and molecular mechanisms underlying disease and treatment, as they relate to the 
metabolic system and the gut microbiome in this age group. Taken together, the findings 
contribute to bridging the knowledge gaps relevant to deliver sustainable control of 
schistosomiasis in PSAC, to inform development of specific interventions targeted at reducing 
morbidity in this age group, and to strengthen elimination programmes and improve overall 
health. 
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Appendix A Supplementary information–Chapter 3 
 
Figure 0.1: Output from growth and nutrition analysis of the study population at baseline. 
Output was generated from the World Health Organization (WHO) Anthro software, version 3.0.1 
(http://www.who.int/childgrowth/en/). The tool, based on raw anthropometric (weight, height) and 
demographic data (age and sex), generates anthropometric estimates and their corresponding Z-scores, 
based on four indicators; length/height–for–age, weight–for–age, weight–for–length/height, and body 
mass index (BMI)–for–age. All values are based on WHO standards (Red) and plots are compared to 
the WHO standard population curve (Green). HAZ, height–for–age Z-scores; WAZ, weight–for–age Z-
scores; BAZ, BMI–for–age Z-scores (BAZ), MUACZ, Mid-upper arm circumference Z-scores; WHZ, 
weight–for–height. Measures below the median, based on indicators were defined as Z-scores < -2. 
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Figure 0.2: Schistosome-related morbidity at baseline, stratified by schistosome infection status. 
With the exception of stunting and microhaematuria (shown in chapter 3), all other indicators were not 
significantly different between groups, although slightly higher amongst S. haematobium-positive 
children. Error bars indicate 95% confidence intervals of the observed prevalence. p-values test for the 
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Appendix B Supplementary information–Chapter 5 
Table 0.1: Important metabolites identified by fold change analysis by sex. 
Metabolite Fold Change (FC) log2 (FC) 
3-Phosphoglyceric acid 0.48062 -1.057 
β-Alanine 0.46924 -1.0916 
cis-Aconitic acid 0.45987 -1.1207 
Sarcosine 0.44656 -1.1631 
Ribulose-5-phosphate 0.32765 -1.6098 
Citrulline 0.28031 -1.8349 
Spermidine 0.25941 -1.9467 
Inosine 0.25062 -1.9965 
Uracil 0.18962 -2.3988 
Glyoxylic acid 0.15585 -2.6817 
Guanine 0.10453 -3.258 
Uridine diphosphate 0.10453 -3.258 
Creatinine 0.10332 -3.2748 
2-Phosphoglyceric acid 0.072414 -3.7876 
Fumaric acid 0.058175 -4.1035 
Glucose-1-phosphate 0.043478 -4.5236 
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Table 0.2: Correlation pattern analysis of metabolites showing a female to male pattern 
Metabolite Correlation t-statistic p-value FDR 
Creatinine 0.50335 5.2427 1.23E-06 7.90E-05 
Citrulline 0.46873 4.7757 7.85E-06 0.00025121 
cis-Aconitic acid 0.31171 2.9525 0.0041229 0.087955 
gamma-aminobutyric acid (GABA) 0.2977 2.8066 0.0062697 0.10031 
Sarcosine 0.26854 2.509 0.014102 0.1805 
2-Oxoisovaleric acid 0.2305 2.1319 0.036047 0.36727 
Isocitric acid 0.22574 2.0855 0.040171 0.36727 
Glucose-1-phosphate 0.21615 1.9925 0.049688 0.3975 
3-Phosphoglyceric acid 0.18689 1.7122 0.090693 0.60492 
Asparagine -0.18475 -1.6918 0.094519 0.60492 
Ribulose-5-phosphate 0.17364 1.5868 0.11644 0.67749 
Fumaric acid 0.16667 1.5213 0.13207 0.70437 
β-Alanine 0.14805 1.3473 0.18164 0.77685 
Inosine 0.14542 1.3228 0.18961 0.77685 
Guanosine monophosphate (GMP) 0.14044 1.2766 0.2054 0.77685 
2-Phosphoglyceric.acid 0.14004 1.2729 0.20669 0.77685 
Glyoxylic acid 0.13052 1.1848 0.23956 0.77685 
Inosine monophosphate (IMP) 0.1264 1.1468 0.25483 0.77685 
Pyruvic acid 0.12088 1.0959 0.27636 0.77685 
Citric acid 0.11845 1.0737 0.28617 0.77685 
N.N-Dimethylglycine 0.11823 1.0716 0.28709 0.77685 
Glucose-6-phosphate 0.10428 0.94363 0.34817 0.77685 
3-Hydroxybutyric acid 0.10402 0.94127 0.34936 0.77685 
Guanine 0.10342 0.93577 0.35217 0.77685 
Uridine diphosphate (UDP) 0.10342 0.93577 0.35217 0.77685 
Adenosine monophosphate (AMP) 0.10328 0.93453 0.35281 0.77685 
Hydroxyproline 0.10234 0.92596 0.35722 0.77685 
Uracil 0.095602 0.86438 0.38993 0.77685 
Methionine 0.095524 0.86367 0.39032 0.77685 
Arginine -0.095024 -0.8591 0.39282 0.77685 
Lysine -0.093629 -0.84638 0.39984 0.77685 
Spermidine 0.092362 0.83483 0.40627 0.77685 
Glutamine 0.090823 0.8208 0.41417 0.77685 
Aspartic acid -0.090674 -0.81944 0.41494 0.77685 
Phenylalanine -0.086671 -0.78298 0.43592 0.77685 
Hypoxanthine -0.086471 -0.78117 0.43698 0.77685 
Malic acid 0.079649 0.71913 0.47413 0.82012 
Betaine -0.075391 -0.68045 0.49816 0.839 
Isoleucine -0.067526 -0.60912 0.54415 0.89296 
Succinic acid -0.063331 -0.57113 0.56949 0.90425 
Ethanolamine phosphate 0.060998 0.55 0.58383 0.90425 
Creatine -0.057916 -0.52212 0.60301 0.90425 
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Metabolite Correlation t-statistic p-value FDR 
Histidine 0.055047 0.49617 0.62112 0.90425 
Lactic acid 0.049938 0.45001 0.65391 0.90425 
2-Oxoglutaric acid 0.048837 0.44006 0.66106 0.90425 
Uridine -0.04522 -0.4074 0.68479 0.90425 
Carnosine 0.043415 0.3911 0.69675 0.90425 
2-Hydroxybutyric acid 0.041292 0.37195 0.7109 0.90425 
Homoserine 0.039607 0.35675 0.72221 0.90425 
Leucine -0.038557 -0.34727 0.72929 0.90425 
Tryptophan 0.037895 0.3413 0.73376 0.90425 
Gluconic acid 0.036951 0.33279 0.74015 0.90425 
Ornithine 0.035674 0.32127 0.74883 0.90425 
Alanine 0.031103 0.28006 0.78014 0.91498 
Choline -0.030209 -0.272 0.78631 0.91498 
Serine -0.025848 -0.23271 0.81657 0.93323 
Glutamic acid -0.019584 -0.17629 0.86051 0.95323 
Proline -0.019108 -0.172 0.86386 0.95323 
Adenosine diphosphate (ADP) -0.011021 -0.099196 0.92123 0.99315 
Valine -0.0084686 -0.07622 0.93943 0.99315 
Tyrosine -0.0074647 -0.067185 0.9466 0.99315 
Glycine 0.0043594 0.039235 0.9688 0.99402 
Guanosine diphosphate (GDP) 0.0013403 0.012063 0.99041 0.99402 
Threonine -0.00083565 -0.0075209 0.99402 0.99402 
Table shows metabolites ranked in order of decreasing significance based on absolute FDR values. 
FDR, adjusted p-value (False discovery rate corrected). 
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Figure 0.1: Principal component analysis (PCA) of metabolite features by sex at baseline. 
a) Scores plot between the selected principal components. The explained variances are shown in 
brackets. b) Scree plot shows the variance explained by principal components. The green line on top 
shows the accumulated variance explained; the blue line underneath shows the variance explained by 
individual principal components. 
b) 
a) 
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Figure 0.2: Orthogonal Projections to Latent Structures Discriminant Analysis (OPLSDA) model 
statistics for metabolite features by sex. 
a) Model overview of the OPLS-DA model for the provided dataset, showing the R2X, R2Y and Q2 
coefficients for the groups (Male and Female). b) Permutation analysis, showing the observed (pink) 
and cross-validated (blue) R2Y and Q2 coefficients. 
a) 
b) 
[Paediatric Schistosomiasis: Dynamics and Consequences] 
252  [Appendices] 
Table 0.3: Output from OPLSDA sex model S-plot along with corresponding VIP values.  
Metabolite p[1] p(corr)[1] VIP 
Creatinine 0.27549 0.83449 2.8572 
Citrulline 0.28376 0.74286 3.0786 
Sarcosine 0.2158 0.58758 1.6958 
GABA 0.24761 0.51792 2.4472 
cis-Aconitic acid 0.24515 0.48237 2.724 
β-Alanine 0.12627 0.45482 0.70673 
Citric acid 0.1852 0.44703 0.84383 
Ribulose-5-phosphate 0.12263 0.44449 0.82369 
Isocitric acid 0.21912 0.39771 2.1385 
Inosine 0.12335 0.39247 0.78589 
Gluconic acid 0.091583 0.38912 0.14954 
Glyoxylic acid 0.091254 0.38088 0.53769 
Hydroxyproline 0.12839 0.37893 0.59623 
Malic acid 0.089404 0.37613 0.32553 
Guanosine monophosphate (GMP) 0.18069 0.36823 1.185 
Lactic acid 0.15143 0.3672 0.3541 
Tyrosine 0.10023 0.3661 0.035139 
Threonine 0.10289 0.36533 0.0040469 
Spermidine 0.078093 0.35967 0.34483 
3-Phosphoglyceric acid 0.106 0.35216 0.96721 
Alanine 0.098844 0.34014 0.15541 
Valine 0.090363 0.33706 0.039038 
Ornithine 0.10801 0.32348 0.20481 
Methionine 0.10469 0.31104 0.55285 
Histidine 0.076237 0.30659 0.23536 
2-Oxoisovaleric-acid 0.20386 0.30528 2.6467 
Glycine 0.080119 0.29608 0.020284 
N.N-Dimethylglycine 0.10961 0.29401 0.75786 
Glucose-1-phosphate 0.080837 0.29223 1.0281 
Creatine 0.085623 0.28529 0.29888 
Proline 0.083795 0.27386 0.10053 
Inosine monophosphate (IMP) 0.10985 0.27044 0.88282 
Pyruvic acid  0.11333 0.25751 0.9147 
Glutamine 0.10691 0.25725 0.64903 
Tryptophan 0.082756 0.24162 0.22317 
Leucine 0.060968 0.24067 0.16795 
Ethanolamine phosphate 0.096447 0.22581 0.44797 
Glutamic acid 0.077948 0.22498 0.11667 
Carnosine 0.077743 0.22476 0.25821 
Adenosine monophosphate (AMP) 0.10243 0.21539 0.84452 
2-Phosphoglyceric acid 0.049194 0.2145 0.55225 
Lysine 0.067508 0.21384 0.50823 
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Metabolite p[1] p(corr)[1] VIP 
Glucose-6-phosphate 0.11745 0.2108 0.99899 
Fumaric-acid 0.058516 0.1974 0.84955 
Serine 0.058128 0.1968 0.13128 
Betaine 0.071743 0.18678 0.49792 
Uracil 0.038722 0.18235 0.34907 
Isoleucine 0.050402 0.15271 0.38322 
Choline 0.040908 0.15246 0.13937 
Aspartic acid 0.034616 0.12663 0.42621 
Homoserine 0.050824 0.11895 0.29098 
Uridine diphosphate (UDP) 0.024667 0.11412 0.38436 
Uridine 0.041775 0.10853 0.29927 
2-Hydroxybutyric acid 0.031232 0.10034 0.221 
Phenylalanine 0.029308 0.093128 0.469 
3-Hydroxybutyric.acid 0.029264 0.080126 0.65323 
Adenosine diphosphate (ADP) 0.032083 0.078068 0.077878 
Guanine 0.015178 0.070223 0.38436 
Succinic acid 0.021835 0.063789 0.37276 
Arginine 0.0083901 0.019567 0.70061 
2-Oxoglutaric acid 0.0085815 0.015868 0.45414 
Hypoxanthine 0.0035884 0.0089486 0.59623 
Guanosine diphosphate (GDP) -0.0044877 -0.012625 0.0081925 
Asparagine -0.048699 -0.10995 1.407 
Table shows metabolites ranked in order of decreasing correlation or reliability coefficient [p(corr)]. 
p[1], covariance or contributions; p(corr)[1], correlation or reliability coefficient; VIP, variable 
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Table 0.4: Important metabolites identified by fold change analysis by infection status. 
Metabolite Fold Change (FC) log2 (FC) 
Choline 8.8175 3.1404 
Lactic acid 6.1847 2.6287 
Glutamic acid 2.4991 1.3214 
Serine 2.4807 1.3107 
Succinic acid 2.4599 1.2986 
Histidine 2.453 1.2946 
Phenylalanine 2.3656 1.2422 
Lysine 2.3145 1.2107 
Pyruvic acid 2.2875 1.1937 
Hypoxanthine 2.1134 1.0796 
Ornithine 2.1105 1.0776 
Leucine 2.1069 1.0752 
Homoserine 2.0195 1.014 
Glucose-6-phosphate 0.48149 -1.0544 
Spermidine 0.4527 -1.1434 
Asparagine 0.44836 -1.1573 
2-Hydroxybutyric acid 0.44462 -1.1694 
Inosine monophosphate (IMP) 0.42322 -1.2405 
Ethanolamine phosphate 0.41315 -1.2752 
Guanosine monophosphate (GMP) 0.32008 -1.6435 
Adenosine monophosphate (AMP) 0.25 -2.000 
Adenosine diphosphate (ADP) 0.1844 -2.4391 
Sarcosine 0.17928 -2.4797 
Inosine 0.13699 -2.8679 
3-Phosphoglyceric acid 0.1361 -2.8773 
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Table 0.5: Correlation pattern analysis of compounds showing patterns from negative to positive 
for infection. 
Metabolite Correlation t-statistic p-value FDR 
Adenosine diphosphate (ADP) 0.43076 4.2959 4.80E-05 0.002689 
3-Phosphoglyceric acid 0.4095 4.0397 0.00012098 0.0033875 
Adenosine monophosphate (AMP) 0.36253 3.5009 0.00075695 0.01413 
Inosine 0.27435 2.5677 0.012077 0.11995 
Asparagine 0.26342 2.4575 0.016124 0.11995 
Lactic acid -0.26245 -2.4479 0.016532 0.11995 
Choline -0.26204 -2.4438 0.016708 0.11995 
Serine -0.2554 -2.3774 0.019791 0.11995 
2-Hydroxybutyric acid 0.25256 2.3492 0.021249 0.11995 
cis-Aconitic acid -0.25007 -2.3245 0.022602 0.11995 
Sarcosine 0.24839 2.3078 0.023561 0.11995 
Histidine -0.23692 -2.1948 0.031042 0.13583 
Guanosine monophosphate (GMP) 0.23626 2.1882 0.031533 0.13583 
Glucose-6-phosphate 0.22272 2.0561 0.042991 0.15628 
Ethanolamine phosphate 0.22243 2.0533 0.04327 0.15628 
Glutamic acid -0.22102 -2.0396 0.044652 0.15628 
Creatinine -0.2157 -1.9881 0.050184 0.1587 
Succinic acid -0.21244 -1.9566 0.053837 0.1587 
Alanine -0.21244 -1.9566 0.053844 0.1587 
Glycine -0.19987 -1.8358 0.070053 0.19615 
Lysine -0.19299 -1.7702 0.080451 0.21213 
Leucine -0.19122 -1.7533 0.083335 0.21213 
Phenylalanine -0.18497 -1.694 0.094112 0.22914 
Aspartic acid -0.17888 -1.6363 0.10566 0.24654 
Ornithine -0.17441 -1.5941 0.11481 0.25718 
Threonine -0.17199 -1.5713 0.12001 0.25848 
Tyrosine -0.13279 -1.2058 0.23141 0.46351 
Inosine monophosphate (IMP) 0.13183 1.1969 0.23484 0.46351 
Tryptophan 0.12799 1.1614 0.24888 0.46351 
2-Oxoisovaleric acid 0.12791 1.1607 0.24917 0.46351 
Spermidine 0.12594 1.1426 0.25658 0.46351 
Pyruvic acid -0.1144 -1.0364 0.30308 0.53039 
Creatine 0.10995 0.99558 0.32242 0.53498 
Citrulline -0.10941 -0.99064 0.32481 0.53498 
2-Oxoglutaric acid -0.087052 -0.78646 0.43389 0.69423 
Hypoxanthine -0.084189 -0.7604 0.44922 0.69879 
Isoleucine -0.075729 -0.68353 0.49623 0.75104 
Gamma aminobutyric acid (GABA) -0.072465 -0.65391 0.51503 0.75406 
Carnosine 0.069942 0.63102 0.5298 0.75406 
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Metabolite Correlation t-statistic p-value FDR 
Homoserine -0.068454 -0.61753 0.53862 0.75406 
Hydroxyproline 0.060526 0.54574 0.58675 0.78979 
Glutamine 0.059074 0.5326 0.59577 0.78979 
Valine -0.057369 -0.51717 0.60645 0.78979 
3-Hydroxybutyric acid 0.052369 0.47197 0.63822 0.81228 
Gluconic acid -0.042401 -0.38196 0.70349 0.86895 
Malic acid -0.040099 -0.36118 0.7189 0.86895 
Uridine -0.038359 -0.34548 0.73063 0.86895 
Ribulose-5-phosphate 0.033535 0.30198 0.76344 0.86895 
Proline -0.033532 -0.30196 0.76345 0.86895 
Arginine -0.031727 -0.28568 0.77585 0.86895 
Methionine -0.029174 -0.26267 0.79347 0.87126 
Citric acid 0.026801 0.2413 0.80993 0.87223 
N.N-Dimethylglycine -0.023034 -0.20736 0.83625 0.88358 
Isocitric acid 0.015931 0.1434 0.88633 0.91916 
Betaine -0.0096291 -0.086666 0.93115 0.93889 
β-Alanine 0.0085451 0.076909 0.93889 0.93889 
Table shows metabolites ranked in order of decreasing significance based on absolute FDR values. 
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Figure 0.3: Principal component analysis (PCA) of metabolite features by infection status. 
a) Scores plot between the selected principal components. The explained variances are shown in 
brackets. b) Scree plot shows the variance explained by principal components. The green line on top 
shows the accumulated variance explained; the blue line underneath shows the variance explained by 
individual principal components. 
a) 
b) 
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Figure 0.4: Orthogonal Projections to Latent Structures Discriminant Analysis (OPLSDA) model 
statistics for metabolite features by infection status. 
a) Model overview of the OPLS-DA model for the provided dataset, showing the R2X, R2Y and Q2 
coefficients for the groups (schistosome negative and schistosome positive). b) Permutation analysis 
showing the observed (pink) and cross-validated (blue) R2Y and Q2 coefficients. 
a) 
b) 
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Table 0.6: Output from OPLSDA infection model S-plot along with corresponding VIP values. 
Metabolite p[1] p(corr)[1] VIP 
Adenosine monophosphate (AMP) 0.16332 0.71903 1.5507 
3-Phosphoglyceric acid 0.13835 0.71135 1.4998 
Adenosine diphosphate (ADP) 0.17779 0.62789 2.297 
Ethanolamine phosphate 0.19096 0.5937 1.3473 
Glucose 6 phosphate 0.2032 0.55796 1.5275 
Guanosine monophosphate (GMP) 0.16846 0.51693 1.4499 
Inosine monophosphate (IMP) 0.11625 0.3841 0.75132 
Asparagine 0.13774 0.32756 2.086 
Sarcosine 0.06345 0.31531 0.94127 
Carnosine 0.094955 0.31492 0.39715 
Spermidine 0.053364 0.29941 0.4227 
2-Hydroxybutyric acid 0.09136 0.27153 1.6003 
Glutamine 0.10048 0.26156 0.42738 
Inosine 0.056996 0.25414 1.1587 
Creatine 0.079849 0.24129 0.68521 
Ribulose-5-phosphate 0.048322 0.20786 0.14681 
2-Oxoisovaleric acid 0.074067 0.17949 0.99399 
Isocitric acid 0.068813 0.17527 0.11779 
Hydroxyproline 0.043562 0.14883 0.33362 
Tryptophan 0.058044 0.14599 0.95828 
Citric acid 0.053018 0.12601 0.21236 
β-Alanine 0.026035 0.10311 0.040634 
N.N-Dimethylglycine 0.025649 0.093055 0.11956 
Proline 0.01185 0.036949 0.20252 
Betaine 0.011335 0.031553 0.065143 
3-Hydroxybutyric acid 0.0062571 0.024438 0.25251 
Pyruvic acid 0.0044649 0.014935 0.64409 
Malic acid -0.0055014 -0.025446 0.16326 
Citrulline -0.0087832 -0.026973 0.67094 
cis-Aconitic acid -0.010699 -0.028551 1.7647 
gamma-aminobutyric acid (GABA) -0.022744 -0.05116 0.60668 
Methionine -0.018806 -0.05124 0.20164 
Gluconic acid -0.017143 -0.071042 0.19269 
Uridine -0.026073 -0.079352 0.23735 
Isoleucine -0.030496 -0.090193 0.4822 
Homoserine -0.02843 -0.10138 0.36151 
Arginine -0.037684 -0.11043 0.20389 
Valine -0.035022 -0.12602 0.30024 
Lactic acid -0.044449 -0.12925 1.6997 
Hypoxanthine -0.052029 -0.12984 0.63531 
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Metabolite p[1] p(corr)[1] VIP 
Tyrosine -0.049312 -0.17242 0.7152 
2-Oxoglutaric acid -0.049913 -0.18307 0.44697 
Succinic acid -0.066637 -0.18646 1.4298 
Asp -0.046762 -0.20107 0.78341 
Creatinine -0.046943 -0.20107 0.94836 
Threonine -0.069166 -0.24389 0.91853 
Ornithine -0.08025 -0.25436 1.0362 
Glycine -0.06732 -0.25854 0.98005 
Alanine -0.070685 -0.26489 1.0675 
Phenylalanine -0.080367 -0.29783 0.93998 
Leucine -0.085806 -0.32052 0.964 
Lysine -0.09314 -0.32526 1.0408 
Glutamic acid -0.11037 -0.33346 1.3776 
Histidine -0.09129 -0.35142 1.159 
Serine -0.10134 -0.36012 1.3535 
Choline -0.12508 -0.40257 1.5333 
Table shows metabolites ranked in order of decreasing correlation or reliability coefficient [p(corr)]. 
p[1], covariance or contributions; p(corr)[1], correlation or reliability coefficient; VIP, variable 
importance in the projection. 
 
Table 0.7: Correlation pattern analysis of metabolites showing patterns from positive for infection 
to negative post-treatment. 
Metabolite Correlation t-statistic p-value FDR 
Glucose-6-phosphate -0.48165 -1.738 0.11285 0.24623 
3-Phosphoglyceric acid -0.47 -1.6839 0.12312 0.24623 
Adenosine diphosphate (ADP) -0.39272 -1.3504 0.20666 0.27554 
Adenosine monophosphate (AMP) -0.25002 -0.81657 0.4332 0.4332 
Table shows metabolites ranked in order of decreasing significance based on absolute FDR values. 
FDR, adjusted p-value (False discovery rate corrected). 
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Figure 0.5: Detailed metabolic pathways of discriminatory metabolites for schistosome infection. 
a) Glycolysis/Gluconeogenesis (hits= glucose-6-phosphate). b) Purine metabolism (hits= AMP, ADP). 
c) Pentose phosphate pathway (hits= glucose-6-phosphate). d) Starch and sucrose metabolism (hits= 
glucose-6-phosphate). For compound colours within each metabolic pathway map–light blue are 
metabolites not in the data set used for pathway analysis and are used as background for enrichment 
analysis; other colours (varying from yellow to red) means the metabolites are in the data with different 
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Figure 0.6: Detailed metabolic pathways of discriminatory metabolites for schistosome infection. 
a) Galactose metabolism (hits= glucose-6-phosphate). b) Nitrogen metabolism (hits= glucose-6-
phosphate). c) Amino, sugar and nucleotide metabolism (hits= glucose-6-phosphate). For compound 
colours within each metabolic pathway map–light blue are metabolites not in the data set used for 
pathway analysis and are used as background for enrichment analysis; other colours (varying from 
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Table 0.8: Analysis output from pathway analysis. 
Metabolic pathway  Total Cmpds Hits Raw p -log(p) 
Holm 
adjust FDR Impact 
Purine metabolism 92 2 3.61E-05 10.229 0.000253 0.000253 0.06428 
Nitrogen metabolism 39 1 0.000757 7.1862 0.004542 0.002650 0 
Glycolysis or 
Gluconeogenesis 31 1 0.042991 3.1468 0.21496 0.042991 0.06977 
Pentose phosphate 
pathway 
32 1 0.042991 3.1468 0.21496 0.042991 0.04348 
Starch and sucrose 
metabolism 
50 1 0.042991 3.1468 0.21496 0.042991 0.02439 
Galactose metabolism 41 1 0.042991 3.1468 0.21496 0.042991 0.01724 
Amino sugar and 
nucleotide sugar 
metabolism 
88 1 0.042991 3.1468 0.21496 0.042991 0.00917 
Table shows metabolites ranked in order of decreasing significance based on absolute FDR values. 
FDR, adjusted p-value (False discovery rate correction for multiple comparisons); Holm adjust, adjusted 
p value (Holm-Bonferroni correction for multiple comparisons); Raw p, unadjusted p values; Hits, 
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Appendix C Supplementary information–Chapter 6 
 
Figure 0.1: Principal component analysis (PCA) plots for microbiota across samples, annotated 
by age. 
Figures a) and b) show PCA plots for fungi classified according to genus and phylum respectively. 
Figures c) and d) show PCA plots for bacteria classified according to genus and phylum respectively. 
Raw counts were clr-transformed, and the resulting matrices were ordinated using PCA. The projections 
of features are plotted as arrows and the projection of samples are plotted as points. The eigenvalues 
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Figure 0.2: Bacteria abundance and composition dendrograms.  
From read mapping to the genomic database, abundance was calculated for each microbial taxa across 
all samples. Clustered dendrograms show bacterial a) phyla and b) genera per sample. Raw counts were 
clr-transformed, the Aitchison distance (Euclidean distance) was calculated, and samples clustered 
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Figure 0.3: Fungi abundance and composition dendrograms.  
From read mapping to the genomic database, abundance was calculated for each microbial taxa across 
all samples. Clustered dendrograms show fungal a) phyla and b) genera per sample. Raw counts were 
clr-transformed, the Aitchison distance (Euclidean distance) was calculated, and samples clustered 
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Figure 0.4: Principal component analysis (PCA) plots for AMR genes and drug classes across 
samples, annotated by age. 
Figures a) and b) show PCA plots for AMR genes and AMR gene function classes respectively. Raw 
counts were clr-transformed, and the resulting matrices were ordinated using PCA. The projections of 
features are plotted as arrows and the projection of samples are plotted as points. The eigenvalues 
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Figure 0.5: Antimicrobial resistance (AMR) genes and drug class dendrograms.  
From read mapping to the ResFinder database, AMR abundance was calculated for each reference gene 
across all samples. Clustered dendrograms show AMR a) drug class and b) genes per sample. Raw 
counts were alr-transformed, the Aitchison distance (Euclidean distance) was calculated, and samples 
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This questionnaire is 3 pages long- please complete ALL pages. 
 
Questionnaire to be completed at the time of visit with parents and enrollment of children 










Date of questionnaire________________________________________________ 
 
Person administering questionnaire_____________________________________ 
 
Parent’s full name_______________________________________________________ 
 
The following details/ questions are about the child. 
 
Name__________________________ Gender    M        F     (circle one)   Study ID #__________ 
 
Date of birth (DD -MM -YY)____________ Age (years)______________ 
 
Years old   <1 1-2        3-4     5-6   (circle one) 
 







1. Has the child ever been treated for bilharzia or worms?   
Yes No (circle  either yes or no) 
 
If yes where they treated ______________________________________________________ 
 
Who treated them?___________________________________________________________ 
 
 
2. Has the child ever been to hospital since birth (other than for vaccinations)?  
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3. Has the child received  vaccination for:  
 
 
a. BCG vaccination (tuberculosis)?  Yes   No  Don’t know (circle  one) 
b. Mumps     Yes   No  Don’t know (circle  one) 
c. Measles     Yes   No    Don’t know (circle  one) 
d. Rubella               Yes   No   Don’t know (circle  one) 
e. Diptheria     Yes   No   Don’t know (circle  one) 
f. Polio 
g. Hepatitis B  
h. others (specify)  _______________________________________________________ 
 
4. Please entre the Childhood vaccination Record from the Child health Card in the table 
below 
 
Vaccine Vaccine abbreviation Dates of vaccination Comments 
BCG BCG   
Polio Polio   
Mumps Measles   
Measles    
Rubella    
Diptheria, Pertusis, 
Tetanus 
DPT   
Hepatitis B HBV   
 
5. Has the child received a vitamin A supplement? 
 Yes No (circle  either yes or no) 
 
 If yes when did they receive it?  (Put full date if available)   
_________________________________________________________________________ 
 
6. Domestic water source  (circle as many as appropriate) 
a. unprotected well 
b. River 
c. Dam 
d. Upgraded well 
e. Borehole 
f. Tap 
g. Other (specify) ____________________________________________________________ 
7. Where does the child normally go to the toilet? (circle as many as appropriate) 
a. Bush 
b. cat sanitation 
c. Latrine/toilet 
d. Other (specify) ____________________________________________________________ 
 
8. Is there a latrine at your home? (circle  either yes or no) 
 Yes    No 
 
9. If yes, are there any problems in using it? (circle  either yes or no) 
 
 Yes    No       
 If yes, explain ____________________________________________________________ 
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10. Did your child do any of these activities in the water yesterday? (circle as many as 





Where?  (If River or Dam) At what time? 
(e.g. 0800, 
1600) River/Dam/Well/ Other 
name of place or nearest 
village/school 
Swimming     
Playing in the water     
Bathing     
Laundry     
Washing dishes     
Washing (face and legs)     
Collecting water     
Fishing     
Crossing river     
Other_______________     
 
11. How many times has your child been to the river or dam in the last week? _______ 
 
12.  Where does the child normally get treated when unwell? (Circle as many as 
appropriate) 
a. At home using herbal medicines 
b. At home using western medicine 
c. At the traditional healer 
d. At the local clinic 
e. Other please specify__________________________________________ 
    
ANY OTHER COMMENTS- 







                                             [Paediatric Schistosomiasis: Dynamics and Consequences] 
[Appendices]  275 
Appendix E Publications 
• Osakunor, D. N. M., M. E. J. Woolhouse and F. Mutapi (2018). "Paediatric 
schistosomiasis: What we know and what we need to know." PLoS Negl Trop Dis 
12(2): e0006144. 
• Osakunor, D. N. M., T. Mduluza, N. Midzi, M. Chase-Topping, M. J. Mutsaka-
Makuvaza, T. Chimponda, E. Eyoh, T. Mduluza, L. T. Pfavayi, W. M. Wami, S. A. 
Amanfo, J. Murray, C. Tshuma, M. E. J. Woolhouse and F. Mutapi (2018). "Dynamics 
of paediatric urogenital schistosome infection, morbidity and treatment: a longitudinal 
study among preschool children in Zimbabwe." BMJ Glob Health 3(2): e000661. 
• Osakunor, D. N. M., D. M. Sengeh and F. Mutapi (2018). "Coinfections and 
comorbidities in African health systems: At the interface of infectious and 
noninfectious diseases." PLoS Negl Trop Dis 12(9): e0006711. 
• Osakunor, D. N. M., D. M. Sengeh and F. Mutapi (2018). "Universal Health 
Coverage in Africa: Coinfections and Comorbidities." Trends Parasitol 34(10): 813-
817. 
• Osakunor, D. N. M., P. Munk, T. Mduluza, T. N. Petersen, C. Brinch, A. Ivens, T. 
Chimponda, S. A. Amanfo, J. Murray, M. E. J. Woolhouse, F. M. Aarestrup and F. 
Mutapi (2020). "The gut microbiome but not the resistome is associated with 
urogenital schistosomiasis in preschool-aged children." Commun Biol 3(1): 155. 
• Mduluza, T., C. Jones, D. N. M. Osakunor, R. Lim, J. K. Kuebel, I. Phiri, P. 
Manangazira, P. Tagwireyi and F. Mutapi (2020). "Six rounds of annual praziquantel 
treatment during a national helminth control program significantly reduced 
schistosome infection and morbidity levels in a cohort of schoolchildren in 
Zimbabwe." PLoS Negl Trop Dis 14(6): e0008388. 
 
[Paediatric Schistosomiasis: Dynamics and Consequences] 
276  [Appendices] 
• Lim R. M, M. E.J. Woolhouse, T. Mduluza, M.Chase-Topping, D. N.M. Osakunor, 
L. Chitsulo, F. Mutapi. “Investigating a strategy for quantifying schistosome infection 
levels in preschool-aged children using prevalence data from school-aged children.” 
PLoS Negl Trop Dis 14(10): e0008650.  
• Osakunor, D. N. M., T. Mduluza, D. Osei-Hyiaman, K. Burgess, M. E. J. Woolhouse, 
F. Mutapi. “Schistosoma haematobium infection is associated with alterations in 
energy and purine-related metabolism in preschool-aged children.” PLoS Negl Trop 
Dis. In Press. 
REVIEW
Paediatric schistosomiasis: What we know
and what we need to know
Derick N. M. Osakunor1, Mark E. J. Woolhouse2,3, Francisca Mutapi1,3
1 Centre for Immunity, Infection and Evolution, Institute of Immunology and Infection Research, University of
Edinburgh, Ashworth Laboratories, Edinburgh, United Kingdom, 2 Centre for Immunity, Infection and
Evolution, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Ashworth
Laboratories, Edinburgh, United Kingdom, 3 NIHR Global Health Research Unit Tackling Infections to Benefit
Africa (TIBA), University of Edinburgh, Ashworth Laboratories, Edinburgh, United Kingdom
* d.osakunor@ed.ac.uk
Abstract
Schistosomiasis affects over 200 million people worldwide, most of whom are children.
Research and control strategies directed at preschool-aged children (PSAC), i.e.,5 years
old, have lagged behind those in older children and adults. With the recent WHO revision of
the schistosomiasis treatment guidelines to include PSAC, and the recognition of gaps in
our current knowledge on the disease and its treatment in this age group, there is now a con-
certed effort to address these shortcomings. Global and national schistosome control strate-
gies are yet to include PSAC in treatment schedules. Maximum impact of schistosome
treatment programmes will be realised through effective treatment of PSAC. In this review,
we (i) discuss the current knowledge on the dynamics and consequences of paediatric
schistosomiasis and (ii) identify knowledge and policy gaps relevant to these areas and to
the successful control of schistosome infection and disease in this age group. Herein, we
highlight risk factors, immune mechanisms, pathology, and optimal timing for screening,
diagnosis, and treatment of paediatric schistosomiasis. We also discuss the tools required
for treating schistosomiasis in PSAC and strategies for accessing them for treatment.
Introduction
Schistosomiasis is a tropical and subtropical disease affecting communities with limited access
to safe water and adequate sanitation provision [1–3]. It affects over 200 million people world-
wide (90% in sub-Saharan Africa), of which a significant number (123 million) are children [3,
4]. The health impact includes poor growth and cognition in affected children [5, 6].
Despite the higher prevalence of schistosomiasis in children, preschool-aged children
(PSAC), i.e., those aged5 years, for a long time were considered to be at a low risk of infec-
tion [7]; and even if infected, the impact on their health was unknown or considered negligible.
Operational difficulties, including obtaining parasitology samples for diagnosis, failure to
detect light infections, and inadequate knowledge about risk factors in PSAC, have biased
studies towards school-aged children (SAC), i.e., 6 years old and adults. Infection prevalence
data from a number of epidemiological studies have led to the estimation that at least 50 mil-
lion PSAC in Africa are infected with schistosomiasis [8], but the true global infection and
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disease burden remains to be quantified. This makes it difficult to make operational and eco-
nomic plans for controlling schistosomiasis in PSAC. Furthermore, gaps relating to infection,
disease dynamics, and treatment need addressing if we are to deliver sustainable schistosome
infection and disease control in PSAC and strengthen schistosomiasis elimination
programmes.
Here, we summarise the current knowledge of paediatric schistosome infection, disease
dynamics, and treatment. We also identify important knowledge gaps in paediatric schistoso-
miasis practice.
Epidemiology of paediatric schistosomiasis
In schistosome-endemic areas, a significant amount of the exposure to infection in PSAC is
passive (i.e., use of contaminated water in the home or children being bathed/sitting in a dish
of fresh water while the guardian conducts domestic chores), particularly in the youngest chil-
dren. Exposure becomes more active as the children grow (e.g., accompanying caregivers to
water sources for domestic chores) [9, 10]. Therefore, in the early years of infants and young
children, exposure to infection is closely linked to that of the caregiver. This disassociates as
children grow older, become independent, and frequently visit contaminated water sources
with friends and/or older siblings.
Exposure to infection is incremental, and almost all children in high transmission areas will
have been exposed to schistosome cercariae by age one [11], with infection prevalence and
intensity increasing as children grow up [12]. Thus, there is a need for inclusion of PSAC in
large-scale projects that map the distribution of schistosomiasis, to inform planning for drug
procurement and operational strategies for including these children in national control
programmes.
In addition to the lack of burden estimates of schistosome infection and disease in PSAC,
there is a paucity of incidence data in this age group. Longitudinal studies tracking the inci-
dence of schistosome infection are required to identify and quantify exposure patterns, risks,
and health impacts of infection at an early age and, most importantly, to plan treatment
strategies.
Risk factors for schistosome infection
Several factors influence the risk for schistosome infection in PSAC, including those already
identified in other age groups [Fig 1]. Environmental factors (including temperature, seasonal
rainfall patterns, and altitudes) influence the survival of the intermediate host snail, as well as
parasite development in the snail, affecting the force of transmission and infection [13, 14].
Exposure patterns of the human host are also affected by climatic changes (e.g., hotter seasons
prompt increased recreational use of infected water sources), and passive contact with infective
water can increase amongst PSAC, while they are waiting for their caregivers to complete
chores. Exposure will vary in both the surface area exposed as well as the duration and fre-
quency of exposure [15].
In addition to these well-studied risk factors, we are beginning to appreciate the impact of
the human gut and urinary microbiome [22–24]. The gut microbiome is believed to be partic-
ularly variable in the early years of life [25]; for example, we have reported that the relative
abundance of different bacterial taxa varies within the first three years of life [26]. The gut
microbiome plays a vital role in maintaining barrier integrity, and subsequently impacts the
host immune system [27], and contributes to the observed differences in infection patterns
[28]. Recently, we demonstrated a significant difference in the microbiome structure (fre-
quency and diversity of the host bacteria species) between schistosome-infected and
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uninfected Zimbabwean children aged 1 to 10 years [26]. From the study design, the mecha-
nistic direction of this relationship and the influence by other factors was unclear. These
aspects together with any mechanistic pathways are yet to be elucidated. In this age group, the
impact of gut microbiome dysbiosis on nutritional status is of particular importance.
Emerging ideas from initiatives such as the Human Microbiome Consortium suggest that
our focus on PSAC should be to understand how the microbiome functions and influences
innate susceptibility to schistosome infection, if at all [29]. Helminths modulate host immune
responses for their survival, and this in turn has a negative impact on the host microbiome
Fig 1. Risk factors for schistosome infection in PSAC. Adapted from: 1 [14]; 2 [14, 15]; 3 [16]; 4 [15], 5 [15, 17, 18]; 6 [13, 14]; 7 [19]; 8 [14]; 9 [18]; 10 [20]; 11 [21].
https://doi.org/10.1371/journal.pntd.0006144.g001
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structure and nutrition [23]. Increasing research in nutraceuticals should thus inform addi-
tional child supplementation programmes in affected countries. At present, schistosomiasis
interventions targeting the microbiome remain theoretical, as mechanistic studies to establish
and quantify causal relationships are lacking.
In schistosome-endemic areas, malnutrition and undernourishment are significant child-
hood problems. Nonetheless, there are no studies detailing the attributable fraction of malnu-
trition due to schistosomiasis or more importantly, the impact of treatment on these factors.
This information is necessary to advocate for control strategies to prioritise PSAC. Studies
have also yet to establish the role/relevance of anthropometric measures as a tool for identifica-
tion of the risk of malnourishment among PSAC in schistosome-endemic areas.
Schistosome-specific immune responses and clinical relevance
The interest in immunity in schistosome infections is twofold. First, hosts in endemic areas
develop protective acquired immunity against infection/reinfection, and second, the severe and
chronic clinical manifestations of schistosomiasis are immune mediated. Decades of studying
immune responses in both human and experimental models have given insights into the aetiol-
ogy and clinical manifestation of morbidity and immunopathology and into the development
of schistosome-specific protective immune responses. The paradigms presented by these studies
are not easy to extrapolate to PSAC, due to differences in the natural history of infection.
Human studies have largely focused on SAC and adults with distinct histories of infection,
which impacts on their immune phenotype [30]. Furthermore, most experimental studies on
schistosome immunology use mouse models, which are limited in their ability to recapitulate
morbidity and pathology occurring in the natural human host. For instance, eggs implanted in
mice were recently used to develop an experimental model for urogenital schistosome pathol-
ogy [31], but the relevance of this to the human disease forms in young children is unclear.
Acute and chronic stages of schistosome infection
In endemic areas, the acute stage of schistosome infection—including the Katayama syndrome—
receives very little research or clinical intervention compared to other areas [32, 33]. As detailed
above, the first infection event in most endemic areas occurs early at the pre-school age, but to
date, no studies of schistosome cercarial dermatitis in PSAC have been published. The immune
responses occurring in the early stages of infection are poorly documented in humans, and these
events in PSAC would be very informative on the nature and development of both pathological
and parasite-protective immunity.
In studies of SAC, protective immunity against schistosomiasis is characterized by a
dynamic shift in the balance between effector and regulatory (humoral and cellular) immune
responses, with effector responses surpassing the regulatory responses as infection progresses
and exemplified by Nausch and colleagues [34]. We have previously proposed a threshold
hypothesis [35] to explain the switch from a predominantly regulatory phenotype to an effector
immune phenotype as infection progresses. Nonetheless, there is a paucity of immunology
studies in PSAC detailing the dynamics occurring at the transition of infection from acute to
chronic. Knowledge of these responses will be informative for schistosome vaccine development
and deployment, as the ideal vaccine would target all children at risk of schistosome infection
who may have already experienced their first schistosome infection exposure/infection event.
Drug-induced protective immunity
Studies in SAC and adults have shown that treatment of schistosome infections with Prazi-
quantel (PZQ) enhances schistosome-specific immune responses by (i) removing the
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immuno-suppressive effects of the adult worms [35–37], and (ii) introducing large amounts
of parasite-specific antigens to the immune system to reach the threshold required to induce
an immune response [38–40]. These changes are associated with reduced reinfection rates
[38, 41]. One of the consequences of the previous schistosome treatment guidelines was
that studies on the effects of PZQ were focused more on SAC and adults. Thus, the immuno-
logical consequences of PZQ in PSAC remain poorly characterised. In a recent study in Zim-
babwean PSAC, we showed an increase in anti-parasite IgM and IgE titres, six weeks after
treatment with PZQ, and this was associated with resistance to reinfection [42]. This mimics
the development of naturally acquired immunity, albeit (in this case) accelerated by treatment
[39, 40, 43].
Evidence from experimental studies suggest that a more rational approach to the timing of
helminth treatment may have additional benefits beyond the transient removal of infection
and may also speed up the development of protective immunity more effectively than treating
chronic infection. These studies have shown that treatment of the first helminth infection
induces earlier and greater levels of protection against reinfection by preferentially inducing
the effector over regulatory responses [44–46]. In this case, chronic infection induces a con-
stant state of anti-parasite Th2 response, reducing the overall effect of Th1 effector responses
required to fight infection [47]. This suggests that treatment of the first schistosome infection
could have a longer-lasting impact on susceptibility to reinfection and presents the possibility
of targeting treatment for maximum benefit in terms of the future health of the child. As
detailed above, a single PZQ treatment can induce resistance to reinfection in PSAC [48], sug-
gesting that if treatment of PSAC is optimally timed then repetitive treatments may be reduced
or not required [49, 50]. Longitudinal studies determining the optimal treatment time are
needed to inform the treatment guidelines for PSAC. Now, we have a window to conduct
these studies, while there is a concerted effort to make a paediatric formulation of PZQ for
deployment within the next few years.
Pathology and morbidity
Schistosome pathology and morbidity are still being defined in older children and adults, e.g.,
only recently was urinary schistosomiasis renamed urogenital schistosomiasis to reflect the
increased recognition of the genital manifestations of S. haematobium-related disease [51].
Pathology and morbidity remain poorly described and studied in PSAC [10] compared to
SAC. However, studies are beginning to shed light on schistosome morbidity in this group,
e.g., a recent study using ultrasound has contributed to describing urinary morbidity in PSAC
[52].
Describing morbidity and pathology at all stages of schistosome infection in PSAC will
inform overall healthcare in this age group. In PSAC, clinical symptoms upon schistosome
exposure and infection (e.g., cercarial dermatitis and fever) may go unrecognised [5, 53, 54] or
be mistaken for symptoms of other illnesses such as malaria, which present with similar symp-
toms (e.g., fever).
It is also possible that schistosome infections have wider impacts in childhood health. In
PSAC, chronic prenatal exposure/sensitisation to helminth infection is reported to be associ-
ated with reduced efficacy of childhood vaccines through induction of a persistent Th2
response phenotype [55, 56]. Chronic exposure is also thought to be associated with environ-
mental enteropathy, which affects the efficacy of vaccines at infancy [57]. Reduced vaccine effi-
cacy means infection and disease from the vaccine-preventable infections. Thus, controlling
schistosomiasis in PSAC may have the added health benefit of improving vaccine efficacy;
appropriate studies are required to investigate if this would be the case.
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Schistosome infections damage epithelial barriers, resulting in anaemia, poor nutrition, and
growth [58, 59]. Thus, even with the low parasite burdens in PSAC, the pro-inflammatory
response generated can quickly lead to chronic morbidity [60]. For example, schistosome-
associated anaemia and malnutrition in older Kenyan children (5–18 years old) was attributed
to pathology beginning much earlier in life [58]. The nutritional effects could also be attributed
to microbiome dysbiosis as reported in the experimental mouse model of helminth infection
[61]. Thus, the impact of schistosomiasis in PSAC should be an integral part of interventions,
targeted at improving early child health and development.
Poor awareness, recognition, and lack of understanding and quantification of schistosome-
associated morbidity has previously made schistosome control in PSAC a lower priority than
in older children and adults, but concerted efforts are now beginning to correct this. There is a
need for biomarkers of environmental enteropathy in PSAC [59], mechanistic studies to infer
causality, and well-defined predictors of growth and nutrition in PSAC exposed to
schistosomiasis.
Paediatric schistosomiasis in coinfected hosts
Similar to all other age groups in tropical regions, PSAC are at risk of coinfections and there-
fore, comorbidities. Studies in older children (5–18 years old) indicate that the presence of
multiple infections in endemic areas lead to significant morbidity, including anaemia and mal-
nutrition and these are important in the formative years of PSAC [58]. Specific coinfection
studies include malaria–schistosomiasis, where studies in SAC suggest that malaria severity is
compounded by schistosome infection, and malaria treatment is more effective when schisto-
some infection is also treated [62, 63]. To date, no detailed studies have been conducted on the
fraction of malaria deaths in PSAC that are attributable to schistosome coinfection. In addi-
tion, S. haematobium infection has been shown to reduce the level of protective IgG responses
to malaria vaccine candidates [64]. In another instance, in vitro studies have shown that Sal-
monella can evade optimal antibiotic treatment by binding to schistosomes using fimbral pro-
teins (FimH) present on its surface [65], and that effective treatment of schistosomiasis results
in the release of Salmonella, causing septicaemia [66]. These findings need validation in PSAC
to allow the implementation of appropriate interventions.
Diagnosis of infection
One operational model being proposed for the treatment of schistosomiasis in PSAC is that
diagnosis is made before treatment, unlike the mass drug administration (MDA) approach
where SAC are treated without diagnosis [67]. This means that in the “diagnose and treat”
model, accurate point of care (POC) diagnostics are key to guide the targeted treatment.
Direct parasitological methods (Kato–Katz and urine filtration) are recommended by the
WHO [68] and are convenient, specific, rapid, cheap, and suitable for field applications in
PSAC [69, 70]. Nonetheless, in addition to the already known limitations of low sensitivity of
the parasitological methods in SAC and adults, these methods have the added operational chal-
lenge of obtaining adequate urine and stool samples in PSAC [71], particularly the collection
of replicate samples on different days to improve sensitivity [72].
Various other methods have been developed in the laboratory to address the issues of sensi-
tivity and are at different stages of translation into field tools. Immunological detection of
schistosome-specific antibodies in sera has been shown to be more sensitive in diagnosing
infection in PSAC than parasitological methods [12]. The non-invasive detection of worm
antigens in urine, i.e., circulating anodic antigen (CAA) [73, 74] and circulating cathodic anti-
gen (CCA) [75] have also been evaluated in PSAC. These have been shown to be a reliable tool
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in diagnosing S. mansoni [76] but less so in S. haematobium diagnosis [77]. Issues of cost,
which pose challenges in low resource settings where schistosomiasis is endemic [78, 79],
would also need to be overcome. Molecular techniques detecting parasite DNA in urine have
shown promise in PSAC [80, 81], although the absence of POC versions of these tests means
they require expertise and specialised equipment [82]. Compared to CCA and parasitology,
polymerase chain reaction (PCR) was most effective in detecting low intensity S. mansoni and
S. haematobium infections [83, 84]. The use of cell-free parasite DNA present in urine and
saliva [85] in PCR techniques can ease sampling difficulties in PSAC and detect early infections
[86]. MicroRNAs have been characterised in animal models of S. japonicum [87] and S. man-
soni [88]. Despite conflicting reports on the utility of miR–223 as a biomarker for helminth
infections [88, 89], microRNAs have great diagnostic potential in PSAC and require further
exploration. However reliable these diagnostics turn out to be at the lab bench, their true utility
will be tested in the field.
Morbidity markers for schistosomiasis
The majority of morbidity biomarkers associated with schistosomiasis are non-specific, relat-
ing to physiological, biochemical, and immunological changes. As such, their interpretation in
the light of coinfections and comorbidities is complex. Recent years have seen studies con-
ducted in PSAC to evaluate the utility of morbidity markers described in SAC. These have
included evaluation of the classic urine markers, haematuria and proteinuria in S. haemato-
bium infection (e.g., in Nigeria [90] and Zimbabwe [91]), and the urine albumin-creatinine
ratio (UACR) in Zimbabwe [91]. Faecal occult blood (FOB), the presence of cryptic blood in
stool, results when S. mansoni eggs perforate the intestinal mucosa and cause a small release of
blood into the bowel [92, 93], along with calprotectin released by granulocytes in response to
the accompanying inflammation [94]. FOB and calprotectin have been evaluated in PSAC in
Uganda [92, 95]. In these studies, FOB and calprotectin correlated positively with S. mansoni
infection pre- and post-treatment although there may be exceptions.
The challenge with these non-specific markers particularly is to determine how schistoso-
miasis influences them; this is a difficult task because even determining the fraction attribut-
able to schistosome infection does not indicate causation. Equally important is the lack of
specific information on what they mean in terms of the child’s overall current and future
health. There is the need for a knowledge base addressing these two issues if these morbidity
markers are to form part of the diagnostic tool kit to inform the “diagnose and treat” approach
for PSAC.
Schistosome treatment in PSAC
Following the recommendation to treat PSAC infected with schistosomes, there is a need for a
drug formulation that is suitable for PSAC. PZQ is the drug of choice for treating schistosomi-
asis at a recommended dose of 40–60 mg/kg body weight. In ill-resourced endemic areas, a
height–dose pole has been developed as a surrogate to weight scales for operational purposes
[96]. Modifications were made to extend the original dose pole used for SAC and adults to
include PSAC [97, 98]. PZQ is currently administered to PSAC as crushed tablets with juice or
bread [4, 10]. Followed by an endorsement from the WHO [99], a recent randomised dose-
ranging trial reports that a single 40 mg/kg dose of PZQ can be used for treatment in PSAC
[100]. Although PZQ is confirmed safe and efficacious [101], there is little information on its
pharmacokinetics in PSAC [102, 103], and this is compounded by variability in bioavailability,
influenced by brand [104, 105].
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PSAC tolerate PZQ well with few reports of adverse effects: normally abdominal pain, vom-
iting, fatigue, and diarrhoea that resolve within 24 hours [98, 100, 101]. Contrary to sugges-
tions of a higher efficacy dose (>40 mg/kg) in PSAC [106], a recent study reported on the
efficacy and safety of escalating doses (20 mg/kg, 40 mg/kg, and 60 mg/kg) of PZQ in PSAC
and SAC [100]. PZQ showed a flat dose-response curve in PSAC compared to that in SAC and
the current 40 mg/kg remains the best option in PSAC [99]. In PSAC, PZQ can be adminis-
tered with other antihelminthics (e.g., Albendazole) as a deworming package. There are cur-
rently no drug–drug interaction studies that have been conducted on these drugs in PSAC
[107]. PZQ is metabolised by the cytochrome P450 enzymes as shown in experimental studies
[108, 109]. With growing evidence of genetic diversity for cytochrome P450 variants in schisto-
some-endemic regions in Africa [110], there are implications for PZQ metabolism and treat-
ment efficacy which remain to be elucidated in PSAC.
Paediatric PZQ formulation
Operationally, the large size and bitter taste of the existing tablet are associated with adminis-
tration difficulties in PSAC [100, 111]. To address these issues, the Paediatric Praziquantel
Consortium has produced a paediatric PZQ tablet meeting a previously suggested target prod-
uct profile (TPP) [4, 112]. This formulation—a smaller, orally dispersible tablet with a masked
taste—has successfully undergone phase I clinical trials and phase II trials are currently under-
way (http://www.pediatricpraziquantelconsortium.org/).
Accessing PSAC for schistosome treatment and control
Preventive chemotherapy programmes targeting SAC are conducted via MDA with antihel-
minthics (usually PZQ and Albendazole) administered in the school setting. PSAC do not go
to school (although some may be in early child development centres) and the “diagnose and
treat” recommendation makes it difficult to treat them outside a health setting. One strategy is
to access PSAC through the Expanded Programme on Immunization (EPI) in primary health
centres [4], and our studies in Zimbabwe confirm the feasibility of accessing PSAC at health
centres [101]. However, in some health systems, the EPIs may already be “crowded,” imple-
menting other interventions at the same time; hence, alternative access strategies are required.
A report from a recent meeting [67] included the approach of empowering health workers to
identify clinical cases (i.e., non-specific signs of suspected cases) of schistosomiasis in PSAC
and treating them, as a potential means of accessing PSAC. This approach has both advantages
and disadvantages; the main disadvantage is the potential of treating non-specific clinical
symptoms due to infections/diseases other than schistosomiasis.
Conclusion
There is now a global move to elevate research on paediatric schistosomiasis and to promote
control, not only for child health but also to move towards eliminating schistosomiasis. The
control of paediatric schistosomiasis will only be prioritised in countries with limited health
budgets when (i) there is compelling evidence on the burden of infection and disease on child
health and development, (ii) there are cost-effective intervention tools, and (iii) engagement at
stakeholder and end-user levels. The research community can contribute to all three aspects,
and bridging the knowledge gaps highlighted in this review will make a significant contribu-
tion to the control of schistosomiasis in PSAC.
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Key learning points
• Preschool-aged children (PSAC) carry significant infection and morbidity to schisto-
somiasis. There is a treatment gap in mass drug administration, and studies mapping
the level of infection and morbidity in this group. Infection and disease quantification
is critical to inform planning and deployment of schistosome treatment in PSAC.
• Existing and new morbidity markers, along with improved multiple diagnostic tools,
are useful for targeted disease identification and treatment in PSAC. The utility of
these along with a proper strategy is important. There is a need for better-defined dis-
ease markers for this age group.
• Treatment with Praziquantel is safe and efficacious. Owing to existing challenges with
the current formulation, there is a need for a paediatric formulation, a better dosing
system, a better treatment strategy, and innovative ways of accessing PSAC for
treatment.
• Most PSAC will experience infection early, and there is a need to characterise and
quantify the consequences of these early infections in terms of impact on the overall
health of children.
• PSAC are capable of mounting an adaptive immune response to schistosome infec-
tions, and a single treatment can illicit this response. Exploring the applicability of this
in resistance to reinfection and morbidity is important.
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ABSTRACT
Background Recent research has shown that in 
schistosome-endemic areas preschool-aged children (PSAC), 
that is, #5 years, are at risk of infection. However, there exists 
a knowledge gap on the dynamics of infection and morbidity 
in this age group. In this study, we determined the incidence 
and dynamics of the "rst urogenital schistosome infections, 
morbidity and treatment in PSAC.
Methods Children (6 months to 5 years) were recruited 
and followed up for 12 months. Baseline demographics, 
anthropometric and parasitology data were collected 
from 1502 children. Urinary morbidity was assessed by 
haematuria and growth-related morbidity was assessed 
using standard WHO anthropometric indices. Children 
negative for Schistosoma haematobium infection were 
followed up quarterly to determine infection and morbidity 
incidence.
Results At baseline, the prevalence of S haematobium 
infection and microhaematuria was 8.5% and 8.6%, 
respectively. Based on different anthropometric indices, 
2.2%–8.2% of children were malnourished, 10.1% 
underweight and 18.0% stunted. The fraction of morbidity 
attributable to schistosome infection was 92% for 
microhaematuria, 38% for stunting and malnutrition at 
9%–34%, depending on indices used. S haematobium-
positive children were at greater odds of presenting 
with microhaematuria (adjusted OR (AOR)=25.6; 95% 
CI 14.5 to 45.1) and stunting (AOR=1.7; 95% CI 1.1 to 
2.7). Annual incidence of S haematobium infection and 
microhaematuria was 17.4% and 20.4%, respectively. 
Microhaematuria occurred within 3 months of "rst 
infection and resolved in a signi"cant number of children, 
12 weeks post-praziquantel treatment, from 42.3% to 
10.3%; P<0.001.
Conclusion We demonstrated for the "rst time the incidence 
of schistosome infection in PSAC, along with microhaematuria, 
which appears within 3 months of "rst infection and resolves 
after praziquantel treatment. A proportion of stunting and 
malnutrition is attributable to S haematobium infection. The 
study adds scienti"c evidence to the calls for inclusion of 
PSAC in schistosome control programmes.
Key questions
What is already known about this topic?
 Ź Epidemiological studies indicate that preschool-
aged children (PSAC) aged #5 years are exposed to 
schistosome infection, the consequences of which 
manifest later in life.
 Ź Unlike school-aged children, there are no 
longitudinal studies tracking the dynamics of 
new infections, the development of morbidity and 
implications on current and future health in this age 
group.
What are the new !ndings?
 Ź We determined for the "rst time levels of 
schistosome morbidity in PSAC attributable to 
Schistosoma haematobium infection, that is, 92% 
of microhaematuria, 38% of stunting and depending 
on what index is used, 9%–34% of malnutrition. 
We recorded signi"cant annual incidence of 
new schistosome infection (17.7%) and urinary 
morbidity (microhaematuria; 20.4%) with signi"cant 
quarterly incidences.
 Ź We showed that microhaematuria occurred within 
3 months of "rst infection and resolved after 
praziquantel (PZQ) treatment.
 Ź We indicated that a signi"cant amount of morbidity, 
as measured by microhaematuria, resolved 
within 3 months of effective treatment with PZQ 
(signi"cant reduction from 42.3% vs to 10.3% 
(P<0.0001)).
Recommendations for policy
 Ź The "ndings indicate that schistosome  
morbidity in PSAC can be reversed by PZQ  
treatment.
 Ź The "ndings contribute to the scienti"c evidence 
base for prioritising schistosome treatment in PSAC, 
to reduce infection and morbidity and promote child 
health and development.
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INTRODUCTION
Of the 123 million children worldwide affected with 
schistosomiasis, about 50 million are preschool-aged chil-
dren (PSAC), that is, !5 years.1 Nonetheless, schistosome 
infection and morbidity dynamics in this age group are 
less characterised compared with school-aged children 
(SAC), that is, "6 years. For example, there are several 
studies describing and quantifying schistosome-related 
morbidity including haematuria, nutritional deficien-
cies and delayed growth and cognition in SAC2 3 but no 
comparable comprehensive studies in PSAC.
Epidemiological studies in PSAC clearly indicate that 
infection occurs in early childhood,4–7 and if untreated, 
the infection can lead to health consequences later in life.8 
Despite this importance of childhood infections, there is 
a paucity of longitudinal studies tracking the dynamics 
of new first infections, the development of morbidity 
and implications on current and future health in this 
age group. The definition of schistosome pathology and 
morbidity continues to be refined in attempts to better 
characterise clinical manifestations, for example, as with 
female genital schistosomiasis,9 and to identify appli-
cable morbidity markers of disease, for example, urine 
albumin–creatinine ratio.10 Growth and nutrition-related 
morbidities associated with schistosomiasis have also 
only recently become more widely recognised.11 There is 
therefore a need to collate all of this new knowledge to 
better define schistosomiasis in PSAC, where manifesta-
tions of disease are poorly described.6
In this study, we aimed to describe the baseline dynamics 
of schistosome infection and morbidity in Zimbabwean 
PSAC exposed to Schistosoma haematobium. A cohort of 
schistosome-negative children was followed for a year 
to document infection and morbidity incidence, as well 
as the effects of treatment on infection and morbidity. 
This study investigates the ability of existing diagnostic 
and morbidity tools to quantify and monitor early infec-
tion and morbidity. It also contributes to disease burden 
estimates and the dynamics of infection and morbidity in 
PSAC. This knowledge will inform the design and imple-
mentation of interventions targeted at this age group.
METHODS
Consent
Permission to conduct the study in the province was 
obtained from the Provincial Medical Director. Prior to 
enrolment, the study aims and procedures were explained 
to all participants and their parents/guardians in English 
or in the local language, Shona. Written informed consent 
was obtained from the participants’ parents/guardians as 
appropriate. Recruitment into the study was voluntary and 
parents/guardians were free to withdraw the participants at 
any time with no further obligation.
Study site and period
The study was conducted in 13 villages in the Shamva 
district, northeast of Zimbabwe (17°10#0$S 31°40#0$E) 
from February 2016 through to February 2017. This is 
one of seven districts in the Mashonaland Central prov-
ince of Zimbabwe, whose people are primarily subsistence 
farmers. There is a cold dry (April–July), hot dry (August–
October) and rainy season (November–March).12 13 The 
area was selected for this study on urogenital schistoso-
miasis because the prevalence of S haematobium is high 
(>50%), while the prevalence of Schistosoma mansoni and 
soil-transmitted helminths is low (<15%).14
Study design
This study was part of a larger longitudinal parasitological 
and immunological project, following the treatment-re-
infection study design widely used in human helminth 
field studies. There was a cross-sectional study at base-
line, followed by a 1-year longitudinal study. Recruited 
children were screened at baseline for schistosome infec-
tion and morbidity to describe the epidemiology of infec-
tion and morbidity in this population. The larger study 
is comparing the impact of regular quarterly screening 
and treatment (group 1) and biennial screening and 
treatment (group 2). This study reports on the findings 
in the children screened quarterly (group 1). Following 
the baseline recruitment, age and sex-matched S haemato-
bium-negative children who fulfilled the inclusion criteria 
were randomly allocated into groups 1 and 2. A total of 
1783 children were invited to participate, of which 1502 
provided samples for parasitological diagnosis at base-
line. After allocation to the two groups of the study, 525 
children who were schistosome-negative by egg count, 
provided a blood sample for serological assays and 
consented to participate in the longitudinal follow-up, 
formed the group 1 cohort, which was followed up every 
3 months to detect new schistosome infections by egg 
count, and morbidity by microhaematuria.
Children were recruited from crèches, early child 
development centres, and preschools. Parents/guard-
ians of children not attending any of the educational 
programmes (eg, children <3 years) were invited through 
the community nurse and village health workers to report 
to the sampling centre; that is, the centre used by the 
community for the Expanded Program for Immunisa-
tion (eg, school or primary health centre) for enrolment 
into the project. A questionnaire designed in English and 
translated into the local dialect (Shona) was adminis-
tered to gather demographic data and establish exposure 
behaviour.
Study inclusion criteria
At baseline, the study enrolled children aged 6 months 
to 5 years who met the following inclusion criteria. Partic-
ipants had to (i) be lifelong residents of the study area, 
(ii) have no previous antihelminthic treatment, (iii) be 
negative for S mansoni and (iv) consent to participate. 
To be included in the longitudinal cohort, children who 
had fulfilled the inclusion criteria described above had to 
meet an additional criterion of being diagnosed negative 
for S haematobium by egg count at baseline.
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Anthropometry
Weight (nearest 0.1 kg) and height (nearest 0.1 cm) 
without shoes and in light clothing was measured using 
an electronic scale and a stadiometer, respectively. For 
very young babies, height was measured with an infan-
tometer baby board, and weight measured with a baby 
scale. The mid-upper arm circumference (MUAC) was 
measured (nearest 1 mm) using a child MUAC tape; on 
the left arm, midpoint between the shoulder and the tip 
of the elbow, with the arm relaxed and hanging down the 
body. Growth and nutritional status was assessed using 
the WHO Anthro software V.3.0.1 (http://www. who. int/ 
childgrowth/ en/).15 This generated Z-scores for specific 
measures of nutrition and growth, that is, stunting by 
height-for-age (HAZ), underweight by weight-for-age 
(WAZ) and body mass index-for-age (BAZ) and malnu-
trition by MUAC (MUAC and MUACZ) and weight-for-
height (WHZ). Measures were considered abnormal 
when Z scores were <–2.16
Parasitological diagnosis
About 50 mL of urine sample was collected from each 
participant on three successive days and a stool spec-
imen was collected on a single day from each partici-
pant. Samples were collected between 10:00 hours and 
14:00 hours, and processed within 2 hours of collection. 
For very young children, urine bags (Hollister 7511 
U-Bag Urine Specimen Collector, Hollister, Chicago, Illi-
nois, USA) and disposable diapers were used to collect 
urine and stool samples respectively. Urine samples were 
examined microscopically for S haematobium infection 
following the standard urine filtration method17 and the 
number of eggs was reported per 10 mL of urine. Stool 
samples collected were processed using the Kato–Katz 
method18 and parasite eggs enumerated under a light 
microscope for S mansoni (in duplicates) per gramme of 
stool.
Children were diagnosed positive for helminth infec-
tion if at least one parasite egg was detected in their 
urine or stool samples. All children who were positive for 
S haematobium infection were treated with a single dose 
of praziquantel (PZQ) at the standard 40 mg/kg body-
weight at each visit. Tablets were crushed and adminis-
tered with squash and sliced bread19 by local nurses. A 
post-treatment efficacy check (egg count) was carried 
out for all such participants at each subsequent follow-up 
(12 weeks post treatment).
Detection of urinary morbidity
Urine samples collected were examined for visible 
haematuria (macrohaematuria). Microhaematuria 
was determined by dipping the reagent end of Uristix 
reagent strips (Uripath, Plasmatec, UK) into fresh, well-
mixed urine for 40 s and the test area compared with a 
standard colour chart as per manufacturer’s instructions. 
The strength of the colour change indicates varying 
concentrations of blood present in the sample, that is, 
negative, trace, positive (+), positive (++), positive (+++) 
and positive (++++). For analysis purposes, microhaema-
turia was classified as either negative or positive.
Sample size calculations
The sample size used for this study was based on the 
larger, longer-lasting study comparing reinfection rates 
following different treatment regimens, of which this 
is a subset. Calculations were based on previous studies 
showing that PZQ treatment reduces reinfection rates by 
at least 50%.5 14 Statistical power analysis was performed 
using Gpower V.3.1.5.20 Based on an expected preva-
lence of 6.7%, as derived from our previous study in 
children aged 1–5 years,21 a sample size of 214 in each 
group would provide %=0.05 and power=0.80. Allowing 
for a 20% dropout rate, the sample size required for each 
group during follow-up was 256. The sample size for the 
larger reinfection study, that is, 525 in a group, was there-
fore sufficient for this aspect of the study.
Statistical methods
Data analyses were performed using SPSS V.22 (IBM) 
and GraphPad Prism V.7.02 (GraphPad Software). The 
&2 (or Fisher’s exact test for small sample sizes) and the 
Mann-Whitney was used to test for differences in cate-
gorical and numerical variables, respectively. Infection 
intensity for S haematobium was defined as the arithmetic 
mean egg count/10 mL of at least two urine samples 
collected on three consecutive days. The egg count data 
was further log-transformed (log10 [egg count+1]) to 
meet the normality assumption of parametric statistics. 
At baseline, infection intensity (log-transformed) and its 
relationship as a function of age was determined using 
a linear regression model. To determine the infection 
prevalence based on a binary response as a function of 
age, logistic regression modelling was used as previously 
described.22 The effect of different factors on the preva-
lence of schistosome infection and morbidity was deter-
mined using logistic regression and the results reported 
as adjusted ORs (AORs) and 95% CI, along with the test 
for significance.
For a given morbidity marker, the attributable fraction 
(AF) in the exposed population (S haematobium-positive) 
and in the total population was calculated using Miettin-
en’s formulae23:




















In the formulae, RR is the risk ratio of morbidity asso-
ciated with exposure, Pe is the prevalence of morbidity 
among the exposed (S haematobium-positive). Because the 
AFs in this case are from a helminth study and estimated 
at the cross-sectional level, we substituted the RR with 
prevalence ratios (PR) as recommended in helminth 
epidemiology.24 The PR was estimated as a ratio of the 
proportion of infected individuals with morbidity to the 
 on M







ealth: first published as 10.1136/bm





4 Osakunor!DNM, et!al. BMJ Glob Health 2018;3:e000661. doi:10.1136/bmjgh-2017-000661
BMJ Global Health
proportion of uninfected individuals with morbidity. 
AFs were calculated on morbidity markers with PR>1, 
suggesting an increased risk of morbidity from schis-
tosome infection.24 Treatment efficacy was assessed by 
means of egg reduction rates (ERR) and cure rates (CR) 
as described previously.21
Approximate CIs were calculated using the modified 
Wald method25 and P<0.05 was considered significant.
RESULTS
Demographics
Of the 1502 recruited into the study, 794 (52.9%) were 
male. Age range was between 0.5 and 5 years (median=3.5 
years; IQR 2.5–4.3). The youngest participant in whom 
S haematobium infection was detected was a year old. 
Maximum loss to follow-up was recorded at first follow-up 
in May 2016 (64 participants; 12.2%). Overall follow-up 
rates in the longitudinal cohort, including participants 
for post-treatment efficacy check, were 87.8% in May 
2016, 93.7% in August 2016, 95.1% in November 2016 
and 88.8% in February 2017.
S!haematobium epidemiology at baseline
S haematobium infection prevalence at baseline in the 1502 
participants was 8.5% (95% CI 7.2 to 10.0). The median 
age of children positive for infection was significantly 
higher compared with those negative for infection (4.0 
vs 3.5 years; P=0.001). Infection prevalence increased 
with age as shown in figure 1A,B. The overall mean infec-
tion intensity was 7.9 eggs/10 mL urine (95% CI 6.4 to 
9.7). The majority of children, 93.7% (95% CI 87.9 to 
97.0) presented with light infections (<50 eggs/10 mL 
of urine) based on the WHO classification.19 Infection 
intensity increased with age as shown in figure 1C,D. 
There was no significant difference in infection preva-
lence between males and females; 8.9% (95% CI 7.1 to 
11.1) and 8.1% (95% CI 6.3 to 10.4; P=0.067), respec-
tively.
Morbidity at baseline
Prevalence of urinary morbidity was 0.7% (95% CI 0.3 
to 1.5) for macrohaematuria and 8.6% (95% CI 6.9 to 
10.6) for microhaematuria. Malnutrition measured by 
different indices were as follows: MUAC, 2.2% (95% 
CI 1.4 to 3.2), MUACZ, 7.4% (95% CI 6.0 to 9.1) and 
WHZ, 8.2% (95% CI 6.8 to 9.9). Prevalence of under-
weight measured by WAZ was 10.1% (95% CI 8.5 to 
11.9), and stunting by HAZ was 18.0% (95% CI 16.0 to 
20.3). Comparing infected versus uninfected children, 
prevalence of microhaematuria (43.5%; 95% CI 34.8 to 
52.6 vs 3.4%; 95% CI 2.4 to 5.0; P<0.001) and stunting 
(27.0%; 95% CI 19.9 to 35.6 vs 17.0%; 95% CI 14.9 to 
Figure 1 (A) Schistosoma haematobium infection prevalence with age; prevalence varied with age (P<0.001) and (B) age-
predicted probability of infection; prevalence increased as children grew older (P=0.002). (C) S haematobium infection intensity 
with age; intensity varied with age (P<0.001) and (D) age-predicted intensity of infection; infection intensity increased as 
children grew older. Error bars indicate 95% CI (A) or SEM (C), and shaded areas indicate 95% CI; (B, D).
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19.4; P=0.009) was significantly higher among children 
with S haematobium infection.
Morbidity attributable to S haematobium infection
Morbidities from schistosome infection are not specific 
and may relate to different physiological, biochemical 
and immunological processes. We determined how much 
of the detected morbidity was attributable to schistosome 
infection by first determining PRs. All the morbidity 
markers considered had PR >1 (significant association 
with schistosome infection) except underweight by BAZ 
(table 1). Based on AFs, microhaematuria was the most 
dominant morbidity marker attributed to schistosome 
infection both in infected children and at the population 
level. Macrohaematuria, on the other hand, was highly 
attributable to schistosome infection in the infected 
population but this was not the case in the total popu-
lation. Of the anthropometric markers, stunting was the 
most dominant marker attributed to schistosome infec-
tion both at the population level and among the infected 
children (figure 2).
Likelihood of schistosome infection and morbidity
Multiple logistic regression analysis showed that with 
every unit increase in age, children were more likely to 
acquire S haematobium infection (AOR=1.4; 95% CI 1.1 
to 1.8; P=0.005). Children who presented with microhae-
maturia were more likely to be positive for S haematobium 
infection (AOR=21.8; 95% CI 11.7 to 40.7; P<0.001) as 
shown in figure 3A. Similarly, children presenting with 
S haematobium infection were more likely to present with 
microhaematuria (AOR=25.6; 95% CI 14.5 to 45.1; 
P<0.001) and stunting (AOR=1.7; 95% CI 1.1 to 2.7; 
P=0.014) as shown in figure 3B.
Incidence of infection and morbidity
To determine infection and morbidity incidence, 525 
schistosome-negative children were followed quarterly 
for 12 months to determine schistosome infection and 
morbidity acquired in the previous three months. Based 
on the longitudinal data, annual incidence of S haemato-
bium infection was 17.4% (95% CI 13.7 to 21.8) and that 
of microhaematuria was 20.4% (95% CI 15.8 to 26.0). S 
haematobium incidence rates in the dry season was 4.9% 
in May (95% CI 3.1 to 7.8) and 6.5% in August (95% 
CI 4.1 to 9.9) while that in the rainy season was 3.8% in 
November (95% CI 2.1 to 6.6) and 3.7% in February 
(95% CI 2.1 to 6.5). Difference in overall incidence rates 
however was not significant between the dry (10.4%; 95% 
CI 7.6 to 14.1) and rainy seasons (7.4% total; 95% CI 5.0 
to 10.9; P=0.175). The quarterly incidence of microhae-
maturia recorded was 2.0% in May (95% CI 0.4 to 5.9), 
2.8% in August (95% CI 1.0 to 6.6), 13.3% in November 
(95% CI 9.6 to 18.3) and 4.3% in February (95% CI 2.2 
to 8.1).
Treatment ef!cacy and effects on morbidity
The treatment efficacy was calculated from children 
positive for infection at baseline and those that became 
infected throughout the year. Thus, a total of 187 chil-
dren were treated for infection (127 at baseline and 60 
from the longitudinal cohort), of which post-treatment 
data were available for 156 (follow-up rate: 83.4%). PZQ 
was efficacious in reducing S haematobium infection, as 
indicated by the high CR (96.2%; 95% CI 91.7 to 98.4) 
and ERR (99.8%; 95% CI 99.2 to 100). In addition, the 
mean infection intensity pretreatment (7.1 eggs/10 mL 
urine; 95% CI 5.9 to 8.6) was significantly reduced at 
post-treatment follow-up (1.1 eggs/10 mL urine; 95% CI 
1.0 to 1.2; P<0.001).
Table 1 Prevalence ratios (PRs) for detected schistosome-
related morbidity
Morbidity Diagnostic tool PR (95% CI)
Microhaematuria Urine dipsticks 12.6 (11.6 to 14.1)
Macrohaematuria Visual inspection 
(colorimetry)
3.4 (1.9 to 5.4)
Stunting HAZ 1.6 (1.05 to 2.31)
Malnutrition WHZ 1.1 (0.9 to 1.4)
MUACZ 1.5 (1.3 to 1.9)
MUAC 1.3 (0.8 to 1.9)
Underweight WAZ 1.4 (1.2 to 1.6)
BAZ 1.0 (0.8 to 1.3)
BAZ, body mass index for age Z scores; HAZ, height-for-age Z 
scores, MUAC, mid-upper arm circumference Z scores; WHZ, 
weight-for-height Z scores; WAZ, weight-for-age Z scores. 
Figure 2 Estimated proportion of morbidity attributable 
to Schistosoma haematobium infection in the infected 
population (blue; AFe) and in the total population (red; AFp). 
Error bars indicate 95% CIs."BAZ, body mass index-for-age 
Z scores; HAZ, height-for-age Z scores; MUAC, mid-upper 
arm circumference Z scores; WAZ, weight-for-age Z scores; 
WHZ, weight-for-height Z scores .
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To determine the effects of treatment on morbidity 
identified at baseline, data for microhaematuria were 
available for 78 of the 127 S haematobium-positive cases 
identified. Within this cohort, 42.3% (95% CI 32.0 
to 53.4) were positive for microhaematuria and this 
declined significantly post-treatment (10.3%; 95% CI 5.1 
to 19.2; P<0.001).
A pooled analysis of participants in whom new infec-
tions were detected throughout the follow-up period 
(group 1) was done to determine the dynamics of 
microhaematuria with infection, before, during and 
post infection. A total of 60 new infections were detected 
throughout the follow-up period. Of this, microhae-
maturia was detected among 18 individuals; 6 (33.3%) 
preinfection, 11 (61.1%) during infection and 2 (11.1%) 
post treatment. In 61.1% of these individuals, microhae-
maturia coincided with the detection of S haematobium 
infection (within 3 months) and had resolved by the next 
survey at 3 months post treatment of infection (figure 4).
DISCUSSION
Contrary to the previously held assumption of low risk 
to schistosome infection in PSAC,26 the frequency of 
schistosome infections among infants and young chil-
dren is being increasingly recognised.27 We conducted 
a longitudinal study in a cohort of Zimbabwean PSAC 
to determine the prevalence, dynamics and incidence 
of first urogenital schistosome infection and morbidity 
and its associated risks and health impacts. We showed 
that PSAC present with schistosome infection (estimated 
by egg count) and associated morbidity (determined by 
microhaematuria, growth and nutritional markers) from 
an early age. We also found that schistosome infection 
and morbidity can be detected early in PSAC using para-
sitology and microhaematuria within 3 months of infec-
tion and is resolved after treatment.
The observed baseline prevalence of S haemato-
bium infection in PSAC (8.5%) is comparable to levels 
recorded in PSAC in Ghana (11.2%),4 Malawi 10.7%28 
and in our recent studies in Zimbabwe, that is, 13.5%10 
and 6.7%.21 PSAC however present with light infec-
tions22 27 29 and parasitological egg counts underestimate 
the prevalence of schistosome infection.4 22 We anticipate 
this prevalence to increase if the more sensitive sero-
logical diagnostic tools are used.22 In agreement with 
previous findings,7 22 30–32 infection prevalence and inten-
sity increased as children grew older.
The majority of morbidity biomarkers associated with 
schistosomiasis are non-specific and relate to various phys-
iological, biochemical and immunological processes.33 
We determined the prevalence of morbidity and how 
much of this was attributable to S haematobium infec-
tion. Microhaematuria was the most dominant marker 
for schistosome-related morbidity, and children with S 
haematobium infection were more likely to present with 
microhaematuria and vice versa. This agrees with our 
previous findings in Zimbabwe10 and that by researchers 
in Nigeria34 on the significance of microhaematuria as a 
point of care field marker of morbidity in PSAC.
In addition to biomarkers, we also investigated the 
prevalence of stunting and malnutrition in the children. 
To the best of our knowledge, this is the first study to 
show the relationship between S haematobium infection 
and chronic growth failure (Stunting by HAZ) in PSAC, 
although studies on polyparasitism35 36 and few schisto-
some-specific studies37 38 have documented this effect in 
older children. In accordance with our findings, stunting 
as detected in older children and adolescents is believed 
to be the result of chronic antiparasite inflammation 
which persists during childhood.39 Causality is difficult 
to establish in this case due to the lag time between the 
initial infection and the time at which we measured 
growth failure, and the impact of confounding factors 
including diet and coinfections. However, there is the 
need for longer-term studies investigating the impact 
of treatment on growth and development measures in 
PSAC. Statistical modelling suggests that with early, repet-
itive treatment of infection before 6 years of age ‘catch-up 
growth’ can be effectively facilitated.40
While baseline prevalence and intensity of schistosome 
infection have been described in PSAC from several 
African countries, there has not been an incidence study 
published to date. Here, we document the incidence 
of urogenital schistosome infection and morbidity in 
PSAC. Our quarterly incidence is an indication of new 
schistosome infections in PSAC in endemic areas and the 
applicability of current tools (urine filtration and urine 
dipstick) to screen for early infection and morbidity. 
The incidence of microhaematuria and the AF analyses 
suggest that even in the very first episodes of infection 
Figure 3 Forest plot showing (A) the odds of presenting 
with Schistosoma  haematobium infection and (B) odds of 
presenting with microhaematuria (left) and stunting (right). 
Error bars indicate the 95% CIs. *P<0.05, ***P<0.001. Non-
signi!cant variables were excluded from the !nal logistic 
regression model.
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PSAC suffer morbidity, reflected as microhaematuria; an 
indication of active bladder and ureteral lesions41 42 and 
blood loss even in mild schistosome infection.43
PZQ, the antihelminthic of choice for treatment of 
schistosomiasis, is safe and efficacious in PSAC.44 Our 
results 12 weeks post treatment showed that a single stan-
dard dose of PZQ was effective against S haematobium infec-
tion. This is consistent with reports on the efficacy of PZQ 
treatment for schistosomiasis in PSAC.5 Microhaematuria 
correlates with S haematobium infection,42 45 and treatment 
with PZQ reduces morbidity (microhaematuria) as used 
in large-scale chemotherapy for SAC.33 46 We observed 
that microhaematuria occurred rapidly within 3 months 
of exposure to infection and resolved within 3 months 
after treatment with PZQ. This is an important indicator 
for non-delayed schistosome screening and treatment 
in PSAC, to avert cumulative morbidity which can affect 
overall health.1 Observation from our field studies prove 
that suggestions to empower health workers to screen for 
infection, and making PZQ available in health centres 
for treatment on detection will be an important control 
strategy in this age group.47
The seasonal pattern of infection incidence detected 
is in agreement with the fact that during the dry seasons 
snail vectors and larval schistosomes become concen-
trated at permanent and slow-moving water sources, 
increasing the risk of infection.48 Our observation from 
fieldwork also indicates that during the rainy seasons, 
households are less reliant on water sources for chores 
and children are less likely to visit water bodies for recre-
ational purposes.
The impact of schistosome infection on the health 
of children is likely to be greater than those explored 
here, for example, its impact on neurocognitive devel-
opment. Mechanistic and epidemiological studies sepa-
rating the effects of schistosome infections from other 
confounders would be informative in identifying and 
portioning causation in AFs. The present study did not 
measure the impact of existing feeding, nutrition habits 
and socioeconomic status on stunting and its relationship 
Figure 4 Impact of Schistosoma haematobium infection and praziquantel (PZQ) treatment on morbidity (microhaematuria). 
Microhaematuria status for 18 individual participants is shown at three time points: before, during and post"infection 
(post"treatment). Each data set (dotted line) represents one individual. Tall, red bars indicate positive microhaematuria, and a 
black dash indicates negative microhaematuria at speci!c time points.
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to schistosome infections. A limitation of the parasitolog-
ical detection of infection is that some light infections 
may have been missed, resulting in underestimation 
of the infection rates observed. Nonetheless, the study 
allows comparison with other studies while parasitolog-
ical methods remain the predominant schistosome diag-
nostic in PSAC.
CONCLUSIONS
We demonstrated for the first time the incidence of 
schistosome infection and morbidity in PSAC. We have 
also shown that a significant proportion of stunting and 
malnutrition is attributable to S haematobium infection. 
Morbidity assessed by microhaematuria occurs rapidly 
within 3 months of first infection and resolves post treat-
ment. More importantly for childhood health and devel-
opment, schistosome treatment leads to a significant 
decline in microhaematuria and this resolution occurs 
within 3 months of PZQ treatment. The study adds scien-
tific evidence to the calls for inclusion of PSAC in schis-
tosome control programmes. Non-delayed schistosome 
screening and treatment in PSAC is essential to avert 
accumulative morbidity which can affect overall health.
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There is a disease epidemiological transition occurring in Africa, with increasing incidence of
noninfectious diseases, superimposed on a health system historically geared more toward
the management of communicable diseases. The persistence and sometimes emergence
of new pathogens allows for the occurrence of coinfections and comorbidities due to both
infectious and noninfectious diseases. There is therefore a need to rethink and restructure
African health systems to successfully address this transition. The historical focus of more
health resources on infectious diseases requires revision. We hypothesise that the growing
burden of noninfectious diseases may be linked directly and indirectly to or further exacer-
bated by the existence of neglected tropical diseases (NTDs) and other infectious diseases
within the population. Herein, we discuss the health burden of coinfections and comorbidi-
ties and the challenges to implementing effective and sustainable healthcare in Africa. We
also discuss how existing NTD and infectious disease intervention programs in Africa can
be leveraged for noninfectious disease intervention. Furthermore, we explore the potential
for new technologies—including artificial intelligence and multiplex approaches—for diagno-
sis and management of chronic diseases for improved health provision in Africa.
Introduction
The top 10 diseases that account for the most disability-adjusted life years (DALYs) and cause
of death in Africa include both infectious and noninfectious diseases, with the amount of
DALYs contributed by noninfectious diseases almost catching up to those of infectious dis-
eases [1]. What these data do not indicate is the level of comorbidity within the population, a
reflection predominantly of the vertical management of diseases in African countries and a
legacy of the historical focus on communicable diseases. In particular, when reporting causes
of death, the contribution of comorbidities arising from infectious and noninfectious diseases
is not reported. Population studies indicate that several tropical infectious diseases show com-
mon epidemiological patterns with age and share risk factors, including poor sanitation and
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lack of safe water [2]. Environmental and socioeconomic factors contribute to the coexistence
of these pathogens in the same individual and cause concomitant morbidity [2].
Infectious disease co-occurrence exhibits distinct spatial patterns [3]. This co-occurrence,
so-called pathogeographic patterns (Fig 1), observed in sub-Saharan Africa (SSA), overlaps
with the distribution of neglected tropical diseases (NTDs) [4] and cancers, directly linked to
infections (Fig 1). These NTDs include bacterial, parasitic, protozoal, and viral infections, as
per the World Health Organisation (WHO) NTD list from the 10th meeting of the WHO Stra-
tegic and Technical Advisory Group for NTDs in 2017 (http://www.who.int/neglected_
diseases/diseases/en/), with the most common NTDs being helminth parasites [4]. Helminths
have been implicated in several noninfectious diseases including endomyocardial fibrosis [5],
hypertension [6, 7], iron deficiency anaemia [8], and cancer [9].
In a recent pilot study, we evaluated a multiplex immunoglobulin (Ig) M and IgG antibody
response fingerprinting platform for determining exposure history to pathogens using serum
from a Zimbabwean population. Initial analysis showed evidence of recent exposure (IgM) to
an array of infections (Fig 2). This platform also allowed the detection of responses to child-
hood vaccinations, as indicated by the high titres of responses against poliovirus in the child
compared to the adolescent and adult. Although this exposure history requires further valida-
tion through other diagnostic methods, including parasitology and molecular approaches, it
gives an indication of potential coinfections, as already described by others [3, 4].
In addition to diseases arising from infectious pathogens, there is also an increase in
chronic noninfectious diseases, including high blood pressure, cardiovascular diseases, diabe-
tes, and cancer. Direct and indirect interactions between infectious and noninfectious diseases
have been poorly studied, particularly in African settings. For instance, there are now
Fig 1. Adapted maps of Africa showing the overlap of neglected tropical diseases (NTDs), infectious, and noninfectious diseases. The figure shows (A)
pathogeographic patterns of 187 global human infectious diseases [3], (B) patterns of the six most common neglected tropical diseases [4], (C) burden of the most
frequently diagnosed cancer among males [10], and (D) probability of dying from the four main noninfectious diseases between the ages of 30 and 70 years [11].
Infectious diseases show distinct spatial patterns (A), which overlap with the most common neglected tropical diseases (B), commonly diagnosed cancers (C), and the
mortality rates from major noninfectious diseases including cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes (D).
https://doi.org/10.1371/journal.pntd.0006711.g001
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suggestions that mental illness may be an inflammatory disease [12, 13], but the sources of
inflammation and their relative contribution to mental illness have yet to be determined.
Aetiological and mechanistic experimental studies suggest that NTDs, including parasitic
infections, may contribute to this inflammation [14]. For example, helminth infection during
pregnancy has been suggested to impair neurocognitive development in infants [15], but
mechanistic studies have yet to be conducted. Apart from well-known infections, such as
human immunodeficiency virus (HIV) and human papilloma virus (HPV) that are risk factors
for some cancers [16, 17], there is increasing evidence that inflammation from infectious path-
ogens contributes to the aetiology of diabetes and coronary artery disease [18, 19].
With increasing coinfections and comorbidities, there is a need to investigate aetiological
links between these two groups of diseases (infectious and noninfectious), and to invest in hor-
izontal health systems approaches and training of healthcare workers to manage multiple and
chronic conditions. In this review, we hypothesise that the growing burden of noninfectious
diseases may be linked directly/indirectly, or further compounded by the existence of NTDs
and other infectious diseases. We explore the challenges/barriers to implementing effective
and consistent healthcare in SSA in the face of the observed disease trends. We discuss how
existing NTDs and other infectious disease intervention programmes and infrastructure can
be leveraged for noninfectious disease intervention, diagnosis, and long-term management of
diseases, for improved health provision in Africa.
Methodology
A literature review was conducted using electronic databases, including Pubmed/Medline,
Google Scholar, and WHO (http://www.who.int). For the entire review, we searched for
research articles with keywords relevant to each section of the review. We analysed all articles
published and included those relevant to the scope of this review. A systematic review of
Fig 2. Host infectome analysis based on IgM reactivity to multiple infections in a Zimbabwean cohort. Results indicate variable responses to infections across all
age groups. IgM, immunoglobulin (Ig) M.
https://doi.org/10.1371/journal.pntd.0006711.g002
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literature (PubMed) was done to determine the impact of coinfections in Africa. Search terms
for the systematic review were (a) [(Co-infection⇤ OR Coinfection⇤) AND (Co-morbid⇤ OR
Comorbid⇤) AND (Africa) AND (Health impact⇤)] (b) [(Co-infection⇤ OR Coinfection⇤)
AND (Co-morbid⇤ OR Comorbid⇤) AND (Africa) AND (Health impact⇤) AND Helminth⇤)].
Selection criteria included human studies, original articles, studies that relate coinfection or
comorbidity to a secondary health impact, and articles published in the last 10 years as at Janu-
ary 2018.
Health impact of coinfections
The outcome of coinfections can be asymptomatic, symptomatic, and sometimes fatal. While
there are studies—predominantly in experimental models—suggesting the health benefits of
infection, e.g., with helminth infections as described through the hygiene hypothesis [20],
there are few studies from human populations. These experimental studies may be informative
at the mechanistic level, but their phenotypic and thus clinical relevance in humans requires
careful and well-designed studies. Animal models of natural infection bridge the gap between
experimental and human studies, and these indicate that coinfections can influence popula-
tion-level disease and mortality patterns, which ultimately influence interventions. For exam-
ple, a study in African cattle showed that concurrent infection of Theileria parva with less
pathogenic species of Theileria resulted in a reduction in T. parva-associated mortality [21].
Nonetheless, parasite coinfections in a cattle study showed antagonistic effects that compro-
mised the health of cattle [22].
In human populations, detrimental effects of coinfections have been reported. Polyparasitic
infections in Africa have been associated with a higher tendency for wasting, splenomegaly,
and anaemia [23]. As shown in Table 1, a systematic review of literature on the health impacts
of coinfections in the SSA region suggests the apparent lack of adequate research evidence on
the subject matter. The impact of coinfections on health will become more evident as more
holistic approaches are taken to studying the health of the host rather than focusing on just
pairs of parasite–host relationships or on the interaction and impact of two infections (pre-
dominantly HIV and another disease) as has been the predominant practice.
Epidemiology in transition
From acute/episodic diseases to chronic conditions
In addition to communicable diseases, there is an increasing burden of noninfectious diseases
such as hypertension, stroke, cancer, and diabetes in the SSA region. This concurrent health
challenge is compounded by the lack of marked progress in the control of infection and mal-
nutrition, if at all [42, 43]. The insurgence of noninfectious diseases is a “time bomb” for
Africa, with the region expected to record the world’s largest increase in noninfectious disease
deaths by 2030 [44]. Already, countries in northern and southern Africa account for more
than three quarters and close to a half of all deaths to noninfectious diseases, respectively [45].
HIV is now a chronic infection; increased access to antiretroviral therapy (ART) has sub-
stantially improved health and reduced the risk of HIV transmission, increasing the life expec-
tancy of HIV patients to one close to that of uninfected populations [46]. Thus, there is an
increasing number of over 50-year-old patients living with chronic HIV, and the impact of
HIV and ageing on the acquisition of noninfectious diseases like diabetes become key [46],
requiring long-term management and care.
Lymphatic filariasis and onchocerciasis pose a serious public health problem in Africa,
causing long-term chronic infection with permanent and long-term disability [47]. In human
filariasis infections, coinfections with other infectious diseases is common and can affect
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protective immune responses for infections like malaria and tuberculosis (TB) [48]. Chronic
long-term management of filarial infections thus become a very important component of
healthcare. This is crucial, especially to prevent secondary infections that may worsen late-
stage diseases.
While there are many risk factors associated with the growing number of cancers in Africa,
infectious diseases play a significant role (Fig 3). About a third of new cancers in Africa are
due to viral, bacterial, or parasitic infections [49]. The implication of this increasing comorbid-
ity of cancer and infectious diseases in Africa means that disease screening, diagnosis, treat-
ment, and care need to be revised to determine potential multiple interventions.
Table 1. Summary of publications on health impacts of coinfections in Africa within the last 10 years.
Year Source Disease dynamics Health impacts
2007 Hoffmann and Thio 2007
[24]
Hepatitis B virus–HIV Liver enzyme alterations, reducing antiretroviral tolerance and increasing its
toxic effects. Blunt immune recovery from antiretroviral therapy.
2009 Hadley and Naude 2009
[25]
HIV–Tuberculosis–Malignant tumours Increased mortality.
Degarege, Animut et al.,
2009 [26]
Malaria–Soil-transmitted helminths Impact on malaria severity, although small.
2010 lsa, Gwamzhi et al., 2010
[27]
Hepatitis B and C viruses–HIV/AIDS Impact on causing hepatotoxicity.
Sangweme, Midzi et al.,
2010 [28]
Schistosomiasis–Malaria Higher peripheral blood malaria parasite density, promoting transmission.
Modjarrad and Vermund
2010 [29]
HIV–Tuberculosis–Syphilis Tuberculosis and syphilis may increase HIV viral load, increasing disease
progression.
2012 Ntusi, Badri et al., 2012
[30]
Acinetobacter baumannii–HIV/AIDS Increased mortality.
Faurholt-Jepsen, Range
et al., 2012 [31]
Tuberculosis–Diabetes Poor treatment outcomes including delayed recovery of body mass and
haemoglobin levels, hence poor recovery from disease.
Webb, Barrett et al., 2012
[32]
Chronic myeloid leukaemia–HIV Poor cytogenic response to leukaemia treatment.
van den Bogaart, Berkhout
et al., 2012 [33]
Visceral leishmaniasis–Malaria Early detection results in good prognosis, but patients stand a high risk of
severe symptoms of leishmaniasis.
2013 Ladep, Agbaji et al., 2013
[34]
Hepatitis B virus–HIV Reduced survival. With the appropriate treatment Tenofovir, this impact may
be annulled
Taye, Alemayehu et al.,
2013 [35]
Podoconiosis–Soil-transmitted helminths Increased blood losses/anaemia.
2014 Baldassarre, Mdodo et al.,
2014 [36]
HIV/AIDS–Cryptococcal meningitis Increased mortality.
Knight, Muloiwa et al.,
2014 [37]
HIV–Stevens Johnson syndrome–Toxic epidermal
necrolysis
Increased risk of systemic bacterial infection and mortality.
Biraro, Egesa et al., 2014
[38]
Helminths, malaria, or HIV coinfection in
household contacts of Tuberculosis patients
No evidence of increased risk to latent Tuberculosis. Th1 cytokine responses
in those with prior BCG vaccination was reduced.
Degarege, Animut et al.,
2014 [39]
Malaria–Helminths Undernutrition; severity is comparable to those with single infections.
2015 Umanah, Ncayiyana et al.,
2015 [40]
HIV–Tuberculosis Treatment failures and increased mortality.
2017 Morawski, Yunus et al.,
2017 [41]
HIV–Hookworm Decreased CD4+ T cell counts during antiretroviral therapy.
Systematic review of literature (PubMed); electronic search terms were (a) [(Co-infection⇤ OR Coinfection⇤) AND (Co-morbid⇤ OR Comorbid⇤) AND (Africa) AND
(Health impact⇤)] (b) [(Co-infection⇤ OR Coinfection⇤) AND (Co-morbid⇤ OR Comorbid⇤) AND (Africa) AND (Health impact⇤) AND Helminth⇤)]. Selection criteria:
human studies, original articles, and studies that relate coinfection or comorbidity to a secondary health impact published in the last 10 years.
Abbreviations: AIDS, acquired immune deficiency syndrome; BCG, Bacillus Calmette–Guérin; CD4+, cluster of differentiation 4.
https://doi.org/10.1371/journal.pntd.0006711.t001
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Developing countries bear over 80% of the global cardiovascular disease burden [50]. At
the same time, although previously rare, diabetes has emerged as an important noninfectious
disease in SSA [51]. Such metabolic diseases are currently affecting individuals at a much
younger age than when compared to developed countries [52]. While individualised
approaches to preventing nutritional and metabolic disease can be effective in developed coun-
tries, they are not affordable or feasible for the poorer population in low-income countries.
Fig 3. Summary of infections and the types of cancers they cause, via direct or indirect links. Each coloured line/alphabet represents a pathological pattern.
Information adapted from aCrosbie, Einstein, and colleagues, 2013 [16]; bAhmadi Ghezeldasht, Shirdel, and colleagues, 2013 [55]; cMarra, Sordelli, and colleagues,
2011 [56]; dMostafa, Sheweita, and colleagues, 1999 [57]; eDittmer and Damania, 2016 [58]; fPolk and Peek, 2010 [59]; and gBower, Nelson, and colleagues, 2005
[17]. HHV8, human herpes virus 8; KSHV, Kaposi sarcoma-associated herpesvirus; HIV, human immunodeficiency virus.
https://doi.org/10.1371/journal.pntd.0006711.g003
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Therefore, societal approaches such as those that have been used in public health educational/
awareness campaigns for infectious diseases, notably HIV, will have to be implemented.
The socioeconomic and cultural environment around this current epidemiologic situation
in SSA differs from that in most Western countries. In SSA, noninfectious diseases were not
anticipated, were accompanied by cultural misconceptions, and have historically received less
attention and health budget allocation compared to communicable diseases [53]. Chronic dis-
eases will require long-term management, incurring a cost for both the individual and an
already overburdened healthcare system. However, healthcare systems in SSA are designed to
provide more acute care, and many are ill-equipped to provide long-term care for chronic con-
ditions, as exemplified in Tanzania [54].
Problems arising from coinfection and comorbidity
The healthcare system. Despite some differences among health systems across Africa,
these exhibit some similar structural and organisational formats. Table 2 summarises the gen-
eral nature and challenges associated with national health systems across Africa by using
model countries in different regions of the continent.
The coexistence of multiple infectious and noninfectious diseases, characterised by multiple
comorbidities, presents unique problems for healthcare delivery in SSA. From the simulated
Table 2. Health systems in Africa: Structure and challenges.
Region Model country System structure Challenges Source
Anglophone Tanzania Bottom–up approach. Village health services for remote
areas at level 1. Level 2 consists of dispensary services for
localities with larger populations. Level 3 offers services to
even larger populations, up to 50,000 people.
Lack of access for the poor due to the copayment system,
insurance requirements, and the insurgence of private
physician practices. Absenteeism, low morale, inadequate
qualified work force, lack of equipment and supplies.
Centralisation at the high level of care.
[63,
64]
Kenya Well organised and pyramidal, with dispensaries, health
centres, subdistrict hospitals/private clinics, provincial and
national hospitals.
Recurrent strikes by doctors, problems with financing health
systems, high cost of health services, HIV/AIDS and malaria
alone consumes the greatest part of resources.
[65]
Uganda Village health teams and community medicine distributors
at level 1. Higher up is the health centre II in parishes,
health centre III in sub-country, health centre IV, the
regional referral hospitals, and three national referral and
teaching hospitals.
Village volunteers can be unreliable, lower levels are quick to
refer cases. Inadequate infrastructure, inequity in health
services, lack of sustenance, low remuneration for staff,
paucity of specialised physicians, poor training, high rates of
staff layoffs. Poor data collection and utilisation.
[66]
Francophone Cote d’Ivoire Follows the 1996 health system organisation with three-tier
pyramidal structure. Level 1: health, urban medical, school
and university health centres. Level 2: general, regional and
specialised hospitals. Level 3: specialised health institutes.
Low level of qualified personnel (one doctor per 10,000). High
cost of universal healthcare led to its abandonment, hence lots
of out of pocket care.
[63]
Senegal Similar structure to that of Cote d’Ivoire. Pyramidal with
three levels. Central level: Ministry of Health. Regional
level: local health systems. Peripheral level: health districts.
Disparities in distribution of facilities across the country.
Sustained by government budget and relies a lot on donor
support. Inadequate workforce, inadequate training, poor
infrastructure and communication machinery. Social and
religious barriers with disparities in quality of care.
[63]
Lusophone Angola Has three levels. Primary level: referral health centres or
district hospitals, health posts. Secondary care: specialised
facilities and general hospitals. Tertiary care: specialised
health facilities and central hospitals
Lack of proper remunerations, inadequate allocation of
resources by leadership, lack of decentralisation, persistent
shortage of essential drugs, lack of data collection and
availability.
[67]
Mozambique Has four levels. Primary level: health posts (the least
equipped) and health centres. Secondary level: rural
hospitals and urban hospitals. Tertiary level: five general
and seven provincial and district hospitals. Quaternary
level: three central hospitals.
Shortage of qualified staff to brain drain, and the system has
some of the lowest salaries in Africa. Over reliance on foreign
donor support makes it unsustainable. Poor infrastructure and





Similar structure to that of other countries with a national
Ministry of health, Tertiary, Secondary, and Primary
healthcare facilities.
Poor leadership and governance, low health financing (93.5%
of health cost is out of pocket). Poor service delivery, lack of
skilled physicians, and poor management of medical
resources. Lack of available health data countrywide.
[69]
https://doi.org/10.1371/journal.pntd.0006711.t002
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global economic output losses of US$47 trillion from noninfectious diseases over the next few
decades [60], low- and middle-income countries are unlikely to be equipped to bear most of
this burden. Lessons from chronic HIV management suggest that identifying infected individ-
uals, creating access to therapy, and addressing the multiple complications associated with
long-term care requires a well-resourced healthcare system [61]. African health systems are
geared toward a more episodic regime of healthcare, without capacity to absorb more patients
into chronic disease care in an efficient, affordable, and sustainable manner [54]. Multiplex
disease management models, differential diagnostic ability, and proper interventions are
essential for long-term patient care. The success of HIV management, including the UNAIDS
HIV 90:90:90 care continuum [62], relies on adherence to prescribed medicines, long-term fol-
low up of patients, self-management, and behavioural change by patients.
Health systems in Africa need to be strengthened to improve effectiveness and efficiency
across both rural and urban areas, reducing resource wastage, tailoring the training of health-
care providers to the needs of the specific population, along with proper compensation for
healthcare providers. Currently, the health system across Africa follows different structural
and funding models (see Table 2) and lessons can be learnt from the different models to
improve on service delivery and accessibility for comorbidities.
Diagnosis
What is the patient suffering from?. The existing infrastructure in most parts of SSA is
not equipped for differential diagnosis. Appropriate basic diagnostic tests to support clinical
symptoms may be lacking. For example, in Tanzania, less than 50% of patients with severe
malaria (based on WHO clinical criteria) were laboratory confirmed [70], and in Ghana, 40%
of such patients were confirmed to have bacterial sepsis and not malaria [71]. Conditions like
anaemia, which are common in areas coendemic for different pathogens, still have no simple
point-of-care diagnostic tests available. In some cases, despite availability of the technology,
conditions are still not diagnosed, e.g., in 15% of Kenyan children with a clinical history of
anaemia or malaria, haemoglobin levels were not measured [72]. Where there are diagnostic
tests available, their utility may be compromised by the lack of a reference standard test, as
occurs in childhood peritoneal tuberculosis (CPTB). In a modelling analysis of five different
methods, including the sensitive mycobacterial cultures, tests failed to detect almost 40% of
CPTB [73]. In addition, there are reports of challenges with quality control and reproduci-
bility, with very few or nonexistent national laboratory guidelines [74]. Most available diagnos-
tic tests are usually validated in Western populations, without guidelines for use in different
populations where a different disease ecology exists. A study in a helminth-infected African
population showed that routine allergy diagnostics are impaired by IgE antibodies to the car-
bohydrate epitope galactose-ċ-Gal, induced by the parasite infection [75]. Hence, some diag-
nostic tests used in the SSA region may be failing due to not having been developed/optimised
for use in polyparasitic individuals or those presenting with comorbidities.
Lack of centralisation of services impacts healthcare delivery, e.g., in HIV management,
nonprofit and commercial organisations are operating specialised independent laboratories
[74], which leads to an efficient but exclusive vertical system for HIV management in popula-
tions affected by other infectious and noninfectious conditions. Indeed, the absence of evi-
dence-based medicine contributes to poor patient outcomes, misdiagnosis in favour of more
common illnesses, delayed treatment, and significant morbidity and mortality.
Patient engagement in healthcare. The importance of the role of the patient in healthcare
decisions is increasingly and internationally being recognised, particularly in interventions
integrating behavioural change [76]. Central to patient engagement is communication, i.e.,
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communicating the diagnostic procedure and results, followed by interventions accessible to
the patient. In African health systems, context-appropriate communication of the diagnosis to
the patient is challenged by poor education and knowledge of the disease process. A study con-
ducted in South Africa showed that within the African cultural context, most patients viewed
the definite diagnosis as having been bewitched, associated it with poor prognosis, and barely
understood their diagnosis. On the other hand, health workers expressed concern of inade-
quate training and lack of competence in communicating diagnosis [77]. In rural Cameroon,
most patients tend to disagree with the diagnosis, depending on how well they understood
explanations given by the provider. Practitioners often do not give appropriate explanations,
do not support patients to express their opinions, and tend to show signs of disapproval when
patients do [78]. The ability to communicate diagnosis and, in effect, treatment options
becomes more important in the context of coinfections and comorbidities. These highlight
important obstacles to appropriate patient care and the need to include proper patient–pro-
vider communication as part of healthcare delivery in the face coinfections and comorbidities.
Knowledge, attitude, and practice (KAP) studies, including those on both infectious [79] and
noninfectious diseases [80], indicate that poor knowledge is associated with practices that
increase risk of disease or poor disease management.
What has the patient died of?. In addition to establishing a final diagnosis, autopsies
relate the cause of death to associated pathologies that may be present, thereby establishing an
interaction [81]. This is important in helping health experts find and track outbreaks, routine
diseases and hazards, and helps family members be aware of the genetic risk of diseases. In
most parts of SSA, issuing a death certificate is not mandatory and full autopsies are rare due
to resource constraints and unwillingness of families to have an autopsy performed [82].
This leads to imprecise approaches to determining the cause of death. A major constraint on
global health and development is the absence of mortality patterns due to specific diseases,
raising questions on how representative available data are, in relation to populations that go
uncounted for. Verbal autopsy is used as an alternative low-cost approach to determine cause
of death, and WHO has developed international standards for verbal autopsy, revising its use
with automated models [83]. This can be improved by combining verbal autopsies with mini-
mally invasive autopsies (MIAs), an initiative endorsed by funding agencies such as the Bill &
Melinda Gates Foundation (BMGF) [84]. Already, reports from Mozambique show significant
agreement of MIA with full autopsies [85]. In most of these areas, where MIA is likely to be of
benefit, infrastructure such as advanced radiology may not be available, and if at all, it may be
expensive. Others have suggested that MIA protocols dependent on needle sampling be used
in low- and middle-income countries, although its suitability has yet to be determined [86].
Data from this MIA–verbal autopsy system could be informative for improving future verbal
autopsy standards and improving viability and cost of large-scale cause-of-death assignments
within SSA.
Interventions
What is the desired outcome?. Diagnosis does not mean cure; therefore, advances in
diagnostics must be matched with advances in interventions. Interventions must be informed
by knowing what the desired outcome is and what tools are required or available to achieve
this. For instance, there is need for a definition of what constitutes a healthy or sick African
and what constitutes a healthy or weak immune system amidst all the coexisting infections and
morbidities. For example, in a Ugandan healthy population, significant disparity has been
described in absolute laboratory values when compared to populations outside SSA, suggesting
the necessity to develop specific ranges for the African population [87]. Such heterogeneity is
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important for contextualising interventions, e.g., initiation of antiretroviral therapy among
HIV patients is informed by CD4 cell counts and any immune reconstitution interventions.
What is the most appropriate drug to use?. Administering treatment in populations
affected by coinfections and requiring chronic long-term management requires sufficient
knowledge of the type and species of infection, drug–drug interactions within specified popu-
lations to inform dosage, and the impact on drug resistance and treatment efficacy. For
instance, experience from malaria intervention programmes shows that treatment regimen
depends on the target species [88], and our recent studies indicated that repeated treatment
was required in multi-Plasmodium species malaria-infected individuals when compared to
individuals with single species infection (Amanfo and colleagues, in prep). Due to high preva-
lence of some conditions, clinicians may favour clinical diagnosis against laboratory evidence,
treating symptoms instead of causes. For example, in malaria endemic areas, fever may not
always be malaria [74], and in the advent of rapid diagnostic tests (RDTs), even in hard to
reach areas, majority of these tests may come out negative; in 2014, about 142 million sus-
pected cases of malaria tested negative worldwide [89]. With similar tests lacking for other dis-
eases that cause fever, health workers are left in a dilemma and with nothing to offer. In 2016,
a high proportion of febrile children in Africa did not receive medical attention due to poor
access to healthcare and lack of awareness among caregivers [89]. Building a stronger health
system to deal with such challenges is recommended [90]. Ideally, in cases of patients receiving
multiple drugs for multiple conditions, drug–drug interactions need to be considered and
managed to maximise efficacy while reducing toxicity. For example, in the administration of
the antihelminthic Praziquantel along with Albendazole in multiparasitic interventions, the
routine coadministration of both drugs may affect the total exposure of Albendazole [91].
Defining the impact of heritable traits on pharmacology and toxicology in African popula-
tions is essential for targeted interventions. For example, cytochrome P450 variants impact
drug metabolism [92]. The application of pharmacogenetics can allow prediction of drug effi-
cacy or failure in patients before a drug is deployed, saving time and cost from trial and error
prescriptions [93] and may indirectly reduce the development of resistance [94]. Although this
requires significant investment, it is clear that near-personalised management of HIV patients
already occurring in Africa has already set the precedent.
Potential solutions
Leveraging existing platforms within health systems for disease control
Africa can leverage the successes of infectious disease control programmes to address the
increasing burden of noninfectious and chronic diseases. These must encompass innovations
that include both prevention and healthcare delivery.
Operational approaches
In many African countries, routine healthcare in the community is delivered through Com-
munity Health Workers/Volunteers (CHW). These CHWs are helping efforts to achieve uni-
versal healthcare at a low cost per person served. They have been trained to support chronic
care and long-term interventions such as supporting community engagement and education,
mass drug campaigns for NTD interventions, and maintaining compliance to HIV and tuber-
culosis treatment. For example, in a population with a high prevalence of HIV, Chibanda and
colleagues initiated a low-cost “friendship bench” intervention, locally adapted from problem-
solving therapy, to manage mental disorders [95]. In context, such interventions can deliver a
successful, practical, yet culturally accepted treatment programme for long-term management
of cases [96], with indirect benefits for compliance to treatment for HIV. In SSA, programmes
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such as these are rewarding for CHWs and can be sustained over long periods at low costs,
hence applicable in the context of available poor health systems. Lessons learnt from HIV con-
trol in Malawi are being applied through integrating screening for hypertension into HIV care
[97], and in Ghana, decentralised community-based hypertension care has been adapted from
HIV management [98].
Control of infectious diseases can also be integrated for greater health impact as exemplified
by antihelminthic treatment. Schistosomiasis has been linked to malaria infection in children
[99], and schistosomiasis treatment in areas where malaria is coendemic has been shown to
reduce malaria transmission [100]. Anthelimintic treatment, in addition to killing the para-
sites, has been shown to restore neurocognitive performance in school children [101, 102].
Of critical importance is the monitoring and evaluation of any changes within health sys-
tems, including integrating health service delivery into existing platforms. For example, what
impact does the introduction of a new vaccine have on the health system? Does the expanded
programme on immunization (EPI) system in affected countries adjust to cope with such
impacts or does this create strains in the system?
Optimising current interventions
Current interventions can be optimised to prevent multiple disease conditions. For example,
coadministration of the childhood vaccinations against influenza type B, whooping cough, tet-
anus, hepatitis B, and diphtheria as a single formulation (Pentavalent) [103] increases compli-
ance. There are already indications that some current vaccines can have broad spectrum
effects; the Bacillus Calmette–Guérin (BCG) vaccine can boost the immune system to resist
multiple infections [104].
Promotion of already existing measures such as extended breastfeeding programmes has a
positive impact on childhood disease and pathology. Breastmilk can contribute to bioactive
factors of the innate immune system as well as enhance the protective ability of the gastrointes-
tinal tract [105].
Integrating other platforms into health systems for control
Probiotics and disease control. The utility of probiotic therapy in maternal and child
health presents great potential for disease prevention and management, and its role has been
extensively reviewed [106]. Experimental studies have shown that intranasal probiotics of Lac-
tobacillus strains stimulate immune responses in the respiratory tract, offering protection from
viral (H1N1) infection [107, 108]. Probiotics have been used to deliver antigens or adjuvants
directly to the “unfriendly” gastrointestinal tract in HIV vaccine development [109] and as a
potential cryopreservative and immunomodulator of mucosal immune response in Hepatitis
B vaccines [110]. Despite existing evidence on the role of probiotics to enhance vaccine-spe-
cific immunity, there is a need for rigorous longitudinal mechanistic and efficacy studies in
paediatrics for different vaccines.
Technology and artificial intelligence. The use of artificial intelligence (AI), a specialised
branch of computer science that deals with the ability of computers to perceive their environ-
ment and make decisions to maximise the chances of success of an event or goal, in African
health systems is still limited but presents great potential. AI solutions can be used for decision
support/validation, multiple-disease screening and diagnosis, including the use of genomic
data and treatment optimisation within resource-constrained environments. A recent report
presented a solution that integrates and analyses data across various sources, including disease
incidence for clinical and operational decision support at the district level in Sierra Leone
[111]. Disease screening, which involves reading images, can be fully or partially automated
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using advances in computer vision and AI algorithms, coupled with the widespread availability
of cell phones in Africa to enhance human expert capacity [112]. Network analyses can be
used to establish links between diseases, ultimately informing treatment plans at the individual
and population level [113]. Improving the rate of uptake and integrating AI platforms to elec-
tronic health records will improve individual healthcare as well as strengthen the African
health system [114].
Mobile devices have become very popular in Africa and present great potential for
improved healthcare delivery. An example is the mTRAC mobile health system being used in
Uganda to report available stocks of medicines and the mHealth in Kenya to better understand
the supply chain of medicines [115]. These will ensure that medicines reach patients who need
it the most.
Where to go from here
Overall, we are in an era in which there is long-term survival and management of chronic con-
ditions. Some health systems have resources for chronic long-term care and support groups
are available in some countries to empower and promote healthy lifestyles for patients living
with such conditions; an example is Diabetes South Africa. The challenge is thus to equip cur-
rent health systems to shift from episodic interventions for acute care and be resourced for
chronic care and to make existing support groups and systems readily available to the poorest
and illiterate groups of affected patients.
Adequate training should be available to next generation scientists and health workers to
build local health, research, and development capabilities. Ongoing programmes include the
Human Health and Heredity in Africa (H3Africa), aimed at training local scientists from
Africa to develop treatments for conditions including infectious (e.g., tuberculosis and
malaria) and noninfectious diseases (e.g., cardiovascular disease) [115]. Guidelines, drugs, and
appropriate monitoring equipment also need to be in place, accessible but affordable to all and
tailored to different levels of care [51].
The role of education through interactive media and mobile devices cannot be overempha-
sised. There have been calls for funding agencies, the media, and health institutions in Africa
to be partisan in health knowledge generation and application beyond publication in scientific
journals [116]. Development partners have promoted innovative ways of delivering HIV and
reproductive health education to young people; for example, the MTV Shuga show (http://
www.mtvshuga.com/). The use of mobile phones is on the rise in Africa and present enormous
potential for mobile health beyond direct patient care [117]. The mobile messaging platform
WhatsApp has been demonstrated to be effective in enhancing the supervision of CHWs and
creating innovative forms of community-based digitally supported professional development
with minimal training [118]. This will go a long way to strengthen the formal healthcare sys-
tem and enhance the role of CHWs in hard-to-reach areas. The photo sharing platform Insta-
gram has been used by WHO, CDC, and others to broadcast public health messages for
education and for sensitisation during public health crises [119].
A marked difference in healthcare can also be achieved through public–private partner-
ships. Ongoing initiatives like the Foundation for Chronic Disease Management (FCDM) by
Novartis, in collaboration with International Business Machines (IBM) and Vodacom, is
doing a great job by linking public health workers to those in the private sector to deliver qual-
ity but affordable healthcare to homes [115].
By conducting more target-oriented research in multiple disease systems, more realistic
interventions will be achieved quickly for coinfections and comorbidities. To do this, re-
searchers must shift toward collaborative and multidisciplinary studies, which can aid in
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understanding disease interactions and their impact on overall health. Funders should be
more willing to support such studies and be willing to fund riskier innovative research pro-
grammes with potential to benefit the health and wellbeing of millions of people. In addition,
governing bodies and policy makers should be willing to incorporate findings from such stud-
ies and to prioritize both infectious and noninfectious diseases management.
Key learning points
• There is an epidemiological transition in sub-Saharan Africa (SSA), with the insur-
gence of coinfection and comorbidities from both infectious/neglected tropical dis-
eases (NTDs) and noninfectious diseases.
• Health systems in SSA are ill equipped to deal with this in terms of diagnosis, interven-
tion, and long-term care.
• Basic scientific research in SSA must be target oriented, collaborative, and on multiple
disease systems (i.e., horizontal approach) to enhance our understanding of disease
interactions and their impact on overall health and to improve implementation.
• Current success stories or interventions in the management of infectious and NTDs in
SSA can be leveraged for noninfectious diseases, addressing coinfections and
comorbidities.
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However, O2 at levels above physiologi-
cally relevant concentrations can be toxic,
causing elevation of oxidative stress in
cells [11]. Pf evolved to grow and prolifer-
ate in RBCs, and almost immediately after
RBC invasion the parasites start to feed
on haemoglobin, resulting in the genera-
tion of free radicals. In order to counteract
the increased stress response, the para-
site must initiate a complex and well-
orchestrated antioxidant response and
maintain equilibrium throughout the com-
plete asexual life cycle [12]. Trophozoite
and schizont forms, in which high levels of
haemoglobin digestion occur, are con-
stantly required to balance what may be
incremental increases in stress levels
throughout development – perhaps
explaining why trophozoites are more
sensitive to drugs generating oxidative
stress as part of their mode of action in
comparison to young ring forms.
Thus, O2 levels greater than those which
are physiologically relevant to the para-
site may potentially be detrimental, caus-
ing elevation in oxidative stress,
speci!cally regarding the trophozoite
forms. Trophozoites are known to
adhere to endothelial cells in various
blood vessels, tissues, and organs,
and in the case of Pf, spend the majority
of their development within recognized
areas of lower oxygen (1–5%) than in
the lungs and arteries [7]. The phenom-
ena of cytoadherence and sequestration
are well established as mechanisms to
evade the host immune response, and
mechanical removal of the iRBCs by the
spleen. However, another reason may be
to enable this microaerophilic parasite to
elude contact with higher O2 levels pres-
ent in other parts of the blood circulation,
thus, continually protecting itself from
adverse events.
It is our opinion that O2 levels between 1
and 5% are the predominant physiologi-
cal conditions for Pf in vivo, and that O2
levels provided in standard CO2 balanced
incubators (18.6%) do not correlate to in
vivo conditions for trophozoite stages of
the parasite and are therefore likely detri-
mental to parasite growth in vitro. Some
strains of Pf are capable of proliferating
within higher O2 levels in vitro (18.6%), but
the consequences to parasite transcrip-
tomics, proteomics, genomics, and
metabolomics data etc. should be con-
sidered when performing in vitro cultiva-
tion within these conditions.
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diseases (NCDs), characterised by
comorbidities.
African governments and international
development partners have invested signi!-
cant infrastructure, personnel, and health-
deliverysystems for infectiousdiseaseman-
agement and control strategies. To suc-
cessfully deliver UHC, particularly related
to NCDs, African health systems and
research agenda need to leverage infec-
tious disease expertise and resources.
Sub-Saharan Africa (SSA) is at a height-
ened risk of comorbidities from infectious
diseases and a rising prevalence of
NCDs. The growing burden of NCDs,
for example, hypertension, stroke, can-
cer, and diabetes, may be linked directly
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and indirectly to, and further exacerbated
by, infectious diseases, including
neglected tropical diseases (NTDs), which
are prevalent in the region. This epidemi-
ological transition is a ‘time bomb’ for
Africa; the region is expected to record
the world’s largest increase in NCD
deaths by 2030 [1].
Coinfections from various combinations
of infectious diseases are common in
SSA. Common amongst them are HIV,
tuberculosis (TB), and malaria. The
outcome and health impacts of such
coinfections are summarised in Figure 1.
It is becoming apparent that coinfections
in humans can in"uence population-level
disease and mortality patterns. This
impacts on the nature and delivery of
targeted interventions. Furthermore,
infectious diseases have been linked to
the emergence of NCDs, and sometimes
complicate or increase the risk of
acquiring NCDs (Figure 2). The success
and effectiveness of control and research
programmes focusing on infectious
diseases, provide opportunities for
integrating and developing interventions
for coinfections and comorbidities.
UHC for Africa will mean that everyone
can access promotive, preventive,
curative, rehabilitative, and palliative
health services. This will need to be of
appropriate quality to be effective, while
ensuring affordabilityi. African health
systems are built on a model for control-
ling infectious diseases, providing more of
episodic and acute care, with exceptions
for HIV management. Given this founda-
tion, we pose two questions: (i) what
lessons can we learn from infectious
disease-control programmes in Africa,
and (ii) how can we leverage these
lessons, expertise, and resources to
deliver UHC for comorbidities? It is thus
informative to review some successful
infectious disease-control programmes.
HIV and TB
Due to increased access to antiretroviral
therapy and preventive measures, includ-
ing condoms and public health cam-
paigns, AIDS-related deaths are
declining in SSA; in some parts, by up
to 50%ii. However, this progress means
that HIV is now a chronic infection requir-
ing long-term management, with a sub-
stantial increase in the risk of coinfections
and NCDs, including diabetes. TB, for
example, accounts for about a third of
AIDS-related deaths worldwide, with the












HIV/AIDS–hepa!!s B and C virus
infec!on
Treatment failures and increased mortality rates[16–18]
Decreased CD4+ T cell counts even during an!retroviral therapy[21]
High risk of severe symptoms of leishmaniasis[22]
Although small, may increase malaria severity[24]
Undernutri!on[25]
Higher peripheral blood malaria parasite density, promo!ng
transmission[23]
Liver enzyme altera!ons, reduced an!retroviral tolerance and
recovery from therapy[19]
Persistent increase in HIV viral load and increased disease
progression in HIV pa!ents[20]
Figure 1. Detrimental Effects and Health Impacts of Coinfections as Described in Sub-Saharan Africa [16–25].
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such as the integrated HIV/TB therapy are
thus crucial for all people living with HIV
(PLWH). The success of this model is in
the feasibility to setup and maintain. Fur-
thermore, the clincal care for both infec-
tions has been intergrated to be available
from a single provider. This model also
promotes the training of health workers.
Such integrated care can help to reduce
loss to follow-up during patient referrals,
reduce travel costs in and out of hospitals
[2], and ensure judicious use of limited
resources. In many parts of SSA there
is a geographic overlap between HIV/
AIDS, TB, andmalaria, and in such places
most individuals have multiple worm
infections [3]. HIV/TB control measures
can thus be scaled up to include NTD
and NCD control. An example is the Tan-
zania Essential Health Interventions Proj-
ect, which is serving as a framework for
the control of other NTDs. In such proj-
ects, routine checks for possible coinfec-
tions, hypertension, and diabetes are
incorporated into HIV/TB programmes;
thus, PLWH will get a holistic health eval-
uation, ensuring better clinical outcomes.
Mass Drug Administration (MDA)
MDA involves the periodic treatment of a
speci!c population, irrespective of infec-
tion status, where treatment is cheaper
than diagnosis. The majority of infections
from soil-transmitted helminths (STHs),
lymphatic !lariasis, and schistosomiasis
are treated with MDAs, with over 700 mil-
lion treatments given annually. MDAs, ‘a
global best buy’, are a success because
they are cheap, effective, havewide cover-
age, reduce morbidity and infection bur-
den, and can reduce transmission and
enhance global health [4]. Lessons from
the success of MDAs include strong
community-wide sensitization, distribution
in schools/clinics to improve access, and
close supervision of treatment by health
workers, all tailored to infection patterns
of speci!c populations.
Following the geographical overlap
between the major NTDs and NCDs alike,
thealready-workingmodelofMDAscanbe
leveraged for the simultaneous control of
coinfections and comorbidities. For exam-
ple, in some programmes, routine prazi-
quantel treatments for schistosomiasis are
supplemented with the administration of
albendazole (for STHs) and routine screen-
ing of malaria. Although time consuming,
the screening for NCDs, including body
mass index and blood glucose measure-
ments, can be incorporated intoMDA pro-
grammes as they tend to attract multiple
generations within a family. An example is
the inclusion of vitamin A supplementation
in Zimbabwe’s 2017 round of helminth
MDA and the WHO’s MDA of antibiotics
as a strategy to clear trachoma infection
and reduce transmission in endemic com-
munities. A recent trial on using broad-
spectrum antibiotics to promote child
health showed that an MDA with azithro-
mycin reduced child mortality. Caution is
however suggested with this approach
dueto thepotentialof facilitating thespread
of antibiotic resistance [5].
Expanded Programme on
Immunisation (EPI) and Global
Polio Eradication Initiative (GPEI)
The EPI, !rst introduced in 1976, was to
make vaccines against the six main child-
hood killer diseases available to every
child, as part of achieving health for all
by the year 2000. Following the eradica-
tion of smallpox, the GPEI was estab-
lished as part of national immunisation
days, which have seen a reduction in polio
cases by over 99%iii. As of 2016, only
Afghanistan, Nigeria, and Pakistan remain
with ongoing transmissioniv. The GPEI’s
main highlights for success are the in"u-
ence of organisational partnership,
Human papilloma virus
Borrelia burgdorferi
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Figure 2. Noncommunicable Diseases and Their Infectious Disease Links or Causes [26,27].
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national leadership, and strong commu-
nity engagement. This shows that well-
planned interventions can reach the most
remote, con"ict-affected, or poorest
areas.
The successes and infrastructure of
immunisation programmes can be lever-
aged for the control of infectious diseases
and NCDs by linking them with other
interventions, ensuring that they are well
coordinated. Due its simplicity, many
countries have also linked deworming
with routine vaccination schedules to
improve coverage. Routine screening of
other infections, including HIV and
malaria, provide opportunities for early
infant diagnosis and overall child health.
Immunisation has also provided the ave-
nue for the distribution of impregnated
bed nets, as well as access to community
members for educational campaigns on
behavioural change for infectious dis-
eases and vector control. Highlighting
the link between infectious diseases
and NCDs, EPIs with concomitant
screening and treatment of other infec-
tious diseases have the potential to pro-
tect the larger population from both
infectious diseases and NCDs.
Research Questions
To leverage these success stories to
deliver UHC for coinfections and comor-
bidities in Africa, knowledge gaps in key
areas need to be addressed. Below, we
explore these areas and the importance
of leveraging lessons from infectious dis-
ease control.
Diagnosis
In Africa, most health systems lack basic
diagnostic tests to explain clinical symp-
toms, and there are challenges with qual-
ity control, reproducibility, and national
laboratory guidelines. A signi!cant num-
ber of diagnostic tests currently available
have been developed and validated in the
West, without appropriate validation in
Africa. For example, in a Zimbabwean
population with a high prevalence of hel-
minths, there is a falsely low prevalence of
allergies, as routine allergy diagnosis is
impaired by IgE antibodies to the carbo-
hydrate epitope galactose-a-Gal,
induced by the parasite infection [6].
The sensitivity of conventional egg-detec-
tion methods for helminth diagnosis is
reduced in light/prepatent infections,
underestimating infection rates [7]. There-
fore, tests must be sensitive, speci!c,
user-friendly, and applicable in
resource-limited settings. This is vital for
accurately quantifying disease burden
and epidemiology, informing policy, and
creating health systems geared towards
the needs of Africa.
Appropriate diagnosis will not only help
to identify those who need treatment, but
also prevent over- or under-treatment,
which lead to drug inef!cacies; for exam-
ple, resistance to treatment of malaria
with chloroquine. New technology must
be informed by social and cultural con-
texts which may hinder the acceptance
and widespread use of diagnostics. A
working example is where health experts
!nd and track outbreaks, routine dis-
eases, and genetic risk of diseases, by
combining the locally accepted verbal
autopsies with minimally invasive
autopsy, in conjunction with cheap nee-
dle sampling methods [8]. Diagnosis
informs contextualised interventions,
and necessitates customisation for spe-
ci!c populations; for example, develop-
ing speci!c reference ranges for the
African population. For example, in HIV
management, initiation of antiretroviral
therapy is informed by CD4 cell counts
and inappropriate standard values will
mean inappropriate interventions [9]. A
gap currently exists in multiplex diagnos-
tic platforms that can be used at point of
care. It is noteworthy that several disease
biomarkers are detected in urine and
sera, so developing platforms that can
detect pathogen and physiological
markers concurrently in a single sample
will signi!cantly strengthen African health
systems.
Interventions: Integrated Approach
Interventions must be targeted, informed
by knowing the desired outcome and
what tools are required/available to
achieve this. The vertical approach of
most interventions targeted against spe-
ci!c diseases should be modi!ed into a
horizontal approach to bene!t other con-
ditions. In the Solomon Islands, ivermec-
tin has been used in scabies control
programmes to reduce secondary strep-
tococcal skin infections and renal disease
[10]. Solutions targeting multiple condi-
tions are receiving increased attention.
These include water, sanitation, and
hygiene strategies targeting better growth
outcomes in children [11], and integrated
interventions delivered concurrently in
health systems, homes, and communities
to improve breastfeeding practices for
overall child health [12]. More studies
demonstrating the positive health impact
of integrated approaches are required,
particularly where health budgets are
already stretched.
Drugs and Drug–Drug Interactions
In the face of coinfections, multiple drugs
for multiple conditions are inevitable,
necessitating the need to consider
drug–drug interactions. In patients coin-
fected with HIV and TB, a lopinavir/rito-
navir combination in HIV therapy has
been found to signi!cantly increase the
exposure and toxicity of bedaquiline,
used during TB treatment [13]. In multi-
parasitic interventions, coadministration
of praziquantel along with albendazole
may affect the total exposure of alben-
dazole [14]. Very few drugs used in Africa
have been evaluated in African popula-
tions in terms of drug–drug interaction
and pharmacogenetics. The advent of
African-speci!c molecular tools, for
example, an African-speci!c genome-
wide association studies (GWAS) array,
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will facilitate the study of genetic factors
involved in disease susceptibility and
drug responsesv. Phase IV clinical trials
will inform African health systems of
appropriate drug coprescription.
Concluding Remarks
In the face of this epidemiological transi-
tion, a vehicle for delivering UHC in Africa
will be the adaptation of an alternative,
"exible, and horizontal disease network
approach to diagnosis and management.
Current successful intervention programs
for infectious diseases that require
community mobilisation and engage-
ment, behavioural change, long-term
adherence to treatment and monitoring
have already laid the foundation for
coinfection/comorbidity management in
resource-poor settings. The increased
involvement of community-based health
workers, new technology at primary
health centres coupled with the
widespread availability of cell phones
and social media in Africa, must be
harnessed for disease screening, training,
and supervision. Arti!cial intelligence
technology, already being used for some
infectious disease programs in Africa, will
enhance human expertise/capacity in the
diagnosis and management of coinfec-
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ARTICLE
The gut microbiome but not the resistome is
associated with urogenital schistosomiasis in
preschool-aged children
Derick N.M. Osakunor 1!, Patrick Munk 2, Taka!ra Mduluza3, Thomas N. Petersen2, Christian Brinch2,
Alasdair Ivens1, Theresa Chimponda3, Seth A. Amanfo4,5, Janice Murray1,5, Mark E.J. Woolhouse 4,5,
Frank M. Aarestrup 2 & Francisca Mutapi1,5
Helminth parasites have been shown to have systemic effects in the host. Using shotgun
metagenomic sequencing, we characterise the gut microbiome and resistome of 113 Zim-
babwean preschool-aged children (1–5 years). We test the hypothesis that infection with the
human helminth parasite, Schistosoma haematobium, is associated with changes in gut
microbial and antimicrobial resistance gene abundance/diversity. Here, we show that bac-
teria phyla Bacteroidetes, Firmicutes, Proteobacteria, and fungi phyla Ascomycota, Microsporidia,
Zoopagomycota dominate the microbiome. The abundance of Proteobacteria, Ascomycota, and
Basidiomycota differ between schistosome-infected versus uninfected children. Speci!cally,
infection is associated with increases in Pseudomonas, Stenotrophomonas, Derxia, Thalassospira,
Aspergillus, Tricholoma, and Periglandula, with a decrease in Azospirillum. We !nd 262 AMR
genes, from 12 functional drug classes, but no association with individual-speci!c data. To our
knowledge, we describe a novel metagenomic dataset of Zimbabwean preschool-aged chil-
dren, indicating an association between urogenital schistosome infection and changes in the
gut microbiome.
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The human gut comprises a diverse ecosystem of microbes,predominantly bacteria, in addition to viruses, fungi andother eukaryotes1. Evidence shows that humans rely on the
symbiotic relationship with the resident microbial taxa present in
humans (microbiota) for extracting essential nutrients from food,
as a !rst line of protection from pathogens, and as a mechanism
for shaping the immune system2. Shotgun metagenomic
sequencing has allowed characterisation of the microbiome (the
assembly of genomes of the microbiota) among different human
populations, showing considerable heterogeneity2,3. Populations
in Africa have been underrepresented in such studies, with a
major focus on Western populations4. Other studies have inclu-
ded diverse but older populations, not allowing the factors
inherent to African childhood to be fully disentangled5–8. Given
the potential window of opportunity for in"uencing health
through the microbiome in infants and young children9, research
focus on this age group is important. Findings from consortiums
including the Human Heredity and Health in Africa (H3 Africa)
and the HapMap Project will be invaluable for informing
nutraceuticals in Africa10,11.
The composition of the gut microbiome is in"uenced by
age8,12, diet and geography5,13,14, host genotype15, exposure to
maternal microbiota16, as well as environmental factors17
including the role of protozoal and helminth parasites18. In
Africa, children are exposed to several acute and chronic parasitic
infections that can impact children’s growth and development19.
In particular, helminth parasites (as shown for schistosome
worms) can be contracted by children as young as 6-month-old
or less20,21, and these can persist into the second decade of life
where they modulate the immune system as well as cause mor-
bidity and pathology22. In very young children, the gut microbial
population continues to evolve until about age 3–5 years8,12, thus
it is important to establish how external factors, especially
infections, that young children are exposed to, in"uence the
microbiome.
Schistosomiasis is a disease caused by infection with trema-
todes of the genus Schistosoma—the predominant human species
found in Africa being the urogenital (S. haematobium) and
intestinal (S. mansoni) forms23. Pathology from the disease is
mostly from immunological reactions to trapped eggs attempting
to migrate through to the bladder or intestinal lumen, depending
on the species involved. The infection causes immunomodulatory
effects which help to promote both parasite and host survival24,25,
and in preschool-aged children, consequences can extend to
malnutrition, poor growth and cognition, reduced vaccine ef!-
cacy, and altered prognosis of co-infections26,27. Treatment for
schistosomiasis is through administration of the antihelminthic
drug, praziquantel, which is effective against all schistosome
species28.
A number of experimental and human studies, including our
own, have examined the association between helminth infections
and the structure and composition of the gut microbiome29–35. It
has been suggested that the immunomodulatory effects of schis-
tosome infection can extend to the gut microbiota through direct
intestinal or systemic interactions18. Work in experimental
models shows that depletion of the gut bacteria is associated with
reduced S. mansoni egg excretion, gut pathology and in"amma-
tion32. Recently, "uctuations in the composition of the gut
microbiota of mice infected with S. mansoni, before and after
intestinal damage from egg transmission was shown36. This is
consistent with a role of the mammalian gut microbiota in the
pathogenesis of schistosome infection. However, unlike S. man-
soni (intestinal form) that inhabits the same environment as the
gut microbiota, S. haematobium predominantly resides in
the venous plexus of the bladder (although occasionally in the
mesenteric circulation37), and thus presents a need to study the
indirect systemic impacts of infection on the gut microbiota—a
more likely interaction. Correlations between the gut microbiome
and systemic diseases such as rheumatoid arthritis suggest the
importance of such systemic interactions38. Phenotypic and
mechanistic studies on systemic interactions between helminths
and the microbiome in natural human infections are still in their
infancy, and more studies are needed. In a previous study, we
found differences in the gut microbiome between S. haematobium
infected versus uninfected children, aged up to 13 years old35.
This was supported by Schneeberger et al.34, suggesting that
genetic and environmental factors may play an additional role.
Recently, a study conducted among older children (11–15 years)
in Nigeria showed that urogenital schistosomiasis is associated
with disruptions in the gut microbiome, suggesting that this may
be a further consequence of schistosome infection39. However,
substantial knowledge gaps on the interaction between the gut
microbiome and Schistosoma infection in preschool-aged children
still exist. The biggest challenges are demonstrating causation and
elucidating mechanistic pathways for any existing interactions.
In addition to the schistosome–microbiota interactions, other
interactions relevant to the health of the host have also been
reported to occur within the gut ecosystem. One such example is
the ability of Salmonella to persist in the body by attaching to
intestinal schistosomes, evading repeated antibiotic treatments,
increasing the Salmonella population and eventually, potential
antibiotic resistance40,41. Furthermore, the microbiome is a reser-
voir for antimicrobial resistance (AMR) genes (resistome)42,43, and
provides an ideal environment for AMR gene exchange among the
“resident” and transitory bacterial population44. Such interactions
are likely to impact the structure and diversity of the resident
microbial population, as well as the overall AMR gene composition.
We therefore investigated the structure of AMR genes to bacteria
and determined if this was associated with any host-related factors
including socio-demography, antibiotic use, current schistosome
infection, as well as feeding, growth and nutritional indices. AMR
remains one of the largest threats to human health, with numerous
calls for antibiotic resistance stewardship worldwide42,45,46. How-
ever, this population of African preschool-aged children is under-
studied, and almost all AMR gene studies are conducted in
industrialised settings43,47–50. Such settings contrast with low-and
middle-income countries in terms of access to safe water and
sanitation, and access to antibiotics, with or without prescriptions51.
Within the framework of a larger paediatric schistosomiasis
study in Zimbabwe, the present study focuses on shotgun meta-
genomic sequencing of stool samples from preschool-aged chil-
dren, aged 1–5 years old. To add to the repository of information
on the gut microbiome and AMR studies in this young popula-
tion, we characterise the structure and diversity of the gut
microbiome (to include the fungi repertoire) and resistome. We
apply these data to test the hypothesis that S. haematobium
infection is associated with alterations in the gut microbial and
AMR gene abundance and diversity. We !nd that the micro-
biome but not the resistome is associated with S. haematobium
infection, independent of age, sex and village.
Results
Population characteristics. Of the 113 participants included in
the study, the mean age was 3.7 ± 1.1 years, of which 56 were
females (49.6%). Sixty-eight (60.2%) and 45 (39.8%) children
were from Chihuri and Mupfure villages, respectively. Anti-
microbial use data showed that 58 (51.3%) participants had
received antibiotics [amoxicillin (31), co-trimoxazole (27), both
(9)], while 18 (15.9%) had not; no information was obtained for
the remaining 37 (32.7%) participants. Previous history of pra-
ziquantel treatment (for schistosome infection) was reported
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among 29/105 (27.6%) children. S. haematobium infection pre-
valence was 15.9% (18/113), with mean infection intensity of 1.79
eggs/10 ml urine (SEM= 0.76; range= 0–74).
We gathered data on the history of feeding habits and
nutritional status of the children. The majority (83.6%) were
breastfed, with duration ranging from 2 to 48 months (median=
18 months IQR: 17–20). Children were introduced to solid foods
between 1 and 24 months after birth. Diet comprised mainly of
traditional maize "our porridges (97%; 96/103), the commercial
Cerelac® porridge (1.9%; 2/103), and potatoes (1%; 1/103).
Anthropometric measures, adjusted for age, were used to assess
nutritional status27. Based on the weight-for-height Z scores
(WHZ), 3.7% (4/107) of individuals were malnourished and
14.7% (16/109) were stunted, based on the height-for-age Z scores
(HAZ)52.
Taxonomic composition of the microbiome. The number of
classi!ed read pairs per sample ranged from 3,994,704 to
13,164,482. An average 45.1% of read pairs were mapped to
speci!c reference sequences in the genomic database; this is
similar to other studies with the proportion of unmapped reads
ranging from 42% to 68%53–55. At any taxonomic level, a putative
taxonomic classi!cation could not be assigned to at least 33% of
the mapped read pairs and were thus classi!ed as “Unknown”.
In the 113 stool samples, 845 bacteria genera (from 20 unique
phyla) and 228 fungi genera (from six unique phyla) were detected.
As shown in Fig. 1, the most abundant bacteria phyla in decreasing
order were Bacteroidetes (genera: Prevotella, Bacteroides, Alistipes),
Firmicutes (genera: Eubacterium, Faecalibacterium, Clostridium,
Roseburia), and Proteobacteria (genus: Succinatimonas). The most
abundant fungi phyla were Ascomycota (genera: Protomyces,
Aspergillus, Taphrina, Saccharomyces, Candida, Nakaseomyces),
Microsporidia (genus: Enterocytozoon), and Zoopagomycota (genus:
Entomophthora) [Fig. 2]. These phyla dominated the microbiome
and were present in all samples.
Variation in the microbiome and association with sample
metadata. Principal component analysis (PCA) was used to
initially examine variability and patterns in the data set across the
!rst two principal components. At the phylum level, PCA
explained 62% and 42.0% of the total variation in fungi and
bacteria, respectively. At the genus level, however, PCA explained
34% and 16% of the total variation in fungi and bacteria
respectively. The model showed homogeneity in components
with no distinct clustering according to metadata and may re"ect
a high diversity in the cohort. PCA plots and cluster dendrograms
for bacteria and fungi content per sample is shown in Supple-
mentary Figs. 1–3.
Permutational multivariate analysis of variance (PERMA-
NOVA) analysis showed a signi!cant effect of age (false discovery
rate (FDR)= 0.024) and village (FDR= 0.039) [details shown in
Supplementary Fig. 4], schistosome infection status (FDR=
0.039) and schistosome infection intensity (FDR= 0.012) on
bacteria genera, across samples. There was also a signi!cant effect
of schistosome infection status (FDR= 0.006) and schistosome
infection intensity (FDR= 0.006) on fungi genera, across the
samples. For both bacteria and fungi genera, no such effects were
found for sex, nutritional and growth variables, feeding, previous
Fig. 1 Overview of bacterial microbiota abundance and composition. From read mapping to the genomic database, abundance was calculated for each
microbial taxa across all samples. Stacked bar charts show the most abundant bacteria (a) phyla and (b) genera per sample, proportional to the total
microbiota within each sample (n= 113 biologically independent samples). Charts were generated using normalised, zero-corrected abundance matrices.
“Unknown” represents abundance data for which a putative taxonomic classi!cation could not be assigned. “-Others” represents abundance data for all
other taxa in the abundance data set.
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praziquantel treatment, and antibiotic use (FDR > 0.05). Sum-
mary output from the analysis is shown in Table 1.
Different genera by schistosome infection status and intensity.
We investigated further, via analysis of composition of micro-
biomes (ANCOM), how speci!c bacteria and fungi genera were
associated with S. haematobium infection, while controlling for
age, sex and village, followed by evaluation for association with
infection intensity. In total, eight genera were identi!ed, !ve from
bacteria (Pseudomonas: W= 347, Azospirillum: W= 346, Steno-
trophomonas: W= 292, Derxia: W= 288, and Thalassospira:
W= 292) and three from fungi (Aspergillus: W= 75, Tricholoma:
W= 73 and Periglandula: W= 70). The magnitude of these
changes were shown by plotting the abundance of each sample to
highlight differences between groups. In schistosome-positive
children, the abundance of all but Azospirillum was higher
(Fig. 3a–e). This observation was consistent with infection
intensity [Pseudomonas (r= 0.3; p= 0.001), Stenotrophomonas
(r= 0.4; p < 0.001), Derxia (r= 0.6; p < 0.001), Thalassospira (r=
0.6; p < 0.001) and Azospirillum (r=!0.4; p < 0.001)] as shown in
Fig. 3f–j. Likewise, the abundance of Aspergillus, Tricholoma, and
Periglandula was higher in schistosome-positive children
(Fig. 4a–c) and was consistent with infection intensity as shown
in Fig. 4d–f [Aspergillus (r= 0.5; p < 0.001), Tricholoma (r= 0.5;
p < 0.001), and Periglandula (r= 0.4; p < 0.001)].
AMR gene characterisation. An average 0.06% of read pairs were
mapped to AMR genes in the ResFinder database. We found
evidence of 262 AMR genes, belonging to 12 functional drug class
levels. AMR genes belonging to tetracycline was the most
common, followed by beta-lactam, macrolide, sulfonamide and
nitroimidazole. Of these, the most abundant genes were cfxA6,
followed by tet(Q), tet(W), sul2, erm(F) and nimE (Fig. 5).
Variation in the resistome and association with sample meta-
data. PCA was used to initially examine variability and to identify
clustering according to individual metadata. The model for the
!rst two components explained 18.0% and 48.0% of the total
variability in AMR genes and drug classes respectively. Similarly,
there was no clustering according to individual metadata,
re"ecting high cohort diversity and the role of other factors in
in"uencing the resistome. PCA plots and cluster dendrograms of
AMR genes and their drug classes per sample is shown in Sup-
plementary Figs. 5–6.
PERMANOVA analysis did not show any signi!cant associa-
tion of AMR genes with age, village, sex, feeding, malnutrition,
stunting, S. haematobium infection, previous praziquantel treat-
ment and antibiotic use on AMR genes. Model summaries of
sample metadata and association with AMR genes is shown in
Supplementary Data 2.
Discussion
Using shotgun metagenomic sequencing, we characterised the
structure and composition of the human gut microbiome and
resistome in this Zimbabwean preschool population (!5 years
old). Age8,12, dietary and environmental patterns5,13,17, ethnicity,
and geography14,56 have a substantial impact on the taxonomic
composition of the microbiome. Prevotella and Candida57,58 have
been associated with carbohydrate-rich diets, and Bacteroides
with protein-rich diets57. This is a re"ection of the dietary lifestyle
Fig. 2 Overview of fungal microbiota abundance and composition. From read mapping to the genomic database, abundance was calculated for each
microbial taxa across all samples. Stacked bar charts show the most abundant fungi (a) phyla and (b) genera per sample, proportional to the total
microbiota within each sample (n= 113 biologically independent samples). Charts were generated using normalised, zero-corrected abundance matrices.
“-Others” represents abundance data for all other taxa in the abundance data set.
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among populations in developing countries5,17, including
infants59, and these genera were among the most abundant
bacteria and fungi genera found in the current study population.
Similar to our previous !ndings35, we found age but not sex-
related associations in bacteria genus diversity. Given that the
population in the current study were !5 years old, this is
consistent with the microbiome being more dynamic in the early
years of life before stabilising to a more adult-like state8,12.
Differences observed in the microbiome between developi-
ng and developed countries have been attributed to factors
inherent to such developing areas5, which may include the role of
persistent prevalence of helminth infections, as reviewed by
Table 1 Model summaries of sample metadata and association with the gut microbiome.
Variable n Bacteria Fungi
p value SSExplain SSTotal FDR p value SSExplain SSTotal FDR
Age (years) 113 0.004 1344.6 82733.4 0.024 0.082 128.6 9489.2 0.197
Sex 113 0.172 878.1 83200.0 0.258 0.439 82.8 9534.9 0.671
Village 113 0.012 1254.0 82824.0 0.039 0.060 140.4 9477.4 0.180
S.h. infection status (pos/
neg)
113 0.013 1185.1 82892.9 0.039 0.001 339.0 9278.7 0.006
S.h. infection intensity 113 0.001 1514.5 82563.6 0.012 0.001 670.1 8947.7 0.006
Malnourished, yes/
no (WHZ)
107 0.866 589.1 78498.2 0.913 0.830 59.5 9145.6 0.830
Stunted, yes/no (HAZ) 109 0.407 754.6 79751.0 0.542 0.611 71.5 9227.2 0.671
Months breastfed 90 0.082 954.9 64235.8 0.140 0.470 75.2 6985.0 0.671
Months solid food
introduced
102 0.913 573.1 75583.0 0.913 0.615 73.5 8792.0 0.671
Previous praziquantel
treatment
105 0.071 991.9 77387.4 0.140 0.233 101.6 8934.5 0.466
Amoxicillin (yes/no) 76 0.771 646.6 55603.4 0.913 0.531 78.4 6567.3 0.671
Co-trimoxazole (yes/no) 76 0.030 1083.6 55166.4 0.072 0.048 158.3 6487.4 0.180
The table represents PERMANOVA output for bacteria and fungi genera. Classi!cation of nutritional status was based on a cut off <!2 Z scores52. Schistosome infection intensity was log transformed
(log10 [egg count + 1]). S.h. S. haematobium, WHA weight-for height Z scores, HAZ height-for-age Z scores, pos/neg positive/negative, p value unadjusted p value, FDR adjusted p value (FDR-corrected),








Pseudomonas Stenotrophomonas Derxia ThalassospiraAzospirillum















































































































































































































































































































































































































































































































































































0 10 0 1 0 1 0 1
a b c d e
[log10(egg count+1)]
Infection intensity 
0.0 0.5 1.0 1.5 2.0
[log10(egg count+1)]
Infection intensity 
0.0 0.5 1.0 1.5 2.0
[log10(egg count+1)]
Infection intensity 
0.0 0.5 1.0 1.5 2.0
[log10(egg count+1)]
Infection intensity 
0.0 0.5 1.0 1.5 2.0
[log10(egg count+1)]
Infection intensity 
Fig. 3 Different bacteria genera between schistosome-infected children compared to uninfected children. (a–e) Box plots showing the abundance of
speci!c bacteria genera, grouped by S. haematobium infection status. The horizontal box lines represent the !rst quartile, the median, and the third quartile.
Whiskers denote the range of points within the !rst quartile !1.5! the interquartile range and the third quartile +1.5! the interquartile range. (f–j) Scatter
plots showing linear regression analysis of S. haematobium infection intensity and bacteria genera abundance. The clr-transformed abundance data were
used for all plots. Infection status was coded as 0 and 1 for negative (n= 95) and positive (n= 18), respectively. S. haematobium infection intensity was log
transformed [log10 (egg count+ 1)]. Shaded areas indicate the 95% con!dence intervals.
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Mishra et al.18. Our !ndings are consistent with observations that
schistosome infection is associated with alterations in the diver-
sity and abundance of speci!c taxonomic groups in the
microbiome34,35. In the aforementioned studies, which included
preschool and school-aged children, 16S rRNA sequencing
showed that Prevotella and Proteobacteria were more abundant in
children infected with S. haematobium35 and S. mansoni34
respectively, when compared to uninfected children. To the best
of our knowledge, the novelty of the current study is the fact that
this population is much younger (!5 years old), an age group
whose gut microbiome structure is most likely still being estab-
lished. Our study thus provides an important insight into hel-
minth infection and its association with changes during the
establishment of the gut microbiome in preschool-aged children
in endemic areas. We also expand on this to include the fungal
component of the microbiome. More relevant to our !nding is
that this association was independent of age, sex and village.
Phyla that clearly differentiated the microbiome of the
schistosome-infected versus uninfected children were Proteo-
bacteria, Ascomycota and Basidiomycota. These were among the
top !ve most abundant bacteria or fungi phyla and were present
in all samples, thus make a major contribution to the overall
microbiome composition. Proteobacteria has been shown to be
present in lower abundances in healthy individuals, and any
increases in abundance of members of this phylum con!rm dys-
biosis and a link with increased disease risk, progression and
burden60. Attempts have been made to expand the body of
knowledge on the fungi repertoire and diversity in the human
microbiome61 and their association with infection and disease62–64.
Studies have suggested that gut fungal populations directly or
indirectly help to maintain healthy intestinal homoeostasis and that
dysbiosis has immunological consequences65. Increases in speci!c
fungi populations such as Aspergillus have been associated with
increased eosinophil levels66 and an exaggerated Th2 response65,
also characteristic of schistosome infection, which may explain our
observation of the association of schistosome infection with speci!c
fungal populations (Aspergillus, Tricholoma and Periglandula).
However, whether our observation was due to primary changes in
the fungal population or were secondary to changes in the bacterial
population is unclear. To the best of our knowledge, this is the !rst
study to examine such an association and further studies into the
role of fungal dysbiosis in schistosome infection are warranted.
Although we cannot infer causation, we are able to determine
that for the genera differentiating the microbiome of the
schistosome-infected versus uninfected children, there was a
positive relationship between microbial abundance and schisto-
some infection intensity. Hence, it is possible that schistosome
infection resulted in alterations in the gut microbiome. However
as S. haematobium worms mostly reside in the pelvic venous
plexus (although some have occasionally been detected in the
intestine in Egyptian autopsies37), the effect of infection on the
diversity of the microbiota is as suggested for intestinal hel-
minths33, but most likely through a more indirect or systemic
route than through direct interactions18. Mishra et al.18 have
suggested that the immunomodulatory effects of helminths can
extend to the gut microbiota through both direct intestinal
interactions and systemic interactions. For example, by enhancing
the mucosal barrier, tissue repair, production of antimicrobial
peptides and reducing dissemination of microbiota to the spleen
and liver18, the upregulation of IL-22 during helminth infection
may favour the abundance of speci!c microbial taxa67.
We identi!ed 262 AMR genes, most of which encoded
for resistance to tetracycline, beta-lactam, macrolide and sulfo-
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Fig. 4 Different fungi genera between schistosome-infected children compared to uninfected children. (a–c) Box plots showing the mean abundance of
speci!c fungi genera, grouped by S. haematobium infection status. The horizontal box lines represent the !rst quartile, the median and the third quartile.
Whiskers denote the range of points within the !rst quartile !1.5! the interquartile range and the third quartile +1.5! the interquartile range. (d–f) Scatter
plots showing linear regression analysis of S. haematobium infection intensity and fungi genera abundance. The clr-transformed abundance data were used
for all plots. Infection status was coded as 0 and 1 for negative (n= 95) and positive (n= 18), respectively. S. haematobium infection intensity was log
transformed [log10 (egg count+ 1)]. Shaded areas indicate the 95% con!dence intervals.
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including urinary, enteric and respiratory infections68. It is thus
not surprising that the data on antimicrobial use for the current
study showed predominantly amoxicillin (beta-lactam) and co-
trimoxazole (sulfonamide) use in the children. In addition, cef-
triaxone and benzylpenicillin (both beta-lactams) and co-
trimoxazole are among the most commonly used antibiotics in
Zimbabwe69.
Increased antimicrobial use impacts the gut microbiota70,71
and is selective for AMR in populations72,73. The limited
association of the obtainable antimicrobial use data with
both the microbiome and resistome in the current study might
be surprising. However, a study by Dethlefsen et al.70 showed
that a majority of the bacterial community that was depleted
post-cipro"oxacin administration was restored after 4 weeks.
Our antimicrobial use data were limited to antibiotic use
within the immediate 6 months prior to sampling and was less
heterogeneous, thus any marked differences in the microbiota
may have been missed. Our !ndings are consistent with those
from recent studies on global sewage samples, which have
shown a much stronger association between socio-econo-
mic factors related to health, sanitation and education with
the resistome, compared to antimicrobial use55,74. This seems
more likely to be the case in low- and middle-income count-
ries, where a high contagion––the spread of resistant strains
and genes––between individuals may take place, and any
antimicrobial use in one individual may have general effects
on the population as a whole75. Thus, antimicrobial use
explains some, but not all variation in AMR genes in this
population72,73, and improving such socio-economic factors
may improve AMR.
Our study had a few limitations. The cross-sectional study
design allowed characterisation of the gut microbiome and its
relationship with S. haematobium infection at a single time point.
A longitudinal study will inform on the dynamic relationship
between the two, as well as the time course or developmental-
related trends in the observed pro!les. A longitudinal study
would also give an indication of the dynamic features of the AMR
genes and how they are associated with individual-speci!c data.
Furthermore, relating the presence of AMR genes to measurable
phenotypic resistance of bacteria would give a stronger indication
of the clinical implications of the AMR genes present.
In conclusion, we characterised, through shotgun metagenomic
sequencing, the microbiome (to include the fungi repertoire) and
resistome in a preschool population (!5 years old) in Zimbabwe.
We identi!ed differences in the gut microbiome between schis-
tosome infected and uninfected children, showing largely an
increase in abundance of speci!c bacteria, and for the !rst time
(to our knowledge), fungi genera in infected children. This
association was independent of age, sex and village. Mechanistic
studies are required to further explain this relationship. To the
best of our knowledge, we also characterised for the !rst time in
this African preschool population, a diversity of AMR genes to
bacteria, belonging to various functional drug classes. Our
microbiome and resistome data add to publicly available data
from different human populations.
Methods
Ethical approval and consent. The current study is part of a larger paediatric
schistosomiasis study, for which ethical and institutional approval was obtained
from the Medical Research Council of Zimbabwe (MRCZ/A/1964) and the
Fig. 5 Overview of antimicrobial resistance (AMR) gene abundance and composition. From read mapping to the ResFinder database, AMR abundance
was calculated for each reference gene across all samples. Stacked bar charts show the most abundant (a) AMR gene and (b) drug class per sample,
proportional to the total AMR within each sample (n= 113 biologically independent samples). Charts were generated using gene length-normalised, zero-
corrected abundance. “-Other” represents abundance data for all other AMR genes or drug classes in the abundance data set.
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University of Edinburgh (fmutapi-0002), respectively. Permission to conduct the
study was obtained from the Mashonaland Central Provincial Medical Director.
The study aims and procedures were explained to all participants and their parents/
guardians in their local language, Shona. Written informed consent was obtained
from the participants’ parents/guardians and recruitment was voluntary with
participants free to withdraw from the study at any stage. For the current study,
only samples from participants who consented to be part of this sub-study
were used.
Study design, population and site. This cross-sectional study forms part of the
baseline survey of a larger study on paediatric schistosomiasis conducted in the
Shamva district, Northeast Zimbabwe, to compare the health bene!ts of early treat-
ment of schistosome infections in preschool-aged children, 6 months to 5 years old27.
In brief, children within this age group who were lifelong residents, and with no
history of tuberculosis, malaria/fever, or recent major illness/surgery were invited to
participate in the baseline survey and onward recruitment into the main cohort, if
they met further criteria of being negative for S. haematobium by egg count and had
no history of antihelminthic treatment. The study followed two groups of
schistosome-negative children for new infections and then compared re-infection
rates across two different regimens, following treatment of !rst schistosome infection.
For the current study, a subset of 116 stool samples (from 1–5 year olds) were
selected from the baseline survey for microbiome analysis. To be recruited as part
of this subset, participants had to consent for their stool samples to be used as part
of the current study. A questionnaire was administered at the time of recruitment
to gather metadata on socio-demography, growth and nutrition, and clinical
history. Clinical records were checked to obtain history of antibiotic use, within the
6 months preceding acquisition of stool samples. Parents/carers were also
interviewed to ascertain the health history of the children, and those who had any
such history were excluded. Children were tested via parasitological diagnosis for S.
mansoni and soil-transmitted helminths (STH) as part of the baseline survey and
none who were positive were included in the subset of 116 children in the current
study. The subset of children was thus selected based on (a) consent for
microbiome analysis, (b) availability of socio-demographic data, (c) availability of
parasitology samples (urine and stool samples), (d) availability of test results and
clinical history and (e) no current episode of diarrhoea (assessed by questionnaire
and visual stool examination).
Samples included in the current study were from two main sites, Mupfure and
Chihuri. The sites are located in the Mashonaland Central province, with 123,650
people living in a 99% rural area of 2695 km!, according to the 2012 national
census76. The inhabitants are primarily subsistence farmers. The area has a high
prevalence of S. haematobium (>50%) with low prevalence of S. mansoni and STH
(<15%)77, making it ideal for studies on the impacts of urogenital schistosomiasis.
Sample size. The samples used in the current study are from the baseline survey of
a larger epidemiological study comparing re-infection rates across two different
treatment regimens. As this is a relatively new !eld in human helminthology, there
are limited published studies, with none focusing on the age group in the current
study, i.e. 1–5 year olds. Thus there were no published baseline data to inform
sample size calculations when we conducted our study. The sample size for the
current study was informed by our previous study35 and those of others34,39 in
older children with sample sizes ranging from 34–139, from which statistically
signi!cant differences were detected in the microbiome of schistosome infected
versus uninfected children.
Sample collection, processing and DNA extraction. Urine and stool specimens
were collected for parasitological diagnosis of S. haematobium and intestinal hel-
minths, respectively. In summary, about 50 ml of urine sample was collected on
three successive days, and a single stool sample was collected on a single day from
each participant. Urine bags (Hollister 7511 U-Bag Urine Specimen Collector,
Hollister Inc., Chicago, IL, USA) and disposable diapers (for stool samples) were
used for sample collection in very young children. Urine samples were examined
microscopically for S. haematobium infection following the standard urine !ltra-
tion method78, and stool samples examined microscopically using the Kato–Katz
method79, to exclude S. mansoni and STH (for at least one parasite egg detected).
Infection intensity for S. haematobium was de!ned as the arithmetic mean egg
count/10 ml of at least two urine samples collected on three consecutive days. All
children who were positive for schistosome infection were treated with a single
dose of praziquantel at the standard 40 mg/kg body weight, crushed and admi-
nistered with squash and sliced bread28 by local nurses.
Aliquots of stool samples in 2ml cryotubes were stored temporarily at 2–8 °C for a
maximum of 24 h prior to processing. For each stool sample, DNA was extracted
using the QIAamp DNA Stool Mini Kit (QIAGEN) according to the manufacturer’s
instructions. To ensure sample aliquots contained puri!ed DNA, each sample was
quanti!ed in-house at the University of Edinburgh using the Qubit "uorometer
(ThermoFisher Scienti!c) prior to shipment for DNA sequencing.
Library preparation and sequencing. DNA samples were shipped on dry ice for
library preparation and sequencing at the Beijing Genomics Institute (BGI,
Shenzhen, China). At BGI, DNA from the stool samples was quanti!ed using the
Qubit "uorometer (ThermoFisher Scienti!c) and the NanoDropTM spectro-
photometer (ThermoFisher Scienti!c). As a quality control measure, the integrity
and purity of DNA was assessed by a 1% agarose gel electrophoresis, run at 150 V
for 40 min; DNA was sheared by ultrasonication into fragments (Covaris). Frag-
ments were mixed with End Repair mix (BGI) and puri!ed using the QIAquick
PCR Puri!cation Kit (Qiagen). Adapter-ligated DNA fragments were separated by
electrophoresis through a 2% agarose gel to recover the target fragments, and
puri!ed using the QIAquick Gel Extraction kit (Qiagen). Library preparation to
enrich the adapter-ligated DNA was done via PCR ampli!cation, size-separated by
electrophoresis, and puri!ed using the QIAquick Gel Extraction kit (Qiagen). The
!nal library was quanti!ed using the Agilent 2100 bioanalyzer. The qualifying 116
DNA libraries were ampli!ed using the cBOT system (Illumina), and sequenced on
the Illumina Hiseq 4000 platform (Illumina) using paired-end 150-bp sequencing.
Bioinformatics processing: quality control and trimming. Raw FASTQ format
sequences from each sample were quality assessed using FASTQC v0.10.0 (https://
www.bioinformatics.babraham.ac.uk/projects/fastqc/). The number of read pairs
generated per sample ranged from 9,263,538 to 21,350,613 [Supplementary
Data 1]. Subsequently, reads were trimmed, to include removing adaptors, using
BBduk2 [BBMap—Bushnell B.—https://sourceforge.net/projects/bbmap/] with an
output quality Phred threshold score of "20 and a minimum read length of 50 bp.
K-mer length for !nding contaminants was k= 19. We looked for shorter k-mers
at read pairs down to k= 11, and reads were trimmed at the right end [Supple-
mentary Data 1].
Bioinformatics processing: mapping of sequence reads. Using a novel reference
based mapping and alignment tool, k-mer alignment (KMA)80, the trimmed reads
were used as input to align directly against reference sequence databases. The KMA
method is designed to improve mapping against redundant databases, and has been
shown to outperform existing mapping methods in terms of speed, precision and
sensitivity80. In summary, KMA, employs heuristic mapping, which involves
directly mapping k-mers between query sequences and selected template databases,
including large redundant databases. It then speeds up mapping by using k-mer
seeding, and utilises a special version of the Needleman–Wunsch algorithm81 to
accurately align regions of mismatching k-mers. To ensure the best match template
for the query reads, multi-mapping reads are resolved using a novel sorting
scheme, ConClave. The scheme enables assembly of reads which results in a !nal
accurate consensus sequence for the reference sequence, and also rules out bias
associated with base calling across different sequencing platforms82.
Bioinformatics processing: microbiome sequence component. To access the
microbiome sequence component present in our samples, read pairs and singletons
were aligned to a custom reference genomic database (last updated 04.04.2019).
Mapped reads were counted as one copy, in cases of read pairs or singletons.
Unless otherwise speci!ed below, databases were primarily downloaded via NCBI
GenBank clade speci!c assembly_summary.txt !les (ftp://ftp.ncbi.nlm.nih.gov/
genomes/genbank). The custom database consisted of the following: bacteria
(closed genomes; downloaded 05.02.2019), archaea (downloaded 13.02.2019),
MetaHitAssembly (PRJEB674–PRJEB1046; downloaded 01.07.2014), HumanMi-
crobiome (genome assemblies; downloaded 02.07.2014), bacteria_draft (down-
loaded 05.02.2019), plasmid (downloaded 05.02.2019), virus (https://bitbucket.org/
genomicepidemiology/kvit_db; downloaded 05.02.2019; https://genome.jgi.doe.
gov/portal/pages/dynamicOrganismDownload.jsf?organism=IMG_VR; down-
loaded 28.01.2019), fungi (downloaded 13.02.2019), protozoa (downloaded
13.02.2019), and parasites (downloaded 04.04.2019). Sequences selected for the
bacteria and bacteria_draft databases from the assembly_summary.txt !le were
annotated with the tags version_status= “latest” and genome_rep= “Full”. Addi-
tional entries, assembly_level= “Complete genome” or “Chromosome” in the
bacteria database and refseq_category= “representative genome” in the bacter-
ia_draft database were also required. The plasmid database was constructed as a
subset of the bacteria and bacteria_draft sequences; keyword in the FASTA entry
header line, “plasmid”. The total read count for each microbial community of
interest in a sample was calculated as the sum of read counts from each of the
databases of interest; bacteria (bacteria, bacteria_draft, MetaHitAssembly, and
HumanMicrobiome), fungi, protozoa, and parasites. Sequence mapping statistics
are shown in Supplementary Data 1.
The primary (most similar) alignment obtained for mapped sequences was used
to assign a putative taxonomy, based on the taxonID obtained. TaxonID’s and
associated taxonomy classi!cations were obtained from downloaded reference
microbial genomes from NCBI (ftp://ftp.ncbi.nih.gov/pub/taxonomy/taxdump.tar.
gz) and assignment at all taxonomic levels was done. Sequences that had no
similarities detected in the nucleotide (nt) database for which we could not assign a
putative taxonomic classi!cation were deemed to be unknown sequences, and
hence termed “Unknown”. The classi!cation of “unknown” is exquisitely time-
sensitive, but was appropriate and correct at the time of this analysis. Details of
taxonID mapping are shown in Supplementary Data 1.
Bioinformatics processing: AMR gene component. To identify any putative
AMR genes present in the samples, the read pairs were aligned to AMR genes (3081
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-0859-7
8 COMMUNICATIONS BIOLOGY |           (2020) 3:155  | https://doi.org/10.1038/s42003-020-0859-7 | www.nature.com/commsbio
genes) present in the ResFinder database (https://bitbucket.org/
genomicepidemiology/res!nder_db; downloaded 13.02.2019) with parameters set
for a query gene to cover at least 2/5 the length of the reference gene to be
selected83. Alignments were !ltered to retain those exhibiting a selected threshold
of identity of 90% (i.e. >90% nucleotide identity between the query and reference
gene over at least 90% of the length of reference gene). Sequence mapping statistics
are shown in Supplementary Data 1.
Data handling and processing. To account for probable sample-wise sequencing
depth differences, as well as a size-dependent probability of observing a reference,
mapping counts from the custom genomic database and from the ResFinder
database were normalised to the total genome sizes for the genomic database and to
the individual gene lengths for the ResFinder database (gene and genome size
details in Supplementary Data 1).
The total observed mapping counts are relative, and may account for confounding
effects on downstream analyses84. This may be due to limitations of an arbitrary total
imposed by different sequencing platforms, technical variations in sequencing
libraries amounts, or even random variation85. To obtain information about the
abundances of features in our data set relative to each other, datasets were treated as
compositional85. Data were transformed using the log-ratio approach as introduced
by Aitchison86, to make the data symmetric, linear and in a log-ratio coordinate space.
However compositional methods such as this do not account for the presence of zeros
associated with abundance datasets. To address this, a small pseudocount of half the
smallest non-zero abundance per feature was added to each respective feature for all
the normalised abundance matrices, prior to transformations87. Microbiota
abundance data tables with counts, x, and k number of populations (taxa members),
were centred log ratio (clr) transformed, de!ned as87








where, g x" # $
Q
xi" #
1=k is the geometric mean of the particular composition.
AMR gene abundances were additive log-ratio (alr) transformed, taking the
bacterial component of the microbiome (xk) as the reference as87








Unless otherwise stated, clr and alr matrices were used for all downstream
analyses. Raw mapping count data and their corresponding alr and clr values for
the analysed samples can be found in Supplementary Data 2.
Visualisation. Data visualisation was performed within the R environment (www.
bioconductor.org; www.r-project.org). Bar plots from normalised, zero-corrected
abundance matrices were used to give an overview of the microbiota and AMR
gene abundances across all samples. For cluster dendrograms, the Aitchison dis-
tance (Euclidean distance) was calculated using clr-transformed abundance data,
and samples clustered based on distances (complete-linkage-clustering). To explore
underlying variabilities in the microbiota and AMR genes across the data set, clr-
transformed abundance data for each matrix, centred on the geometric mean,
scaled by the total variance were ordinated using PCA87, based on eigenvectors and
eigenvalues88. The PCA involves using multivariate data reduction techniques
through linear combinations of variables (principal components), each of which
explains a percentage variation89. Box plots were used to highlight differences in
microbiota abundance between two groups, and scatter plots to show the rela-
tionship between schistosome infection intensity and microbiota abundance.
Statistics and reproducibility. Statistical analyses were performed using various
Bioconductor packages within the R environment (www.bioconductor.org; www.r-
project.org). To test whether sample-related metadata predict within-group dis-
persion of the microbiota and the AMR genes, the Euclidean distances were cal-
culated, using the R/Bioconductor package vegan90. The effect of such metadata on
sample dissimilarities were determined using permutational multivariate analysis of
variance (PERMANOVA; adonis2 function in the vegan package) using P < 0.05 as
the signi!cance threshold. An FDR (Benjamini–Hochberg FDR) correction was
applied to counteract multiple testing91.
To investigate further how speci!c taxa composition vary across the statistically
signi!cant metadata (from PERMOANOVA), while controlling for other variables
of interest, analysis of composition of microbiomes (ANCOM) was used92.
ANCOM was the preferred choice because it does not make any distributional
assumptions of the data. The algorithm computes log-ratios of raw count data (clr),
where the normalising reference value is the abundance of all remaining taxa, taken
one at a time. ANCOM uses bootstrapped intervals to perform hypotheses tests
while maintaining the Benjamini–Hochberg FDR set at 0.05 (ref. 91). A taxa
member was considered varying in composition across an independent variable of
interest when it varied across the independent variable of interest with respect to
80% of the rest of the taxa in the data set (W!statistic cutoff: 0.80). By de!nition,
the W value generated (the number of times the null hypothesis is rejected for a
given taxonomic group) is the ratio of a speci!c taxonomic group and a number of
other groups (i.e. the W value) that are different across two groups. The ANCOM
test for the in"uence of S. haematobium infection was controlled for age, sex and
village.
As ANCOM only provides a list of taxa that vary in composition, the magnitude
and direction of associations of taxa that vary in composition across independent
variables was further determined. Box plots strati!ed by speci!c independent
variables, using the clr-transformed abundance data of taxa previously identi!ed as
statistically signi!cant by ANCOM were used to highlight differences in groups. To
determine how these taxa varied with schistosome infection intensity, clr-
transformed abundance data were regressed on the log transformed infection
intensity (log10 [egg count+ 1]).
The sample size used in the current study was based on availably of stool
samples from the subset of children who gave consent and met the required
selection criteria. Three samples were excluded from the overall analysis using a
prede!ned criteria. To appropriately explain variations in the data, samples with
non-missing data from at least one variable metadata from growth and nutritional
indices, schistosome infection status, previous schistosome treatment and antibiotic
use data (see Supplementary Data 1) were used for all downstream analysis (i.e.
n= 113). Duplicate samples collected from two participants were used as
biological/technical replicates for shotgun metagenomic sequencing.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Raw sequence data !les from all 116 samples and associated metadata used in the current
study are deposited in the Sequence Read Archive (SRA) of the National Centre for
Biotechnology Information (NCBI) database under the BioProject accession number
PRJNA521455. In Supplementary Data 1, we present sample metadata and all summary
statistics generated from the analyses of sequence reads. The source data underlying
statistical analyses and !gures are shown in Supplementary Data 2. All other data are
available on request to the corresponding author.
Code availability
The updated R codes used for analysis of composition of microbiomes (ANCOM) are
available on https://github.com/zellerlab/crc_meta/blob/master/src/ANCOM_updated.R
OR from the author’s webpage at https://sites.google.com/site/siddharthamandal1985/
research.
Received: 1 November 2019; Accepted: 25 February 2020;
References
1. Lukes, J., Stensvold, C. R., Jirku-Pomajbikova, K. & Wegener Parfrey, L. Are
human intestinal eukaryotes bene!cial or commensals? PLoS Pathog. 11,
e1005039 (2015).
2. Human Microbiome Project Consortium. Structure, function and diversity of
the healthy human microbiome. Nature 486, 207–214 (2012).
3. Turnbaugh, P. J. et al. The human microbiome project. Nature 449, 804–810
(2007).
4. Brewster, R. et al. Surveying gut microbiome research in Africans: toward
improved diversity and representation. Trends Microbiol. 27, 824–835
(2019).
5. De Filippo, C. et al. Impact of diet in shaping gut microbiota revealed by a
comparative study in children from Europe and rural Africa. Proc. Natl Acad.
Sci. USA 107, 14691–14696 (2010).
6. Rampelli, S. et al. Metagenome sequencing of the Hadza hunter-gatherer gut
microbiota. Curr. Biol. 25, 1682–1693 (2015).
7. Schnorr, S. L. et al. Gut microbiome of the Hadza hunter-gatherers. Nat.
Commun. 5, 3654 (2014).
8. Yatsunenko, T. et al. Human gut microbiome viewed across age and
geography. Nature 486, 222–227 (2012).
9. Robertson, R. C., Manges, A. R., Finlay, B. B. & Prendergast, A. J. The human
microbiome and child growth—!rst 1000 days and beyond. Trends Microbiol.
27, 131–147 (2019).
10. International HapMap, C. The International HapMap Project. Nature 426,
789–796 (2003).
11. Mulder, N. et al. H3Africa: current perspectives. Pharmgenomics Pers. Med.
11, 59–66 (2018).
12. Rodriguez, J. M. et al. The composition of the gut microbiota throughout
life, with an emphasis on early life. Micro. Ecol. Health Dis. 26, 26050
(2015).
13. Fan, W., Huo, G., Li, X., Yang, L. & Duan, C. Impact of diet in shaping gut
microbiota revealed by a comparative study in infants during the six months
of life. J. Microbiol. Biotechnol. 24, 133–143 (2014).
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-0859-7 ARTICLE
COMMUNICATIONS BIOLOGY |           (2020) 3:155  | https://doi.org/10.1038/s42003-020-0859-7 | www.nature.com/commsbio 9
14. Senghor, B., Sokhna, C., Ruimy, R. & Lagier, J.-C. Gut microbiota diversity
according to dietary habits and geographical provenance. Hum. Microbiome J.
7, 1–9 (2018).
15. Goodrich, J. K. et al. Human genetics shape the gut microbiome. Cell 159,
789–799 (2014).
16. Dominguez-Bello, M. G. et al. Delivery mode shapes the acquisition and
structure of the initial microbiota across multiple body habitats in newborns.
Proc. Natl Acad. Sci. USA 107, 11971–11975 (2010).
17. Martinez, I. et al. The gut microbiota of rural papua new guineans:
composition, diversity patterns, and ecological processes. Cell Rep. 11,
527–538 (2015).
18. Mishra, P., Palma, M., Bleich, D., Loke, P. & Gause, W. Systemic impact of
intestinal helminth infections. Mucosal Immunol. 7, 753 (2014).
19. Bustinduy, A. L. et al. Impact of polyparasitic infections on anemia and
undernutrition among Kenyan children living in a Schistosoma haematobium-
endemic area. Am. J. Trop. Med. Hyg. 88, 433–440 (2013).
20. Ma!ana, C. F., Ekpo, U. F. & Ojo, D. A. Urinary schistosomiasis in preschool
children in settlements around Oyan Reservoir in Ogun State, Nigeria:
implications for control. Trop. Med. Int. Health 8, 78–82 (2003).
21. Bosompem, K. M. et al. Infant schistosomiasis in Ghana: a survey in an
irrigation community. Trop. Med. Int. Health 9, 917–922 (2004).
22. McManus, D. P. et al. Schistosomiasis. Nat. Rev. Dis. Prim. 4, 13 (2018).
23. World Health Organization. Schistosomiasis, http://www.who.int/
mediacentre/factsheets/fs115/en/ (2016).
24. Pearce, E. J. & MacDonald, A. S. The immunobiology of schistosomiasis. Nat.
Rev. Immunol. 2, 499–511 (2002).
25. van Riet, E., Hartgers, F. C. & Yazdanbakhsh, M. Chronic helminth infections
induce immunomodulation: consequences and mechanisms. Immunobiology
212, 475–490 (2007).
26. Osakunor, D. N. M., Woolhouse, M. E. J. & Mutapi, F. Paediatric
schistosomiasis: what we know and what we need to know. PLoS Negl. Trop.
Dis. 12, e0006144 (2018).
27. Osakunor, D. N. M. et al. Dynamics of paediatric urogenital schistosome
infection, morbidity and treatment: a longitudinal study among preschool
children in Zimbabwe. BMJ Glob. Health 3, e000661 (2018).
28. WHO Expert Committee. Prevention and control of schistosomiasis and soil-
transmitted helminthiasis.World Health Organ Tech. Rep. Ser. 912, i–vi, 1–57,
back cover (2002).
29. Rosa, B. A. et al. Differential human gut microbiome assemblages during soil-
transmitted helminth infections in Indonesia and Liberia. Microbiome 6, 33
(2018).
30. Jenkins, T. P. et al. Infections by human gastrointestinal helminths are
associated with changes in faecal microbiota diversity and composition. PLoS
ONE 12, e0184719 (2017).
31. Cooper, P. et al. Patent human infections with the whipworm, Trichuris
trichiura, are not associated with alterations in the faecal microbiota. PLoS
ONE 8, e76573 (2013).
32. Holzscheiter, M. et al. Lack of host gut microbiota alters immune responses
and intestinal granuloma formation during schistosomiasis. Clin. Exp.
Immunol. 175, 246–257 (2014).
33. Broadhurst, M. J. et al. Therapeutic helminth infection of macaques with
idiopathic chronic diarrhea alters the in"ammatory signature and mucosal
microbiota of the colon. PLoS Pathog. 8, e1003000 (2012).
34. Schneeberger, P. H. H. et al. Investigations on the interplays between
Schistosoma mansoni, praziquantel and the gut microbiome. Parasit. Vectors
11, 168 (2018).
35. Kay, G. L. et al. Differences in the faecal microbiome in Schistosoma
haematobium Infected children vs. uninfected children. PLoS Negl. Trop. Dis.
9, e0003861 (2015).
36. Jenkins, T. P. et al. Schistosoma mansoni infection is associated with quantitative
and qualitative modi!cations of the mammalian intestinal microbiota. Sci Rep.
UK 8, https://doi.org/10.1038/s41598-018-30412-x (2018).
37. Cheever, A. W., Kamel, I. A., Elwi, A. M., Mosimann, J. E. & Danner, R.
Schistosoma mansoni and S. haematobium infections in Egypt. II. Quantitative
parasitological !ndings at necropsy. Am. J. Trop. Med. Hyg. 26, 702–716
(1977).
38. Scher, J. U. et al. Expansion of intestinal Prevotella copri correlates with
enhanced susceptibility to arthritis. Elife 2, e01202 (2013).
39. Ajibola, O. et al. Urogenital schistosomiasis is associated with signatures of
microbiome dysbiosis in Nigerian adolescents. Sci. Rep. UK 9, https://doi.org/
10.1038/s41598-018-36709-1 (2019).
40. Barnhill, A. E., Novozhilova, E., Day, T. A. & Carlson, S. A. Schistosoma-
associated Salmonella resist antibiotics via speci!c !mbrial attachments to the
"atworm. Parasit. Vectors 4, 123 (2011).
41. LoVerde, P. T., Amento, C. & Higashi, G. I. Parasite-parasite interaction of
Salmonella typhimurium and Schistosoma. J. Infect. Dis. 141, 177–185 (1980).
42. Qin, J. et al. A human gut microbial gene catalogue established by
metagenomic sequencing. Nature 464, 59–65 (2010).
43. Hu, Y. et al. Metagenome-wide analysis of antibiotic resistance genes in a large
cohort of human gut microbiota. Nat. Commun. 4, 2151 (2013).
44. Jernberg, C., Lofmark, S., Edlund, C. & Jansson, J. K. Long-term impacts of
antibiotic exposure on the human intestinal microbiota. Microbiology 156,
3216–3223 (2010).
45. De Waele, J. J. et al. Antimicrobial resistance and antibiotic stewardship
programs in the ICU: insistence and persistence in the !ght against resistance.
A position statement from ESICM/ESCMID/WAAAR round table on multi-
drug resistance. Intensive Care Med. 44, 189–196 (2018).
46. Doron, S. & Davidson, L. E. Antimicrobial stewardship. Mayo Clin. Proc. 86,
1113–1123 (2011).
47. Blair, J. M., Webber, M. A., Baylay, A. J., Ogbolu, D. O. & Piddock, L. J. Molecular
mechanisms of antibiotic resistance. Nat. Rev. Microbiol. 13, 42–51 (2015).
48. Holmes, A. H. et al. Understanding the mechanisms and drivers of
antimicrobial resistance. Lancet 387, 176–187 (2016).
49. Woolhouse, M. E. & Ward, M. J. Microbiology. Sources of antimicrobial
resistance. Science 341, 1460–1461 (2013).
50. Wellington, E. M. et al. The role of the natural environment in the emergence
of antibiotic resistance in gram-negative bacteria. Lancet Infect. Dis. 13,
155–165 (2013).
51. Okeke, I. N. et al. Antimicrobial resistance in developing countries. Part I:
recent trends and current status. Lancet Infect. Dis. 5, 481–493 (2005).
52. MOH Malawi. Guidelines for Community-Based Management of Acute
Malnutrition (Ministry of Health, Lilongwe, Malawi, 2016).
53. Nordahl Petersen, T. et al. Meta-genomic analysis of toilet waste from long
distance "ights; a step towards global surveillance of infectious diseases and
antimicrobial resistance. Sci. Rep. 5, 11444 (2015).
54. Afshinnekoo, E. et al. Geospatial resolution of human and bacterial diversity
with city-scale metagenomics. Cell Syst. 1, 72–87 (2015).
55. Hendriksen, R. S. et al. Global monitoring of antimicrobial resistance based on
metagenomics analyses of urban sewage. Nat. Commun. 10, 1124 (2019).
56. Deschasaux, M. et al. Depicting the composition of gut microbiota in a
population with varied ethnic origins but shared geography. Nat. Med. 24,
1526–1531 (2018).
57. Gorvitovskaia, A., Holmes, S. P. & Huse, S. M. Interpreting Prevotella and
Bacteroides as biomarkers of diet and lifestyle. Microbiome 4, 15 (2016).
58. Hoffmann, C. et al. Archaea and fungi of the human gut microbiome:
correlations with diet and bacterial residents. PLoS ONE 8, e66019 (2013).
59. Yassour, M. et al. Natural history of the infant gut microbiome and impact of
antibiotic treatment on bacterial strain diversity and stability. Sci. Transl. Med.
8, 343ra381 (2016).
60. Shin, N. R., Whon, T. W. & Bae, J. W. Proteobacteria: microbial signature of
dysbiosis in gut microbiota. Trends Biotechnol. 33, 496–503 (2015).
61. Gouba, N., Raoult, D. & Drancourt, M. Eukaryote culturomics of the gut
reveals new species. PLoS ONE 9, e106994 (2014).
62. Gouba, N. & Drancourt, M. Digestive tract mycobiota: a source of infection.
Med Mal. Infect. 45, 9–16 (2015).
63. Mukherjee, P. K. et al. Oral mycobiome analysis of HIV-infected patients:
identi!cation of Pichia as an antagonist of opportunistic fungi. PLoS Pathog.
10, e1003996 (2014).
64. Mar Rodriguez, M. et al. Obesity changes the human gut mycobiome. Sci. Rep.
5, 14600 (2015).
65. Wheeler, M. L. et al. Immunological consequences of intestinal fungal
dysbiosis. Cell Host Microbe 19, 865–873 (2016).
66. Bukelskien!, V., Baltriukien!, D. & Repe"kien!, J. Study of health risks
associated with Aspergillus amstelodami and its mycotoxic effects. Ekologija, 3,
42–47 (2006).
67. Leung, J. M. & Loke, P. A role for IL-22 in the relationship between intestinal
helminths, gut microbiota and mucosal immunity. Int. J. Parasitol. 43,
253–257 (2013).
68. Frank, T., Gautier, V., Talarmin, A., Bercion, R. & Arlet, G. Characterization
of sulphonamide resistance genes and class 1 integron gene cassettes in
Enterobacteriaceae, Central African Republic (CAR). J. Antimicrob.
Chemother. 59, 742–745 (2007).
69. Zimbabwe National Antimicrobial Resistance Core Group. Situation Analysis
of Antimicrobial Use and Resistance in Humans and Animals in Zimbabwe
(Global Antibiotic Resistance Partnership (GARP), Action on ANtibiotic
Resistance (REACT), Zimbabwe, 2017).
70. Dethlefsen, L., Huse, S., Sogin, M. L. & Relman, D. A. The pervasive effects of
an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA
sequencing. PLoS Biol. 6, e280 (2008).
71. Bartosch, S., Fite, A., Macfarlane, G. T. & McMurdo, M. E. Characterization of
bacterial communities in feces from healthy elderly volunteers and
hospitalized elderly patients by using real-time PCR and effects of antibiotic
treatment on the fecal microbiota. Appl. Environ. Microbiol. 70, 3575–3581
(2004).
72. Davies, J. & Davies, D. Origins and evolution of antibiotic resistance.
Microbiol. Mol. Biol. Rev. 74, 417–433 (2010).
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-0859-7
10 COMMUNICATIONS BIOLOGY |           (2020) 3:155  | https://doi.org/10.1038/s42003-020-0859-7 | www.nature.com/commsbio
73. Van De Sande-Bruinsma, N. et al. Antimicrobial drug use and resistance in
Europe. Emerg. Infect. Dis. 14, 1722 (2008).
74. Collignon, P., Beggs, J. J., Walsh, T. R., Gandra, S. & Laxminarayan, R.
Anthropological and socioeconomic factors contributing to global
antimicrobial resistance: a univariate and multivariable analysis. Lancet Planet
Health 2, e398–e405 (2018).
75. Pehrsson, E. C. et al. Interconnected microbiomes and resistomes in low-
income human habitats. Nature 533, 212–216 (2016).
76. Zimbabwe National Statistics Agency. Zimbabwe Population Census 2012,
http://www.zimstat.co.zw/sites/default/!les/img/publications/Population/
National_Report.pdf (2012).
77. Midzi, N. et al. Distribution of schistosomiasis and soil transmitted
helminthiasis in Zimbabwe: towards a national plan of action for control and
elimination. PLoS Negl. Trop. Dis. 8, e3014 (2014).
78. Mott, K. E., Baltes, R., Bambagha, J. & Baldassini, B. Field studies of a reusable
polyamide !lter for detection of Schistosoma haematobium eggs by urine
!ltration. Tropenmed. Parasitol. 33, 227–228 (1982).
79. Katz, N., Chaves, A. & Pellegrino, J. A simple device for quantitative stool
thick-smear technique in Schistosomiasis mansoni. Rev. Inst. Med. Trop. Sao
Paulo 14, 397–400 (1972).
80. Clausen, P., Aarestrup, F. M. & Lund, O. Rapid and precise alignment of raw
reads against redundant databases with KMA. BMC Bioinformatics 19, 307
(2018).
81. Needleman, S. B. & Wunsch, C. D. A general method applicable to the search
for similarities in the amino acid sequence of two proteins. J. Mol. Biol. 48,
443–453 (1970).
82. Kaas, R. S., Leekitcharoenphon, P., Aarestrup, F. M. & Lund, O. Solving the
problem of comparing whole bacterial genomes across different sequencing
platforms. PLoS ONE 9, e104984 (2014).
83. Zankari, E. et al. Identi!cation of acquired antimicrobial resistance genes. J.
Antimicrob. Chemother. 67, 2640–2644 (2012).
84. McMurdie, P. J. & Holmes, S. Waste not, want not: why rarefying microbiome
data is inadmissible. PLoS Comput. Biol. 10, e1003531 (2014).
85. Gloor, G. B., Macklaim, J. M., Pawlowsky-Glahn, V. & Egozcue, J. J.
Microbiome datasets are compositional: and this is not optional. Front.
Microbiol. 8, 2224 (2017).
86. Aitchison, J. The Statistical Analysis of Compositional Data (Chapman and
Hall, 1986).
87. Calle, M. L. Statistical analysis of metagenomics data. Genomics Inf. 17, e6
(2019).
88. Arfken, G. in Mathematical Methods for Physicists (ed George Arfken) 229–
237 (Academic Press, 1985).
89. Le Cao, K. A. et al. MixMC: a multivariate statistical framework to gain insight
into microbial communities. PLoS ONE 11, e0160169 (2016).
90. Oksanen, J. et al. Community Ecology Package, https://CRAN.R-project.org/
package=vegan (2016).
91. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical
and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289–300
(1995).
92. Mandal, S. et al. Analysis of composition of microbiomes: a novel method for
studying microbial composition. Microb. Ecol. Health Dis. 26, 27663 (2015).
Acknowledgements
We thank the local nurses, village health workers and community nurses for their help
with the !eldwork. Special thanks to all study participants and their parents/guar-
dians. We also thank members of the Understanding Bilharzia project in Zimbabwe
for their technical help, and all the members of the Parasite Immuno-epidemiology
Group at the University of Edinburgh for their useful comments in shaping this
manuscript. Our research is supported by the Thrasher Research Fund 12440, Well-
come Trust 108061/Z/15/Z, and the Oak Foundation. This research was
commissioned in part by the National Institute for Health Research (NIHR) Global
Health Research programme (16/136/33) using UK aid from the UK Government. The
views expressed in this publication are those of the author(s) and not necessarily those
of the NIHR or the Department of Health and Social Care. D.N.M.O. is supported by
the Darwin Trust of Edinburgh. C.B., T.N.P., P.M., and F.M.A. are funded by the Novo
Nordisk Foundation (NNF16OC0021856: Global Surveillance of Antimicrobial
Resistance).
Author contributions
D.N.M.O., T.M., F.M.A., M.E.J.W. and F.M. conceptualised and designed the study.
D.N.M.O., T.M., T.C., S.A.A., J.M. and F.M. were involved in the !eldwork, sample
collection and DNA extractions. D.N.M.O. and T.C., curated the !eld data. D.N.M.O.,
J.M. and F.M. organised the sequencing. T.N.P. and A.I. carried out the bioinfor-
matics processing. D.N.M.O., P.M., T.N.P., C.B. and A.I. analysed, produced
!gures and interpreted the data. D.N.M.O. prepared the draft manuscript and all
authors were involved in review, editing and approval of the !nal version of the
manuscript.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s42003-
020-0859-7.
Correspondence and requests for materials should be addressed to D.N.M.O.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional af!liations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2020
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-0859-7 ARTICLE
COMMUNICATIONS BIOLOGY |           (2020) 3:155  | https://doi.org/10.1038/s42003-020-0859-7 | www.nature.com/commsbio 11

RESEARCH ARTICLE
Six rounds of annual praziquantel treatment
during a national helminth control program
significantly reduced schistosome infection
and morbidity levels in a cohort of
schoolchildren in Zimbabwe
Takafira Mduluza1,2, Caitlin Jones3,4, Derick N. M. OsakunorID
3, Rivka Lim3,4, Julius




1 Department of Biochemistry, University of Zimbabwe, Mount Pleasant, Harare, Zimbabwe, 2 TIBA
Zimbabwe, NIHR Global Health Research Unit Tackling Infections to Benefit Africa (TIBA) at the University of
Edinburgh, Edinburgh, United Kingdom, 3 Centre for Infection, Immunity & Evolution and Institute of
Immunology & Infection Research, University of Edinburgh, Ashworth Laboratories, King’s Buildings,
Edinburgh, United Kingdom, 4 NIHR Global Health Research Unit Tackling Infections to Benefit Africa (TIBA)
at the University of Edinburgh, Ashworth Laboratories, King’s Buildings, Edinburgh, United Kingdom,
5 Epidemiology & Disease Control, Ministry of Health and Child Care, Harare, Zimbabwe, 6 Department of
Geography and Environmental Science, Geo-information and Earth Observation Centre, University of




The World Health Organization recommends that schistosomiasis be treated through Mass
Drug Administration (MDA). In line with this recommendation, Zimbabwe commenced a
national helminth control program in 2012 targeting schoolchildren throughout the country
for 6 years. This study, part of a larger investigation of the impact of helminth treatment on
the overall health of the children, determined the effect of annual praziquantel treatment on
schistosome infection and morbidity in a cohort of children during Zimbabwe’s 6-year
national helminth control program.
Methodology/Principal findings
A school-based longitudinal study was carried out in 35 sentinel sites across Zimbabwe
from September 2012 to November 2017. The sentinel sites were selected following a coun-
trywide survey conducted in 280 primary schools. Schistosoma haematobium was diag-
nosed using the urine filtration technique. Schistosoma mansoni was diagnosed using both
the Kato-Katz and formol-ether concentration techniques. S. haematobium morbidity was
determined through detection of macro and microhaematuria. A cohort of children aged
6–15 years old was surveyed annually before MDA and 6 weeks post treatment. Maximum
treatment coverage reached 90% over the 6 rounds of MDA. At baseline S. haematobium
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infection prevalence and intensity were 31.7% (95% CI = 31.1–32.2) and 28.75 eggs/10ml
urine (SEM = 0.81) respectively, while S. mansoni prevalence and intensity were 4.6%
(95% CI = 4.4–4.8) and 0.28 eggs/25mg (SEM = 0.02). Prior to the 6th round of MDA, S. hae-
matobium infection prevalence had reduced to 1.56% (p0.001) and infection intensity to
0.07 (SEM 0.02). Six weeks later after the 6th MDA, both were 0. Similarly the prevalence of
S. haematobium morbidity as indicated by haematuria also fell significantly from 32.3%
(95% CI = 29.9–34.6) to 0% (p 0.0001) prior to the final MDA. For S.mansoni, both preva-
lence and intensity had decreased to 0 prior to the 6th MDA. After 6 rounds of annual MDA,
prevalence and intensity of both schistosome species decreased significantly to 0% (p
0.0001).
Conclusion
Zimbabwe’s helminth control program significantly reduced schistosome infection intensity
and prevalence and urogenital schistosomiasis morbidity prevalence in a cohort of school-
aged children, moving the schistosome prevalence in the children from moderate to low by
WHO classification. These findings will inform the design of the country’s next stage inter-
ventions for helminth control and eventual elimination.
Author summary
Following a national helminth prevalence survey conducted in 2010/2011, Zimbabwe
launched a national schistosomiasis and intestinal worm control program in 2012 targeting
school children aged 6–15 years who carry the highest infection burden. The control strat-
egy as advocated by the World Health Assembly in 2012 was adopted to suit the country
context. We conducted a study in a cohort of children to assess the effect of praziquantel
treatment on schistosome infection intensity and prevalence as well as on urogenital schis-
tosomiasis morbidity prevalence after every annual MDA for 6 years. Maximum treatment
coverage in a cohort of children reached 90% over the 6 rounds of annual treatment.
Annual surveys in sentinel sites throughout the country showed that schistosome infection
prevalence and intensity as well as the marker of urogenital schistosomiasis, haematuria
decreased significantly after each round of treatment from the pre-treatment levels in the
same year. Most notably, both urogenital schistosomiasis infection and morbidity preva-
lence reduced from 32% at baseline in 2012 to 1.56% before the 6th MDA in 2017, and
infection intensity reduced from 28.75 eggs/10ml urine to a mean of 0.07eggs/10ml urine
prior to the 6th MDA. Both infection prevalence and intensity fell to 0 after the 6th MDA.
Intestinal schistosomiasis prevalence and intensity reduced from 4.6% and 0.28 eggs/25mg
of stool to 0% and 0 eggs, respectively. Thus, the control program significantly reduced
schistosome infection and morbidity in this cohort of schoolchildren.
Introduction
Zimbabwe is endemic to several of the neglected tropical diseases (NTDs) as listed by the
World Health Organization (WHO) [1]. Of these NTDs, schistosomiasis is the most prevalent
in the country. Both forms of schistosomiasis; urogenital and intestinal, occur in Zimbabwe
with the former being more prevalent [2]. From the very first community survey in Zimbabwe,
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then Rhodesia, in 1932 [3], Zimbabwe has had programs to control schistosomiasis [4]. These
programs have targeted workers and schoolchildren using several approaches including treat-
ment of infected people (first with tartar emetic and then praziquantel(PZQ)), improving
water and sanitation, snail control and education/awareness campaigns [4]. However, these
programs have mostly been focal in space and time [5–8]. In 2012 the WHO set out a roadmap
for NTDs, including controlling schistosomiasis morbidity by 2020 and elimination of schisto-
somiasis as a public health problem and interrupting transmission in various African countries
by 2025 [9]. As part of implementing this roadmap, Zimbabwe has been conducting a national
helminth control program targeting school children aged 6 to 15 years, whom previous studies
in the country have shown to carry the heaviest burden of schistosome infection in Zimbabwe
[8, 10–13].
To inform the national control program, we performed a nationwide school-based survey
in 2010/2011, mapping S. mansoni, S. haematobium, and the soil-transmitted helminth species:
Ascaris lumbricoides, Trichuris trichiura and hookworm [2]. This was done by collecting data
at district level, and thereby representative of the corresponding provinces. Data from this
study revealed high schistosomiasis prevalence in 55 districts and soil transmitted helminths
occurring in 47 districts, with 33 districts being endemic to both types of NTDs. The nation-
wide combined prevalence of schistosomiasis was 22.7% while that for STH was 5.5% [2].
These levels of infection demanded urgent interventions. Following this, the Ministry of
Health formulated a national NTD control policy, an initial 5-year action plan and imple-
mented school-based mass drug administration (MDA) targeting primary and secondary
school children across the country [4]. Crucially, Zimbabwe’s control program treated all chil-
dren annually irrespective of the regional prevalence of infection. This is in contrast to the
WHO preventive chemotherapy guidelines that recommend the frequency of treatment based
on community/regional infection level, i.e. high risk communities, those with a prevalence of
50% and over, should be treated annually, whereas those at lower risk should be treated every
two years (over 10% but less than 50%). In cases where prevalence was less than 10%, then the
recommendation is that children should be treated twice within their school career [14] [15].
While data on the coverage of the country’s helminth control program has been docu-
mented (see http://espen.afro.who.int/countries/zimbabwe), there had been no indication of
the effectiveness of the control program in terms of efficacy of praziquantel treatment on infec-
tion intensity and prevalence as well as on levels of urogenital schistosomiasis morbidity as
measured by haematuria. This study is part of an investigation on the impact of schistosomia-
sis treatment with PZQ during the national control program on overall human health includ-
ing morbidity markers, inflammatory markers, allergic responses and autoreactivity in school
children. For this study, we determined egg reduction rates (ERR) and cure rates (CR) in a
cohort of school children. This current study focuses on the effect of annual PZQ treatment on
schistosome infection intensity and prevalence and urogenital schistosomiasis morbidity in
this cohort of school children during Zimbabwe’s national helminth control program and
compares infection levels from the start of the MDA to our last survey six weeks after the 6th
round of MDA.
Materials and methods
Ethical approval and consent
The study received institutional approval from the University of Zimbabwe and Ethical
approval from the Medical Research Council of Zimbabwe MRCZ/A/1710. Permission to con-
duct the study in the provinces was obtained from the Ministry of Health & Child Care.
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Recruitment into the study was voluntary and parents/guardians gave written parental consent
and were free to withdraw the participants at any time with no further obligation.
Background and national MDA
Between September 2010 and August 2011, a national schistosomiasis and soil transmitted hel-
minths survey was conducted in Zimbabwe by the Ministry of Health and Child Welfare
through the Epidemiology and Disease Control Department and National Institute of Health
Research with support from the Ministry of Education, the WHO and UNICEF [2].
In keeping with the observation that school children constitute the high-risk age group for
schistosomiasis and STH in the community [14], the survey was conducted in school children
aged 10–15 years old. The survey was a countrywide cross-sectional survey carried out by sam-
pling 50 children in each of 280 primary schools in all the 68 districts of the country’s total
eight provinces. The national survey indicated the different districts in the country which fell
in the WHO classification of heavy, moderate and low schistosome endemicity based on the
infection levels in the school children [15].
Following this national survey, annual MDAs were carried out in September 2012, October
2013, January 2015, November 2015, November 2016 and November 2017. The third MDA
was delayed due to logistical reasons, resulting in the reduced gap between the third and fourth
MDA being less than 12 months. The children in the cohort study described here were treated
during these MDAs.
Study design
The study presented here was designed to follow a cohort of primary school children who
were targeted by this MDA from September 2012 to November 2017. Sites throughout the
country were purposely chosen before the commencement of the MDA program to represent
the 3 levels of schistosomiasis infection prevalence as described by WHO i.e. low, moderate
and high [14] at both district and province level as shown in Fig 1. The sentinel sites were also
chosen to represent the baseline prevalence classification of the district (low, medium or high)
(see S1 Fig). In total 35 schools located in 29 districts and 8 provinces were included in the
study. The sample sizes are given in Table 1 and the map of the 8 provinces is given in Fig 2A.
Of the 8 provinces, 6 had at least one sentinel site included in every MDA, while 2 provinces
were not included in all the surveys. Matabeleland South and Mashonaland West were not sur-
veyed in all MDAs. The national survey showed that Matabeleland South had the lowest schis-
tosomiasis prevalence in the country [2] and it was deemed not cost effective to survey this
province after every MDA. Therefore, this province was surveyed at the start of this project in
2012 and at the end in 2017, i.e. pre- and post-MDA 1 and post-MDA 6. Similarly other sites
including all those in Mashonaland West were sampled at the start-point (MDA1), mid-point
(MDA4) and end-point (MDA6) of the control program. These are detailed in S1 Fig and in
Table 1. In the remaining sentinel sites children were surveyed annually for the duration of
the study.
For each MDA, the school children were sampled at two points, prior to treatment (pre-
MDA) and 6 weeks after treatment was given (post-MDA). Twelve schools (sentinel sites;
Gonye, Siabuwa, Muzarabani, Kafura, Chiguri, Mukwakwe, Negato, Mareya, Ruzongwe,
Mbembi, Bandanyenje, Kanyaga) (see Fig 2B) were followed up annually. As indicated in the
study design in Fig 1, these 12 schools were purposely selected to represent the full range of
the different levels of baseline schistosomiasis infection prevalence i.e. low, moderate and high.
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Study population
The study recruited children aged 6–15 years old and these children would typically be in
grades 3–7 in primary school. The children were randomly selected prior to the start of the
study in 2012 and the same children were followed up for the duration of the study i.e. until
2017. The selected children were sampled at each sampling point regardless of whether they
had received treatment in the last MDA or not. The treatment records of the children were
extracted during the post-MDA visit for each MDA, from the MDA records kept by the school.
These records informed the treatment coverage rates. Children leave primary school in Zimba-
bwe for senior school after grade 7, therefore, children who moved out of grade 7 were fol-
lowed up if enrolled at a local secondary school to ensure the post treatment follow-up. The
majority of children lost to follow-up were those who had completed primary school and
moved on to secondary school as well as those who transferred to other distant schools.
Inclusion criteria
To be included in the study, children had to i) provide all 2 stool samples and 3 urine samples
for schistosome parasitology and morbidity determination at pre-treatment and 6 weeks post-
treatment survey points, ii) have been offered treatment with PZQ during that year’s MDA.
Study sample sizes
Our national survey sampled 50 children from each school based on the sample size calcula-
tion previously published which gave a total sample size of 15, 818 [2] for the national survey.
Fig 1. Study design. The schistosome endemicity levels (low, medium, high) were stratified based on combined S. mansoni and S. haematobium infection prevalence.
https://doi.org/10.1371/journal.pntd.0008388.g001
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Briefly, in that national survey calculation using 37% as the assumed mean prevalence of schis-
tosomiasis and the error margin of 0.75%, the number of schools selected per district was
determined by dividing the district sample size calculated proportionally from the national
sample size by the number of children that would be screened per school (n = 50). In this sur-
vey, we based our study design on that original study design for consistency and our sample
sizes were informed by the original countrywide survey. The present study was to follow the
children for 6 years, we were cognizant of the possibility of loss due to migration. Thus, using
the national sample size calculation we aimed to recruit a sample size of 250 children per
school, with a minimum school sample size of 150 to give a total of 8750 children which would
be 55% of the number of children sampled in the national survey. At baseline, a total of 8015
Table 1. Summary study sample sizes by MDA.
Province District School Total number of surveys Number of children surveyed per MDA
1 2 3 4 5 6
Manicaland Bikita Chitenderano 2 195 - - - - 195
Manicaland Buhera Masocha 6 242 - - 242 - 242
Manicaland Chipinge Chitepo 6 250 - - 250 - 250
Manicaland Makoni Bandanyenje 12 242 242 211 242 242 193
Manicaland Nyanga Chipataronga 6 398 - - 398 - 398
Mashonaland Central Guruve Nyanhunzi 6 179 - - 179 - 179
Mashonaland Central Mazowe Mbebi 6 186 - - 186 - 186
Mashonaland Central Mt Darwin Bemberi 12 201 206 206 222 196 145
Mashonaland Central Muzarabani Muzarabani 12 298 297 298 298 298 213
Mashonaland Central Rushinga Mazowe Valley 12 250 250 250 250 250 208
Mashonaland Central Shamva Chihuri 6 218 - - 218 - 218
Mashonaland Central Shamva Gono 3 200 - - - - 200
Mashonaland East Chikomba Nhidza 6 250 - - 250 - 250
Mashonaland East Murewa Chiguri 12 198 198 198 198 198 175
Mashonaland East Murewa Chingono 6 224 - - 224 - 224
Mashonaland East Mutoko Chimukopa 12 250 198 224 224 224 201
Mashonaland East Mutoko Kushinga 6 198 - - 198 - 198
Mashonaland East UMP Kafura 12 250 250 250 250 250 226
Mashonaland West Chegutu Gadzema 6 267 - - 267 - 267
Mashonaland West Hurungwe Dandawa 6 206 - - 206 - 206
Mashonaland West Hurungwe Gache-gache 6 233 - - 233 - 233
Mashonaland West Makonde Kanyanga 6 250 - - 249 - 249
Mashonaland West Zvimba Chomutamba 3 247 - - - - 247
Masvingo Chiredzi Mareya 12 220 218 218 218 218 200
Masvingo Gutu Mutendeure 3 192 - - - - 192
Masvingo Mwenezi Rudzongwe 12 267 267 267 267 267 210
Matabeleland North Binga Siabuwa 3 233 - - - - 233
Matabeleland North Nkayi Gonye 12 242 242 211 242 242 193
Matabeleland North Insiza Insiza 3 248 - - - - 240
Midlands Chirumanzu Gambiza 3 123 - - - - 123
Midlands Gokwe North Chireya 3 192 - - - - 192
Midlands Mberengwa Mukwakwe 12 177 179 160 179 179 156
Midlands Mberengwa Nhemga 3 250 - - - - 248
Midlands Mberengwa Zverenje 3 253 - - - - 253
Midlands Shurugwi New Gato 12 186 186 186 186 186 186
https://doi.org/10.1371/journal.pntd.0008388.t001
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children satisfied the eligibility criteria. Of these children, 7529 (94%) were followed up at the
last survey after MDA 6. Of the children from the 12 sentinel sites followed every year, 2781
children were recruited, with 2306 (83%) followed up. Annual sample sizes are summarised in
Table 1. Overall there was a loss to follow-up of 6% from MDA1 to MDA6.
Parasitology
Stool and urine samples were collected from each child between 1000 and 1400 hours, the
period when peak egg excretion is expected [16], S. mansoni infection status and intensity
were determined by microscopic examination of slides prepared using the Kato-Katz tech-
nique [17] and the formol-ether concentration technique [18] for collecting parasite eggs from
stool samples. Two stool samples were collected from each individual over two consecutive
days. A single slide was prepared following the Kato-Katz procedure using the 41.7mg tem-
plate from each stool sample. The egg count from the 41.7mg template was multiplied by 24 as
per WHO protocol guidelines (https://www.who.int/medical_devices/diagnostics/selection_
in-vitro/selection_in-vitro-meetings/00054_01_kato-katzBench_aids.pdf). The participant’s
egg count was the arithmetic mean calculated from the two slides and recoded as the mean
eggs per gram of stool. Stool left over from one stool sample was used for the formol-ether con-
centration technique [18]. There were no indicators for S. mansoni morbidity assessed due to
lack of a point of care rapid diagnostic.
For S. haematobium infection status and intensity, a urine sample was collected from each
participant on three consecutive days. 10mls of this urine was processed following the urine fil-
tration method [19]. Thus, from each participant the three slides were prepared one from each
day. The individual’s egg count was the arithmetic mean calculated from the three slides. S.
haematobium morbidity was determined by detection of blood in urine using dipsticks, pres-
ence of blood in urine in S. haematobium endemic areas is also used as indicative of S. haema-
tobium infection [20]. Individuals were only considered positive if schistosome eggs were
detected in their urine/stool samples.
Antihelminthic treatment
As previously indicated, the treatment was administered by the National Helminth Control
treatment team as part of the annual national helminth MDA program. Children were mea-
sured using the PZQ dose poles to determine treatment dose and regardless of infection status,
were co-administered a standard dose of PZQ i.e. 40mg/kg and albendazole at 400mg per
child. During treatment, children were checked to confirm they had swallowed the tablet, and
were given bread and juice. Treatment was administered by nurses and the school health coor-
dinators, as is the Ministry of Health practice in Zimbabwe for the national helminth control
program. The number and type of tablets administered was recorded for each child in MDA
registers, for accurate recording of the MDA reach as well as to distinguish non-compliance
from treatment failure in subsequent follow-ups.
Treatment coverage data
Summary treatment coverage data were available at program level for the country’s MDA pro-
gram annually for the duration of the study. In 2017, these data were present at district level
Fig 2. Maps showing sentinel sites at different administration levels. The maps were generated using GIS raw data for the
schools using ArcMap 10.1. Sentinel sites are italicized and the number of MDA surveys indicated. A. Map showing sentinel sites
at province level. B. Maps showing sentinel sites at different administration levels. The maps were generated using GIS raw data
for the schools using ArcMap 10.1. Map showing sentinel sites at district level.
https://doi.org/10.1371/journal.pntd.0008388.g002
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and the findings of the study were related to these data. All children followed up in the study
were confirmed to have received PZQ treatment at each MDA.
Statistical analysis
Data recorded on field sheets was double entered and proof read in an Excel spreadsheet and
comprised data from MDA 1 to 6 with both pre-MDA and post-MDA data recorded for each
individual. Infection prevalence and intensity for each time point was calculated for each
district.
To determine the effect of treatment on infection level, the ERR, a measure of the change in
parasite egg burden upon treatment, and the CR, a measure of those cured of infection upon
treatment, were calculated using data from treated children (as confirmed by the school MDA
registers) who were positive for schistosome infection using Eqs 1–4 below.
Infection intensity à Arithmetic Mean egg count for all individuals
Total number of individuals sampled
Eq 1
Prevalence à Number of individuals positive for infection
Total number of individuals sampled
✓ ◆
x 100 Eq 2
ERR %Ö Ü à 1  Arithemtic mean infection intensity following Rx
Arithmetic mean infection intesity in infected people at baseline
✓ ◆✓ ◆
x100Eq 3
CR Ö%Ü à Number of individuals positive at baseline and negative following RX
No of individuals positive at baseline
✓ ◆
x100Eq 4
where: ERR = egg reduction rate, CR = cure rate, RX = treatment.
Prevalence data and infection intensities were analysed using Minitab Statistical Software
18 and GraphPad Prism 8. Due to the non-parametric nature of the data, differences in preva-
lence between annual MDAs were tested for significance using a Fisher’s exact test, whereas
difference between pre- and post-MDA time points were analysed using a paired McNemar’s
test [21]. Infection intensities between annual MDAs were tested using an unpaired Student’s
t-test following Log10 (X+1) transformation to normalise data, and between pre- and post-
MDA a paired two-way Student’s t-test was calculated. For all analyses, a value of p<0.05 was
considered significant. Infection prevalence maps were generated using this primary raw data
and plotted using the software package ArcMap 10.1.
Results
Effect of treatment in the school children cohort at national level
Prior to the MDA, Schistosoma haematobium prevalence in the sentinel sites was 31.7% and,
consistent with Zimbabwe’s 2010 national schistosomiasis survey. S. haematobium was the
most prevalent schistosome species in the country [2]. Following 6 annual rounds of MDA,
the prevalence of S. haematobium decreased significantly to 0% (p<0.0001) (Fig 3A). When
comparing infection prevalence pre-treatment, the pre-MDA 1 prevalence of 31.7% decreased
to 1.56% (p<0.001) at pre-MDA 6 i.e. 12 months after the last MDA allowing for a full reinfec-
tion cycle (Fig 3A).
Schistosoma mansoni was tested for using both the Kato-Katz and formol-ether technique,
and the prevalence resulting from each at baseline was found to be 4.6% and 1.4% respectively.
The results of the more widely used Kato-Katz diagnostic are shown in Fig 3B. After the last
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MDA in 2017, S. mansoni prevalence was 0% when tested by both diagnostic techniques
(p<0.0001). When comparing infection prevalence pre-treatment, the pre-MDA 1 prevalence
of 4.6% by Kato-Katz decreased to 0% (p<0.0001) at pre-MDA 6 and from 1.4% at pre-MDA
1 by formol-ether also to 0% at pre-MDA 6 (see Fig 3B for the Kato-Katz data).
For both causative species of human schistosomiasis in Zimbabwe, S. haematobium and S.
mansoni, arithmetic mean infection intensity (analysed using the Log10(mean egg count+1)
transformation) in the cohort of school children decreased significantly from the initiation of
the MDA programme to the end (p =<0.0001) (see Fig 4). S. haematobium decreased from a
mean of 0.49 (SEM = 0.01) to 0.07 (SEM 0.02) at pre-MDA 6 (see Fig 4A) and 0 (SEM = 0) at
post-MDA 6. S. mansoni infection intensity determined by Kato-Katz decreased from 0.03
(SEM = 0.002) at pre-MDA 1 to 0 (SEM = 0) at both pre- and post-MDA 6, and from 0.006
(SEM = 0.0007) at pre-MDA 1 to 0 (SEM = 0) again at both pre- and post-MDA 6 using the
formol-ether diagnostic technique (4b).
Schistosome morbidity
Macro or visible haematuria measured as a marker of morbidity of S. haematobium infection
fell significantly from 32.3% in pre-MDA 1 to 0% at post-MDA 6 (p<0.001) and the gradual
decline is shown in Fig 5. The prevalence of haematuria had fallen to 0% prior to the 6th MDA.
Effect of treatment in the school cohort at province level
The impact of treatment was investigated in all 8 provinces. The study shows that the first
MDA had a significant effect on infection levels. Investigations in the sentinel sites in the 6
provinces surveyed at every MDA for the 6 MDAs shows a gradual decline in infection level.
Fig 6A shows the decline in S. haematobium infection prevalence while Fig 6B shows the
decline in S. mansoni prevalence as assessed by Kato-Katz.
Matabeleland North started with a prevalence of 5.3% for S. haematobium and 1.5% for
S. mansoni in 2012 and decreased in both species to 0% by 2017. Masvingo had the highest
starting prevalence among the provinces, calculated at 51.9% for S. haematobium and 16.1%
for S. mansoni in 2012. These both decreased to 0% following the last MDA in 2017. The
prevalence of S. haematobium in the Midlands was 32.3% in 2012 decreasing to 0% in 2017
and S. mansoni prevalence in the Midlands started at 0% in 2012, and remained at 0% in
2017. Mashonaland West province had a prevalence of 18.1% for S. haematobium and 2.1%
in S. mansoni in 2012, both of which decreased to 0% in 2017. Mashonaland Central had a
prevalence of 36.4% for S. haematobium and 3.7% for S. mansoni in 2012, and again, both
decreased to 0% in 2017. Mashonaland East had an initial prevalence of 30.4% for S. haema-
tobium and 3.9% for S. mansoni. These decreased to 0% after the 6th MDA. Manicaland
province had a prevalence of 35.6% for S. haematobium and 8.8% for S. mansoni before the
first MDA, and both decreased to 0% after the last MDA. Overall, the final data collected
following the 2017 annual MDA revealed that every province had decreased to 0% for both
S. haematobium and S. mansoni.
The overall change in prevalence between pre-MDA 1 and post-MDA 6 was significant in
both S. haematobium (p =<0.0001) and S. mansoni (p =<0.0001) (Fig 2). When investigating
this at a province level, the difference in prevalence of S. haematobium was significant for
Fig 3. Decline in overall infection prevalence in the cohort of children during the MDAs. Red bars = pre-treatment
infection prevalence for each MDA. Blue bars = post-treatment infection prevalence for each MDA. A. S.
haematobium. B. S. mansoni as diagnosed through the Kato-Katz procedure during the MDAs. Red bars = pre
treatment infection prevalence for each MDA.
https://doi.org/10.1371/journal.pntd.0008388.g003
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Mashonaland West, East, Central, Midlands, Masvingo, Manicaland (all p =<0.0001) and
Matabeleland North (p = 0.0002). The change in prevalence of S. mansoni on the province
level was also significant in Mashonaland East, West, Central, Manicaland and Masvingo (all p
=<0.0001), however Matabeleland North was not (p = 0.2000) and Midlands had no detect-
able S. mansoni at either time points. The impact of the MDAs on both schistosome species is
shown in S2 Fig.
Effect of treatment in the school cohort at district level
Of the 29 districts investigated in MDA 1, 24 (82.8%) districts were positive for S. haemato-
bium, 33.3% for both and 10 (34.5%) districts were positive for S. mansoni. District prevalences
ranged from 0% to 88.1% pre-MDA 1 for S. haematobium and 0% to 25.5% for S. mansoni as
shown by the data of pre-MDA 1 prevalences in Fig 6A for S. haematobium and Fig 6B for S.
mansoni. Infection prevalence in all districts was 0% post-MDA 6 for both species.
The summary of the overall impact on national prevalence in the cohort of children, pre-
senting the initial data collected prior to the commencement of the first MDA in 2012, to the
final measurements taken following the 6th MDA in 2017 is shown in Fig 7.
Egg reduction and cure rates
The egg reduction rates (ERR) and cure rates (CR) were calculated for each MDA. Overall
ERR and CR are given in Tables 2 and 3 respectively. Across all provinces, for both S. mansoni
and S. haematobium, ERR were all above 90%. Across the MDAs, average CR ranged from
83.4% to 100% for S. haematobium and 92.8% to 100% for S. mansoni diagnosed by Kato-Katz
and 95.8% to 100% for S. mansoni diagnosed by formol-ether technique.
Fig 4. Decline in overall S. haematobium infection intensity during the MDAs in the cohort of children. Red bars = pre-
treatment infection intensity for each MDA. Blue bars = post treatment infection intensity for each MDA. A. S.
haematobium, B. S. mansoni infection intensity as measured by Kato-Katz.
https://doi.org/10.1371/journal.pntd.0008388.g004
Fig 5. Decline in the prevalence of S. haematobium morbidity as measured by visible haematuria in the cohort of children.
https://doi.org/10.1371/journal.pntd.0008388.g005
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Fig 6. Decline in infection prevalence at province level during the MDAs. A. S. haematobium. B. S. mansoni as measured by Kato-Katz in the
cohort of children.
https://doi.org/10.1371/journal.pntd.0008388.g006
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Treatment coverage
Mean coverage across all the provinces was lowest in MDA 1 at 48%, but this increased gradu-
ally peaking at 90.3% in the cohort during MDA 5 (Fig 8). While the mean national coverage
Fig 7. Changes in prevalence at national level in the cohort of children. A. S. haematobium. B. S. mansoni. The maps were generated using GIS raw data for
the schools using ArcMap 10.1.
https://doi.org/10.1371/journal.pntd.0008388.g007
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at MDA 6 was 82.3% there was heterogeneity between districts with coverage ranging from
73.5% (Mashonaland West) to 96.5% (Mashonaland Central) for MDA 6 (S3 Fig).
Discussion
The Uniting to Combat NTDs score card calculates Zimbabwe’s efforts to combat NTDs in
terms of average of coverage across the five diseases amenable to mass treatment (schistosomi-
asis, soil transmitted helminths (STH), river blindness, trachoma, elephantitis) as 12% but
indicates that the coverage for schistosomiasis is 100% (see https://unitingtocombatntds.org/
africa/zimbabwe/). However, these score card data do not indicate the effectiveness of the
country’s helminth control program in terms of reducing infection level or morbidity. This
study presents the results from the analysis of the effect of annual praziquantel treatment on
schistosome infection and morbidity in a cohort of primary school children during the
national helminth control program in Zimbabwe. The study showed that upon sustained
annual MDA using PZQ to treat schistosome infections and morbidity, both schistosome
infection and morbidity have been significantly reduced in this cohort of children, meeting the
WHO aim of reducing morbidity and infection in school-aged children [22].
Zimbabwe adopted a country strategy to treat all affected areas annually for 6 years. By sur-
veying sentinel sites before the MDA and 6 weeks after the MDA every year, we have been able
to demonstrate that following the third MDA, the prevalence of schistosomiasis in the cohort
of school children in every province fell under the low-risk category deemed by the WHO i.e.
prevalence of less than 10% [14][15] and remained there consistently throughout the rest of
the programme.
Zimbabwe is one of the 41 African countries mentioned in the latest WHO Report on
NTDs [23], as currently having preventive chemotherapy programs for schistosomiasis. Of
these countries 28 (68.3%) which include Zimbabwe, were implementing preventative
Table 2. Mean egg reduction rate (%).
MDA S. haematobium S. mansoni (Kato-Katz) S. mansoni (Formol-Ether)
1 99.29 95.72 98.58
2 91.16 N/A 100
3 96.99 100 N/A
4 100 100 N/A
5 97.77 100 N/A
6 100 N/A N/A
N/A represents MDA where the pre-treatment infection intensity was 0 eggs/ml or 0 eggs/mg.
https://doi.org/10.1371/journal.pntd.0008388.t002
Table 3. Mean cure rates (%).
MDA S. haematobium S. mansoni (Kato-Katz) S. mansoni (Formol-Ether)
1 93.98 92.83 95.83
2 84.84 100.00 100.00
3 83.39 N/A N/A
4 100.00 100.00 N/A
5 100.00 100.00 100.00
6 100.00 N/A N/A
N/A represents MDA where the pre-treatment infection intensity was 0 eggs/ml or 0 eggs/mg.
https://doi.org/10.1371/journal.pntd.0008388.t003
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chemotherapy programs in 2015. Of these only 15 had extended coverage to all endemic areas.
In addition to this annual treatment across all levels of schistosome endemicity, the treatment
coverage obtained each year generally increased from MDA 1 throughout the program. Maxi-
mum coverage reached for all school children targeted in Zimbabwe’s helminth control pro-
gram which included the cohort of children in this study, was 90%. This was above the
recommended 75% coverage of school-aged children as detailed in the “2020 roadmap” set out
by the WHO [9].
While there was an overall reduction in infection prevalence and intensity over the duration
of the control program in the cohort of school children, there was some rebound in infection
particularly over the first 3 years. This is unsurprising as there were no control efforts directed
at breaking the transmission cycle. Studies in Kenya indicate that the reinfection can be suffi-
ciently intense as to warrant more than an annual treatment [24]. In Zimbabwe, with increas-
ing treatment coverage came lower re-infection rates culminating in the reduction of
prevalence to 0% in this cohort of school children following the last MDA.
For both S. mansoni and S. haematobium, ERR were above 90%. Across the MDAs, average
CR ranged from 83.4% to 100% for S. haematobium and 92.8% to 100% for S. mansoni diag-
nosed by Kato-Katz and 95.8% to 100% for S. mansoni diagnosed by formol-ether technique.
Variations in treatment outcome have been previously reported and have prompted studies
into trying to identify better measures of PZQ efficacy since parasite egg excretion is only a
proxy for drug effects on adult worms [25]. Egg excretion can be confounded by various host
or parasite factors, including facultative temporary cessation of excretion by the adult worms
[25]. Variation in both CR and ERR measures could be attributable to parasite- or host-based
factors including varying efficacy of PZQ in the killing of S. haematobium and S. mansoni in
co-endemic areas [26], the intensity of the initial infection, host genetics, and the sensitivity of
the diagnostic tests used to identify either species. For example, the urine filtration technique
and Kato-Katz technique can miss low-level infections [27]. In areas with a particularly high
prevalence of schistosomiasis, there is a greater chance of individuals being infected with
immature schistosomes at the time of MDA treatment and therefore will not be completely
cleared by one dose of praziquantel [28]. Furthermore, in areas of high transmission, high lev-
els of reinfection can occur especially if the MDA occurs before the transmission period.
Fig 8. Relationship between treatment coverage rates and schistosome infection prevalence across the MDAs in the cohort of
children.
https://doi.org/10.1371/journal.pntd.0008388.g008
PLOS NEGLECTED TROPICAL DISEASES Efficacy of Zimbabwe’s schistosomiasis control program in a cohort of school children
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008388 June 22, 2020 17 / 23
Treatment of only school children excluding adults and preschool children potentially main-
tains transmission. All of these factors may explain the observed persistence of infection post-
treatment, such as that of Mashonaland Central in both Schistosoma species, for the first 3
MDAs in this study [29, 30].
The possibility of the parasites developing resistance to PZQ is always a present threat, with
reports of low CR in certain regions [31, 32]. Indeed reduced efficacy of PZQ has been
reported following multiple rounds of MDA in Uganda for S. mansoni [33]. To counteract
these fears, investigations into multiple cases of laboratory and field PZQ resistance deter-
mined that the reduced efficacy of drug treatment due to resistance was rare [34]. Further-
more, a meta-analysis of PZQ CR and ERR we have conducted indicates that these have not
changed significantly in the past 20 years. The reduction of infection at the sentinel sites to 0%
and 0 egg counts for both schistosome species reflects that treatment remained efficacious
throughout the MDA period. As Zimbabwe intensifies control efforts to move towards elimi-
nating schistosomiasis as a public health problem, it will be important to collect parasite sam-
ples from infection hot spots to determine causes of persistent infection [35].
While Zimbabwe has made significant progress towards the control of schistosomiasis
through this 6-year MDA program, more still needs to be done; first to maintain the low infec-
tions achieved in the primary school children who were the target of Zimbabwe’s helminth
control program represented by the cohort of children studied here and, second to include all
populations at risk of infection i.e. adults and preschool children. The 2012 World Health
Assembly resolution 65.21 advocates for elimination of schistosomiasis transmission in mem-
ber states. This is an aspirational goal for Zimbabwe although in practise a difficult task.
Annual MDA is not sustainable long-term for most endemic countries both for economic and
logistical reasons in health systems with low budgets. It is also not effective on its own, at meet-
ing the elimination aspiration of WHA 65.21. Thus, Zimbabwe, similar to all other schisto-
some endemic countries aiming to eliminate the disease, needs to strengthen concerted efforts
to both reduce infection and morbidity, and also interrupt transmission. This must be based
on integrated control approaches including intense PZQ treatment targeted at any hot spots of
infection/transmission, snail control, treatment of infective water and improved access to safe
water, sanitation and hygiene (WASH) [36]. The impact of such an integrated approach has
been demonstrated in Egypt, where schistosomiasis is being tackled through targeted MDA
and WASH improvements [37]. The lack of integrated comprehensive approaches to reduce
both infection levels and transmission as well as the short-term timescale of MDA may explain
the challenge experienced by other counties for example, Kenya [24] and Uganda [38], in
improving the impact of MDA alone on infection levels/transmission. A comprehensive
national impact assessment exercise for the national control program as is planned by Zim-
babwe’s Ministry of Health at the end of this initial phase of the country’s helminth control
program will be informative in shaping the next stages in the country’s control of
schistosomiasis.
We designed the study sampling framework based on the results of the national control sur-
vey which formed the basis of Zimbabwe’s national control program [2]. Surveying all sentinel
sites at every survey point would have given more information, but the perceived benefit from
this did not justify the associated expense. In the national survey, 50 children per school were
sampled, whereas in this study, in the majority of schools we sampled at least 200 children.
Sample sizes lower than 200 were reflective of the enrolment numbers of children of the appro-
priate age group at the school. The follow-up of 75% of the children over the 6 years reflects
predominantly children who moved school to a different area and could not be traced. Chil-
dren remained eligible for follow-up if they moved to the local catchment area senior school
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i.e. within the same district and often served by the same river system to avoid following chil-
dren who moved to areas of different schistosome transmission dynamics.
The data were presented summarily at province level; however, as control efforts strengthen
in the move towards elimination, more refined mapping at district level, therefore more
schools, will be more informative. For infection diagnosis, we used the parasitological exami-
nation of urine and stool samples and this showed the reduction of egg counts to 0 for both
species of schistosome infections. Although the parasitological examination of urine and stool
is the currently recommend diagnostic for schistosomiasis, we and others have previously
shown that the approach is less sensitive when infection levels are low [27] and therefore more
accurate diagnostic tools are needed to monitor progress of control efforts. Alternative diag-
nostic approaches including PCR [39] and parasite antigens [40–43] have been used by others,
albeit not routinely in national MDA programs where there may be challenges with diagnostic
accuracy [44]. Although beyond the scope of this study, information on the transmission
dynamics in the local infective water bodies which the children frequented would have added
valuable information on the impact of treatment on the force of infection.
On a schistosome elimination agenda, there is need to extend treatment to cover the whole
community, including preschool aged children (aged 5 years and below) as well as adults.
Indeed the guidelines from WHO indicate that preventative chemotherapy should be targeted
at all groups at risk of infection in highly endemic communities [45]. Quantitative work has
shown that integrated community-wide treatment for schistosomiasis and soil-transmitted
helminths can be highly cost effective even in areas of low endemicity for either schistosomia-
sis or STH [46]. It is also important to be cognizant of the fact the current WHO guidelines
were not designed with the goal of elimination so current control strategies will need to be
adapted to deliver elimination while new or better tools for diagnosis and verification of cessa-
tion of transmission will need to be developed. Indeed, the WHO already acknowledges the
need for flexibility in control approaches for different counties in the roadmap for controlling
and eliminating NTDs [9]. Thus Zimbabwe’s approach of annual treatments regardless of the
schistosomiasis endemicity level at the operational region may have been more effective. Zim-
babwe’s last MDA was in 2017 and the country is now evaluating the impact of the control
program to inform the next steps in the country’s helminth control action plan.
In conclusion, based on the survey of schistosome infection and S. haematobium morbidity
in a cohort of school children in sentinel sites across the country, Zimbabwe’s helminth con-
trol program significantly reduced schistosome infection and morbidity levels in this cohort of
school-age children to levels where elimination is a possible goal. If extrapolated to national
level, the control program moved the country from a moderate to low endemicity levels as per
WHO classification for schistosomiasis [14]. The findings of this study will inform the design
of the country’s integrated control strategy towards elimination following a national assess-
ment of the impact of the national helminth control program at all previously surveyed sites.
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S1 Fig. The 35 sentinel sites chosen to represent districts (and thus provinces) in the coun-
try. The districts are colour coded to represent baseline schistosome infection prevalence clas-
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infection (coloured red) and indicating the number of surveys conducted per sentinel site.
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S2 Fig. Combined prevalence of S. haematobium and S. mansoni in the cohort of Zimbabwean
school children (a) before year 2012, and (b) after year 2017 Mass Drug Administration with
Praziquantel. Maps were generated using the primary raw data and plotted using ArcMap
10.1.
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S3 Fig. Summary % coverage of schistosome treatment at provincial level in the school
children cohort in the last MDA in 2017.
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In 2012, the World Health Organisation (WHO) set out a roadmap for eliminating schistoso-
miasis as a public health problem by 2025. To achieve this target, preschool-aged children
(PSAC; aged 6 years and below) will need to be included in schistosomiasis treatment pro-
grammes. As the global community discusses the tools and approaches for treating this
group, one of the main questions that remains unanswered is how to quantify infection in
this age group to inform treatment strategies. The aim of this study was thus to determine
whether a relationship exists between levels of schistosome infection in PSAC and school-
aged children (SAC), that can be used to determine unknown schistosome infection preva-
lence levels in PSAC. A systematic search of publications reporting schistosomiasis preva-
lence in African PSAC and SAC was conducted. The search strategy was formulated using
the PRISMA guidelines and SPIDER search strategy tool. The published data was sub-
jected to regression analysis to determine if a relationship exists between infection levels in
PSAC and SAC. The interaction between SAC and community treatment history was also
entered in the regression model to determine if treatment history significantly affected the
relationship between PSAC and SAC prevalence. The results showed that a significant posi-
tive relationship exists between infection prevalence levels in PSAC and SAC for Schisto-
soma mansoni (r = 0.812, df (88, 1), p = 0.0001) and S. haematobium (r = 0.786, df (53, 1),
p = 0.0001). The relationship was still significant after allowing for diagnostic method, treat-
ment history, and the African sub-region where the study was conducted (S. mansoni: F =
25.63, df (88, 9), p = 0.0001; S. haematobium: F = 10.20, df (53, 10), p = 0.0001). Using
the regression equation for PSAC and SAC prevalence, over 90% of the PSAC prevalence
studies were placed in the correct WHO classifications category based on the SAC levels,
regardless of treatment history. The study indicated that schistosome prevalence in SAC
can be extended as a proxy for infection levels in PSAC, extending on its current use in the
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Author summary
Preschool-aged children (PSAC), i.e. aged 6 years, are not included in preventative che-
motherapy programmes, currently advocated by the WHO for the treatment of schistoso-
miasis. This is due to the lack of a paediatric formulation of the drug of choice,
praziquantel, and the current guidelines which requires diagnosis before treatment. As the
global community prepares for the deployment of a new paediatric formulation of prazi-
quantel, there is a need to find a strategy to quantify infection in this age group. In schisto-
some endemic areas, infection levels in school-aged children (SAC) are already used to
inform infection levels in the community. Thus, we investigated the relationship between
SAC and PSAC schistosome prevalence levels within the same community, to determine
if data from SAC could be used to predict infection levels in PSAC. Our results show that
PSAC prevalence levels are significantly correlated with SAC prevalence levels. Our find-
ings are applicable to communities that have received preventative chemotherapy in SAC
or in SAC and adults, as well as those that have not received any. Our study indicates that
it is possible to extrapolate PSAC prevalence levels from SAC prevalence, and to make a
treatment decision on that basis.
Introduction
Schistosomiasis is a widespread parasitic disease found in tropical and subtropical areas [1].
The World Health Organization (WHO) estimated that at least 206 million people worldwide
required treatment for schistosomiasis in 2016, with at least 91% living in Africa [2]. The most
widely used treatment for schistosomiasis is the antihelminthic drug of choice, praziquantel
(PZQ), which is both safe and efficacious against adult worms [3]. Currently, schistosomiasis
is controlled through preventative chemotherapy, targeting school-aged children (SAC) who
are treated with PZQ through mass drug administration (MDA). The frequency of treatment
follows guidelines from the WHO, which are based on the schistosome endemicity of the area
rather than individual infection status [4]. The endemicity of the area is determined by quanti-
fying schistosome infection prevalence in SAC, following sampling of a group of the children.
The reason SAC are used for determining community schistosome endemicity and are the pri-
mary target of MDA is that they have been shown to have the highest prevalence of infection
and are easily accessible in schools [5, 6].
As of November 2018, 29 of the 41 African countries requiring preventive chemotherapy
have implemented MDA preventative chemotherapy in SAC; approximately 75 million chil-
dren have already received treatment [7]. However, none of these programmes include pre-
school-aged children (PSAC; aged 6 years and below). In endemic areas, children can be
infected as early as 1 year old, and the burden of infection as well as disease morbidity
increases with age [8, 9]. Several authors have highlighted the gap in treatment strategies, cre-
ated by the exclusion of PSAC (reviewed by Stothard et al. 2013) [10]. This creates a health
inequity for approximately 50 million African PSAC exposed to schistosomiasis [11].
In order to eliminate schistosomiasis as a public health problem by 2025, based on the
WHO roadmap on neglected tropical diseases (NTDs) [12], there is a need to include PSAC in
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treatment programmes. The WHO have responded by recommending the treatment of PSAC
[13], and also calling for the development of a paediatric formulation of PZQ, suitable for treat-
ing PSAC. There is now a paediatric formulation of PZQ under development (currently under-
going Phase III clinical trials) targeting children aged 3 months to 6 years. Thus, in preparation
for inclusion of PSAC in treatment programmes, either as part of MDA or treatment upon diag-
nosis, there is a need to develop a strategy for quantifying infection in this age group.
Unlike SAC who are readily accessible in schools, PSAC are not often as accessible, and
conducting mapping exercises to quantify their infection levels can be challenging and costly.
Therefore, we aimed to determine if SAC infection prevalence data could be used to determine
infection prevalence in PSAC. In this study, we investigated the relationship between schisto-
some prevalence levels in SAC and PSAC, to determine if SAC infection levels in Africa can be
used as a predictor of the prevalence levels in PSAC from the same community [13, 14].
Methods
This study focused on published manuscripts reporting schistosome infection prevalence,
derived from parasitological detection of schistosome eggs excreted in urine or stool. A sys-
tematic search of publications that reported schistosomiasis prevalence in PSAC and SAC in
Africa was carried out. The search strategy was formulated using the PRISMA guideline (Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analysis) [15], and the SPIDER
search strategy tool (Sample, Phenomenon of Interest, Design, Evaluation, Research type) [16]
in order to formulate a search question (see Table 1).
Published studies were identified using three online databases: PubMed (conception to 30th
October 2018), Embase (1980–2018, week 44) and Web of Science (1983 – 30th October 2018).
The results were filtered to show only those published in English.
Criteria for inclusion and exclusion of studies
Results from the literature searches were consolidated and extracted using EndNote referenc-
ing software (X8.01). Endnote and a Python script were used to match and remove duplicate
titles.
Eligibility for inclusion was based on the following criteria: i) the survey was carried out in
Africa, ii) it was published/written in English, iii) it contained prevalence data for PSAC, SAC
Table 1. Search terms created using the SPIDER search strategy.
Sample Children (preschool and school age)
Phenomenon of interest Schistosomiaisis infection, either S. haematobium or S. mansoni
Design Cross-section, survey
Evaluation Egg count in urine or stool
Research type Not included in search criteria but reviews and meta-analysis were removed during
screening
Terms used in search
S Children OR Preschool OR Pre - school OR Infant OR Infants OR PSAC OR SAC
AND
PI Schisto⇤ OR Bilharzia
AND
D Cross section OR Cross-section OR Cross-sectional OR Survey OR Prevalence
AND
E Urine OR Stool OR Katz OR egg OR eggs
R N/A
https://doi.org/10.1371/journal.pntd.0008650.t001
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or both, iv) the sample size was clearly stated, v) the sample size for each age group was above
10 people, vi) parasites identified were either S. mansoni or S. haematobium, vii) diagnosis was
via egg count in stool or urine samples, viii) the age ranges were clearly defined, and ix) PSAC
age range was between 0 up to 6 years and SAC age range was between 6–16 years.
The studies were further assessed using the following criteria: recruitment of participants
was random and non-biased, and sample collection and diagnostics was clearly explained and
carried out according to standard protocols [6]. Any studies not meeting these criteria were
excluded from the analyses. Data were entered based on prevalence of schistosomiasis per
water source/village, therefore one citation could yield multiple datasets.
Quality assessment
The quality of each study included in the analysis was assessed using a graded scale. Each study
was scored either 1 (yes) or 0 (no) against multiple criteria. There were 7 criteria–i) population
sampling methods described; ii) results stratified by gender; iii) a description of laboratory
diagnostics included; iv) multiple samples taken on different days; v) multiple tests of a single
sample carried out (S. mansoni only); vi) water source and/or the sanitary conditions
described; and vii) statistical analysis described in the methods. The scores were added
together and the overall score per article graded as follows: high 6–7, medium 3–5, and low
0–2 for S. mansoni, and for S. haematobium, high 5–6, medium 3–4 and low 0–2. If any of the
studies scored low on quality assessment, the analysis was conducted with and without the
study, to determine if it had an effect on the overall results.
Study variables
Study variables extracted from the publications were: sample size, age range, egg detection
method used for schistosome diagnosis, schistosome treatment history of the study communi-
ties, and the antihelminthic drug used for the treatment. The studies used different age ranges
for defining PSAC and SAC. For this study PSAC was defined as ages 0–6 years and SAC were
defined as 6 years up to 16 years of age. Techniques for detecting eggs in stool for S. mansoni
diagnosis were i) formol-ether sedimentation [17], ii) the Bell Method [18], and iii) Kato-Katz
thick smear [19]. For S. haematobium, egg techniques reported were urine sedimentation and
filtration methods [20]. Studies were included in the analysis providing the paired PSAC and
SAC infection were diagnosed using the same technique. History of schistosome treatment of
the community or the study participants was recorded and included in the statistical analyses;
this information was available at a community/group level but not individual participant level.
Four categories of treatment history were recorded; 1) No treatment taken place prior to study
(i.e. no recorded mass treatment in the past 50 years), 2) Treatment currently underway, 3)
Treatment has been recorded within the past 5 years, and 4) No information available about
treatment history. If the study did not state whether the community had undergone previous
MDA, the WHO Preventative Chemotherapy Treatment (PCT) databank was used to assess
whether treatment strategies were in place in this country or had taken place in the past 5 years
[21].
Data extraction
All eligible articles were read in full. The following information was extracted and tabulated
(Microsoft Excel); first author name, year of publication, dates of survey, country, African sub-
region, sample size, age range, male to female ratio, overall prevalence of infection, infection
intensity, male and female infection prevalence, standard deviation, standard error of the
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mean and 95% confidence intervals, previous schistosome treatment history and method used
for collecting the eggs for schistosomiasis diagnosis.
If the data were presented in smaller age ranges, for example, one of the studies specified
groups were 6–10 years and 10–16 years, the sample sizes were added together, and from this
combined group an average prevalence was calculated. When the age groups exceeded the lim-
its defined by this study e.g. above 6 years old for PSAC or above 16 years old for SAC, the
study was removed from the analysis. Furthermore, if the SAC group was partitioned into two,
and the older group exceeded the upper limit of the grouping, only the younger group within
the SAC was included. Where the published data were presented in graphs, Data-Thief soft-
ware (Data Thief III), a highly accurate data extraction tool, was used to extract the exact
numerical data [22].
Two categories of data were identified, Category 1 in which both PSAC and SAC data come
from the same study, and Category 2 in which the data were from two separate studies. Cate-
gory 2 studies were matched using the following additional criteria: the surveys were carried
out within one year of each other, the population used the same water source, and the parasi-
tology diagnostic techniques were the same.
Statistical analysis
Data analysis was carried out using MINITAB (version 18). As the infection data for both SAC
and PSAC were provided as prevalences (recorded as percentage data), both variables were
transformed using the arcsine square root transformation to satisfy the assumptions for
parametric tests, and to avoid resultant negative prevalence values post-transformation [23].
We determined whether or not data satisfied the parametric assumptions through analysing
the residuals (e.g. normality plots and histogram). We also validated the regression model by
analysing the goodness of fit of the regression and analysing whether the regression residuals
are random.
To determine the relationship between PSAC and SAC, Pearson’s correlation and linear
regression without any confounding factors were used. Thereafter, the relationship was ana-
lysed through linear regression, allowing for the effect of confounding categorical variables:
the African sub-region where the study was conducted (North, South, East, West and Central
(see https://unstats.un.org/unsd/methodology/m49/), diagnostic technique (S. mansoni–Kato
katz, Formol-ether or Bell, and S. haematobium–Filtration or sedimentation), and history of
schistosomiasis treatment (No previous treatment in population, treatment within the past 5
years, treatment currently underway and history not given). Also included in the model was
the interaction between SAC infection prevalence and treatment history, to determine if the
relationship between the two prevalences differed according to the treatment history of the
study population.
The relationship between PSAC and SAC was tested for (after allowing for the effects of the
above mentioned confounding variables), using adjusted sums of squares to calculate the F-
value. Adherence to the assumptions of parametric tests was confirmed by a series of residuals
plots including histogram plots, residual vs. fits and residuals vs. plots. The significance value
was p <0.05.
The goodness of fit of the model to the data was recorded as the r-squared value, and the
regression coefficient’s 95% confidence intervals were calculated using the equation:
95% CI = b ± tc(n-2) x SE
Where;
b = regression coefficient
tc = Critical T = T value at 0.05 for n-2 degrees of freedom
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n = study sample size.
SE = standard error of the coefficient
The 95% prediction band of the regression line were generated and plotted in GraphPad
(Version 8). Statistical analyses were conducted with and without the data from the studies
scoring low on the quality assessment (see S3 Table and S4 Table). This did not affect the
result, and so the studies were included in the analysis.
Results
Literature search
The selection process is presented in Fig 1. Literature searches of online databases returned
3515 studies. 1263 duplications were identified and removed, leaving 2252 unique studies.
After the screening and full text read, 68 studies and 143 datasets (89 for S. mansoni and 54 for
S. haematobium) were used in the analysis.
Eligible studies
In total, 23 African countries had prevalence data which could be used in the analysis (Table 2)
and these were spread across the continent (Fig 2).
Fig 1. Flowchart for search and selection of included studies.
https://doi.org/10.1371/journal.pntd.0008650.g001
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Schistosoma mansoni extracted data
There were 89 paired data points for S. mansoni extracted from 40 manuscripts with surveys
between 1974 and 2018. S1 Table, shows characteristics of all studies used in the meta-analysis
for S. mansoni infection in PSAC and SAC. Sample sizes ranged from 11 to 1122 in PSAC
(mean = 145, median = 68). Sample sizes in SAC ranged from 12 to 2856 (mean = 333,
median = 107). The prevalence of infection ranged from 0–100% in PSAC (mean = 25%,
median = 15%, the interquartile range (IQR) = 33.1, standard deviation (SD) = 25.8) and 2.5–
100% in SAC, (mean = 50%, median = 47%, IQR = 58.6, SD = 30.3).
For infection detection, the Kato-Katz technique was used in 86 of the 89 (96.6%) investiga-
tions, 2 (2.2%) used the formol-ether technique, and 1 (1.1%) used the Bell Method for egg
detection in stool. Out of 89 data points, no treatment had previously taken place in 72 (80.9%)
communities, 13 (14.6%) of the communities reported treatment currently underway, 1 (1.1%)
study reported one round of MDA 2 years previously but no further treatment had taken place,
and 2 communities (2.2%) did not report whether control strategies had taken place or not. For
the S. mansoni analysis, 77 were Category 1 (data was from the same study) and 11 were from
Category 2 (data was from two separate studies and adhere to the additional inclusion criteria).
Schistosoma haematobium extracted data
For S. haematobium, there were 54 paired data points from 39 manuscripts, and surveys
occurred between 1962 and 2016. S2 Table shows characteristics of all studies that investigated
Table 2. Publications and data sets included in analysis, broken down by country of origin.
S. mansoni S. haematobium
Country Publications Data sets Publications Data sets
Botswana 0 0 1 1
Burundi 1 1 0 0
Cameroon 0 0 2 5
Cote d’Ivoire 4 7 5 6
Egypt 5 8 2 3
Ethiopia 4 8 1 1
The Gambia 0 0 1 1
Ghana 0 0 3 3
Kenya 5 9 0 0
Liberia 1 1 1 1
Malawi 1 1 0 0
Mali 1 1 1 1
Niger 1 1 3 3
Nigeria 1 1 7 7
Senegal 2 2 2 2
Sierra Leone 2 7 0 0
Somalia 0 0 1 3
South Africa 1 1 1 1
Sudan 1 5 2 6
Tanzania 1 1 3 2
Uganda 4 5 0 0
Zaire (DRC) 1 29 0 0
Zimbabwe 1 1 4 8
https://doi.org/10.1371/journal.pntd.0008650.t002
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S. haematobium prevalence in PSAC and SAC. Sample sizes ranged from 11 to 1018 in PSAC
(mean = 141, median = 78). Sample sizes of SAC ranged from 21 and 4326 (mean = 557,
median = 215). The prevalence of infection ranged from 0–88% in PSAC (mean = 26.2%,
median = 19.9%, IQR = 29.5, SD = 23.84) and 0–99% in SAC (mean = 51.5%, median = 54.2%,
IQR = 36.7, SD = 27.9). Two diagnostic methods were included in the analysis, the filtration
technique [20] was used in 36 of the 54 investigations, and the sedimentation technique was
used in the remaining 18 studies.
No treatment had taken place prior to the study in 41 out of 54 (75.9%) of the data sets ana-
lysed, 8 out of 54 (14.8%) reported treatment currently underway, 1 (1.9%) study reported
treatment of previously positive SAC with Niridazole, about 5 years previously, and 4 (7.4%)
had no information on previous treatment status. For the S. haematobium analysis, 51 were
Category 1, and 3 were from Category 2.
The sample sizes for the different independent variables are given in Table 3. Age range for
PSAC across the published studies for both schistosome species was<1 up to 6 years, and for
SAC, age range was 6–16 years. While for all studies PSAC sample sizes were lower than SAC
Fig 2. Map of African countries included in the analysis. The map shows the countries where the data came from,
partitioned by schistosome species, red = both S. mansoni and S. haematobium data present, blue = S. mansoni only,
purple = S. haematobium only and pale blue = no data used from these countries. The map was made using the online
MAPCHART software package (https://mapchart.net/africa.html).
https://doi.org/10.1371/journal.pntd.0008650.g002
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sample sizes, the sample sizes recorded in the published studies for both species were corre-
lated in PSAC and SAC i.e. those studies with low sample sizes for PSAC also had low sample
sizes for SAC and the converse was true. Therefore, the regression analysis was weighted with
the square root of the PSAC sample size.
Relationship in schistosome infection prevalence between preschool-aged
children (PSAC) and school-aged children (SAC)
The Pearson correlation showed a linear relationship between PSAC infection prevalences and
SAC infection prevalence in the same communities for both S.mansoni (r = 0.812, df = 1, p =
<0.0001) and S. haematobium (r = 0.786, df = 1, p = <0.0001). This was subsequently analysed
through linear regression.
The simple regression analysis was carried out without the effect of confounding variables, and
was weighted by the square root of PSAC sample size. This showed a significant relationship
between S. mansoni PSAC and SAC prevalences, with 65.9% of the variation in S. mansoni PSAC
prevalence being explained by the model with SAC infection prevalence alone (95% CI = 54.7–
77.1). Similarly, the regression analysis showed a significant linear relationship between S. haemato-
bium PSAC and SAC prevalences with 61.8% of the variation in S. haematobium PSAC prevalence
being explained by the model with SAC infection prevalence alone (95% CI = 46.4–77.2). The sim-
ple relationship between PSAC and SAC prevalences is shown in Fig 3A and 3B, and the results of
the regression analysis are summarised in Table 4 (S. mansoni) and Table 5 (S. haematobium).
The WHO provides guidelines [4] for the optimal frequency of schistosome treatment of
SAC, by assessing the prevalence of infection or visible haematuria in a community. We there-
fore coded the infection prevalence in PSAC using the guidelines for SAC (low, moderate and
high) to indicate levels of infection in PSAC, which would be captured under those categories
(see Fig 4). It can be seen that when SAC prevalence levels are low, there is a low infection
prevalence in PSAC, whereas when infection levels are high in SAC, levels in PSAC are moder-
ate to high. There are two instances where PSAC infection levels are higher than in SAC, only
one published report for each schistosome species, and the fitted line in Fig 4 predicts that a
100% infection prevalence is reached earlier in SAC than PSAC.
Table 3. Summary of sample sizes for categories.
Variable Categories Schistosoma mansoni Schistosoma haematobium





Treatment History No previous treatment 73 41
Currently undergoing treatment 13 8
MDA previously conducted in the area 1 1
Treatment history information not provided 2 4
Diagnostic Method Urine Filtration N/A 36
Sedimentation N/A 18
Kato Katz 87 N/A
Formol Ether Technique 1 N/A
Bell 1 N/A
N/A = does not apply
https://doi.org/10.1371/journal.pntd.0008650.t003
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The regression predicts PSAC prevalences for the WHO categories based on the SAC preva-
lences. For example, when SAC levels are low in S. mansoni, i.e. 0–9%, the PSAC levels are
interpolated to be<1% (Fig 4A). Therefore based on the prediction, we determined the pro-
portion of PSAC studies wrongly classified into a lower infection level, based on the SAC prev-
alences. Being, misclassified into a lower level is important from a public health perspective, as
it means infection levels in PSAC will be underestimated.
For S. mansoni, the PSAC infection was underestimated in 4/89 study populations (4.5%).
One study population (out of 4) had a PSAC prevalence that was classified in the low WHO
category based on its SAC prevalence when it had a PSAC prevalence greater than 1% and
therefore, should have been in the moderate category. This study reported the same prevalence
6.7% for both SAC and PSAC. Additionally, 3/42 (7.1%) study populations were classified as
Fig 3. Scatterplots of PSAC vs SAC prevalence with 95% confidence band of the regression line for A) S. mansoni and
B) S. haematobium. Fitted line is from the linear regression analysis.
https://doi.org/10.1371/journal.pntd.0008650.g003
PLOS NEGLECTED TROPICAL DISEASES Predicting schistosomiasis prevalence in preschool-aged children
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008650 October 1, 2020 10 / 20
moderate when their PSAC prevalences would have put them in high infection level. Of these
3 populations, 1 was undergoing treatment. For S. haematobium, in total 4/54 (7.4%) PSAC
study populations were underestimated. One of the study populations (out of 4) had a PSAC
prevalence that was classified in the low infection WHO category when it should have been in
the moderate category. This study had a PSAC prevalence of 9% which was greater than the
SAC prevalence of 7.9%. Further, 4/18 (22.2%) study populations were classified as moderate
when their PSAC prevalences would have put them in high infection level. Of these 4 popula-
tions, 1 was undergoing treatment.
Effect of treatment history on the relationship between infection
prevalence between preschool-aged children (PSAC) and school age
children (SAC)
We conducted a regression analysis, allowing for the African sub-region where the study was
conducted for both schistosome species, as well as the parasitology diagnostic method for S.
haematobium only as there was not enough data in the diagnostic categories in the S.mansoni
analysis to give a meaningful investigation. This was to determine if the relationship between
PSAC and SAC prevalences varied significantly with the treatment history of the study com-
munity. The African sub-region was included in the analysis, as earlier descriptive statistics
had indicated that there was heterogeneity in infection prevalences reported by studies from
the different countries in Africa; this is confirmed by the significant effect of this variable on
Table 4. Analysis of variance and coefficients—S. mansoni, basic regression weighted by square root of PSACn.
Source df F-value P- value
Regression 88 (1) 168.17 <0.001
Prevalence in SAC 88 (1) 168.17 <0.001
Coefficients Coef SE Coef 95% CI Lower 95% CI Upper P- value
Constant -0.136 0.049 -0.265 -0.007 0.006
Prevalence in SAC 0.734 0.056 0.623 0.845 <0.001
Abbreviations: n–sample size, PSAC–preschool age children, SAC–School age children-square root arcsine transformed, df- degrees of freedom, Coef–coefficient, SE–
Standard error.
Mathematical equation for the model: PSAC prevalence = A + bSAC prevalence
Where A is the constant coefficient and b is the Prevalence in SAC coefficient
Therefore: PSAC prevalence = -0.136 + 0.734 x SAC prevalence
https://doi.org/10.1371/journal.pntd.0008650.t004
Table 5. Analysis of variance and coefficients—S. haematobium, basic regression weighted by square root of PSACn.
Source df F-value P- value
Regression 54 (1) 84.28 <0.001
Prevalence in SAC 54 (1) 84.28 <0.001
Coefficients Coef SE Coef 95% CI Lower 95% CI Upper P- value
Constant -0.065 0.062 -0.189 0.059 0.300
Prevalence in SAC 0.680 0.074 0.531 0.828 <0.001
Abbreviations: n–sample size, PSAC–preschool age children, SAC–School age children-square root arcsine transformed, df- degrees of freedom, Coef–coefficient, SE–
Standard error.
Mathematical equation for the model: PSAC prevalence = A + bSAC prevalence
Where A is the constant coefficient and b is the Prevalence in SAC coefficient
Therefore: PSAC prevalence = -0.065 + 0.680 x SAC prevalence
https://doi.org/10.1371/journal.pntd.0008650.t005
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PSAC prevalence (see Table 6). We conducted the analysis with and without the studies from
the Southern region which had the smallest sample sizes. Excluding these studies did not alter
the results significantly, therefore we included all studies in the final analyses.
Fig 4. Scatterplots of PSAC vs SAC prevalence demarcated into the WHO prevalence classes for A) S. mansoni and B)
S. haematobium. The classes are shown according to SAC prevalence levels showing the corresponding PSAC level on
the Y-axis. Red = High, Orange = Moderate, Yellow = Low. The fitted line is from the linear regression analysis.
https://doi.org/10.1371/journal.pntd.0008650.g004
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Including the other variables and the interacting term in the model increased the r-squared
value from 65.9% (95% CI = 54.7–77.1) to 74.5% (95% CI = 65.6–83.4) for S. mansoni and
from 61.8% (95% CI = 46.4–77.2) to 70.3% (95% CI = 57.6–83.0) for S. haematobium. The cor-
relation between PSAC and SAC prevalence was still significant. The results of this full model
analysis are summarised in Tables 6 and 7. This analysis showed that the relationship between
PSAC and SAC prevalences was not significantly altered by treatment history (S. mansoni, F
value = 0.02, df = 88, 2, p = 0.983, and S haematobium, F value = 0.36, df = 53, 2, p = 0.966).
It is worth noting that although statistical significance was not detected for the effect of
treatment history on PSAC infection prevalence or for the interaction factor between SAC
infection prevalence and treatment history, for both S. mansoni and S. haematobium, SAC
infection levels in populations where schistosome treatment was underway (e.g. through
MDA), consistently mapped to lower PSAC infection levels (see Fig 5).
Discussion
This is the first study investigating an association between the prevalence of schistosomiasis in
African school-aged children (SAC) and preschool-aged children (PSAC). This study is driven
by the current need to define strategies to include PSAC in schistosomiasis treatment pro-
grammes. The current WHO guidelines for treating PSAC is to treat children on a case-by-
Table 6. Analysis of variance and coefficients—S. mansoni, regression weighted by square root of PSACn.
Source df F-value P- value
Regression 88 (9) 25.63 <0.001
Prevalence in SAC 88 (1) 163.15 <0.001
African Regions (North, South, East, West and Central) 88 (4) 4.09 0.005
Treatment History 88 (2) 0.10 0.908
Prevalence in SAC ⇤ Treatment History 88 (2) 0.02 0.983
Coefficients Coef SE Coef 95% CI Lower 95% CI Upper P- value
Constant -0.137 0.065 -0.267 -0.008 0.038
Prevalence in SAC 0.7209 0.0564 0.6086 0.8333 <0.001
African Regions: 0.005⇤
North 0.000 0.000 0.000 0.000
South -0.198 0.191 -0.578 0.182 0.303
East -0.037 0.057 -0.151 0.077 0.519
West 0.055 0.063 -0.071 0.181 0.385
Central 0.132 0.064 0.004 0.260 0.044
Treatment History: 0.908⇤
No previous treatment 0.000 0.000 0.000 0.000
Treatment underway -0.060 0.153 -0.364 0.244 0.696
Unknown 0.46 2.65 -4.81 5.73 0.861
SAC ⇤Treatment History: 0.983⇤
No previous treatment 0.000 0.000 0.000 0.000
Treatment underway -0.026 0.200 -0.425 0.373 0.897
Unknown -1.08 7.71 -16.43 14.28 0.889
Abbreviations: n–sample size, PSAC–preschool age children, SAC–School age children-square root arcsine transformed, df- degrees of freedom, Coef–coefficient, SE–
Standard error.
⇤Overall P-value from regression model
Mathematical equation for the model: PSAC prevalence = A + bSAC prevalence + cAfrican Region +dTreatment History + eSAC⇤Treatment History
Where A is the constant coefficient and b,c,d and e are the variable coefficients.
https://doi.org/10.1371/journal.pntd.0008650.t006
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case basis upon diagnosis, with the current formulation of PZQ [13]. As the global community
prepares for the deployment of the paediatric formulation of PZQ (currently undergoing
Phase III clinical trials), and for eventual elimination of schistosomiasis, one of the main oper-
ational questions that remain unanswered is how to quantify infection in PSAC, and to iden-
tify areas/populations to target for treatment. PSAC are out of the school system and therefore
not as easily accessible as SAC. A further operational question is, at what level of schistosome
endemicity would it be practical to conduct an infection survey in this age group to diagnose
and treat infections? We investigated the relationship between currently available data on SAC
and PSAC within the same community to determine if data from SAC, who are the current
target of control programmes could be used to predict infection levels in PSAC.
Previous studies have investigated using SAC as a proxy group for community-wide preva-
lence levels, showing that SAC prevalence is closely related to adult prevalence, and therefore
this age group could be used as a proxy group [24, 25]. Our findings confirm that this approach
Table 7. Analysis of variance and coefficients—S. haematobium, regression weighted by square root of PSACn.
Source df F-value P- value
Regression 53(11) 10.20 <0.0001
Prevalence in SAC 53(1) 57.42 <0.0001
African Regions (North, South, East, West and Central) 53(4) 1.21 0.319
Treatment History 53(2) 0.33 0.721
Diagnostic Technique 53(1) 0.01 0.910
Prevalence in SAC ⇤ Treatment History 53(2) 0.36 0.966
Coefficients Coef SE Coef 95% CI Lower 95% CI Upper P- value
Constant -0.095 0.102 -0.300 0.111 0.359
Prevalence in SAC 0.6776 0.894 0.497 0.8580 <0.0001
African Regions: 0.319⇤
North 0.00 0.00 0.00 0.00
South 0.007 0.177 -0.350 0.364 0.968
East 0.1080 0.098 -0.090 0.306 0.276
West 0.019 0.102 -0.187 0.224 0.855
Central 0.181 0.181 -0.093 0.454 0.189
Treatment history: 0.721⇤
No previous treatment 0.00 0.00 0.00 0.00
Treatment underway -0.074 0.183 -0.433 0.295 0.688
Unknown -0.483 0.706 -1.908 0.941 0.497
Diagnostic technique: 0.910⇤
Filtration 0.00 0.00 0.00 0.00
Sedimentation 0.007 0.056 -0.106 0.119 0.614
SAC ⇤ Treatment history: 0.966⇤
No previous treatment 0.00 0.00 0.00 0.00
Treatment underway -0.107 0.210 -0.529 0.319 0.614
Unknown 0.544 0.789 -1.047 2.135 0.494
Abbreviations: n–sample size, PSAC–preschool age children, SAC–School age children-square root arcsine transformed, df- degrees of freedom, Coef–coefficient, SE–
Standard error.
⇤Overall P-value from regression model
Mathematical equation for the model: PSAC prevalence = A + bSAC prevalence + cAfrican Region +dTreatment History + eDiagnostic Technique + fSAC⇤Treatment
history
Where A is the constant coefficient and b,c,d,e and f are the variable coefficients.
https://doi.org/10.1371/journal.pntd.0008650.t007
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Fig 5. Scatterplots of PSAC vs SAC prevalence partitioned by, treatment history of the SAC for A) S. mansoni and B) S. haematobium.
https://doi.org/10.1371/journal.pntd.0008650.g005
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can be extended to quantify infection levels in PSAC. Our results show that PSAC infection
levels are significantly correlated with SAC prevalence levels, and indicate that it is possible to
extrapolate PSAC prevalence levels from known SAC prevalence and treat them accordingly.
This finding is not surprising as SAC tend to use the same water sources as the rest of the com-
munity, and their contact with infective water is related to activities of older family members
[26], so that when a high proportion of SAC are infected, the community risk of infection
accumulates rapidly.
Several countries have embarked on preventative chemotherapy through mass drug admin-
istration (MDA). Thus, some of the data we analysed came from communities undergoing
MDA programmes targeted at SAC, or in a few cases, targeting both SAC and adults, while
others had not experienced MDA in the past 50 years; no current MDA programme includes
PSAC. Therefore, we included the SAC, or SAC and adult’s treatment history in our analyses.
The current study indicated that the relationship between PSAC and SAC prevalences did not
change significantly depending on treatment history of the study population. This finding may
be due to the small sample sizes in the study because, albeit not significant in areas undergoing
treatment, SAC levels translated to lower PSAC levels than in areas which had not experienced
any treatment. In other words, to get the same levels of PSAC prevalence in areas that had
undergone treatment, higher SAC prevalence levels were required than when compared to
that in areas without treatment, for both S. mansoni and S. haematobium. In areas undergoing
MDA, treatment of SAC has the potential of lowering levels of contamination of shared water
sources with the infection, especially if treatment coverage is high and includes adults in the
community; in this case, PSAC are exposed to lower levels of infection. In two examples where
treatment was underway, one for S. mansoni and one for S. haematobium, infection prevalence
in PSAC was greater than in SAC, presumably because the PSAC are excluded from the MDA
programmes.
The maintenance of a relationship between PSAC and SAC prevalences during treatment,
is relevant for most countries targeting SAC via preventative chemotherapy, and will need to
include PSAC. This will become particularly prominent if the paediatric formulation of PZQ
currently undergoing phase III clinical trials becomes available. This means that even data
from national treatment impact assessment exercises that are mostly conducted by surveying
SAC, are informative for developing strategies for treating PSAC. Thus, PSAC prevalence can
be inferred from current levels of SAC prevalence data (as can be found in the Espen WHO
database [27]), which can now be used to map prevalence levels of schistosomiasis in PSAC in
Africa. Our results suggest that where prevalence of schistosomiasis infection is high in SAC,
limited surveys could be used to validate infection in PSAC to justify preventive chemotherapy.
This may obviate the need to conduct extensive surveys for schistosomiasis in PSAC. This is
also in keeping with the WHO recommendation that given the financial and human resources
required for surveys, existing epidemiological data including historical records should be used
to generate baseline information for implementing a control strategy [6].
Unsurprisingly the relationship between SAC and PSAC indicates that infection levels in
PSAC are zero or undetectable below a certain prevalence of SAC infection. This is due to both
the low sensitivity of the widely used parasitological schistosomiasis diagnostic tests in detect-
ing low intensity infections [28], as well as the infection transmission dynamics. Infection
accumulates with age, with most children being exposed to infection within their first year of
life, mainly as a result of increasing water contact and exposure patterns [29, 30]. While we can
determine exposure to infection in the very young children serologically, infection detection
by egg counts is less reliable because of the low levels of infection the children carry [29].
There is also the operational challenge of collecting stool and urine samples from the younger
PSAC, who may not be toilet-trained; in this study PSAC age ranged from <1 year up to 6
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years. Similarly, the number of samples collected would also affect the accuracy of diagnosis
and not all studies indicated the number of urine or stool samples collected for the parasitology
diagnosis.
Where we had sufficient data to investigate the influence of parasite egg collection methods,
we found that for example with S. haematobium, the choice of egg collection methods, did not
affect the PSAC infection prevalence. This is not surprising as both methods relied on enumer-
ating parasite eggs excreted in urine, and thus suffer the same limitations of low sensitivity in
people with low infection intensities [30].
Looking at methodological aspects, as with most meta-analyses and literature reviews, some
publication bias can occur. Thus, we conducted a quality assessment exercise of the data pub-
lished in the source reference. We then conducted the analyses both including and excluding
the data from studies scoring low on the quality assessment, and as this did not alter the results,
the data from all studies satisfying the inclusion criteria were kept in the analysis.
There were other possible analyses that would have been more informative, but sample
sizes were too small for the data to be partitioned or analysed by those categories. For example,
for both S. mansoni and S. haematobium, only one study reported previous, but no current
MDA in the SAC. These both had their most recent MDA 2 years prior to the study quantify-
ing SAC and PSAC infection, where the one examining S. haematobium used Niridazole
instead of PZQ. The impact of MDA on the relationship between PSAC and SAC infection lev-
els after cessation of MDA in SAC thus remains unexplored, but may likely not vary signifi-
cantly due to infection rebound [31]. It would also have been informative to have the data for
both SAC and PSAC in each age group, but this more granular data were not presented in the
source publication. We attempted to capture some of the heterogeneity in the data by includ-
ing factors such as the African sub-region where the data were collected, but other factors
which could not be determined from the information presented in the publications might also
account for the variation in the PSAC infection prevalence (the model explained 74.5% of the
variation in S. mansoni and 70.3% in S. haematobium) This includes factors such as number of
parasitology samples collected, number of slides prepared for diagnosis and age-related water
contact. Nonetheless, the strong correlation between the two variables (i.e. PSAC and SAC
prevalence) in these heterogeneous studies suggest that when quantifying infection in the same
community with less heterogeneity, the SAC infection prevalence should be a more informa-
tive proxy for PSAC infection prevalence.
We determined the proportion of study populations classified into a lower infection level
i.e. misclassified into a lower WHO classifications category based on the SAC levels. For S.
mansoni, 4/89 (4.5%) of PSAC prevalences were underestimated and therefore misclassified,
based on the interpolation of the regression equation. For S. haematobium, 4/54 (7.4%) of
PSAC prevalences were misclassified. There are several reasons that could explain this, an
example is treatment history. One of the S. mansoni studies reported that MDA was underway
in SAC, and had similar prevalences in SAC and PSAC. The published source studies reported
treatments via MDA but there was no indication if there had been any individual treatment
provisions through health facilities. For S. haematobium, one study reported higher infection
prevalence in PSAC than SAC, and the population had not had MDA targeted at the SAC.
However, no explanation was given for this observation. The fact that even with the heteroge-
neities highlighted, over 90% of the studies were classified into the correct WHO classifications
category based on the SAC levels from the regression model indicates that the SAC prevalences
can be extended as a proxy for infection levels in PSAC as they are already being used for the
adult population.
In conclusion, it has already been demonstrated that in schistosome endemic areas, PSAC
are at high risk of schistosome infection and disease and therefore should be included in
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treatment strategies. Here, we have demonstrated that schistosomiasis infection levels in PSAC
are highly correlated to levels in SAC, giving the potential for using already existing data from
SAC as a predictor of infection levels in PSAC, for both S. mansoni and S. haematobium. Criti-
cally, we have shown that the relationship between PSAC and SAC infection levels is informa-
tive during ongoing community or SAC-targeted treatment, as well as in communities that
have not received schistosome treatment. With the increasing concern of the health impact of
schistosomiasis in this PSAC, using already existing SAC data to inform PSAC chemotherapy
could accelerate and facilitate the treatment of PSAC who are in urgent need of treatment.
This will allow endemic countries to move closer towards the goal of eliminating schistosomia-
sis as a public health burden by 2025 [32].
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